<?xml version="1.0" encoding="UTF-8"?><search-results xmlns="http://www.w3.org/2005/Atom" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:opensearch="http://a9.com/-/spec/opensearch/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/"><opensearch:totalResults>2992343</opensearch:totalResults><opensearch:startIndex>2200</opensearch:startIndex><opensearch:itemsPerPage>100</opensearch:itemsPerPage><opensearch:Query role="request" searchTerms="heart" startPage="2200"/><link ref="self" href="http://api.elsevier.com:80/content/search/index:scopus?start=2200&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="first" href="http://api.elsevier.com:80/content/search/index:scopus?start=0&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="prev" href="http://api.elsevier.com:80/content/search/index:scopus?start=2100&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="next" href="http://api.elsevier.com:80/content/search/index:scopus?start=2300&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="last" href="http://api.elsevier.com:80/content/search/index:scopus?start=4900&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929461369"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929461369?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929461369&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929461369&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0041010115001282"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929461369</prism:url><dc:identifier>SCOPUS_ID:84929461369</dc:identifier><eid>2-s2.0-84929461369</eid><dc:title>Mechanisms of microcystin-LR-induced cytoskeletal disruption in animal cells</dc:title><dc:creator>Zhou M.</dc:creator><prism:publicationName>Toxicon</prism:publicationName><prism:issn>00410101</prism:issn><prism:eIssn>18793150</prism:eIssn><prism:volume>101</prism:volume><prism:pageRange>92-100</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.toxicon.2015.05.005</prism:doi><pii>S0041010115001282</pii><dc:description>© 2015 Elsevier Ltd. All rights reserved. Microcystin-LR (MC-LR), a potent hepatotoxin produced by certain bloom-forming cyanobacteria, covalently binds to serine/threonine protein phosphatases and acts as an efficient inhibitor of this group of enzymes. MC-LR induces oxidative stress and the unfolded protein response in multiple cell types, leading to apoptosis through the mitochondrial and endoplasmic reticulum pathways. Histologic lesions of acute MC-LR toxicosis exhibit membrane blebbing, cell rounding and dissociation, indicating that this toxin may exert hepatotoxic effects by causing cytoskeletal disruption. Both in vivo and in vitro studies have revealed that exposure of human, mouse, or rat hepatocytes to MC-LR induces the rearrangement or collapse of the three components of the cytoskeleton. In addition, multiple cytoskeletal and cytoskeleton- A ssociated proteins have been found to be affected by MC-LR. This review summarizes the increasing information in the literature pertaining to the molecular mechanisms of MC-LR-induced cytoskeletal disruption and may increase our understanding of its toxicity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031419</affiliation-url><afid>60031419</afid><affilname>Ningbo University</affilname><name-variant>Ningbo University</name-variant><affiliation-city>Ningbo</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031419</affiliation-url><afid>60031419</afid><affilname>Ningbo University</affilname><name-variant>Ningbo University</name-variant><affiliation-city>Ningbo</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56647254500</author-url><authid>56647254500</authid><authname>Zhou M.</authname><surname>Zhou</surname><given-name>Mi</given-name><initials>M.</initials><afid>60031419</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55990074600</author-url><authid>55990074600</authid><authname>Tu W.</authname><surname>Tu</surname><given-name>Wei Wei</given-name><initials>W.W.</initials><afid>60031419</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7407007022</author-url><authid>7407007022</authid><authname>Xu J.</authname><surname>Xu</surname><given-name>Jin</given-name><initials>J.</initials><afid>60031419</afid><afid>60031419</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7407007022</author-url><authid>7407007022</authid><authname>Xu J.</authname><surname>Xu</surname><given-name>Jin</given-name><initials>J.</initials><afid>60031419</afid><afid>60031419</afid></author><authkeywords>Cytoskeleton | Disruption | Hepatotoxin | Microcystin-LR | Mitogen- A ctivated protein kinase | Protein phosphatase</authkeywords><intid>35963310</intid><source-id>22319</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929395948"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929395948?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929395948&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929395948&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0024320515001721"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929395948</prism:url><dc:identifier>SCOPUS_ID:84929395948</dc:identifier><eid>2-s2.0-84929395948</eid><dc:title>Adhesion of platelets through thromboxane A&lt;inf&gt;2&lt;/inf&gt; receptor signaling facilitates liver repair during acute chemical-induced hepatotoxicity</dc:title><dc:creator>Minamino T.</dc:creator><prism:publicationName>Life Sciences</prism:publicationName><prism:issn>00243205</prism:issn><prism:eIssn>18790631</prism:eIssn><prism:volume>132</prism:volume><prism:pageRange>85-92</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.lfs.2015.03.015</prism:doi><pii>S0024320515001721</pii><dc:description>© 2015 Elsevier Inc. All rights reserved. Aims Platelets have been suggested to play an important role in liver regeneration and repair after hepatic resection and acute liver injury. However, the underlying mechanisms of liver repair remain elusive. Signaling through thromboxane prostanoid (TP) receptor participates in inflammation and tissue injury through platelet aggregation. On the other hand, TP receptor signaling also is involved in tissue repair and tumor growth through angiogenesis. The present study was examined whether or not TP receptor signaling contributes to liver repair and sinusoidal restoration from acute liver injury through platelet adhesion to the hepatic sinusoids. Main methods Carbon tetrachrolide (CCl&lt;inf&gt;4&lt;/inf&gt;) was used to induce acute liver injury in TP receptor knockout mice (TP&lt;sup&gt;-/-&lt;/sup&gt; mice) and their wild-type littermates (WT mice). Key findings Compared with WT mice, TP&lt;sup&gt;-/-&lt;/sup&gt; mice exhibited delayed in liver repair and sinusoidal restoration after CCl&lt;inf&gt;4&lt;/inf&gt; treatment, which were associated with attenuated hepatic expression of pro-angiogenic factors. Intravital microscopic observation revealed that adhering platelets to the sinusoids was increased in WT livers during the repair phase as compared with TP&lt;sup&gt;-/-&lt;/sup&gt; livers, and platelet adhesion was dependent on TP receptor signaling. The levels of hepatocyte growth factor (HGF) in platelets from WT mice treated with CCl&lt;inf&gt;4&lt;/inf&gt; for 48 h were greater than those form TP&lt;sup&gt;-/-&lt;/sup&gt; mice, and HGF enhanced the expression of angiogenic factors in cultured human umbilical vein endothelial cells (HUVECs). Significance These results suggested that TP receptor signaling facilitates liver repair and sinusoidal restoration from acute liver injury through HGF release from platelets adhering to the sinusoids.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002391</affiliation-url><afid>60002391</afid><affilname>Kitasato University School of Medicine</affilname><name-variant>Kitasato University</name-variant><affiliation-city>Sagamihara</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002391</affiliation-url><afid>60002391</afid><affilname>Kitasato University School of Medicine</affilname><name-variant>Kitasato University</name-variant><affiliation-city>Sagamihara</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002391</affiliation-url><afid>60002391</afid><affilname>Kitasato University School of Medicine</affilname><name-variant>Kitasato University</name-variant><affiliation-city>Sagamihara</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030354</affiliation-url><afid>60030354</afid><affilname>Kyoto University Faculty of Medicine</affilname><name-variant>Kyoto University School of Medicine</name-variant><affiliation-city>Kyoto</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:17135674700</author-url><authid>17135674700</authid><authname>Minamino T.</authname><surname>Minamino</surname><given-name>Tsutomu</given-name><initials>T.</initials><afid>60002391</afid><afid>60002391</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:17135674700</author-url><authid>17135674700</authid><authname>Minamino T.</authname><surname>Minamino</surname><given-name>Tsutomu</given-name><initials>T.</initials><afid>60002391</afid><afid>60002391</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7410024696</author-url><authid>7410024696</authid><authname>Ito Y.</authname><surname>Ito</surname><given-name>Yoshiya</given-name><initials>Y.</initials><afid>60002391</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55261883200</author-url><authid>55261883200</authid><authname>Ohkubo H.</authname><surname>Ohkubo</surname><given-name>Hirotoki</given-name><initials>H.</initials><afid>60002391</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56646389800</author-url><authid>56646389800</authid><authname>Shimuzu Y.</authname><surname>Shimuzu</surname><given-name>Yuki</given-name><initials>Y.</initials><afid>60002391</afid><afid>60002391</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56646389800</author-url><authid>56646389800</authid><authname>Shimuzu Y.</authname><surname>Shimuzu</surname><given-name>Yuki</given-name><initials>Y.</initials><afid>60002391</afid><afid>60002391</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:54393399400</author-url><authid>54393399400</authid><authname>Kojo K.</authname><surname>Kojo</surname><given-name>Ken</given-name><initials>K.</initials><afid>60002391</afid><afid>60002391</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:54393399400</author-url><authid>54393399400</authid><authname>Kojo K.</authname><surname>Kojo</surname><given-name>Ken</given-name><initials>K.</initials><afid>60002391</afid><afid>60002391</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56646606500</author-url><authid>56646606500</authid><authname>Nishizwa N.</authname><surname>Nishizwa</surname><given-name>Nobuyuki</given-name><initials>N.</initials><afid>60002391</afid><afid>60002391</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56646606500</author-url><authid>56646606500</authid><authname>Nishizwa N.</authname><surname>Nishizwa</surname><given-name>Nobuyuki</given-name><initials>N.</initials><afid>60002391</afid><afid>60002391</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7201931663</author-url><authid>7201931663</authid><authname>Amano H.</authname><surname>Amano</surname><given-name>Hideki</given-name><initials>H.</initials><afid>60002391</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36071602400</author-url><authid>36071602400</authid><authname>Narumiya S.</authname><surname>Narumiya</surname><given-name>Shuh</given-name><initials>S.</initials><afid>60030354</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35426312000</author-url><authid>35426312000</authid><authname>Koizumi W.</authname><surname>Koizumi</surname><given-name>Wasaburo</given-name><initials>W.</initials><afid>60002391</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005085800</author-url><authid>7005085800</authid><authname>Majima M.</authname><surname>Majima</surname><given-name>Masataka</given-name><initials>M.</initials><afid>60002391</afid></author><authkeywords>Liver | Microcirculation | Platelet | Repair | Thromboxane</authkeywords><intid>2035950441</intid><source-id>20473</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225475"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225475?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225475&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225475&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225475</prism:url><dc:identifier>SCOPUS_ID:84930225475</dc:identifier><eid>2-s2.0-84930225475</eid><dc:title>Crucial genes and pathways in chicken germ stem cell differentiation</dc:title><dc:creator>Zhang Z.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>21</prism:issueIdentifier><prism:pageRange>13605-13621</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M114.601401</prism:doi><dc:description>© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Male germ cell differentiation is a subtle and complex regulatory process. Currently, its regulatory mechanism is still not fully understood. In our experiment, we performed the first comprehensive genome and transcriptome-wide analyses of the crucial genes and signaling pathways in three kinds of crucial cells (embryonic stem cells, primordial germ cell, and spermatogonial stem cells) that are associated with the male germ cell differentiation. We identified thousands of differentially expressed genes in this process, and from these we chose 173 candidate genes, of which 98 genes were involved in cell differentiation, 19 were involved in the metabolic process, and 56 were involved in the differentiation and metabolic processes, like GAL9, AMH, PLK1, and PSMD7 and so on. In addition, we found that 18 key signaling pathways were involved mainly in cell proliferation, differentiation, and signal transduction processes like TGF-β, Notch, and Jak-STAT. Further exploration found that the candidate gene expression patterns were the same between in vitro induction experiments and transcriptome results. Our results yield clues to the mechanistic basis of male germ cell differentiation and provide an important reference for further studies.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007381</affiliation-url><afid>60007381</afid><affilname>Yangzhou University</affilname><name-variant>Yangzhou University</name-variant><affiliation-city>Yangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017705</affiliation-url><afid>60017705</afid><affilname>Chinese Academy of Agricultural Sciences</affilname><name-variant>Chinese Academy of Agricultural Sciences</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020304</affiliation-url><afid>60020304</afid><affilname>University of Maryland</affilname><name-variant>University of Maryland</name-variant><affiliation-city>College Park</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020322</affiliation-url><afid>60020322</afid><affilname>Suez Canal University</affilname><name-variant>Suez Canal University</name-variant><affiliation-city>Ismalia</affiliation-city><affiliation-country>Egypt</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">21</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55695965500</author-url><authid>55695965500</authid><authname>Zhang Z.</authname><surname>Zhang</surname><given-name>Zhentao</given-name><initials>Z.</initials><afid>60007381</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55830115400</author-url><authid>55830115400</authid><authname>Elsayed A.</authname><surname>Elsayed</surname><given-name>Ahmed Kamel</given-name><initials>A.K.</initials><afid>60007381</afid><afid>60020322</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55830115400</author-url><authid>55830115400</authid><authname>Elsayed A.</authname><surname>Elsayed</surname><given-name>Ahmed Kamel</given-name><initials>A.K.</initials><afid>60007381</afid><afid>60020322</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:49662250400</author-url><authid>49662250400</authid><authname>Shi Q.</authname><surname>Shi</surname><given-name>Qingqing</given-name><initials>Q.</initials><afid>60007381</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55010277700</author-url><authid>55010277700</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yani</given-name><initials>Y.</initials><afid>60007381</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56382111900</author-url><authid>56382111900</authid><authname>Zuo Q.</authname><surname>Zuo</surname><given-name>Qisheng</given-name><initials>Q.</initials><afid>60007381</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56381697000</author-url><authid>56381697000</authid><authname>Li D.</authname><surname>Li</surname><given-name>Dong</given-name><initials>D.</initials><afid>60007381</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56513416000</author-url><authid>56513416000</authid><authname>Lian C.</authname><surname>Lian</surname><given-name>Chao</given-name><initials>C.</initials><afid>60007381</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56567209800</author-url><authid>56567209800</authid><authname>Tang B.</authname><surname>Tang</surname><given-name>Beibei</given-name><initials>B.</initials><afid>60007381</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56567411300</author-url><authid>56567411300</authid><authname>Xiao T.</authname><surname>Xiao</surname><given-name>Tianrong</given-name><initials>T.</initials><afid>60007381</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55636690500</author-url><authid>55636690500</authid><authname>Xu Q.</authname><surname>Xu</surname><given-name>Qi</given-name><initials>Q.</initials><afid>60007381</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:26636299200</author-url><authid>26636299200</authid><authname>Chang G.</authname><surname>Chang</surname><given-name>Guobin</given-name><initials>G.</initials><afid>60007381</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:23003372100</author-url><authid>23003372100</authid><authname>Chen G.</authname><surname>Chen</surname><given-name>Guohong</given-name><initials>G.</initials><afid>60007381</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:55894739000</author-url><authid>55894739000</authid><authname>Zhang L.</authname><surname>Zhang</surname><given-name>Lei</given-name><initials>L.</initials><afid>60007381</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:56642113900</author-url><authid>56642113900</authid><authname>Wang K.</authname><surname>Wang</surname><given-name>Kehua</given-name><initials>K.</initials><afid>60017705</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:56568509300</author-url><authid>56568509300</authid><authname>Wang Y.</authname><surname>Wang</surname><given-name>Yingjie</given-name><initials>Y.</initials><afid>60007381</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:56513249100</author-url><authid>56513249100</authid><authname>Jin K.</authname><surname>Jin</surname><given-name>Kai</given-name><initials>K.</initials><afid>60007381</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:56662743300</author-url><authid>56662743300</authid><authname>Wang Y.</authname><surname>Wang</surname><given-name>Yilin</given-name><initials>Y.</initials><afid>60007381</afid></author><author seq="18"><author-url>http://api.elsevier.com/content/author/author_id:24073749500</author-url><authid>24073749500</authid><authname>Song J.</authname><surname>Song</surname><given-name>Jiuzhou</given-name><initials>J.</initials><afid>60020304</afid></author><author seq="19"><author-url>http://api.elsevier.com/content/author/author_id:56662661200</author-url><authid>56662661200</authid><authname>Cui H.</authname><surname>Cui</surname><given-name>Hengmi</given-name><initials>H.</initials><afid>60007381</afid></author><author seq="20"><author-url>http://api.elsevier.com/content/author/author_id:14033284200</author-url><authid>14033284200</authid><authname>Li B.</authname><surname>Li</surname><given-name>Bichun</given-name><initials>B.</initials><afid>60007381</afid></author><intid>2036082200</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929990152"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929990152?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929990152&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929990152&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929990152</prism:url><dc:identifier>SCOPUS_ID:84929990152</dc:identifier><eid>2-s2.0-84929990152</eid><dc:title>Hetero-oligomeric complex between the G protein-coupled estrogen receptor 1 and the plasma membrane Ca&lt;sup&gt;2+&lt;/sup&gt;-ATPase 4b</dc:title><dc:creator>Tran Q.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>21</prism:issueIdentifier><prism:pageRange>13293-13307</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M114.628743</prism:doi><dc:description>© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. The new G protein-coupled estrogen receptor 1 (GPER/GPR30) plays important roles in many organ systems. The plasma membrane Ca&lt;sup&gt;2+&lt;/sup&gt;-ATPase (PMCA) is essential for removal of cytoplasmic Ca&lt;sup&gt;2+&lt;/sup&gt; and for shaping the time courses of Ca&lt;sup&gt;2+&lt;/sup&gt;-dependent activities. Here, we show that PMCA and GPER/GPR30 physically interact and functionally influence each other. In primary endothelial cells, GPER/GPR30 agonist G-1 decreases PMCA-mediated Ca&lt;sup&gt;2+&lt;/sup&gt; extrusion by promoting PMCA tyrosine phosphorylation. GPER/GPR30 overexpression decreases PMCA activity, and G-1 further potentiates this effect. GPER/GPR30 knockdown increases PMCA activity, whereas PMCA knockdown substantially reduces GPER/GPR30-mediated phosphorylation of the extracellular signal-related kinase (ERK1/2). GPER/GPR30 co-immunoprecipitates with PMCA with or without treatment with 17β-estradiol, thapsigargin, or G-1. Heterologously expressed GPER/GPR30 in HEK 293 cells co-localizes with PMCA4b, the main endothelial PMCA isoform. Endothelial cells robustly express the PDZ post-synaptic density protein (PSD)-95, whose knockdown reduces the association between GPER/GPR30 and PMCA. Additionally, the association between PMCA4b and GPER/GPR30 is substantially reduced by truncation of either or both of their C-terminal PDZ-binding motifs. Functionally, inhibition of PMCA activity is significantly reduced by truncation of GPER/GPR30's C-terminal PDZ-binding motif. These data strongly indicate that GPER/GPR30 and PMCA4b form a hetero-oligomeric complex in part via the anchoring action of PSD-95, in which they constitutively affect each other's function. Activation of GPER/GPR30 further inhibits PMCA activity through tyrosine phosphorylation of the pump. These interactions represent crosstalk between Ca&lt;sup&gt;2+&lt;/sup&gt; signaling and GPER/GPR30-mediated activities.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004279</affiliation-url><afid>60004279</afid><affilname>Des Moines University</affilname><name-variant>Des Moines University</name-variant><affiliation-city>Des Moines</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005612474</author-url><authid>7005612474</authid><authname>Tran Q.</authname><surname>Tran</surname><given-name>Quang Kim</given-name><initials>Q.K.</initials><afid>60004279</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56081586600</author-url><authid>56081586600</authid><authname>VerMeer M.</authname><surname>VerMeer</surname><given-name>Mark</given-name><initials>M.</initials><afid>60004279</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56658418900</author-url><authid>56658418900</authid><authname>Burgard M.</authname><surname>Burgard</surname><given-name>Michelle A.</given-name><initials>M.A.</initials><afid>60004279</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56658236500</author-url><authid>56658236500</authid><authname>Hassan A.</authname><surname>Hassan</surname><given-name>Ali B.</given-name><initials>A.B.</initials><afid>60004279</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56658329200</author-url><authid>56658329200</authid><authname>Giles J.</authname><surname>Giles</surname><given-name>Jennifer</given-name><initials>J.</initials><afid>60004279</afid></author><intid>1786050280</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930224784"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930224784?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930224784&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930224784&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930224784</prism:url><dc:identifier>SCOPUS_ID:84930224784</dc:identifier><eid>2-s2.0-84930224784</eid><dc:title>Possible role of electrodynamic interactions in long-distance biomolecular recognition</dc:title><dc:creator>Preto J.</dc:creator><prism:publicationName>Physical Review E - Statistical, Nonlinear, and Soft Matter Physics</prism:publicationName><prism:issn>15393755</prism:issn><prism:eIssn>15502376</prism:eIssn><prism:volume>91</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1103/PhysRevE.91.052710</prism:doi><dc:description>© 2015 American Physical Society. The issue of retarded long-range resonant interactions between two molecules with oscillating dipole moments is revisited within the framework of classical electrodynamics. By taking advantage of a theorem in complex analysis, we present a simple method to calculate the frequencies of the normal modes, which are then used to estimate the interaction potential. The possibility that such interactions play a non-negligible role in ensuring the effective functioning of the biomolecular functions is investigated. On the basis of experimental results reported in the literature and simple numerical estimates, it is found that long-range interactions involving electromagnetic fields of frequencies 0.1-1THz could be temporarily activated despite radiation losses and solvent dissipation. Moreover, the theoretical background used to derive the mentioned interactions sheds light on Fröhlich's theory of selective long-range forces between biomolecules. At variance with a long-standing belief, we show that sizable resonant long-range interactions may exist only if the interacting system is out of thermal equilibrium.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005286</affiliation-url><afid>60005286</afid><affilname>Rice University</affilname><name-variant>Rice University</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60102127</affiliation-url><afid>60102127</afid><affilname>Aix Marseille Universite</affilname><name-variant>Aix-Marseille University</name-variant><affiliation-city>Marseille</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019417</affiliation-url><afid>60019417</afid><affilname>Centre de Physique Theorique</affilname><name-variant>Centre de Physique Théorique</name-variant><affiliation-city>Marseille</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020048</affiliation-url><afid>60020048</afid><affilname>Cross Cancer Institute</affilname><name-variant>Cross Cancer Institute</name-variant><affiliation-city>Edmonton</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030835</affiliation-url><afid>60030835</afid><affilname>University of Alberta</affilname><name-variant>University of Alberta</name-variant><affiliation-city>Edmonton</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55179257700</author-url><authid>55179257700</authid><authname>Preto J.</authname><surname>Preto</surname><given-name>Jordane</given-name><initials>J.</initials><afid>60005286</afid><afid>60102127</afid><afid>60019417</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55179257700</author-url><authid>55179257700</authid><authname>Preto J.</authname><surname>Preto</surname><given-name>Jordane</given-name><initials>J.</initials><afid>60005286</afid><afid>60102127</afid><afid>60019417</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55179257700</author-url><authid>55179257700</authid><authname>Preto J.</authname><surname>Preto</surname><given-name>Jordane</given-name><initials>J.</initials><afid>60005286</afid><afid>60102127</afid><afid>60019417</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005460723</author-url><authid>7005460723</authid><authname>Pettini M.</authname><surname>Pettini</surname><given-name>Marco</given-name><initials>M.</initials><afid>60102127</afid><afid>60019417</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005460723</author-url><authid>7005460723</authid><authname>Pettini M.</authname><surname>Pettini</surname><given-name>Marco</given-name><initials>M.</initials><afid>60102127</afid><afid>60019417</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35568347800</author-url><authid>35568347800</authid><authname>Tuszynski J.</authname><surname>Tuszynski</surname><given-name>Jack A.</given-name><initials>J.A.</initials><afid>60020048</afid><afid>60030835</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35568347800</author-url><authid>35568347800</authid><authname>Tuszynski J.</authname><surname>Tuszynski</surname><given-name>Jack A.</given-name><initials>J.A.</initials><afid>60020048</afid><afid>60030835</afid></author><intid>1786088385</intid><article-number>052710</article-number><source-id>29148</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930004495"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930004495?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930004495&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930004495&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930004495</prism:url><dc:identifier>SCOPUS_ID:84930004495</dc:identifier><eid>2-s2.0-84930004495</eid><dc:title>Binding of substrates to the central pore of the Vps4 ATPase is autoinhibited by the Microtubule Interacting and Trafficking (MIT) domain and activated by MIT Interacting Motifs (MIMs)</dc:title><dc:creator>Han H.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>21</prism:issueIdentifier><prism:pageRange>13490-13499</prism:pageRange><prism:coverDate>2015-05-22</prism:coverDate><prism:coverDisplayDate>22 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M115.642355</prism:doi><dc:description>© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. The endosomal sorting complexes required for transport (ESCRT) pathway drives reverse topology membrane fission events within multiple cellular pathways, including cytokinesis, multivesicular body biogenesis, repair of the plasma membrane, nuclear membrane vesicle formation, and HIV budding. The AAA ATPase Vps4 is recruited to membrane necks shortly before fission, where it catalyzes disassembly of the ESCRT-III lattice. The N-terminal Vps4 microtubule-interacting and trafficking (MIT) domains initially bind the C-terminal MIT-interacting motifs (MIMs) of ESCRT-III subunits, but it is unclear how the enzyme then remodels these substrates in response to ATP hydrolysis. Here, we report quantitative binding studies that demonstrate that residues from helix 5 of the Vps2p subunit of ESCRT-III bind to the central pore of an asymmetric Vps4p hexamer in a manner that is dependent upon the presence of flexible nucleotide analogs that can mimic multiple states in the ATP hydrolysis cycle. We also find that substrate engagement is autoinhibited by the Vps4p MIT domain and that this inhibition is relieved by binding of either Type 1 or Type 2 MIM elements, which bind the Vps4p MIT domain through different interfaces. These observations support the model that Vps4 substrates are initially recruited by an MIM-MIT interaction that activates the Vps4 central pore to engage substrates and generate force, thereby triggering ESCRT-III disassembly.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024978</affiliation-url><afid>60024978</afid><affilname>University of Utah School of Medicine</affilname><name-variant>Univ. of Utah School of Medicine</name-variant><affiliation-city>Salt Lake City</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55948348400</author-url><authid>55948348400</authid><authname>Han H.</authname><surname>Han</surname><given-name>Han</given-name><initials>H.</initials><afid>60024978</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36998653300</author-url><authid>36998653300</authid><authname>Monroe N.</authname><surname>Monroe</surname><given-name>Nicole</given-name><initials>N.</initials><afid>60024978</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16319870200</author-url><authid>16319870200</authid><authname>Votteler J.</authname><surname>Votteler</surname><given-name>Jörg</given-name><initials>J.</initials><afid>60024978</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55837739800</author-url><authid>55837739800</authid><authname>Shakya B.</authname><surname>Shakya</surname><given-name>Binita</given-name><initials>B.</initials><afid>60024978</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004120416</author-url><authid>7004120416</authid><authname>Sundquist W.</authname><surname>Sundquist</surname><given-name>Wesley I.</given-name><initials>W.I.</initials><afid>60024978</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7403558854</author-url><authid>7403558854</authid><authname>Hill C.</authname><surname>Hill</surname><given-name>Christopher P.</given-name><initials>C.P.</initials><afid>60024978</afid></author><intid>1536049518</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930193175"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930193175?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930193175&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930193175&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1290072914003202"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930193175</prism:url><dc:identifier>SCOPUS_ID:84930193175</dc:identifier><eid>2-s2.0-84930193175</eid><dc:title>Clinical assessment of Shenfu injection loading in the treatment of patients with exacerbation of chronic heart failure due to coronary heart disease: Study protocol for a randomized controlled trial</dc:title><dc:creator>Liu C.</dc:creator><prism:publicationName>Trials</prism:publicationName><prism:eIssn>17456215</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>May 21, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13063-015-0729-7</prism:doi><dc:description>© Liu et al.; licensee BioMed Central. Background: Acute exacerbation is a common cause of hospitalization in patients with chronic heart failure, and coronary heart disease is the most common cause. Shenfu injection, a Traditional Chinese Medicine injection, widely used in the adjuvant treatment of patients with acute exacerbation of chronic heart failure, shows some treatment effect in improving the symptoms and the quality of life, but it lacks the rigorous clinical evaluation of research reports. This paper describes the protocol for the clinical assessment of Shenfu injection loading in the treatment of patients with acute exacerbation of chronic heart failure. Methods: This protocol adopts the design of a prospective, randomized, multicenter, blind imitation, placebo-controlled trial to assess the efficacy and safety of Shenfu injection loading in the treatment of patients with acute exacerbation of chronic heart failure due to coronary heart disease. The research will be carried out in 12 hospitals in China and is expected to enroll 160 inpatients with acute exacerbation of chronic heart failure due to coronary heart disease (yang and qi deficiency syndrome). On the basis of the conventional therapy of western medicine, patients will be randomized to either the treatment group (100 ml 5% glucose injection + 50 ml Shenfu injection) or the control group (150 ml 5% glucose injection) for 7 ± 1 days and follow-up for 28 ± 3 days. The primary outcomes are New York Heart Association cardiac function classification and Traditional Chinese Medicine syndromes. The secondary outcomes are left ventricular ejection fraction, brain natriuretic peptide level, Lee's heart failure score, 6-minute walking distance, and the incidence and readmission rate of cardiovascular events (including the emergency rate due to acute exacerbation of chronic heart failure). Discussion: This trial will assess the effect of loading Shenfu injection in the treatment of patients with acute exacerbation of chronic heart failure caused by coronary heart disease (yang-qi deficiency syndrome) on the symptoms and signs of heart failure, exercise tolerance, and other aspects, and observe its influence on the short-term prognosis with follow-up. The results of the study will provide clinical research evidence for application of Shenfu injection in the treatment. Trial registration: This trial was registered on 26 December 2012 at the Chinese Clinical Trials Register (Identifier: ChiCTR-TRC-12002857).</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012594</affiliation-url><afid>60012594</afid><affilname>Tianjin University of Traditional Chinese Medicine</affilname><name-variant>Tianjin University of Traditional Chinese Medicine</name-variant><affiliation-city>Tianjin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012594</affiliation-url><afid>60012594</afid><affilname>Tianjin University of Traditional Chinese Medicine</affilname><name-variant>Tianjin University of Traditional Chinese Medicine</name-variant><affiliation-city>Tianjin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012594</affiliation-url><afid>60012594</afid><affilname>Tianjin University of Traditional Chinese Medicine</affilname><name-variant>Tianjin University of Traditional Chinese Medicine</name-variant><affiliation-city>Tianjin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016424</affiliation-url><afid>60016424</afid><affilname>Beijing University of Chinese Medicine</affilname><name-variant>Beijing University of Traditional Chinese Medicine</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012594</affiliation-url><afid>60012594</afid><affilname>Tianjin University of Traditional Chinese Medicine</affilname><name-variant>Tianjin University of Traditional Chinese Medicine</name-variant><affiliation-city>Tianjin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36677696800</author-url><authid>36677696800</authid><authname>Liu C.</authname><surname>Liu</surname><given-name>Chunxiang</given-name><initials>C.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36677696800</author-url><authid>36677696800</authid><authname>Liu C.</authname><surname>Liu</surname><given-name>Chunxiang</given-name><initials>C.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35317359900</author-url><authid>35317359900</authid><authname>Hou Y.</authname><surname>Hou</surname><given-name>Yazhu</given-name><initials>Y.</initials><afid>60012594</afid><afid>60012594</afid><afid>60012594</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35317359900</author-url><authid>35317359900</authid><authname>Hou Y.</authname><surname>Hou</surname><given-name>Yazhu</given-name><initials>Y.</initials><afid>60012594</afid><afid>60012594</afid><afid>60012594</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35317359900</author-url><authid>35317359900</authid><authname>Hou Y.</authname><surname>Hou</surname><given-name>Yazhu</given-name><initials>Y.</initials><afid>60012594</afid><afid>60012594</afid><afid>60012594</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36678350600</author-url><authid>36678350600</authid><authname>Wang X.</authname><surname>Wang</surname><given-name>Xianliang</given-name><initials>X.</initials><afid>60012594</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55492334800</author-url><authid>55492334800</authid><authname>Zhao Z.</authname><surname>Zhao</surname><given-name>Zhiqiang</given-name><initials>Z.</initials><afid>60012594</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56395653700</author-url><authid>56395653700</authid><authname>Liu Z.</authname><surname>Liu</surname><given-name>Zhi</given-name><initials>Z.</initials><afid>60012594</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55621610500</author-url><authid>55621610500</authid><authname>Zhai J.</authname><surname>Zhai</surname><given-name>Jingbo</given-name><initials>J.</initials><afid>60012594</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35318585600</author-url><authid>35318585600</authid><authname>Mao J.</authname><surname>Mao</surname><given-name>Jingyuan</given-name><initials>J.</initials><afid>60012594</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:14519684100</author-url><authid>14519684100</authid><authname>Shang H.</authname><surname>Shang</surname><given-name>Hongcai</given-name><initials>H.</initials><afid>60012594</afid><afid>60016424</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:14519684100</author-url><authid>14519684100</authid><authname>Shang H.</authname><surname>Shang</surname><given-name>Hongcai</given-name><initials>H.</initials><afid>60012594</afid><afid>60016424</afid></author><authkeywords>Acute heart failure | Shenfu injection | Traditional Chinese medicine</authkeywords><intid>1536088182</intid><article-number>222</article-number><source-id>4700151726</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929688608"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929688608?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929688608&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929688608&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929688608</prism:url><dc:identifier>SCOPUS_ID:84929688608</dc:identifier><eid>2-s2.0-84929688608</eid><dc:title>Temporal dynamics of the circadian heart rate following low and high volume exercise training in sedentary male subjects</dc:title><dc:creator>Jelinek H.</dc:creator><prism:publicationName>European Journal of Applied Physiology</prism:publicationName><prism:issn>14396319</prism:issn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00421-015-3185-x</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg Purpose: Increased risk of arrhythmic events occurs at certain times during the circadian cycle with the highest risk being in the second and fourth quarter of the day. Exercise improves treatment outcome in individuals with cardiovascular disease. How different exercise protocols affect the circadian rhythm and the associated decrease in adverse cardiovascular risk over the circadian cycle has not been shown. Methods: Fifty sedentary male participants were randomized into an 8-week high volume and moderate volume training and a control group. Heart rate was recorded using Polar Electronics and investigated with Cosinor analysis and by Poincaré plot derived features of SD1, SD2 and the complex correlation measure (CCM) at 1-h intervals over the 24-h period. Results: Moderate exercise significantly increased vagal modulation and the temporal dynamics of the heart rate in the second quarter of the circadian cycle (p = 0.004 and p = 0.007 respectively). High volume exercise had a similar effect on vagal output (p = 0.003) and temporal dynamics (p = 0.003). Cosinor analysis confirms that the circadian heart rate displays a shift in the acrophage following moderate and high volume exercise from before waking (1st quarter) to after waking (2nd quarter of day). Conclusions: Our results suggest that exercise shifts vagal influence and increases temporal dynamics of the heart rate to the 2nd quarter of the day and suggest that this may be the underlying physiological change leading to a decrease in adverse arrhythmic events during this otherwise high-risk period.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60088314</affiliation-url><afid>60088314</afid><affilname>Macquarie University, Australian School of Advanced Medicine</affilname><name-variant>Macquarie University</name-variant><affiliation-city/><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001248</affiliation-url><afid>60001248</afid><affilname>Charles Sturt University</affilname><name-variant>Charles Sturt University</name-variant><affiliation-city>Bathurst</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026553</affiliation-url><afid>60026553</afid><affilname>University of Melbourne</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Parkville</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60081130</affiliation-url><afid>60081130</afid><affilname>Verve</affilname><name-variant>Verve Research</name-variant><affiliation-city>Oulu</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012954</affiliation-url><afid>60012954</afid><affilname>Oulun Yliopisto</affilname><name-variant>University of Oulu</name-variant><affiliation-city>Oulu</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104134</affiliation-url><afid>60104134</afid><affilname>Khalifa University</affilname><name-variant>Khalifa University</name-variant><affiliation-city>Abu Dhabi</affiliation-city><affiliation-country>United Arab Emirates</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6701411651</author-url><authid>6701411651</authid><authname>Jelinek H.</authname><surname>Jelinek</surname><given-name>Herbert F.</given-name><initials>H.F.</initials><afid>60088314</afid><afid>60001248</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6701411651</author-url><authid>6701411651</authid><authname>Jelinek H.</authname><surname>Jelinek</surname><given-name>Herbert F.</given-name><initials>H.F.</initials><afid>60088314</afid><afid>60001248</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35615801900</author-url><authid>35615801900</authid><authname>Karmakar C.</authname><surname>Karmakar</surname><given-name>C.</given-name><initials>C.</initials><afid>60026553</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602509636</author-url><authid>6602509636</authid><authname>Kiviniemi A.</authname><surname>Kiviniemi</surname><given-name>A. M.</given-name><initials>A.M.</initials><afid>60081130</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701667110</author-url><authid>6701667110</authid><authname>Hautala A.</authname><surname>Hautala</surname><given-name>A. J.</given-name><initials>A.J.</initials><afid>60081130</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701317969</author-url><authid>6701317969</authid><authname>Tulppo M.</authname><surname>Tulppo</surname><given-name>M. P.</given-name><initials>M.P.</initials><afid>60081130</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56540088300</author-url><authid>56540088300</authid><authname>Mäkikallio T.</authname><surname>Mäkikallio</surname><given-name>T. H.</given-name><initials>T.H.</initials><afid>60012954</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:14121483000</author-url><authid>14121483000</authid><authname>Huikuri H.</authname><surname>Huikuri</surname><given-name>H. V.</given-name><initials>H.V.</initials><afid>60012954</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:23091108200</author-url><authid>23091108200</authid><authname>Khandoker A.</authname><surname>Khandoker</surname><given-name>A. H.</given-name><initials>A.H.</initials><afid>60026553</afid><afid>60104134</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:23091108200</author-url><authid>23091108200</authid><authname>Khandoker A.</authname><surname>Khandoker</surname><given-name>A. H.</given-name><initials>A.H.</initials><afid>60026553</afid><afid>60104134</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7005048570</author-url><authid>7005048570</authid><authname>Palaniswami M.</authname><surname>Palaniswami</surname><given-name>M.</given-name><initials>M.</initials><afid>60026553</afid></author><authkeywords>Circadian | Cosinor modeling | Exercise | Heart rate variability</authkeywords><intid>35996518</intid><source-id>23402</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929698551"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929698551?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929698551&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929698551&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929698551</prism:url><dc:identifier>SCOPUS_ID:84929698551</dc:identifier><eid>2-s2.0-84929698551</eid><dc:title>Inward rectifier potassium current (I&lt;inf&gt;K1&lt;/inf&gt;) and Kir2 composition of the zebrafish (Danio rerio) heart</dc:title><dc:creator>Hassinen M.</dc:creator><prism:publicationName>Pflugers Archiv European Journal of Physiology</prism:publicationName><prism:issn>00316768</prism:issn><prism:eIssn>14322013</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00424-015-1710-8</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg Electrophysiological properties and molecular background of the zebrafish (Danio rerio) cardiac inward rectifier current (I&lt;inf&gt;K1&lt;/inf&gt;) were examined. Ventricular myocytes of zebrafish have a robust (−6.7 ± 1.2 pA pF&lt;sup&gt;−1&lt;/sup&gt; at −120 mV) strongly rectifying and Ba&lt;sup&gt;2+&lt;/sup&gt;-sensitive (IC&lt;inf&gt;50&lt;/inf&gt; = 3.8 μM) I&lt;inf&gt;K1&lt;/inf&gt;. Transcripts of six Kir2 channels (drKir2.1a, drKir2.1b, drKir2.2a, drKir2.2b, drKir2.3, and drKir2.4) were expressed in the zebrafish heart. drKir2.4 and drKir2.2a were the dominant isoforms in both the ventricle (92.9 ± 1.5 and 6.3 ± 1.5 %) and the atrium (28.9 ± 2.9 and 64.7 ± 3.0 %). The remaining four channels comprised together less than 1 and 7 % of the total transcripts in ventricle and atrium, respectively. The four main gene products (drKir2.1a, drKir2.2a, drKir2.2b, drKir2.4) were cloned, sequenced, and expressed in HEK cells for electrophysiological characterization. drKir2.1a was the most weakly rectifying (passed more outward current) and drKir2.2b the most strongly rectifying (passed less outward current) channel, whilst drKir2.2a and drKir2.4 were intermediate between the two. In regard to sensitivity to Ba&lt;sup&gt;2+&lt;/sup&gt; block, drKir2.4 was the most sensitive (IC&lt;inf&gt;50&lt;/inf&gt; = 1.8 μM) and drKir2.1a the least sensitive channel (IC&lt;inf&gt;50&lt;/inf&gt; = 132 μM). These findings indicate that the Kir2 isoform composition of the zebrafish heart markedly differs from that of mammalian hearts. Furthermore orthologous Kir2 channels (Kir2.1 and Kir2.4) of zebrafish and mammals show striking differences in Ba&lt;sup&gt;2+&lt;/sup&gt;-sensitivity. Structural and functional differences needs to be taken into account when zebrafish is used as a model for human cardiac electrophysiology, cardiac diseases, and in screening cardioactive substances.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103673</affiliation-url><afid>60103673</afid><affilname>Ita-Suomen yliopisto</affilname><name-variant>University of Eastern Finland</name-variant><affiliation-city>Kuopio</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003771</affiliation-url><afid>60003771</afid><affilname>University of Manchester</affilname><name-variant>University of Manchester</name-variant><affiliation-city>Manchester</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8970577800</author-url><authid>8970577800</authid><authname>Hassinen M.</authname><surname>Hassinen</surname><given-name>Minna</given-name><initials>M.</initials><afid>60103673</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:12760794000</author-url><authid>12760794000</authid><authname>Haverinen J.</authname><surname>Haverinen</surname><given-name>Jaakko</given-name><initials>J.</initials><afid>60103673</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56653061800</author-url><authid>56653061800</authid><authname>Hardy M.</authname><surname>Hardy</surname><given-name>Matt E.</given-name><initials>M.E.</initials><afid>60003771</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701595390</author-url><authid>6701595390</authid><authname>Shiels H.</authname><surname>Shiels</surname><given-name>Holly A.</given-name><initials>H.A.</initials><afid>60003771</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005037255</author-url><authid>7005037255</authid><authname>Vornanen M.</authname><surname>Vornanen</surname><given-name>Matti</given-name><initials>M.</initials><afid>60103673</afid></author><authkeywords>Heart | Inward rectifier potassium current | Kir2 channel | Zebrafish</authkeywords><intid>35997024</intid><source-id>17025</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929688197"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929688197?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929688197&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929688197&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929688197</prism:url><dc:identifier>SCOPUS_ID:84929688197</dc:identifier><eid>2-s2.0-84929688197</eid><dc:title>Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT&lt;inf&gt;1&lt;/inf&gt;/AT&lt;inf&gt;2&lt;/inf&gt; Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart</dc:title><dc:creator>Zhang L.</dc:creator><prism:publicationName>Cardiovascular Drugs and Therapy</prism:publicationName><prism:issn>09203206</prism:issn><prism:eIssn>15737241</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10557-015-6592-7</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Purpose: The glucagon-like peptide-1 (GLP-1) has been shown to exert cardioprotective effects in animals and patients. This study tests the hypothesis that preservation of GLP-1 by the GLP-1 receptor agonist liraglutide or the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is associated with a reduction of angiotensin (Ang) II-induced cardiac fibrosis. Methods and Results: Sprague–Dawley rats were subjected to Ang II (500 ng/kg/min) infusion using osmotic minipumps for 4 weeks. Liraglutide (0.3 mg/kg) was subcutaneously injected twice daily or linagliptin (8 mg/kg) was administered via oral gavage daily during Ang II infusion. Relative to the control, liraglutide, but not linagliptin decreased MAP (124 ± 4 vs. 200 ± 7 mmHg in control, p &lt; 0.003). Liraglutide and linagliptin comparatively reduced the protein level of the Ang II AT&lt;inf&gt;1&lt;/inf&gt; receptor and up-regulated the AT&lt;inf&gt;2&lt;/inf&gt; receptor as identified by a reduced AT&lt;inf&gt;1&lt;/inf&gt;/AT&lt;inf&gt;2&lt;/inf&gt; ratio (0.4 ± 0.02 and 0.7 ± 0.01 vs. 1.4 ± 0.2 in control, p &lt; 0.05), coincident with the less locally-expressed AT&lt;inf&gt;1&lt;/inf&gt; receptor and enhanced AT&lt;inf&gt;2&lt;/inf&gt; receptor in the myocardium and peri-coronary vessels. Both drugs significantly reduced the populations of macrophages (16 ± 6 and 19 ± 7 vs. 61 ± 29 number/HPF in control, p &lt; 0.05) and α-SMA expressing myofibroblasts (17 ± 7 and 13 ± 4 vs. 66 ± 29 number/HPF in control, p &lt; 0.05), consistent with the reduction in expression of TGFβ1 and phospho-Smad2/3, and up-regulation of Smad7. Furthermore, ACE2 activity (334 ± 43 and 417 ± 51 vs. 288 ± 19 RFU/min/μg protein in control, p &lt; 0.05) and GLP-1 receptor expression were significantly up-regulated. Along with these modulations, the synthesis of collagen I and tissue fibrosis were inhibited as determined by the smaller collagen-rich area and more viable myocardium. Conclusion: These results demonstrate for the first time that preservation of GLP-1 using liraglutide or linagliptin is effective in inhibiting Ang II-induced cardiac fibrosis, suggesting that these drugs could be selected as an adjunctive therapy to improve clinical outcomes in the fibrosis-derived heart failure patients with or without diabetes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000338</affiliation-url><afid>60000338</afid><affilname>Shanxi Medical University</affilname><name-variant>Shanxi Medical University</name-variant><affiliation-city>Taiyuan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000338</affiliation-url><afid>60000338</afid><affilname>Shanxi Medical University</affilname><name-variant>Shanxi Medical University</name-variant><affiliation-city>Taiyuan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026005</affiliation-url><afid>60026005</afid><affilname>Mercer University School of Medicine</affilname><name-variant>Mercer University School of Medicine</name-variant><affiliation-city>Macon</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026005</affiliation-url><afid>60026005</afid><affilname>Mercer University School of Medicine</affilname><name-variant>Mercer University School of Medicine</name-variant><affiliation-city>Macon</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026005</affiliation-url><afid>60026005</afid><affilname>Mercer University School of Medicine</affilname><name-variant>Mercer University School of Medicine</name-variant><affiliation-city>Macon</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55972780900</author-url><authid>55972780900</authid><authname>Zhang L.</authname><surname>Zhang</surname><given-name>Li Hui</given-name><initials>L.H.</initials><afid>60000338</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55503357800</author-url><authid>55503357800</authid><authname>Pang X.</authname><surname>Pang</surname><given-name>Xue Fen</given-name><initials>X.F.</initials><afid>60000338</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55503131500</author-url><authid>55503131500</authid><authname>Bai F.</authname><surname>Bai</surname><given-name>Feng</given-name><initials>F.</initials><afid>60000338</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56431695800</author-url><authid>56431695800</authid><authname>Wang N.</authname><surname>Wang</surname><given-name>Ning Ping</given-name><initials>N.P.</initials><afid>60026005</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56652919000</author-url><authid>56652919000</authid><authname>Shah A.</authname><surname>Shah</surname><given-name>Ahmed Ijaz</given-name><initials>A.I.</initials><afid>60026005</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602588532</author-url><authid>6602588532</authid><authname>McKallip R.</authname><surname>McKallip</surname><given-name>Robert J.</given-name><initials>R.J.</initials><afid>60026005</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56652829500</author-url><authid>56652829500</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xue Wen</given-name><initials>X.W.</initials><afid>60000338</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56653541600</author-url><authid>56653541600</authid><authname>Wang X.</authname><surname>Wang</surname><given-name>Xiong</given-name><initials>X.</initials><afid>60000338</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7404148302</author-url><authid>7404148302</authid><authname>Zhao Z.</authname><surname>Zhao</surname><given-name>Zhi Qing</given-name><initials>Z.Q.</initials><afid>60000338</afid><afid>60026005</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7404148302</author-url><authid>7404148302</authid><authname>Zhao Z.</authname><surname>Zhao</surname><given-name>Zhi Qing</given-name><initials>Z.Q.</initials><afid>60000338</afid><afid>60026005</afid></author><authkeywords>ACE2 | Angiotensin II receptors | Cardiac fibrosis | Collagen | Dipeptidyl peptidase-4 | Glucagon-like peptide-1</authkeywords><intid>535999311</intid><source-id>22552</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929678317"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929678317?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929678317&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929678317&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929678317</prism:url><dc:identifier>SCOPUS_ID:84929678317</dc:identifier><eid>2-s2.0-84929678317</eid><dc:title>Sedation and Anesthesia in Pediatric and Congenital Cardiac Catheterization: A Prospective Multicenter Experience</dc:title><dc:creator>Lin C.</dc:creator><prism:publicationName>Pediatric Cardiology</prism:publicationName><prism:issn>01720643</prism:issn><prism:eIssn>14321971</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00246-015-1167-8</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Sedation/anesthesia is critical to cardiac catheterization in the pediatric/congenital heart patient. We sought to identify current sedation/anesthesia practices, the serious adverse event rate related to airway, sedation, or anesthesia, and the rate of intra-procedural conversion from procedural sedation to the use of assisted ventilation or an artificial airway. Data from 13,611 patients who underwent catheterization at eight institutions were prospectively collected from 2007 to 2010. Ninety-four (0.69 %) serious sedation/airway-related adverse events occurred; events were more likely to occur in smaller patients (&lt;4 kg, OR 4.4, 95 % CI 2.3–8.2, p &lt; 0.001), patients with non-cardiac comorbidities (OR 1.7, 95 % CI 1.1–26, p &lt; 0.01), and patients with low mixed venous oxygen saturation (OR 2.3, 95 % CI 1.4–3.6, p &lt; 0.001). Nine thousand three hundred and seventy-nine (69 %) patients were initially managed with general endotracheal anesthesia, LMA, or tracheostomy, whereas 4232 (31 %) were managed with procedural sedation without an artificial airway, of which 75 (1.77 %) patients were converted to assisted ventilation/general anesthesia. Young age (&lt;12 months, OR 5.2, 95 % CI 2.3–11.4, p &lt; 0.001), higher-risk procedure (category 4, OR 10.1, 95 % CI 6.5–15.6, p &lt; 0.001), and continuous pressor/inotrope requirement (OR 11.0, 95 % CI 8.6–14.0, p &lt; 0.001) were independently associated with conversion. Cardiac catheterization in pediatric/congenital patients was associated with a low rate of serious sedation/airway-related adverse events. Smaller patients with non-cardiac comorbidities or low mixed venous oxygen saturation may be at higher risk. Patients under 1 year of age, undergoing high-risk procedures, or requiring continuous pressor/inotrope support may be at higher risk of requiring conversion from procedural sedation to assisted ventilation/general anesthesia.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112770264</affiliation-url><afid>112770264</afid><affilname>DeBakey Heart and Vascular Center</affilname><name-variant>Methodist DeBakey Heart and Vascular Center</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030118</affiliation-url><afid>60030118</afid><affilname>The Children's Hospital of Philadelphia</affilname><name-variant>The Children's Hospital of Philadelphia</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029607</affiliation-url><afid>60029607</afid><affilname>St. Louis Children's Hospital</affilname><name-variant>St. Louis Children's Hospital</name-variant><affiliation-city>St Louis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030521</affiliation-url><afid>60030521</afid><affilname>Children's Hospital Boston</affilname><name-variant>Children's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008666</affiliation-url><afid>60008666</afid><affilname>Children's Hospital of Wisconsin Wauwatosa</affilname><name-variant>Children's Hospital of Wisconsin</name-variant><affiliation-city>Wauwatosa</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016733</affiliation-url><afid>60016733</afid><affilname>Oregon Health and Science University</affilname><name-variant>Oregon Health and Science University</name-variant><affiliation-city>Portland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008319</affiliation-url><afid>60008319</afid><affilname>Morgan Stanley</affilname><name-variant>Morgan Stanley Children's Hospital of New York-Presbyterian</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002645</affiliation-url><afid>60002645</afid><affilname>Rady Children's Hospital</affilname><name-variant>Rady Children's Hospital</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030440</affiliation-url><afid>60030440</afid><affilname>Cincinnati Children's Hospital Medical Center</affilname><name-variant>Children's Hospital Medical Center</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000076</affiliation-url><afid>60000076</afid><affilname>Children's Hospital Columbus</affilname><name-variant>Columbus Children's Hospital</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005708</affiliation-url><afid>60005708</afid><affilname>University of Pittsburgh Medical Center, Children's Hospital of Pittsburgh</affilname><name-variant>University of Pittsburgh</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">18</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37001035300</author-url><authid>37001035300</authid><authname>Lin C.</authname><surname>Lin</surname><given-name>C. Huie</given-name><initials>C.H.</initials><afid>112770264</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56340029800</author-url><authid>56340029800</authid><authname>Desai S.</authname><surname>Desai</surname><given-name>Sanyukta</given-name><initials>S.</initials><afid>60030118</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7004273678</author-url><authid>7004273678</authid><authname>Nicolas R.</authname><surname>Nicolas</surname><given-name>Ramzi</given-name><initials>R.</initials><afid>60029607</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004245260</author-url><authid>7004245260</authid><authname>Gauvreau K.</authname><surname>Gauvreau</surname><given-name>Kimberlee</given-name><initials>K.</initials><afid>60030521</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24381821500</author-url><authid>24381821500</authid><authname>Foerster S.</authname><surname>Foerster</surname><given-name>Susan</given-name><initials>S.</initials><afid>60008666</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56652831800</author-url><authid>56652831800</authid><authname>Sharma A.</authname><surname>Sharma</surname><given-name>Anshuman</given-name><initials>A.</initials><afid>60029607</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6507471443</author-url><authid>6507471443</authid><authname>Armsby L.</authname><surname>Armsby</surname><given-name>Laurie</given-name><initials>L.</initials><afid>60016733</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7401645583</author-url><authid>7401645583</authid><authname>Marshall A.</authname><surname>Marshall</surname><given-name>Audrey C.</given-name><initials>A.C.</initials><afid>60030521</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6602753538</author-url><authid>6602753538</authid><authname>Odegard K.</authname><surname>Odegard</surname><given-name>Kirsten</given-name><initials>K.</initials><afid>60030521</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7003972410</author-url><authid>7003972410</authid><authname>DiNardo J.</authname><surname>DiNardo</surname><given-name>James</given-name><initials>J.</initials><afid>60030521</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7403123589</author-url><authid>7403123589</authid><authname>Vincent J.</authname><surname>Vincent</surname><given-name>Julie</given-name><initials>J.</initials><afid>60008319</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6602137289</author-url><authid>6602137289</authid><authname>El-Said H.</authname><surname>El-Said</surname><given-name>Howaida</given-name><initials>H.</initials><afid>60002645</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56653181300</author-url><authid>56653181300</authid><authname>Spaeth J.</authname><surname>Spaeth</surname><given-name>James</given-name><initials>J.</initials><afid>60030440</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:35487454500</author-url><authid>35487454500</authid><authname>Goldstein B.</authname><surname>Goldstein</surname><given-name>Bryan</given-name><initials>B.</initials><afid>60030440</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7005783518</author-url><authid>7005783518</authid><authname>Holzer R.</authname><surname>Holzer</surname><given-name>Ralf</given-name><initials>R.</initials><afid>60000076</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:7006891657</author-url><authid>7006891657</authid><authname>Kreutzer J.</authname><surname>Kreutzer</surname><given-name>Jackie</given-name><initials>J.</initials><afid>60005708</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:7006466154</author-url><authid>7006466154</authid><authname>Balzer D.</authname><surname>Balzer</surname><given-name>David</given-name><initials>D.</initials><afid>60029607</afid></author><author seq="18"><author-url>http://api.elsevier.com/content/author/author_id:6602348674</author-url><authid>6602348674</authid><authname>Bergersen L.</authname><surname>Bergersen</surname><given-name>Lisa</given-name><initials>L.</initials><afid>60030521</afid></author><authkeywords>Anesthesia | Angioplasty | Catheterization | Congenital | Heart defects | Pediatrics</authkeywords><intid>1785998145</intid><source-id>20526</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929688170"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929688170?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929688170&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929688170&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929688170</prism:url><dc:identifier>SCOPUS_ID:84929688170</dc:identifier><eid>2-s2.0-84929688170</eid><dc:title>Four-year cardiac magnetic resonance (CMR) follow-up of patients treated with percutaneous pulmonary valve stent implantation</dc:title><dc:creator>Secchi F.</dc:creator><prism:publicationName>European Radiology</prism:publicationName><prism:issn>09387994</prism:issn><prism:eIssn>14321084</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00330-015-3781-5</prism:doi><dc:description>© 2015 European Society of Radiology Objectives: To investigate follow-up after percutaneous pulmonary valve implantation (PPVI). Methods: Forty patients with pulmonary conduit dysfunction (males/females 24/16; 21 ± 08 years; 12 tetralogy of Fallot, 11 aortic valve disease, 17 other congenital heart disease) were planned for CMR before PPVI and repeated 7 times up to 48 months. CMR prospective results regarded: pressure gradient (PG) and regurgitation fraction (RF); end-diastolic volume, end-systolic volume, and stroke volume indexed to body surface area (EDVI, ESVI, and SVI); ejection fraction (EF) of right and left ventricles (RV, LV). A Friedman test was used for comparisons. Results: Overall, PG (31 ± 06 to 16 ± 4 mmHg), RF (16 ± 17 to 0.3 ± 1 %), RVEDVI (82 ± 38 to 58 ± 12 ml/m&lt;sup&gt;2&lt;/sup&gt;), and RVESVI (44 ± 12 to 30 ± 13 ml/m&lt;sup&gt;2&lt;/sup&gt;) declined (p &lt; 0.001), RVEF (49 ± 13 to 58 ± 12 %) and RVSVI (from 38 ± 14 to 40 ± 8 ml/m&lt;sup&gt;2&lt;/sup&gt;) increased (p &lt; 0.001), LVEDVI (67 ± 17 to 73 ± 18 ml/m&lt;sup&gt;2&lt;/sup&gt;) and LVSVI (37 ± 11 to 43 ± 10 ml/m&lt;sup&gt;2&lt;/sup&gt;) increased (p = 0.034 and p &lt; 0.001). Two patients had valve fracture at 24 and 36 months and underwent surgery. One patient had stent restenosis at 24 months and underwent percutaneous retreatment. Baseline/follow-up CMR did not predict PPVI failure. Conclusions: CMR demonstrated restored pulmonary conduit function, reduced RV volumes and increased RV and LV function but did not predict valve fracture/restenosis. Key points: • A CMR 4-year follow-up after PPVI showed restored pulmonary conduit function• RV volumes were significantly reduced• RV function was significantly better in terms of increased EF and SVI• LV function was significantly better in terms of increased EDVI and SVI• Baseline/follow-up CMR did not predict three cases of PPVI failure</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070490</affiliation-url><afid>60070490</afid><affilname>Gruppo Ospedaliero San Donato</affilname><name-variant>IRCCS Policlinico San Donato</name-variant><affiliation-city>San Donato Milanese</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030318</affiliation-url><afid>60030318</afid><affilname>Universita degli Studi di Milano</affilname><name-variant>University of Milan</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113023339</affiliation-url><afid>113023339</afid><affilname>Azienda Ospedaliera San Paolo</affilname><name-variant>Azienda Ospedaliera San Paolo</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070490</affiliation-url><afid>60070490</afid><affilname>Gruppo Ospedaliero San Donato</affilname><name-variant>IRCCS Policlinico San Donato</name-variant><affiliation-city>San Donato Milanese</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030318</affiliation-url><afid>60030318</afid><affilname>Universita degli Studi di Milano</affilname><name-variant>University of Milan</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603114086</author-url><authid>6603114086</authid><authname>Secchi F.</authname><surname>Secchi</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60070490</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506919100</author-url><authid>6506919100</authid><authname>Resta E.</authname><surname>Resta</surname><given-name>Elda Chiara</given-name><initials>E.C.</initials><afid>60030318</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55934536800</author-url><authid>55934536800</authid><authname>Cannaò P.</authname><surname>Cannaò</surname><given-name>Paola Maria</given-name><initials>P.M.</initials><afid>60030318</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:14020735600</author-url><authid>14020735600</authid><authname>Tresoldi S.</authname><surname>Tresoldi</surname><given-name>Silvia</given-name><initials>S.</initials><afid>113023339</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005107297</author-url><authid>7005107297</authid><authname>Butera G.</authname><surname>Butera</surname><given-name>Gianfranco</given-name><initials>G.</initials><afid>60070490</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006583186</author-url><authid>7006583186</authid><authname>Carminati M.</authname><surname>Carminati</surname><given-name>Mario</given-name><initials>M.</initials><afid>60070490</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006400410</author-url><authid>7006400410</authid><authname>Sardanelli F.</authname><surname>Sardanelli</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60070490</afid><afid>60030318</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006400410</author-url><authid>7006400410</authid><authname>Sardanelli F.</authname><surname>Sardanelli</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60070490</afid><afid>60030318</afid></author><authkeywords>Cardiac magnetic resonance | Congenital heart disease | Percutaneous pulmonary valve implantation | Pulmonary conduit | Right and left ventricles</authkeywords><intid>1535998257</intid><source-id>16687</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930203252"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930203252?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930203252&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930203252&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930203252</prism:url><dc:identifier>SCOPUS_ID:84930203252</dc:identifier><eid>2-s2.0-84930203252</eid><dc:title>Erratum: Mesenchymal stem cell pretreatment of non-heart-beating-donors in experimental lung transplantation [J Cardiothorac Surg. 9, (2014), 151]</dc:title><dc:creator>Wittwer T.</dc:creator><prism:publicationName>Journal of Cardiothoracic Surgery</prism:publicationName><prism:eIssn>17498090</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>May 21, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13019-014-0198-1</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024025</affiliation-url><afid>60024025</afid><affilname>Universitat zu Koln</affilname><name-variant>Universität zu Köln</name-variant><affiliation-city>Koln</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024025</affiliation-url><afid>60024025</afid><affilname>Universitat zu Koln</affilname><name-variant>Universität zu Köln</name-variant><affiliation-city>Koln</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024052</affiliation-url><afid>60024052</afid><affilname>Medizinische Hochschule Hannover (MHH)</affilname><name-variant>Hannover Medical School</name-variant><affiliation-city>Hannover</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113768612</affiliation-url><afid>113768612</afid><affilname>Cluster of Excellence REBIRTH (From Regenerative Biology to Reconstructive Therapy)</affilname><name-variant>Cluster of Excellence Rebirth (From Regenerative Biology to Reconstructive Therapy)</name-variant><affiliation-city>Hannover</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024025</affiliation-url><afid>60024025</afid><affilname>Universitat zu Koln</affilname><name-variant>Universität zu Köln</name-variant><affiliation-city>Koln</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>er</subtype><subtypeDescription>Erratum</subtypeDescription><author-count limit="100">22</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003801440</author-url><authid>7003801440</authid><authname>Wittwer T.</authname><surname>Wittwer</surname><given-name>Thorsten</given-name><initials>T.</initials><afid>60024025</afid><afid>60024025</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003801440</author-url><authid>7003801440</authid><authname>Wittwer T.</authname><surname>Wittwer</surname><given-name>Thorsten</given-name><initials>T.</initials><afid>60024025</afid><afid>60024025</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:14007936100</author-url><authid>14007936100</authid><authname>Rahmanian P.</authname><surname>Rahmanian</surname><given-name>Parwis</given-name><initials>P.</initials><afid>60024025</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14008276900</author-url><authid>14008276900</authid><authname>Choi Y.</authname><surname>Choi</surname><given-name>Yeong Hoon</given-name><initials>Y.H.</initials><afid>60024025</afid><afid>60024025</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14008276900</author-url><authid>14008276900</authid><authname>Choi Y.</authname><surname>Choi</surname><given-name>Yeong Hoon</given-name><initials>Y.H.</initials><afid>60024025</afid><afid>60024025</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6506399801</author-url><authid>6506399801</authid><authname>Zeriouh M.</authname><surname>Zeriouh</surname><given-name>Mohamed</given-name><initials>M.</initials><afid>60024025</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56389559200</author-url><authid>56389559200</authid><authname>Karavidic S.</authname><surname>Karavidic</surname><given-name>Samira</given-name><initials>S.</initials><afid>60024025</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:15734145500</author-url><authid>15734145500</authid><authname>Neef K.</authname><surname>Neef</surname><given-name>Klaus</given-name><initials>K.</initials><afid>60024025</afid><afid>60024025</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:15734145500</author-url><authid>15734145500</authid><authname>Neef K.</authname><surname>Neef</surname><given-name>Klaus</given-name><initials>K.</initials><afid>60024025</afid><afid>60024025</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56389433300</author-url><authid>56389433300</authid><authname>Christmann A.</authname><surname>Christmann</surname><given-name>Astrid</given-name><initials>A.</initials><afid>60024052</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55773256000</author-url><authid>55773256000</authid><authname>Piatkowski T.</authname><surname>Piatkowski</surname><given-name>Tanja</given-name><initials>T.</initials><afid>60024052</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6603945584</author-url><authid>6603945584</authid><authname>Schnapper A.</authname><surname>Schnapper</surname><given-name>Anke</given-name><initials>A.</initials><afid>60024052</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7006272356</author-url><authid>7006272356</authid><authname>Ochs M.</authname><surname>Ochs</surname><given-name>Matthias</given-name><initials>M.</initials><afid>60024052</afid><afid>113768612</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7006272356</author-url><authid>7006272356</authid><authname>Ochs M.</authname><surname>Ochs</surname><given-name>Matthias</given-name><initials>M.</initials><afid>60024052</afid><afid>113768612</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56243294700</author-url><authid>56243294700</authid><authname>Mühlfeld C.</authname><surname>Mühlfeld</surname><given-name>Christian</given-name><initials>C.</initials><afid>60024052</afid><afid>113768612</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56243294700</author-url><authid>56243294700</authid><authname>Mühlfeld C.</authname><surname>Mühlfeld</surname><given-name>Christian</given-name><initials>C.</initials><afid>60024052</afid><afid>113768612</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:55891320100</author-url><authid>55891320100</authid><authname>Sterner-Kock A.</authname><surname>Sterner-Kock</surname><given-name>Anja</given-name><initials>A.</initials><afid>60024025</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:35867106000</author-url><authid>35867106000</authid><authname>Guschlbauer M.</authname><surname>Guschlbauer</surname><given-name>Maria</given-name><initials>M.</initials><afid>60024025</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:37034043800</author-url><authid>37034043800</authid><authname>Hofmaier F.</authname><surname>Hofmaier</surname><given-name>Florian</given-name><initials>F.</initials><afid>60024025</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:56589683700</author-url><authid>56589683700</authid><authname>Maul A.</authname><surname>Maul</surname><given-name>Alexandra C.</given-name><initials>A.C.</initials><afid>60024025</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:7005549835</author-url><authid>7005549835</authid><authname>Wahlers T.</authname><surname>Wahlers</surname><given-name>Thorsten</given-name><initials>T.</initials><afid>60024025</afid><afid>60024025</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:7005549835</author-url><authid>7005549835</authid><authname>Wahlers T.</authname><surname>Wahlers</surname><given-name>Thorsten</given-name><initials>T.</initials><afid>60024025</afid><afid>60024025</afid></author><intid>1536087310</intid><article-number>75</article-number><source-id>5800179605</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929105102"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929105102?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929105102&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929105102&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929105102</prism:url><dc:identifier>SCOPUS_ID:84929105102</dc:identifier><eid>2-s2.0-84929105102</eid><dc:title>Regional assessment of LV wall in infarcted heart using tagged MRI and cardiac modelling</dc:title><dc:creator>Jahanzad Z.</dc:creator><prism:publicationName>Physics in Medicine and Biology</prism:publicationName><prism:issn>00319155</prism:issn><prism:eIssn>13616560</prism:eIssn><prism:volume>60</prism:volume><prism:issueIdentifier>10</prism:issueIdentifier><prism:pageRange>4015-4031</prism:pageRange><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1088/0031-9155/60/10/4015</prism:doi><dc:description>© 2015 Institute of Physics and Engineering in Medicine. A segmental two-parameter empirical deformable model is proposed for evaluating regional motion abnormality of the left ventricle. Short-axis tagged MRI scans were acquired from 10 healthy subjects and 10 postinfarct patients. Two motion parameters, contraction and rotation, were quantified for each cardiac segment by fitting the proposed model using a non-rigid registration algorithm. The accuracy in motion estimation was compared to a global model approach. Motion parameters extracted from patients were correlated to infarct transmurality assessed with delayed-contrast-enhanced MRI. The proposed segmental model allows markedly improved accuracy in regional motion analysis as compared to the global model for both subject groups (1.22-1.40 mm versus 2.31-2.55 mm error). By end-systole, all healthy segments experienced radial displacement by ∼25-35% of the epicardial radius, whereas the 3 short-axis planes rotated differently (basal: 3.3°; mid: -1° and apical: -4.6°) to create a twisting motion. While systolic contraction showed clear correspondence to infarct transmurality, rotation was nonspecific to either infarct location or transmurality but could indicate the presence of functional abnormality. Regional contraction and rotation derived using this model could potentially aid in the assessment of severity of regional dysfunction of infarcted myocardium.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029157</affiliation-url><afid>60029157</afid><affilname>University of Malaya</affilname><name-variant>University of Malaya</name-variant><affiliation-city>Kuala Lumpur</affiliation-city><affiliation-country>Malaysia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023033</affiliation-url><afid>60023033</afid><affilname>Adnan Menderes Universitesi</affilname><name-variant>Adnan Menderes University</name-variant><affiliation-city>Aydin</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031806</affiliation-url><afid>60031806</afid><affilname>University of Western Australia</affilname><name-variant>University of Western Australia</name-variant><affiliation-city>Perth</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029157</affiliation-url><afid>60029157</afid><affilname>University of Malaya</affilname><name-variant>University of Malaya</name-variant><affiliation-city>Kuala Lumpur</affiliation-city><affiliation-country>Malaysia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029157</affiliation-url><afid>60029157</afid><affilname>University of Malaya</affilname><name-variant>University of Malaya</name-variant><affiliation-city>Kuala Lumpur</affiliation-city><affiliation-country>Malaysia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029157</affiliation-url><afid>60029157</afid><affilname>University of Malaya</affilname><name-variant>University of Malaya</name-variant><affiliation-city>Kuala Lumpur</affiliation-city><affiliation-country>Malaysia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56638487800</author-url><authid>56638487800</authid><authname>Jahanzad Z.</authname><surname>Jahanzad</surname><given-name>Zeinab</given-name><initials>Z.</initials><afid>60029157</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56572416300</author-url><authid>56572416300</authid><authname>Liew Y.</authname><surname>Liew</surname><given-name>Yih Miin</given-name><initials>Y.M.</initials><afid>60029157</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003955325</author-url><authid>7003955325</authid><authname>Bilgen M.</authname><surname>Bilgen</surname><given-name>Mehmet</given-name><initials>M.</initials><afid>60023033</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202581180</author-url><authid>7202581180</authid><authname>McLaughlin R.</authname><surname>McLaughlin</surname><given-name>Robert A.</given-name><initials>R.A.</initials><afid>60031806</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56637861100</author-url><authid>56637861100</authid><authname>Leong C.</authname><surname>Leong</surname><given-name>Chen Onn</given-name><initials>C.O.</initials><afid>60029157</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56572365800</author-url><authid>56572365800</authid><authname>Chee K.</authname><surname>Chee</surname><given-name>Kok Han</given-name><initials>K.H.</initials><afid>60029157</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55736705800</author-url><authid>55736705800</authid><authname>Aziz Y.</authname><surname>Aziz</surname><given-name>Yang Faridah Abdul</given-name><initials>Y.F.A.</initials><afid>60029157</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:24479132000</author-url><authid>24479132000</authid><authname>Ung N.</authname><surname>Ung</surname><given-name>Ngie Min</given-name><initials>N.M.</initials><afid>60029157</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56585276900</author-url><authid>56585276900</authid><authname>Lai K.</authname><surname>Lai</surname><given-name>Khin Wee</given-name><initials>K.W.</initials><afid>60029157</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:43761330600</author-url><authid>43761330600</authid><authname>Ng S.</authname><surname>Ng</surname><given-name>Siew Cheok</given-name><initials>S.C.</initials><afid>60029157</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56459526500</author-url><authid>56459526500</authid><authname>Lim E.</authname><surname>Lim</surname><given-name>Einly</given-name><initials>E.</initials><afid>60029157</afid></author><intid>35900657</intid><source-id>29203</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929465429"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929465429?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929465429&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929465429&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929465429</prism:url><dc:identifier>SCOPUS_ID:84929465429</dc:identifier><eid>2-s2.0-84929465429</eid><dc:title>Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: A meta-analysis of 330,376 patients from 47 landmark studies</dc:title><dc:creator>Hermans M.</dc:creator><prism:publicationName>Cardiovascular Diabetology</prism:publicationName><prism:eIssn>14752840</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>May 21, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12933-015-0226-z</prism:doi><dc:description>© 2015 Hermans et al.; licensee BioMed Central. Background: Diabetes is a major cardiovascular risk factor. However, its influence on the rate of occurrence of cardiovascular (CV) events during a clinical trial that included a diabetes subgroup has not yet been quantified. Aims: To establish equations relating baseline diabetes prevalence and incident CV events, based on comparator arms data of major lipid-modifying trials. Methods: Meta-analysis of primary outcomes (PO) rates of key prospective trials, for which the baseline proportion of diabetics was reported, including studies having specifically reported CV outcomes within their diabetic subgroups. Results: 47 studies, representing 330,376 patients (among whom 124,115 diabetics), were analyzed as regards the relationship between CV outcomes rates (including CHD) and the number of diabetics enrolled. Altogether, a total of 18,445 and 16,156 events occurred in the comparator and treatment arms, respectively. There were significant linear relationships between diabetes prevalence and both PO and CHD rates (%/year): y = 0.0299*x + 3.12 [PO] (p = 0.0128); and y = 0.0531*x + 1.54 [CHD] (p = 0.0094), baseline diabetes predicting PO rates between 3.12 %/year (no diabetic included) and 6.11 %/year (all patients diabetic); and CHD rates between 1.54 %/year (no diabetic) and 6.85 %/year (all patients diabetic). The slopes of the equations did not differ according to whether they were derived from primary or secondary prevention trials. Conclusions: Absolute and relative CV risk associated with diabetes at inclusion can be readily predicted using linear equations relating diabetes prevalence to primary outcomes or CHD rates.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012936</affiliation-url><afid>60012936</afid><affilname>Cliniques Universitaires Saint-Luc, Brussels</affilname><name-variant>Cliniques Universitaires Saint-Luc</name-variant><affiliation-city>Brussels</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072525</affiliation-url><afid>60072525</afid><affilname>Centre Hospitalier et Universitaire de Brazzaville</affilname><name-variant>CHU de Brazzaville</name-variant><affiliation-city>Brazzaville</affiliation-city><affiliation-country>Congo</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072094</affiliation-url><afid>60072094</afid><affilname>University of Abomey-Calavi</affilname><name-variant>Université d'Abomey-Calavi</name-variant><affiliation-city>Cotonou</affiliation-city><affiliation-country>Benin</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012936</affiliation-url><afid>60012936</afid><affilname>Cliniques Universitaires Saint-Luc, Brussels</affilname><name-variant>Cliniques Universitaires Saint-Luc</name-variant><affiliation-city>Brussels</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55604840700</author-url><authid>55604840700</authid><authname>Hermans M.</authname><surname>Hermans</surname><given-name>Michel P.</given-name><initials>M.P.</initials><afid>60012936</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7801393506</author-url><authid>7801393506</authid><authname>Bouenizabila E.</authname><surname>Bouenizabila</surname><given-name>Evariste</given-name><initials>E.</initials><afid>60072525</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:26655283400</author-url><authid>26655283400</authid><authname>Amoussou-guenou D.</authname><surname>Amoussou-guenou</surname><given-name>Daniel K.</given-name><initials>D.K.</initials><afid>60072094</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7401989943</author-url><authid>7401989943</authid><authname>Ahn S.</authname><surname>Ahn</surname><given-name>Sylvie A.</given-name><initials>S.A.</initials><afid>60012936</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7101954099</author-url><authid>7101954099</authid><authname>Rousseau M.</authname><surname>Rousseau</surname><given-name>Michel F.</given-name><initials>M.F.</initials><afid>60012936</afid></author><authkeywords>Cardiovascular | Clinical trial | Coronary heart disease | Diabetes | Lipids | Residual risk</authkeywords><intid>35963652</intid><article-number>60</article-number><source-id>25441</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928940136"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928940136?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928940136&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928940136&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928940136</prism:url><dc:identifier>SCOPUS_ID:84928940136</dc:identifier><eid>2-s2.0-84928940136</eid><dc:title>Fabrication and characterization of optogenetic, multi-strip cardiac muscles</dc:title><dc:creator>Chan V.</dc:creator><prism:publicationName>Lab on a Chip - Miniaturisation for Chemistry and Biology</prism:publicationName><prism:issn>14730197</prism:issn><prism:eIssn>14730189</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>10</prism:issueIdentifier><prism:pageRange>2258-2268</prism:pageRange><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1039/c5lc00222b</prism:doi><dc:description>© The Royal Society of Chemistry 2015. Cardiac tissue engineering aims to recreate functional tissue constructs similar to the structure and function of the native myocardium. To date, in vitro tissue constructs lack the architectural complexity of a vascular network and the precise motor unit control of muscle fibers. Here, we present a method to construct engineered multi-strip cardiac muscle that simulates the bundle-like architecture of the native myocardium. Densely packed primary myocytes and cardiac fibroblasts were co-cultured with optogenetic, non-excitable cells. The resulting 3D syncytium triggered contraction upon localized blue light illumination to selectively activate and pace the multi-strip cardiac muscles, similar to the activity of pacemaker cells. Acting on a single load, we demonstrated graded force production through light-modulated multi-strip recruitment. These results demonstrate an in vitro platform of optogenetic, multi-strip cardiac muscles that can be used in a wide variety of applications, such as drug discovery, tissue engineering, and bio-hybrid robotic systems.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022195</affiliation-url><afid>60022195</afid><affilname>Massachusetts Institute of Technology</affilname><name-variant>Massachusetts Inst. of Technology</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000745</affiliation-url><afid>60000745</afid><affilname>University of Illinois at Urbana-Champaign</affilname><name-variant>University of Illinois</name-variant><affiliation-city>Urbana</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56528953200</author-url><authid>56528953200</authid><authname>Chan V.</authname><surname>Chan</surname><given-name>Vincent</given-name><initials>V.</initials><afid>60022195</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35092836300</author-url><authid>35092836300</authid><authname>Neal D.</authname><surname>Neal</surname><given-name>Devin M.</given-name><initials>D.M.</initials><afid>60022195</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:22942444000</author-url><authid>22942444000</authid><authname>Uzel S.</authname><surname>Uzel</surname><given-name>Sebastien G M</given-name><initials>S.G.M.</initials><afid>60022195</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56204548100</author-url><authid>56204548100</authid><authname>Kim H.</authname><surname>Kim</surname><given-name>Hyeonyu</given-name><initials>H.</initials><afid>60022195</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56637104500</author-url><authid>56637104500</authid><authname>Bashir R.</authname><surname>Bashir</surname><given-name>Rashid</given-name><initials>R.</initials><afid>60000745</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56623991200</author-url><authid>56623991200</authid><authname>Asada H.</authname><surname>Asada</surname><given-name>H. Harry</given-name><initials>H.H.</initials><afid>60022195</afid></author><intid>2035872539</intid><source-id>24738</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930224976"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930224976?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930224976&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930224976&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930224976</prism:url><dc:identifier>SCOPUS_ID:84930224976</dc:identifier><eid>2-s2.0-84930224976</eid><dc:title>Comparative transcriptomic analysis of multiple cardiovascular fates from embryonic stem cells predicts novel regulators in human cardiogenesis</dc:title><dc:creator>Li Y.</dc:creator><prism:publicationName>Scientific Reports</prism:publicationName><prism:eIssn>20452322</prism:eIssn><prism:volume>5</prism:volume><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1038/srep09758</prism:doi><pii>srep09758</pii><dc:description>Dissecting the gene expression programs which control the early stage cardiovascular development is essential for understanding the molecular mechanisms of human heart development and heart disease. Here, we performed transcriptome sequencing (RNA-seq) of highly purified human Embryonic Stem Cells (hESCs), hESC-derived Multipotential Cardiovascular Progenitors (MCPs) and MCP-specified three cardiovascular lineages. A novel algorithm, named as Gene Expression Pattern Analyzer (GEPA), was developed to obtain a refined lineage-specificity map of all sequenced genes, which reveals dynamic changes of transcriptional factor networks underlying early human cardiovascular development. Moreover, our GEPA predictions captured ∼90% of top-ranked regulatory cardiac genes that were previously predicted based on chromatin signature changes in hESCs, and further defined their cardiovascular lineage-specificities, indicating that our multi-fate comparison analysis could predict novel regulatory genes. Furthermore, GEPA analysis revealed the MCP-specific expressions of genes in ephrin signaling pathway, positive role of which in cardiomyocyte differentiation was further validated experimentally. By using RNA-seq plus GEPA workflow, we also identified stage-specific RNA splicing switch and lineage-enriched long non-coding RNAs during human cardiovascular differentiation. Overall, our study utilized multi-cell-fate transcriptomic comparison analysis to establish a lineage-specific gene expression map for predicting and validating novel regulatory mechanisms underlying early human cardiovascular development.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005708</affiliation-url><afid>60005708</afid><affilname>University of Pittsburgh Medical Center, Children's Hospital of Pittsburgh</affilname><name-variant>University of Pittsburgh</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56158172900</author-url><authid>56158172900</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yang</given-name><initials>Y.</initials><afid>60005708</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55278148800</author-url><authid>55278148800</authid><authname>Lin B.</authname><surname>Lin</surname><given-name>Bo</given-name><initials>B.</initials><afid>60005708</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7406279169</author-url><authid>7406279169</authid><authname>Yang L.</authname><surname>Yang</surname><given-name>Lei</given-name><initials>L.</initials><afid>60005708</afid></author><intid>36086079</intid><article-number>9758</article-number><source-id>21100200805</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929094193"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929094193?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929094193&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929094193&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929094193</prism:url><dc:identifier>SCOPUS_ID:84929094193</dc:identifier><eid>2-s2.0-84929094193</eid><dc:title>Dose-mass inverse optimization for minimally moving thoracic lesions</dc:title><dc:creator>Mihaylov I.</dc:creator><prism:publicationName>Physics in Medicine and Biology</prism:publicationName><prism:issn>00319155</prism:issn><prism:eIssn>13616560</prism:eIssn><prism:volume>60</prism:volume><prism:issueIdentifier>10</prism:issueIdentifier><prism:pageRange>3927-3937</prism:pageRange><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1088/0031-9155/60/10/3927</prism:doi><dc:description>© 2015 Institute of Physics and Engineering in Medicine. In the past decade, several different radiotherapy treatment plan evaluation and optimization schemes have been proposed as viable approaches, aiming for dose escalation or an increase of healthy tissue sparing. In particular, it has been argued that dose-mass plan evaluation and treatment plan optimization might be viable alternatives to the standard of care, which is realized through dose-volume evaluation and optimization. The purpose of this investigation is to apply dose-mass optimization to a cohort of lung cancer patients and compare the achievable healthy tissue sparing to that one achievable through dose-volume optimization. Fourteen non-small cell lung cancer (NSCLC) patient plans were studied retrospectively. The range of tumor motion was less than 0.5 cm and motion management in the treatment planning process was not considered. For each case, dose-volume (DV)-based and dose-mass (DM)-based optimization was performed. Nine-field step-and-shoot IMRT was used, with all of the optimization parameters kept the same between DV and DM optimizations. Commonly used dosimetric indices (DIs) such as dose to 1% the spinal cord volume, dose to 50% of the esophageal volume, and doses to 20 and 30% of healthy lung volumes were used for cross-comparison. Similarly, mass-based indices (MIs), such as doses to 20 and 30% of healthy lung masses, 1% of spinal cord mass, and 33% of heart mass, were also tallied. Statistical equivalence tests were performed to quantify the findings for the entire patient cohort. Both DV and DM plans for each case were normalized such that 95% of the planning target volume received the prescribed dose. DM optimization resulted in more organs at risk (OAR) sparing than DV optimization. The average sparing of cord, heart, and esophagus was 23, 4, and 6%, respectively. For the majority of the DIs, DM optimization resulted in lower lung doses. On average, the doses to 20 and 30% of healthy lung were lower by approximately 3 and 4%, whereas lung volumes receiving 2000 and 3000 cGy were lower by 3 and 2%, respectively. The behavior of MIs was very similar. The statistical analyses of the results again indicated better healthy anatomical structure sparing with DM optimization. The presented findings indicate that dose-mass-based optimization results in statistically significant OAR sparing as compared to dose-volume-based optimization for NSCLC. However, the sparing is case-dependent and it is not observed for all tallied dosimetric endpoints.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029251</affiliation-url><afid>60029251</afid><affilname>University of Miami</affilname><name-variant>University of Miami</name-variant><affiliation-city>Coral Gables</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115228855</affiliation-url><afid>115228855</afid><affilname>Radiation Oncology and Cancer Imaging</affilname><name-variant>Radiation Oncology and Cancer Imaging</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:12141546000</author-url><authid>12141546000</authid><authname>Mihaylov I.</authname><surname>Mihaylov</surname><given-name>I. B.</given-name><initials>I.B.</initials><afid>60029251</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35498758600</author-url><authid>35498758600</authid><authname>Moros E.</authname><surname>Moros</surname><given-name>E. G.</given-name><initials>E.G.</initials><afid>115228855</afid></author><intid>535902465</intid><source-id>29203</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929995890"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929995890?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929995890&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929995890&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929995890</prism:url><dc:identifier>SCOPUS_ID:84929995890</dc:identifier><eid>2-s2.0-84929995890</eid><dc:title>User-initialized active contour segmentation and golden-angle real-time cardiovascular magnetic resonance enable accurate assessment of LV function in patients with sinus rhythm and arrhythmias</dc:title><dc:creator>Contijoch F.</dc:creator><prism:publicationName>Journal of Cardiovascular Magnetic Resonance</prism:publicationName><prism:issn>10976647</prism:issn><prism:eIssn>1532429X</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12968-015-0146-9</prism:doi><dc:description>© 2015 Contijoch et al.; licensee BioMed Central. Background: Data obtained during arrhythmia is retained in real-time cardiovascular magnetic resonance (rt-CMR), but there is limited and inconsistent evidence to show that rt-CMR can accurately assess beat-to-beat variation in left ventricular (LV) function or during an arrhythmia. Methods: Multi-slice, short axis cine and real-time golden-angle radial CMR data was collected in 22 clinical patients (18 in sinus rhythm and 4 patients with arrhythmia). A user-initialized active contour segmentation (ACS) software was validated via comparison to manual segmentation on clinically accepted software. For each image in the 2D acquisitions, slice volume was calculated and global LV volumes were estimated via summation across the LV using multiple slices. Real-time imaging data was reconstructed using different image exposure times and frame rates to evaluate the effect of temporal resolution on measured function in each slice via ACS. Finally, global volumetric function of ectopic and non-ectopic beats was measured using ACS in patients with arrhythmias. Results: ACS provides global LV volume measurements that are not significantly different from manual quantification of retrospectively gated cine images in sinus rhythm patients. With an exposure time of 95.2 ms and a frame rate of &gt; 89 frames per second, golden-angle real-time imaging accurately captures hemodynamic function over a range of patient heart rates. In four patients with frequent ectopic contractions, initial quantification of the impact of ectopic beats on hemodynamic function was demonstrated. Conclusion: User-initialized active contours and golden-angle real-time radial CMR can be used to determine time-varying LV function in patients. These methods will be very useful for the assessment of LV function in patients with frequent arrhythmias.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006297</affiliation-url><afid>60006297</afid><affilname>University of Pennsylvania</affilname><name-variant>University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006297</affiliation-url><afid>60006297</afid><affilname>University of Pennsylvania</affilname><name-variant>University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006297</affiliation-url><afid>60006297</afid><affilname>University of Pennsylvania</affilname><name-variant>University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005281</affiliation-url><afid>60005281</afid><affilname>National Heart, Lung, and Blood Institute</affilname><name-variant>NIH</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006297</affiliation-url><afid>60006297</afid><affilname>University of Pennsylvania</affilname><name-variant>University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35770427900</author-url><authid>35770427900</authid><authname>Contijoch F.</authname><surname>Contijoch</surname><given-name>Francisco</given-name><initials>F.</initials><afid>60006297</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15761650600</author-url><authid>15761650600</authid><authname>Witschey W.</authname><surname>Witschey</surname><given-name>Walter R T</given-name><initials>W.R.T.</initials><afid>60006297</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56609749700</author-url><authid>56609749700</authid><authname>Rogers K.</authname><surname>Rogers</surname><given-name>Kelly</given-name><initials>K.</initials><afid>60006297</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56610194900</author-url><authid>56610194900</authid><authname>Rears H.</authname><surname>Rears</surname><given-name>Hannah</given-name><initials>H.</initials><afid>60006297</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35562748700</author-url><authid>35562748700</authid><authname>Hansen M.</authname><surname>Hansen</surname><given-name>Michael</given-name><initials>M.</initials><afid>60005281</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602550724</author-url><authid>6602550724</authid><authname>Yushkevich P.</authname><surname>Yushkevich</surname><given-name>Paul</given-name><initials>P.</initials><afid>60006297</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35427943700</author-url><authid>35427943700</authid><authname>Gorman J.</authname><surname>Gorman</surname><given-name>Joseph</given-name><initials>J.</initials><afid>60006297</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:34770566800</author-url><authid>34770566800</authid><authname>Gorman R.</authname><surname>Gorman</surname><given-name>Robert C.</given-name><initials>R.C.</initials><afid>60006297</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56135832200</author-url><authid>56135832200</authid><authname>Han Y.</authname><surname>Han</surname><given-name>Yuchi</given-name><initials>Y.</initials><afid>60006297</afid></author><authkeywords>Arrhythmia | Real-time CMR | Temporal resolution</authkeywords><intid>1786050337</intid><article-number>37</article-number><source-id>23845</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929687614"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929687614?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929687614&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929687614&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929687614</prism:url><dc:identifier>SCOPUS_ID:84929687614</dc:identifier><eid>2-s2.0-84929687614</eid><dc:title>Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice</dc:title><dc:creator>Zheng D.</dc:creator><prism:publicationName>Diabetologia</prism:publicationName><prism:issn>0012186X</prism:issn><prism:eIssn>14320428</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00125-015-3622-8</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg Aims/hypothesis: MicroRNAs (miRs) have been suggested as potential therapeutic targets for heart diseases. Inhibition of miR-195 prevents apoptosis in cardiomyocytes stimulated with palmitate and transgenic overexpression of miR-195 induces cardiac hypertrophy and heart failure. We investigated whether silencing of miR-195 reduces diabetic cardiomyopathy in a mouse model of streptozotocin (STZ)-induced type 1 diabetes. Methods: Type 1 diabetes was induced in C57BL/6 mice (male, 2 months old) by injections of STZ. Results: MiR-195 expression was increased and levels of its target proteins (B cell leukaemia/lymphoma 2 and sirtuin 1) were decreased in STZ-induced type 1 and db/db type 2 diabetic mouse hearts. Systemically delivering an anti-miR-195 construct knocked down miR-195 expression in the heart, reduced caspase-3 activity, decreased oxidative stress, attenuated myocardial hypertrophy and improved myocardial function in STZ-induced mice with a concurrent upregulation of B cell leukaemia/lymphoma 2 and sirtuin 1. Diabetes reduced myocardial capillary density and decreased maximal coronary blood flow in mice. Knockdown of miR-195 increased myocardial capillary density and improved maximal coronary blood flow in diabetic mice. Upregulation of miR-195 sufficiently induced apoptosis in cardiomyocytes and attenuated the angiogenesis of cardiac endothelial cells in vitro. Furthermore, inhibition of miR-195 prevented apoptosis in cardiac endothelial cells in response to NEFA, an important feature of diabetes. Conclusions/interpretation: Therapeutic silencing of miR-195 reduces myocardial hypertrophy and improves coronary blood flow and myocardial function in diabetes, at least in part by reducing oxidative damage, inhibiting apoptosis and promoting angiogenesis. Thus, miR-195 may represent an alternative therapeutic target for diabetic heart diseases.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010432</affiliation-url><afid>60010432</afid><affilname>Soochow University</affilname><name-variant>Suzhou University</name-variant><affiliation-city>Suzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026135</affiliation-url><afid>60026135</afid><affilname>Lawson Health Research Institute</affilname><name-variant>Lawson Health Research Institute</name-variant><affiliation-city>London</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010884</affiliation-url><afid>60010884</afid><affilname>Western University</affilname><name-variant>University of Western Ontario</name-variant><affiliation-city>London</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010884</affiliation-url><afid>60010884</afid><affilname>Western University</affilname><name-variant>University of Western Ontario</name-variant><affiliation-city>London</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009860</affiliation-url><afid>60009860</afid><affilname>Fudan University</affilname><name-variant>Fudan University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008073</affiliation-url><afid>60008073</afid><affilname>Wenzhou Medical College</affilname><name-variant>Wenzhou Medical College</name-variant><affiliation-city>Wenzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017412</affiliation-url><afid>60017412</afid><affilname>University of Cincinnati College of Medicine</affilname><name-variant>Univ. of Cincinnati Coll. of Med.</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010884</affiliation-url><afid>60010884</afid><affilname>Western University</affilname><name-variant>University of Western Ontario</name-variant><affiliation-city>London</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">21</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56508856500</author-url><authid>56508856500</authid><authname>Zheng D.</authname><surname>Zheng</surname><given-name>Dong</given-name><initials>D.</initials><afid>60010432</afid><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56508856500</author-url><authid>56508856500</authid><authname>Zheng D.</authname><surname>Zheng</surname><given-name>Dong</given-name><initials>D.</initials><afid>60010432</afid><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56508856500</author-url><authid>56508856500</authid><authname>Zheng D.</authname><surname>Zheng</surname><given-name>Dong</given-name><initials>D.</initials><afid>60010432</afid><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56508856500</author-url><authid>56508856500</authid><authname>Zheng D.</authname><surname>Zheng</surname><given-name>Dong</given-name><initials>D.</initials><afid>60010432</afid><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56652779800</author-url><authid>56652779800</authid><authname>Ma J.</authname><surname>Ma</surname><given-name>Jian</given-name><initials>J.</initials><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56652779800</author-url><authid>56652779800</authid><authname>Ma J.</authname><surname>Ma</surname><given-name>Jian</given-name><initials>J.</initials><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56652779800</author-url><authid>56652779800</authid><authname>Ma J.</authname><surname>Ma</surname><given-name>Jian</given-name><initials>J.</initials><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55628587913</author-url><authid>55628587913</authid><authname>Yu Y.</authname><surname>Yu</surname><given-name>Yong</given-name><initials>Y.</initials><afid>60009860</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56652744400</author-url><authid>56652744400</authid><authname>Li M.</authname><surname>Li</surname><given-name>Minghui</given-name><initials>M.</initials><afid>60009860</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56139403200</author-url><authid>56139403200</authid><authname>Ni R.</authname><surname>Ni</surname><given-name>Rui</given-name><initials>R.</initials><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56139403200</author-url><authid>56139403200</authid><authname>Ni R.</authname><surname>Ni</surname><given-name>Rui</given-name><initials>R.</initials><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56139403200</author-url><authid>56139403200</authid><authname>Ni R.</authname><surname>Ni</surname><given-name>Rui</given-name><initials>R.</initials><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56508547300</author-url><authid>56508547300</authid><authname>Wang G.</authname><surname>Wang</surname><given-name>Grace</given-name><initials>G.</initials><afid>60010884</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56652832900</author-url><authid>56652832900</authid><authname>Chen R.</authname><surname>Chen</surname><given-name>Ruizhen</given-name><initials>R.</initials><afid>60009860</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56652972500</author-url><authid>56652972500</authid><authname>Li J.</authname><surname>Li</surname><given-name>Jianmin</given-name><initials>J.</initials><afid>60008073</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56508907600</author-url><authid>56508907600</authid><authname>Fan G.</authname><surname>Fan</surname><given-name>Guo Chang</given-name><initials>G.C.</initials><afid>60017412</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6603927961</author-url><authid>6603927961</authid><authname>Lacefield J.</authname><surname>Lacefield</surname><given-name>James C.</given-name><initials>J.C.</initials><afid>60010884</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7201447922</author-url><authid>7201447922</authid><authname>Peng T.</authname><surname>Peng</surname><given-name>Tianqing</given-name><initials>T.</initials><afid>60010432</afid><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7201447922</author-url><authid>7201447922</authid><authname>Peng T.</authname><surname>Peng</surname><given-name>Tianqing</given-name><initials>T.</initials><afid>60010432</afid><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7201447922</author-url><authid>7201447922</authid><authname>Peng T.</authname><surname>Peng</surname><given-name>Tianqing</given-name><initials>T.</initials><afid>60010432</afid><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7201447922</author-url><authid>7201447922</authid><authname>Peng T.</authname><surname>Peng</surname><given-name>Tianqing</given-name><initials>T.</initials><afid>60010432</afid><afid>60026135</afid><afid>60010884</afid><afid>60010884</afid></author><authkeywords>Angiogenesis | Apoptosis | Cardiomyopathy | Diabetes | Hypertrophy | miR-195 | Myocardial dysfunction</authkeywords><intid>535998910</intid><source-id>25584</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929441431"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929441431?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929441431&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929441431&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929441431</prism:url><dc:identifier>SCOPUS_ID:84929441431</dc:identifier><eid>2-s2.0-84929441431</eid><dc:title>Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: A meta-analysis of 330,376 patients from 47 landmark studies</dc:title><dc:creator>Hermans M.</dc:creator><prism:publicationName>Cardiovascular Diabetology</prism:publicationName><prism:eIssn>14752840</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>May 21, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12933-015-0226-z</prism:doi><dc:description>© 2015 Hermans et al.; licensee BioMed Central. Background: Diabetes is a major cardiovascular risk factor. However, its influence on the rate of occurrence of cardiovascular (CV) events during a clinical trial that included a diabetes subgroup has not yet been quantified. Aims: To establish equations relating baseline diabetes prevalence and incident CV events, based on comparator arms data of major lipid-modifying trials. Methods: Meta-analysis of primary outcomes (PO) rates of key prospective trials, for which the baseline proportion of diabetics was reported, including studies having specifically reported CV outcomes within their diabetic subgroups. Results: 47 studies, representing 330,376 patients (among whom 124,115 diabetics), were analyzed as regards the relationship between CV outcomes rates (including CHD) and the number of diabetics enrolled. Altogether, a total of 18,445 and 16,156 events occurred in the comparator and treatment arms, respectively. There were significant linear relationships between diabetes prevalence and both PO and CHD rates (%/year): y = 0.0299*x + 3.12 [PO] (p = 0.0128); and y = 0.0531*x + 1.54 [CHD] (p = 0.0094), baseline diabetes predicting PO rates between 3.12 %/year (no diabetic included) and 6.11 %/year (all patients diabetic); and CHD rates between 1.54 %/year (no diabetic) and 6.85 %/year (all patients diabetic). The slopes of the equations did not differ according to whether they were derived from primary or secondary prevention trials. Conclusions: Absolute and relative CV risk associated with diabetes at inclusion can be readily predicted using linear equations relating diabetes prevalence to primary outcomes or CHD rates.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012936</affiliation-url><afid>60012936</afid><affilname>Cliniques Universitaires Saint-Luc, Brussels</affilname><name-variant>Cliniques Universitaires Saint-Luc</name-variant><affiliation-city>Brussels</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072525</affiliation-url><afid>60072525</afid><affilname>Centre Hospitalier et Universitaire de Brazzaville</affilname><name-variant>CHU de Brazzaville</name-variant><affiliation-city>Brazzaville</affiliation-city><affiliation-country>Congo</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072094</affiliation-url><afid>60072094</afid><affilname>University of Abomey-Calavi</affilname><name-variant>Université d'Abomey-Calavi</name-variant><affiliation-city>Cotonou</affiliation-city><affiliation-country>Benin</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012936</affiliation-url><afid>60012936</afid><affilname>Cliniques Universitaires Saint-Luc, Brussels</affilname><name-variant>Cliniques Universitaires Saint-Luc</name-variant><affiliation-city>Brussels</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55604840700</author-url><authid>55604840700</authid><authname>Hermans M.</authname><surname>Hermans</surname><given-name>Michel P.</given-name><initials>M.P.</initials><afid>60012936</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7801393506</author-url><authid>7801393506</authid><authname>Bouenizabila E.</authname><surname>Bouenizabila</surname><given-name>Evariste</given-name><initials>E.</initials><afid>60072525</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:26655283400</author-url><authid>26655283400</authid><authname>Amoussou-guenou D.</authname><surname>Amoussou-guenou</surname><given-name>Daniel K.</given-name><initials>D.K.</initials><afid>60072094</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7401989943</author-url><authid>7401989943</authid><authname>Ahn S.</authname><surname>Ahn</surname><given-name>Sylvie A.</given-name><initials>S.A.</initials><afid>60012936</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7101954099</author-url><authid>7101954099</authid><authname>Rousseau M.</authname><surname>Rousseau</surname><given-name>Michel F.</given-name><initials>M.F.</initials><afid>60012936</afid></author><authkeywords>Cardiovascular | Clinical trial | Coronary heart disease | Diabetes | Lipids | Residual risk</authkeywords><intid>1785956427</intid><source-id>25441</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929678354"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929678354?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929678354&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929678354&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929678354</prism:url><dc:identifier>SCOPUS_ID:84929678354</dc:identifier><eid>2-s2.0-84929678354</eid><dc:title>Sublingual Nitroglycerin Administration in Coronary Computed Tomography Angiography: a Systematic Review</dc:title><dc:creator>Takx R.</dc:creator><prism:publicationName>European Radiology</prism:publicationName><prism:issn>09387994</prism:issn><prism:eIssn>14321084</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00330-015-3791-3</prism:doi><dc:description>© 2015 The Author(s) Objective: To systematically investigate the literature for the influence of sublingual nitroglycerin administration on coronary diameter, the number of evaluable segments, image quality, heart rate and blood pressure, and diagnostic accuracy of coronary computed tomography (CT) angiography. Methods: A systematic search was performed in PubMed, EMBASE and Web of Science. The studies were evaluated for the effect of sublingual nitroglycerin on coronary artery diameter, evaluable segments, objective and subjective image quality, systemic physiological effects and diagnostic accuracy. Due to the heterogeneous reporting of outcome measures, a narrative synthesis was applied. Results: Of the 217 studies identified, nine met the inclusion criteria: seven reported on the effect of nitroglycerin on coronary artery diameter, six on evaluable segments, four on image quality, five on systemic physiological effects and two on diagnostic accuracy. Sublingual nitroglycerin administration resulted in an improved evaluation of more coronary segments, in particular, in smaller coronary branches, better image quality and improved diagnostic accuracy. Side effects were mild and were alleviated without medical intervention. Conclusion: Sublingual nitroglycerin improves the coronary diameter, the number of assessable segments, image quality and diagnostic accuracy of coronary CT angiography without major side effects or systemic physiological changes. Key Points: • Sublingual nitroglycerin administration results in significant coronary artery dilatation. • Nitroglycerin increases the number of evaluable coronary branches. • Image quality is improved the most in smaller coronary branches. • Nitroglycerin increases the diagnostic accuracy of coronary CT angiography. • Most side effects are mild and do not require medical intervention.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032724</affiliation-url><afid>60032724</afid><affilname>University Medical Center Utrecht</affilname><name-variant>University Medical Center Utrecht</name-variant><affiliation-city>Utrecht</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016908</affiliation-url><afid>60016908</afid><affilname>Universitat Heidelberg</affilname><name-variant>Universität Heidelberg</name-variant><affiliation-city>Heidelberg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36997583000</author-url><authid>36997583000</authid><authname>Takx R.</authname><surname>Takx</surname><given-name>Richard A P</given-name><initials>R.A.P.</initials><afid>60029929</afid><afid>60032724</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36997583000</author-url><authid>36997583000</authid><authname>Takx R.</authname><surname>Takx</surname><given-name>Richard A P</given-name><initials>R.A.P.</initials><afid>60029929</afid><afid>60032724</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56012636600</author-url><authid>56012636600</authid><authname>Suchá D.</authname><surname>Suchá</surname><given-name>Dominika</given-name><initials>D.</initials><afid>60032724</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56652846300</author-url><authid>56652846300</authid><authname>Park J.</authname><surname>Park</surname><given-name>Jakob</given-name><initials>J.</initials><afid>60029929</afid><afid>60016908</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56652846300</author-url><authid>56652846300</authid><authname>Park J.</authname><surname>Park</surname><given-name>Jakob</given-name><initials>J.</initials><afid>60029929</afid><afid>60016908</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004171845</author-url><authid>7004171845</authid><authname>Leiner T.</authname><surname>Leiner</surname><given-name>Tim</given-name><initials>T.</initials><afid>60032724</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7102993925</author-url><authid>7102993925</authid><authname>Hoffmann U.</authname><surname>Hoffmann</surname><given-name>Udo</given-name><initials>U.</initials><afid>60029929</afid></author><authkeywords>Computed tomography | Coronary artery disease | Coronary CT angiography | Coronary vasodilation | Nitroglycerin</authkeywords><intid>1785998046</intid><source-id>16687</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929693087"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929693087?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929693087&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929693087&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929693087</prism:url><dc:identifier>SCOPUS_ID:84929693087</dc:identifier><eid>2-s2.0-84929693087</eid><dc:title>The clinical significance and costs of herbs and food supplements used by complementary and alternative medicine for the treatment of cardiovascular diseases and hypertension</dc:title><dc:creator>Chrysant S.</dc:creator><prism:publicationName>Journal of Human Hypertension</prism:publicationName><prism:issn>09509240</prism:issn><prism:eIssn>14765527</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1038/jhh.2015.42</prism:doi><pii>jhh201542</pii><dc:description>© 2015 Macmillan Publishers Limited Complementary and alternative medicine (CAM) is widely used by people in the United States and other countries for the treatment of health conditions that include hypertension (HTN), cardiovascular disease (CVD), heart failure, hyperlipidemia and other condtions. The visits to CAM practitioners result in significant out-of-pocket expenses, as CAM is not covered by health insurance in the majority of cases. The reasons for this are that the products used are not closely regulated by governmental regulatory agencies and lack scientific evidence about their effectiveness and safety. The people regard these products as being ‘natural’ and, consequently, safe. However, there is evidence that these products can be contaminated and adulterated with other substances and could cause harm to the persons who take them. The responsibility falls on the health professionals, who should become familiar with the various CAM products, inquire their patients whether they taking any of these products and advise them accordingly. This review is based on a recent statement issued by the American Medical for the use of CAM for the treatment of HTN. For its preparation, a Medline search of the English language literature was performed between 2010 and 2014 restricted in the use of CAM for CVD and HTN, and from the 88 abstracts reviewed, 23 pertinent papers were selected. These papers together with collateral literature will be discussed in this review regarding CAM and CAM products on their effectiveness and safety for the treatment of CVD and HTN.Journal of Human Hypertension advance online publication, 21 May 2015; doi:10.1038/jhh.2015.42.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012414</affiliation-url><afid>60012414</afid><affilname>University of Oklahoma College of Medicine</affilname><name-variant>University of Oklahoma School of Medicine</name-variant><affiliation-city>Oklahoma City</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006968883</author-url><authid>7006968883</authid><authname>Chrysant S.</authname><surname>Chrysant</surname><given-name>S. G.</given-name><initials>S.G.</initials><afid>60012414</afid></author><intid>2035992003</intid><source-id>23875</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929453735"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929453735?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929453735&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929453735&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929453735</prism:url><dc:identifier>SCOPUS_ID:84929453735</dc:identifier><eid>2-s2.0-84929453735</eid><dc:title>Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: An open-label, multi-center, non-comparative phase II study</dc:title><dc:creator>Rau K.</dc:creator><prism:publicationName>BMC Cancer</prism:publicationName><prism:eIssn>14712407</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>May 21, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12885-015-1433-4</prism:doi><dc:description>© 2015 Rau et al.; licensee BioMed Central. Background: Anthracycline and taxane are classes of drugs that are frequently used in the adjuvant and palliative settings of metastatic breast cancer (MBC); however, treatment failure occurs in most cases. Limited data demonstrated favorable response in MBC after previous taxane-based treatment. The aim of this study was to evaluate the efficacy and safety of pegylated liposomal doxorubicin (Lipo-Dox®) used as part of a combination salvage therapy for patients with MBC whose tumors progressed during or after taxane-based treatment. Methods: Patients with MBC who failed to respond to previous taxane-based treatments were recruited. Treatment with pegylated liposomal doxorubicin (40 mg/m&lt;sup&gt;2&lt;/sup&gt;), cyclophosphamide (500 mg/m&lt;sup&gt;2&lt;/sup&gt;), and 5-fluorouracil (500 mg/m&lt;sup&gt;2&lt;/sup&gt;) was administered every 3 weeks. Tumor response to treatment was determined by using the Response Evaluation Criteria in Solid Tumor criteria version 1.0, and left ventricular ejection fraction was measured before and after treatment using echocardiography. Each patient was followed for 30 days after the last dose of study medication or until resolution/stabilization of any drug-related adverse event. Results: Forty-five patients were recruited. As of December 2012, the median follow-up duration was 29.8 months, the overall response rate was 41.9 %, the median progression-free survival was 8.2 months, and the median overall survival was 36.6 months for all treated patients. Grade 3/4 neutropenia, leucopenia, and neutropenic fever were observed in 14 %, 9 %, and 1 % of the cycles, respectively. Other non-hematologic adverse effects were mild to moderate and were manageable. No decrease in left ventricular ejection function was noted. Conclusion: This regimen of combined of pegylated liposomal doxorubicin, cyclophosphamide, and 5-fluorouracil exhibited a promising overall response rate, progression-free survival rate, and overall survival rate, with a safe cardiac toxicity profile and manageable adverse effects. This regimen could be considered as a treatment option for patients with MBC whose tumors progressed during or after taxane-based treatment.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031913</affiliation-url><afid>60031913</afid><affilname>Chang Gung Memorial Hospital</affilname><name-variant>Chang Gung Memorial Hospital</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020351</affiliation-url><afid>60020351</afid><affilname>Chang Gung University</affilname><name-variant>Chang Gung University</name-variant><affiliation-city>Taoyuan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031913</affiliation-url><afid>60031913</afid><affilname>Chang Gung Memorial Hospital</affilname><name-variant>Chang Gung Memorial Hospital</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031913</affiliation-url><afid>60031913</afid><affilname>Chang Gung Memorial Hospital</affilname><name-variant>Chang Gung Memorial Hospital</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020351</affiliation-url><afid>60020351</afid><affilname>Chang Gung University</affilname><name-variant>Chang Gung University</name-variant><affiliation-city>Taoyuan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031913</affiliation-url><afid>60031913</afid><affilname>Chang Gung Memorial Hospital</affilname><name-variant>Chang Gung Memorial Hospital</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:11238821400</author-url><authid>11238821400</authid><authname>Rau K.</authname><surname>Rau</surname><given-name>Kun Ming</given-name><initials>K.M.</initials><afid>60031913</afid><afid>60020351</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:11238821400</author-url><authid>11238821400</authid><authname>Rau K.</authname><surname>Rau</surname><given-name>Kun Ming</given-name><initials>K.M.</initials><afid>60031913</afid><afid>60020351</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8585890900</author-url><authid>8585890900</authid><authname>Lin Y.</authname><surname>Lin</surname><given-name>Yung Chang</given-name><initials>Y.C.</initials><afid>60020351</afid><afid>60031913</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8585890900</author-url><authid>8585890900</authid><authname>Lin Y.</authname><surname>Lin</surname><given-name>Yung Chang</given-name><initials>Y.C.</initials><afid>60020351</afid><afid>60031913</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56174117400</author-url><authid>56174117400</authid><authname>Chen Y.</authname><surname>Chen</surname><given-name>Yen Yang</given-name><initials>Y.Y.</initials><afid>60031913</afid><afid>60020351</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56174117400</author-url><authid>56174117400</authid><authname>Chen Y.</authname><surname>Chen</surname><given-name>Yen Yang</given-name><initials>Y.Y.</initials><afid>60031913</afid><afid>60020351</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35075804900</author-url><authid>35075804900</authid><authname>Chen J.</authname><surname>Chen</surname><given-name>Jen Shi</given-name><initials>J.S.</initials><afid>60020351</afid><afid>60031913</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35075804900</author-url><authid>35075804900</authid><authname>Chen J.</authname><surname>Chen</surname><given-name>Jen Shi</given-name><initials>J.S.</initials><afid>60020351</afid><afid>60031913</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7501498128</author-url><authid>7501498128</authid><authname>Lee K.</authname><surname>Lee</surname><given-name>Kuan Der</given-name><initials>K.D.</initials><afid>60031913</afid><afid>60031913</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7501498128</author-url><authid>7501498128</authid><authname>Lee K.</authname><surname>Lee</surname><given-name>Kuan Der</given-name><initials>K.D.</initials><afid>60031913</afid><afid>60031913</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7501645420</author-url><authid>7501645420</authid><authname>Wang C.</authname><surname>Wang</surname><given-name>Cheng Hsu</given-name><initials>C.H.</initials><afid>60020351</afid><afid>60020351</afid><afid>60031913</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7501645420</author-url><authid>7501645420</authid><authname>Wang C.</authname><surname>Wang</surname><given-name>Cheng Hsu</given-name><initials>C.H.</initials><afid>60020351</afid><afid>60020351</afid><afid>60031913</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7501645420</author-url><authid>7501645420</authid><authname>Wang C.</authname><surname>Wang</surname><given-name>Cheng Hsu</given-name><initials>C.H.</initials><afid>60020351</afid><afid>60020351</afid><afid>60031913</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56198088100</author-url><authid>56198088100</authid><authname>Chang H.</authname><surname>Chang</surname><given-name>Hsien Kun</given-name><initials>H.K.</initials><afid>60031913</afid></author><authkeywords>Advanced breast cancer | Metastatic breast cancer | Pegylated liposomal doxorubicin | Safety | Taxane failure</authkeywords><intid>2035959257</intid><article-number>423</article-number><source-id>28747</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929698729"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929698729?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929698729&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929698729&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929698729</prism:url><dc:identifier>SCOPUS_ID:84929698729</dc:identifier><eid>2-s2.0-84929698729</eid><dc:title>Dispelling dogma and misconceptions regarding the most pharmacologically targetable source of reactive species in inflammatory disease, xanthine oxidoreductase</dc:title><dc:creator>Kelley E.</dc:creator><prism:publicationName>Archives of Toxicology</prism:publicationName><prism:issn>03405761</prism:issn><prism:eIssn>14320738</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00204-015-1523-8</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg Xanthine oxidoreductase (XOR), the molybdoflavin enzyme responsible for the terminal steps of purine degradation in humans, is also recognized as a significant source of reactive species contributory to inflammatory disease. In animal models and clinical studies, inhibition of XOR has resulted in diminution of symptoms and enhancement of function in a number of pathologies including heart failure, diabetes, sickle cell anemia, hypertension and ischemia–reperfusion injury. For decades, XOR involvement in pathologic processes has been established by salutary outcomes attained from treatment with the XOR inhibitor allopurinol. This has served to frame a working dogma that elevation of XOR-specific activity is associated with enhanced rates of reactive species generation that mediate negative outcomes. While adherence to this narrowly focused practice of designating elevated XOR activity to be “bad” has produced some benefit, it has also led to significant underdevelopment of the processes mediating XOR regulation, identification of alternative reactants and products as well as micro-environmental factors that alter enzymatic activity. This is exemplified by recent reports: (1) identifying XOR as a nitrite reductase and thus a source of beneficial nitric oxide (&lt;sup&gt;•&lt;/sup&gt;NO) under in vivo conditions similar to those where XOR inhibition has been assumed an optimal treatment choice, (2) describing XOR-derived uric acid (UA) as a critical pro-inflammatory mediator in vascular and metabolic disease and (3) ascribing an antioxidant/protective role for XOR-derived UA. When taken together, these proposed and countervailing functions of XOR affirm the need for a more comprehensive evaluation of product formation as well as the factors that govern product identity. As such, this review will critically evaluate XOR-catalyzed oxidant, &lt;sup&gt;•&lt;/sup&gt;NO and UA formation as well as identify factors that mediate their production, inhibition and the resultant impact on inflammatory disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015543</affiliation-url><afid>60015543</afid><affilname>University of Pittsburgh</affilname><name-variant>University of Pittsburgh</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005930467</author-url><authid>7005930467</authid><authname>Kelley E.</authname><surname>Kelley</surname><given-name>Eric E.</given-name><initials>E.E.</initials><afid>60015543</afid></author><authkeywords>Hypoxia | Inflammation | Nitric oxide | Nitrite | Uric acid | Xanthine oxidoreductase</authkeywords><intid>1035993429</intid><source-id>24604</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929683088"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929683088?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929683088&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929683088&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929683088</prism:url><dc:identifier>SCOPUS_ID:84929683088</dc:identifier><eid>2-s2.0-84929683088</eid><dc:title>Obstructive shock | Obstruktiver Schock</dc:title><dc:creator>Pich H.</dc:creator><prism:publicationName>Anaesthesist</prism:publicationName><prism:issn>00032417</prism:issn><prism:eIssn>1432055X</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00101-015-0031-9</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg An acute obstruction of blood flow in central vessels of the systemic or pulmonary circulation causes the clinical symptoms of shock accompanied by disturbances of consciousness, centralization, oliguria, hypotension and tachycardia. In the case of an acute pulmonary embolism an intravascular occlusion results in an acute increase of the right ventricular afterload. In the case of a tension pneumothorax, an obstruction of the blood vessels supplying the heart is caused by an increase in extravascular pressure. From a hemodynamic viewpoint circulatory shock caused by obstruction is closely followed by cardiac deterioration; however, etiological and therapeutic options necessitate demarcation of cardiac from non-cardiac obstructive causes. The high dynamics of this potentially life-threatening condition is a hallmark of all types of obstructive shock. This requires an expeditious and purposeful diagnosis and a rapid and well-aimed therapy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025676</affiliation-url><afid>60025676</afid><affilname>Dresden University Faculty of Medicine and University Hospital Carl Gustav Carus</affilname><affiliation-city>Dresden</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56653471000</author-url><authid>56653471000</authid><authname>Pich H.</authname><surname>Pich</surname><given-name>H.</given-name><initials>H.</initials><afid>60025676</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56653098600</author-url><authid>56653098600</authid><authname>Heller A.</authname><surname>Heller</surname><given-name>A. R.</given-name><initials>A.R.</initials><afid>60025676</afid></author><authkeywords>Cardiac tamponade | Leriche syndrome | Mediastinal mass syndrome | Pulmonary embolism | Tension pneumothorax</authkeywords><intid>1035993217</intid><source-id>50004</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930221766"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930221766?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930221766&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930221766&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930221766</prism:url><dc:identifier>SCOPUS_ID:84930221766</dc:identifier><eid>2-s2.0-84930221766</eid><dc:title>Complex network models reveal correlations among network metrics, exercise intensity and role of body changes in the fatigue process</dc:title><dc:creator>Pereira V.</dc:creator><prism:publicationName>Scientific Reports</prism:publicationName><prism:eIssn>20452322</prism:eIssn><prism:volume>5</prism:volume><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1038/srep10489</prism:doi><pii>srep10489</pii><dc:description>The aims of the present study were analyze the fatigue process at distinct intensity efforts and to investigate its occurrence as interactions at distinct body changes during exercise, using complex network models. For this, participants were submitted to four different running intensities until exhaustion, accomplished in a non-motorized treadmill using a tethered system. The intensities were selected according to critical power model. Mechanical (force, peak power, mean power, velocity and work) and physiological related parameters (heart rate, blood lactate, time until peak blood lactate concentration (lactate time), lean mass, anaerobic and aerobic capacities) and IPAQ score were obtained during exercises and it was used to construction of four complex network models. Such models have both, theoretical and mathematical value, and enables us to perceive new insights that go beyond conventional analysis. From these, we ranked the influences of each node at the fatigue process. Our results shows that nodes, links and network metrics are sensibility according to increase of efforts intensities, been the velocity a key factor to exercise maintenance at models/intensities 1 and 2 (higher time efforts) and force and power at models 3 and 4, highlighting mechanical variables in the exhaustion occurrence and even training prescription applications.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029570</affiliation-url><afid>60029570</afid><affilname>Universidade Estadual de Campinas</affilname><name-variant>State University of Campinas</name-variant><affiliation-city>Campinas</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033012</affiliation-url><afid>60033012</afid><affilname>Naval Postgraduate School</affilname><name-variant>Naval Postgraduate School</name-variant><affiliation-city>Monterey</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662790000</author-url><authid>56662790000</authid><authname>Pereira V.</authname><surname>Pereira</surname><given-name>Vanessa Helena</given-name><initials>V.H.</initials><afid>60029570</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662864300</author-url><authid>56662864300</authid><authname>Gama M.</authname><surname>Gama</surname><given-name>Maria Carolina Traina</given-name><initials>M.C.T.</initials><afid>60029570</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662815000</author-url><authid>56662815000</authid><authname>Sousa F.</authname><surname>Sousa</surname><given-name>Filipe Antônio Barros</given-name><initials>F.A.B.</initials><afid>60029570</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7403138287</author-url><authid>7403138287</authid><authname>Lewis T.</authname><surname>Lewis</surname><given-name>Theodore Gyle</given-name><initials>T.G.</initials><afid>60033012</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6603496317</author-url><authid>6603496317</authid><authname>Gobatto C.</authname><surname>Gobatto</surname><given-name>Claudio Alexandre</given-name><initials>C.A.</initials><afid>60029570</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55397857800</author-url><authid>55397857800</authid><authname>Manchado-Gobatto F.</authname><surname>Manchado-Gobatto</surname><given-name>Fúlvia Barros</given-name><initials>F.B.</initials><afid>60029570</afid></author><intid>1786087796</intid><article-number>10489</article-number><source-id>21100200805</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929693115"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929693115?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929693115&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929693115&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929693115</prism:url><dc:identifier>SCOPUS_ID:84929693115</dc:identifier><eid>2-s2.0-84929693115</eid><dc:title>256-Slice coronary computed tomographic angiography in patients with atrial fibrillation: optimal reconstruction phase and image quality</dc:title><dc:creator>Oda S.</dc:creator><prism:publicationName>European Radiology</prism:publicationName><prism:issn>09387994</prism:issn><prism:eIssn>14321084</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00330-015-3822-0</prism:doi><dc:description>© 2015 European Society of Radiology Objectives: To assess the optimal reconstruction phase and the image quality of coronary computed tomographic angiography (CCTA) in patients with atrial fibrillation (AF). Methods: We performed CCTA in 60 patients with AF and 60 controls with sinus rhythm. The images were reconstructed in multiple phases in all parts of the cardiac cycle, and the optimal reconstruction phase with the fewest motion artefacts was identified. The coronary artery segments were visually evaluated to investigate their assessability. Results: In 46 (76.7 %) patients, the optimal reconstruction phase was end-diastole, whereas in 6 (10.0 %) patients it was end-systole or mid-diastole, and in 2 (3.3 %) patients it was another cardiac phase. In 53 (88.3 %) of the controls, the optimal reconstruction phase was mid-diastole, whereas it was end-systole in 4 (6.7 %), and in 3 (5.0 %) it was another cardiac phase. There was a significant difference between patients with AF and the controls in the optimal phase (p &lt; 0.01) but not in the visual image quality score (p = 0.06). Conclusions: The optimal reconstruction phase in most patients with AF was the end-diastolic phase. The end-systolic phase tended to be optimal in AF patients with higher average heart rates. Key Points: • The optimal reconstruction phase in 76.7 % of patients with atrial fibrillation (AF) was end-diastole. • The end-systolic phase was optimal in AF patients with higher heart rates. • ECG and heart-rate control are necessary to obtain end-diastolic images with fewer motion artefacts.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021120</affiliation-url><afid>60021120</afid><affilname>Kumamoto University</affilname><name-variant>Kumamoto University</name-variant><affiliation-city>Kumamoto</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008354</affiliation-url><afid>60008354</afid><affilname>Kumamoto Chuo Hospital</affilname><name-variant>Kumamoto Chuo Hospital</name-variant><affiliation-city>Kumamoto</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008354</affiliation-url><afid>60008354</afid><affilname>Kumamoto Chuo Hospital</affilname><name-variant>Kumamoto Chuo Hospital</name-variant><affiliation-city>Kumamoto</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23474890600</author-url><authid>23474890600</authid><authname>Oda S.</authname><surname>Oda</surname><given-name>Seitaro</given-name><initials>S.</initials><afid>60021120</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:51561871900</author-url><authid>51561871900</authid><authname>Honda K.</authname><surname>Honda</surname><given-name>Keiichi</given-name><initials>K.</initials><afid>60008354</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55603488100</author-url><authid>55603488100</authid><authname>Yoshimura A.</authname><surname>Yoshimura</surname><given-name>Akira</given-name><initials>A.</initials><afid>60008354</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006342316</author-url><authid>7006342316</authid><authname>Katahira K.</authname><surname>Katahira</surname><given-name>Kazuhiro</given-name><initials>K.</initials><afid>60008354</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56653012400</author-url><authid>56653012400</authid><authname>Noda K.</authname><surname>Noda</surname><given-name>Katsuo</given-name><initials>K.</initials><afid>60008354</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56653106300</author-url><authid>56653106300</authid><authname>Oshima S.</authname><surname>Oshima</surname><given-name>Shuichi</given-name><initials>S.</initials><afid>60008354</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55962809900</author-url><authid>55962809900</authid><authname>Yuki H.</authname><surname>Yuki</surname><given-name>Hideaki</given-name><initials>H.</initials><afid>60021120</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55314334700</author-url><authid>55314334700</authid><authname>Kidoh M.</authname><surname>Kidoh</surname><given-name>Masafumi</given-name><initials>M.</initials><afid>60021120</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6603154912</author-url><authid>6603154912</authid><authname>Utsunomiya D.</authname><surname>Utsunomiya</surname><given-name>Daisuke</given-name><initials>D.</initials><afid>60021120</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:8965100900</author-url><authid>8965100900</authid><authname>Nakaura T.</authname><surname>Nakaura</surname><given-name>Takeshi</given-name><initials>T.</initials><afid>60021120</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:6603874855</author-url><authid>6603874855</authid><authname>Namimoto T.</authname><surname>Namimoto</surname><given-name>Tomohiro</given-name><initials>T.</initials><afid>60021120</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56498344100</author-url><authid>56498344100</authid><authname>Yamashita Y.</authname><surname>Yamashita</surname><given-name>Yasuyuki</given-name><initials>Y.</initials><afid>60021120</afid></author><authkeywords>Atrial fibrillation | Coronary CT angiography | Image quality | Motion artefact | Optimal reconstruction phase</authkeywords><intid>1035992934</intid><source-id>16687</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929687884"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929687884?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929687884&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929687884&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929687884</prism:url><dc:identifier>SCOPUS_ID:84929687884</dc:identifier><eid>2-s2.0-84929687884</eid><dc:title>Waist circumference to height ratio and left ventricular mass in children and adolescents</dc:title><dc:creator>Mehta S.</dc:creator><prism:publicationName>Cardiology in the Young</prism:publicationName><prism:issn>10479511</prism:issn><prism:eIssn>14671107</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1017/S1047951115000803</prism:doi><pii>S1047951115000803</pii><dc:description>© Cambridge University Press 2015 Objectives: Waist circumference to height ratio, a measure of central obesity, is a better predictor of cardiovascular risk than body mass index in the paediatric population. Increased left ventricular mass secondary to obesity and hypertension increases the risk for death and cardiovascular disease in adults. Similar data on left ventricular mass are lacking among young patients with central obesity, as defined by waist circumference/height. The present study evaluates left ventricular mass in young patients with central obesity as defined by waist circumference/height. Methods: A total of 156 patients, 2- to 20-years old, without evidence of structural heart disease were studied. As the left ventricular mass is related to age and gender, 52 patients with central obesity – waist circumference/height ⩾0.55 – were randomly matched for age and gender with 52 patients at risk for central obesity – waist circumference/height ⩾0.5 to &lt;0.55 – and 52 patients with no central obesity – waist circumference/height &lt;0.5. The left ventricular mass parameters measured by echocardiography were compared across the three groups. Results: Patients with central obesity had significantly (p&lt;0.05) increased Z scores for left ventricular mass, left ventricular mass/height&lt;sup&gt;2.7&lt;/sup&gt;, and left ventricular mass/height&lt;sup&gt;1.7&lt;/sup&gt; compared with patients at risk for central obesity and patients with no central obesity. Z scores for left ventricular mass were higher among patients at risk for central obesity compared with patients with no central obesity. Conclusions: Left ventricular mass data of the present study support maintaining an ideal waist circumference/height &lt;0.5. Aggressive efforts to identify and manage patients with central obesity are warranted.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080345</affiliation-url><afid>60080345</afid><affilname>Cleveland Clinic Lerner College of Medicine of Case Western Reserve University</affilname><name-variant>Cleveland Clinic Lerner College of Medicine of Case Western Reserve University</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7401670415</author-url><authid>7401670415</authid><authname>Mehta S.</authname><surname>Mehta</surname><given-name>Sudhir Ken</given-name><initials>S.K.</initials><afid>60080345</afid></author><authkeywords>Central obesity | left ventricular mass/Ht&lt;sup&gt;1.7&lt;/sup&gt; | left ventricular mass/Ht&lt;sup&gt;2.7&lt;/sup&gt; | Z score for left ventricular mass</authkeywords><intid>1785999173</intid><source-id>22531</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929689096"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929689096?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929689096&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929689096&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929689096</prism:url><dc:identifier>SCOPUS_ID:84929689096</dc:identifier><eid>2-s2.0-84929689096</eid><dc:title>Preoperative anxiety induces no clinically relevant effect on intraoperative nociceptive levels during breast surgery under general anesthesia</dc:title><dc:creator>Hashimoto K.</dc:creator><prism:publicationName>Journal of Anesthesia</prism:publicationName><prism:issn>09138668</prism:issn><prism:eIssn>14388359</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00540-015-2032-x</prism:doi><dc:description>© 2015 Japanese Society of Anesthesiologists Anxiety can affect acute and chronic postoperative pain after breast surgery. Nociceptive response during surgery might also be affected by preoperative anxiety even under unconscious state during general anesthesia. The aim of this retrospective study was to investigate nociceptive responses during breast surgery under general anesthesia in patients with or without preoperative anxiety. Patients (n = 45) were divided into a low-anxiety group (n = 25) and a high-anxiety group (n = 20) in accordance with preoperative scores for the State Trait Anxiety Inventory. We performed discriminant analysis to compare nociception during surgery using three intraoperative averaged values: heart rate; systolic blood pressure; and perfusion index. No significant differences in discriminant score were seen between groups (p = 0.10). Although we performed propensity score-matching to reduce the bias due to confounding variables in this retrospective study, there was also no significant difference in levels of nociceptive response between groups (p = 0.06). In conclusion, the level of nociception during breast surgery is not significantly affected by preoperative anxiety.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030873</affiliation-url><afid>60030873</afid><affilname>Hyogo College of Medicine</affilname><name-variant>Hyogo College of Medicine</name-variant><affiliation-city>Nishinomiya</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56606566400</author-url><authid>56606566400</authid><authname>Hashimoto K.</authname><surname>Hashimoto</surname><given-name>Kazuma</given-name><initials>K.</initials><afid>60030873</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55768314500</author-url><authid>55768314500</authid><authname>Iwayama S.</authname><surname>Iwayama</surname><given-name>Sachiko</given-name><initials>S.</initials><afid>60030873</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56653016100</author-url><authid>56653016100</authid><authname>Sano Y.</authname><surname>Sano</surname><given-name>Yuka</given-name><initials>Y.</initials><afid>60030873</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55405660300</author-url><authid>55405660300</authid><authname>Tatara T.</authname><surname>Tatara</surname><given-name>Tsuneo</given-name><initials>T.</initials><afid>60030873</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56402492200</author-url><authid>56402492200</authid><authname>Hirose M.</authname><surname>Hirose</surname><given-name>Munetaka</given-name><initials>M.</initials><afid>60030873</afid></author><authkeywords>Anxiety | Mastectomy | Nociception</authkeywords><intid>535998102</intid><source-id>21909</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929682948"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929682948?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929682948&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929682948&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929682948</prism:url><dc:identifier>SCOPUS_ID:84929682948</dc:identifier><eid>2-s2.0-84929682948</eid><dc:title>Access to shade changes behavioral and physiological attributes of dairy cows during the hot season in the subtropics</dc:title><dc:creator>Vizzotto E.</dc:creator><prism:publicationName>Animal</prism:publicationName><prism:issn>17517311</prism:issn><prism:eIssn>1751732X</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1017/S1751731115000877</prism:doi><pii>S1751731115000877</pii><dc:description>© The Animal Consortium 2015 The effect of shade on behavior and physiological attributes of grazing cows in a high altitude subtropical zone is not well established. This work aimed to investigate how social and ingestive behaviors, as well as physiological and other attributes of dairy cows such as milk production, change in a subtropical environment during the hot season either with or without free access to shade. Fourteen lactating cows were kept on pasture either with no shade or with free access to shade for 5 days and their behavior was recorded with instantaneous scan sampled every 10 min, from sunrise, 0530 h (Greenwich mean time, GMT−0200 h) to sunset, 2100 h (GMT−0200 h). Behavior traits included (1) time spent in activities such as grazing, ruminating, resting, lying, standing, walking, seeking shade and staying in the proximity to the water trough and (2) number of events such as water ingestion, aggressive interactions, as well as competition for shade and water. Physiological attributes such as heart and respiratory rates, rectal temperature, number of rumen movements, panting score, as well as milk yield, were evaluated. Time spent in behavioral activities, number of behavioral events and physiological attributes varied between groups (with and without access to shade). Cows with no shade showed increased respiratory and heart rates and panting score at 1300 h, higher values for time of permanence near the water trough, number of competition and aggression events for shade. On the other hand, they showed lower values for time spent resting while lying, ruminating while standing, seeking shade. Access to shade did not change time spent lying, standing, walking with the head up, ruminating while lying, resting while standing, as well as milk yield and number of ruminal movements. Significant interactions between access to shade and days of measurements were detected for time spent walking, ruminating, grazing, resting, number of water ingestion events, competition events near the water trough and for shade, as well as for rectal temperature and panting score measured at 1700 h. In the high altitude subtropical region, access to shade minimizes negative heat stress effects on behavior and physiological aspects of dairy cows.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006726</affiliation-url><afid>60006726</afid><affilname>Universidade Federal do Rio Grande do Sul</affilname><name-variant>Universidade Federal do Rio Grande do Sul</name-variant><affiliation-city>Porto Alegre</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115264585</affiliation-url><afid>115264585</afid><affilname>Departamento de Ciência Animal</affilname><name-variant>Departamento de Ciência Animal</name-variant><affiliation-city>Lages</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024989</affiliation-url><afid>60024989</afid><affilname>Universidade de Brasilia</affilname><name-variant>University of Brasilia</name-variant><affiliation-city>Brasilia</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023857</affiliation-url><afid>60023857</afid><affilname>Universidade Federal do Rio Grande do Norte</affilname><name-variant>Universidade Federal do Rio Grande do Norte</name-variant><affiliation-city>Natal</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56653455900</author-url><authid>56653455900</authid><authname>Vizzotto E.</authname><surname>Vizzotto</surname><given-name>E. F.</given-name><initials>E.F.</initials><afid>60006726</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102522403</author-url><authid>7102522403</authid><authname>Fischer V.</authname><surname>Fischer</surname><given-name>V.</given-name><initials>V.</initials><afid>60006726</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602539353</author-url><authid>6602539353</authid><authname>Thaler Neto A.</authname><surname>Thaler Neto</surname><given-name>A.</given-name><initials>A.</initials><afid>115264585</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006264800</author-url><authid>7006264800</authid><authname>Abreu A.</authname><surname>Abreu</surname><given-name>A. S.</given-name><initials>A.S.</initials><afid>60006726</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55343534800</author-url><authid>55343534800</authid><authname>Stumpf M.</authname><surname>Stumpf</surname><given-name>M. T.</given-name><initials>M.T.</initials><afid>60023857</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56653471300</author-url><authid>56653471300</authid><authname>Werncke D.</authname><surname>Werncke</surname><given-name>D.</given-name><initials>D.</initials><afid>60006726</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56653013400</author-url><authid>56653013400</authid><authname>Schmidt F.</authname><surname>Schmidt</surname><given-name>F. A.</given-name><initials>F.A.</initials><afid>115264585</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55753232300</author-url><authid>55753232300</authid><authname>McManus C.</authname><surname>McManus</surname><given-name>C. M.</given-name><initials>C.M.</initials><afid>60024989</afid></author><authkeywords>behavior | heat stress | lactation | shadow | warm climate</authkeywords><intid>535999176</intid><source-id>5300152613</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929440314"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929440314?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929440314&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929440314&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929440314</prism:url><dc:identifier>SCOPUS_ID:84929440314</dc:identifier><eid>2-s2.0-84929440314</eid><dc:title>User-initialized active contour segmentation and golden-angle real-time cardiovascular magnetic resonance enable accurate assessment of LV function in patients with sinus rhythm and arrhythmias</dc:title><dc:creator>Contijoch F.</dc:creator><prism:publicationName>Journal of Cardiovascular Magnetic Resonance</prism:publicationName><prism:issn>10976647</prism:issn><prism:eIssn>1532429X</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>May 21, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12968-015-0146-9</prism:doi><dc:description>© 2015 Contijoch et al.; licensee BioMed Central. Background: Data obtained during arrhythmia is retained in real-time cardiovascular magnetic resonance (rt-CMR), but there is limited and inconsistent evidence to show that rt-CMR can accurately assess beat-to-beat variation in left ventricular (LV) function or during an arrhythmia. Methods: Multi-slice, short axis cine and real-time golden-angle radial CMR data was collected in 22 clinical patients (18 in sinus rhythm and 4 patients with arrhythmia). A user-initialized active contour segmentation (ACS) software was validated via comparison to manual segmentation on clinically accepted software. For each image in the 2D acquisitions, slice volume was calculated and global LV volumes were estimated via summation across the LV using multiple slices. Real-time imaging data was reconstructed using different image exposure times and frame rates to evaluate the effect of temporal resolution on measured function in each slice via ACS. Finally, global volumetric function of ectopic and non-ectopic beats was measured using ACS in patients with arrhythmias. Results: ACS provides global LV volume measurements that are not significantly different from manual quantification of retrospectively gated cine images in sinus rhythm patients. With an exposure time of 95.2 ms and a frame rate of &gt; 89 frames per second, golden-angle real-time imaging accurately captures hemodynamic function over a range of patient heart rates. In four patients with frequent ectopic contractions, initial quantification of the impact of ectopic beats on hemodynamic function was demonstrated. Conclusion: User-initialized active contours and golden-angle real-time radial CMR can be used to determine time-varying LV function in patients. These methods will be very useful for the assessment of LV function in patients with frequent arrhythmias.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006297</affiliation-url><afid>60006297</afid><affilname>University of Pennsylvania</affilname><name-variant>University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006297</affiliation-url><afid>60006297</afid><affilname>University of Pennsylvania</affilname><name-variant>University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006297</affiliation-url><afid>60006297</afid><affilname>University of Pennsylvania</affilname><name-variant>University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005281</affiliation-url><afid>60005281</afid><affilname>National Heart, Lung, and Blood Institute</affilname><name-variant>NIH</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006297</affiliation-url><afid>60006297</afid><affilname>University of Pennsylvania</affilname><name-variant>University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35770427900</author-url><authid>35770427900</authid><authname>Contijoch F.</authname><surname>Contijoch</surname><given-name>Francisco</given-name><initials>F.</initials><afid>60006297</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15761650600</author-url><authid>15761650600</authid><authname>Witschey W.</authname><surname>Witschey</surname><given-name>Walter R T</given-name><initials>W.R.T.</initials><afid>60006297</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56609749700</author-url><authid>56609749700</authid><authname>Rogers K.</authname><surname>Rogers</surname><given-name>Kelly</given-name><initials>K.</initials><afid>60006297</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56610194900</author-url><authid>56610194900</authid><authname>Rears H.</authname><surname>Rears</surname><given-name>Hannah</given-name><initials>H.</initials><afid>60006297</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35562748700</author-url><authid>35562748700</authid><authname>Hansen M.</authname><surname>Hansen</surname><given-name>Michael</given-name><initials>M.</initials><afid>60005281</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602550724</author-url><authid>6602550724</authid><authname>Yushkevich P.</authname><surname>Yushkevich</surname><given-name>Paul</given-name><initials>P.</initials><afid>60006297</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35427943700</author-url><authid>35427943700</authid><authname>Gorman J.</authname><surname>Gorman</surname><given-name>Joseph</given-name><initials>J.</initials><afid>60006297</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:34770566800</author-url><authid>34770566800</authid><authname>Gorman R.</authname><surname>Gorman</surname><given-name>Robert C.</given-name><initials>R.C.</initials><afid>60006297</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56135832200</author-url><authid>56135832200</authid><authname>Han Y.</authname><surname>Han</surname><given-name>Yuchi</given-name><initials>Y.</initials><afid>60006297</afid></author><authkeywords>Arrhythmia | Real-time CMR | Temporal resolution</authkeywords><intid>35955903</intid><source-id>23845</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929687739"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929687739?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929687739&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929687739&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929687739</prism:url><dc:identifier>SCOPUS_ID:84929687739</dc:identifier><eid>2-s2.0-84929687739</eid><dc:title>Utility of cardiac computed tomography for evaluation of pannus in mechanical aortic valve</dc:title><dc:creator>Suh Y.</dc:creator><prism:publicationName>International Journal of Cardiovascular Imaging</prism:publicationName><prism:issn>15695794</prism:issn><prism:eIssn>15730743</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10554-015-0683-1</prism:doi><dc:description>© 2015 Springer Science+Business Media Dordrecht The clinical significance of pannus detected on computed tomography (CT) has not yet been investigated. The purposes of this study were to investigate the clinical significance of pannus detected on cardiac CT in patients who underwent aortic valve replacement (AVR) with mechanical valves, and to determine predictors for pannus severity. A total of 92 patients who underwent cardiac CT and TTE and who had undergone mechanical AVR were included. The geometric orifice area (GOA), the presence of limitation of motion (LOM) and pannus were evaluated on CT. The GOA, presence of LOM, and presence and severity of pannus were compared with echocardiographic parameters. Logistic regression analysis was performed to determine the predictors for pannus severity. The GOA on CT positively correlated with effective orifice area on TTE (r = 0.733, P &lt; 0.0001). Pannus was found in 77.2 % and LOM in 14.0 %. With increasing pannus severity, mean transvalvular pressure gradient (PG) was significantly higher (P &lt; 0.0001). Patients with elevated PG showed a smaller GOA, a higher incidence of pannus, more severe pannus and LOM than patients with normal PG (P &lt; 0.05). Small valve size (≤19 mm), Carbomedics valve, rheumatic etiology, and young age at AVR (&lt;48.8 years) were independent predictors of moderate to severe pannus (P &lt; 0.05). Cardiac CT is helpful in the evaluation of pannus formation in patients with mechanical aortic valves. Moderate to severe pannus formation frequently occurred in patients with small mechanical valve size, Carbomedics valves, rheumatic heart disease and young age at AVR.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60095571</affiliation-url><afid>60095571</afid><affilname>Severance Hospital</affilname><name-variant>Yonsei University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016728</affiliation-url><afid>60016728</afid><affilname>Yonsei University College of Medicine</affilname><name-variant>Yonsei University College of Medicine</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56486903000</author-url><authid>56486903000</authid><authname>Suh Y.</authname><surname>Suh</surname><given-name>Young Joo</given-name><initials>Y.J.</initials><afid>60095571</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36062692700</author-url><authid>36062692700</authid><authname>Kim Y.</authname><surname>Kim</surname><given-name>Young Jin</given-name><initials>Y.J.</initials><afid>60095571</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55901563200</author-url><authid>55901563200</authid><authname>Lee S.</authname><surname>Lee</surname><given-name>Sak</given-name><initials>S.</initials><afid>60016728</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:14019471200</author-url><authid>14019471200</authid><authname>Hong Y.</authname><surname>Hong</surname><given-name>Yoo Jin</given-name><initials>Y.J.</initials><afid>60095571</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56144770400</author-url><authid>56144770400</authid><authname>Lee H.</authname><surname>Lee</surname><given-name>Hye Jeong</given-name><initials>H.J.</initials><afid>60095571</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56486996400</author-url><authid>56486996400</authid><authname>Hur J.</authname><surname>Hur</surname><given-name>Jin</given-name><initials>J.</initials><afid>60095571</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:16554128500</author-url><authid>16554128500</authid><authname>Choi B.</authname><surname>Choi</surname><given-name>Byoung Wook</given-name><initials>B.W.</initials><afid>60095571</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7402600338</author-url><authid>7402600338</authid><authname>Chang B.</authname><surname>Chang</surname><given-name>Byung Chul</given-name><initials>B.C.</initials><afid>60016728</afid></author><authkeywords>Aortic valve replacement | Computed tomography | Mechanical valve | Pannus formation</authkeywords><intid>1785998335</intid><source-id>37971</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929625956"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929625956?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929625956&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929625956&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929625956</prism:url><dc:identifier>SCOPUS_ID:84929625956</dc:identifier><eid>2-s2.0-84929625956</eid><dc:title>Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes</dc:title><dc:creator>von Scholten B.</dc:creator><prism:publicationName>Cardiovascular Diabetology</prism:publicationName><prism:eIssn>14752840</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>May 21, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12933-015-0225-0</prism:doi><dc:description>© 2015 von Scholten et al. Background: In patients with type 2 diabetes, cardiovascular disease (CVD) is the major cause of morbidity and mortality. We evaluated the combination of NT-proBNP and coronary artery calcium score (CAC) for prediction of combined fatal and non-fatal CVD and mortality in patients with type 2 diabetes and microalbuminuria (&gt;30 mg/24-h), but without known coronary artery disease. Moreover, we assessed the predictive value of a predefined categorisation of patients into a high- and low-risk group at baseline. Methods: Prospective study including 200 patients. All received intensive multifactorial treatment. Patients with baseline NT-proBNP &gt;45.2 ng/L and/or CAC ≥400 were stratified as high-risk patients (n = 133). Occurrence of fatal- and nonfatal CVD (n = 40) and mortality (n = 26), was traced after 6.1 years (median). Results: High-risk patients had a higher risk of the composite CVD endpoint (adjusted hazard ratio [HR] 10.6 (95 % confidence interval [CI] 2.4-46.3); p = 0.002) and mortality (adjusted HR 5.3 (95 % CI 1.2-24.0); p = 0.032) compared to low-risk patients. In adjusted continuous analysis, both higher NT-proBNP and CAC were strong predictors of the composite CVD endpoint and mortality (p ≤ 0.0001). In fully adjusted models mutually including NT-proBNP and CAC, both risk factors remained associated with risk of CVD and mortality (p ≤ 0.022). There was no interaction between NT-proBNP and CAC for the examined endpoints (p ≥ 0.31). Conclusions: In patients with type 2 diabetes and microalbuminuria but without known coronary artery disease, NT-proBNP and CAC were strongly associated with fatal and nonfatal CVD, as well as with mortality. Their additive prognostic capability holds promise for identification of patients at high risk.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016428</affiliation-url><afid>60016428</afid><affilname>Steno Diabetes Center</affilname><name-variant>Steno Diabetes Center</name-variant><affiliation-city>Gentofte</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007006</affiliation-url><afid>60007006</afid><affilname>Frederiksberg Hospital</affilname><name-variant>Frederiksberg Hospital</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014959</affiliation-url><afid>60014959</afid><affilname>Amtssygehuset i Gentofte</affilname><name-variant>Gentofte Hospital</name-variant><affiliation-city>Hellerup</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006564</affiliation-url><afid>60006564</afid><affilname>Rigshospitalet</affilname><name-variant>Copenhagen University Hospital</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029616</affiliation-url><afid>60029616</afid><affilname>Aarhus Universitet</affilname><name-variant>University of Aarhus</name-variant><affiliation-city>Aarhus</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55776817100</author-url><authid>55776817100</authid><authname>von Scholten B.</authname><surname>von Scholten</surname><given-name>Bernt Johan</given-name><initials>B.J.</initials><afid>60016428</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35410412800</author-url><authid>35410412800</authid><authname>Reinhard H.</authname><surname>Reinhard</surname><given-name>Henrik</given-name><initials>H.</initials><afid>60016428</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35274875200</author-url><authid>35274875200</authid><authname>Hansen T.</authname><surname>Hansen</surname><given-name>Tine Willum</given-name><initials>T.W.</initials><afid>60016428</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55972505900</author-url><authid>55972505900</authid><authname>Lindhardt M.</authname><surname>Lindhardt</surname><given-name>Morten</given-name><initials>M.</initials><afid>60016428</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7202258266</author-url><authid>7202258266</authid><authname>Petersen C.</authname><surname>Petersen</surname><given-name>Claus Leth</given-name><initials>C.L.</initials><afid>60030840</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603906186</author-url><authid>6603906186</authid><authname>Wiinberg N.</authname><surname>Wiinberg</surname><given-name>Niels</given-name><initials>N.</initials><afid>60007006</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7403236446</author-url><authid>7403236446</authid><authname>Hansen P.</authname><surname>Hansen</surname><given-name>Peter Riis</given-name><initials>P.R.</initials><afid>60014959</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56240680800</author-url><authid>56240680800</authid><authname>Parving H.</authname><surname>Parving</surname><given-name>Hans Henrik</given-name><initials>H.H.</initials><afid>60006564</afid><afid>60030840</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56240680800</author-url><authid>56240680800</authid><authname>Parving H.</authname><surname>Parving</surname><given-name>Hans Henrik</given-name><initials>H.H.</initials><afid>60006564</afid><afid>60030840</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7101913318</author-url><authid>7101913318</authid><authname>Jacobsen P.</authname><surname>Jacobsen</surname><given-name>Peter Karl</given-name><initials>P.K.</initials><afid>60030840</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005170096</author-url><authid>7005170096</authid><authname>Rossing P.</authname><surname>Rossing</surname><given-name>Peter</given-name><initials>P.</initials><afid>60016428</afid><afid>60030840</afid><afid>60029616</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005170096</author-url><authid>7005170096</authid><authname>Rossing P.</authname><surname>Rossing</surname><given-name>Peter</given-name><initials>P.</initials><afid>60016428</afid><afid>60030840</afid><afid>60029616</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005170096</author-url><authid>7005170096</authid><authname>Rossing P.</authname><surname>Rossing</surname><given-name>Peter</given-name><initials>P.</initials><afid>60016428</afid><afid>60030840</afid><afid>60029616</afid></author><intid>1535989962</intid><article-number>59</article-number><source-id>25441</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929698389"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929698389?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929698389&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929698389&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929698389</prism:url><dc:identifier>SCOPUS_ID:84929698389</dc:identifier><eid>2-s2.0-84929698389</eid><dc:title>Recombinant Tissue Plasminogen Activator in the Treatment of Neonates with Intracardiac and Great Vessels Thrombosis</dc:title><dc:creator>El-Segaier M.</dc:creator><prism:publicationName>Pediatric Cardiology</prism:publicationName><prism:issn>01720643</prism:issn><prism:eIssn>14321971</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00246-015-1199-0</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Abstract: Life-threatening intracardiac and great vessels thrombi are rare in neonates. Recombinant tissue plasminogen activator (rTPA) is used in adults to stimulate fibrinolysis and facilitate thrombus resolution. Its use in neonates, along with heparin, remains controversial because of potential risk of serious bleeding. We aim to present our experience with the use of thrombolytic agents in seven neonates and young infants. In a retrospective study, over a period of 6 years, the medical records of neonates and young infants, who were diagnosed with intracardiac and great vessels thrombi, were reviewed. The following factors were collected: demographic data, primary diagnosis, thrombus site, risk factors, method of diagnosis, thrombolytic and/or anticoagulation agent, route, dose and duration of treatment, complications, and outcome. Six neonates and one 45-day-old infant were analyzed. Age ranged from 5 to 45 days (median age 12 days), and median weight was 2.9 kg (range 0.9–3.8 kg). The thrombi were diagnosed by echocardiography in five and by angiography in two cases. All patients had life-threatening thrombi; four were treated with rTPA (0.5 mg kg&lt;sup&gt;−1&lt;/sup&gt; h&lt;sup&gt;−1&lt;/sup&gt;) and heparin infusions with complete dissolution of the thrombi, within a median time of 60 h (6–72 h), and without complications. The remaining three patients (two who were premature, at 28 and 34 weeks of gestation, and the third who had a deranged coagulation profile) were treated with unfractionated heparin due to fear of bleeding. The thrombi dissolved in the premature babies (within 2 weeks and 3 months, respectively) but embolized and resulted in the death of the third infant after 2 weeks of treatment. The current case series confirmed the effectiveness and safety of intravenous rTPA infusion, at the dosages used, in neonates and young infants with life-threatening thrombi.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114820795</affiliation-url><afid>114820795</afid><affilname>Prince Salman Heart Center</affilname><name-variant>King Salman Heart Center</name-variant><affiliation-city>Riyadh</affiliation-city><affiliation-country>Saudi Arabia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014077</affiliation-url><afid>60014077</afid><affilname>Universitssjukhuset i Lund</affilname><name-variant>University Hospital</name-variant><affiliation-city>Lund</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014264</affiliation-url><afid>60014264</afid><affilname>Universitat Duisburg-Essen</affilname><name-variant>University of Essen</name-variant><affiliation-city>Essen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106701122</affiliation-url><afid>106701122</afid><affilname>Comprehensive Cancer Center</affilname><name-variant>Comprehensive Cancer Centre</name-variant><affiliation-city>Riyadh</affiliation-city><affiliation-country>Saudi Arabia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8921117200</author-url><authid>8921117200</authid><authname>El-Segaier M.</authname><surname>El-Segaier</surname><given-name>Milad</given-name><initials>M.</initials><afid>114820795</afid><afid>60014077</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8921117200</author-url><authid>8921117200</authid><authname>El-Segaier M.</authname><surname>El-Segaier</surname><given-name>Milad</given-name><initials>M.</initials><afid>114820795</afid><afid>60014077</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36999972900</author-url><authid>36999972900</authid><authname>Khan M.</authname><surname>Khan</surname><given-name>Muhammad A.</given-name><initials>M.A.</initials><afid>114820795</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56653005300</author-url><authid>56653005300</authid><authname>Khan Z.</authname><surname>Khan</surname><given-name>Zaheer Ullah</given-name><initials>Z.U.</initials><afid>106701122</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:9846510800</author-url><authid>9846510800</authid><authname>Momenah T.</authname><surname>Momenah</surname><given-name>Tarek</given-name><initials>T.</initials><afid>114820795</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003879467</author-url><authid>7003879467</authid><authname>Galal M.</authname><surname>Galal</surname><given-name>Mohammed Omar</given-name><initials>M.O.</initials><afid>114820795</afid><afid>60014264</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003879467</author-url><authid>7003879467</authid><authname>Galal M.</authname><surname>Galal</surname><given-name>Mohammed Omar</given-name><initials>M.O.</initials><afid>114820795</afid><afid>60014264</afid></author><authkeywords>Neonates | Thrombolysis | Thrombosis | Tissue plasminogen activator (rTPA)</authkeywords><intid>35996018</intid><source-id>20526</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929688381"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929688381?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929688381&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929688381&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929688381</prism:url><dc:identifier>SCOPUS_ID:84929688381</dc:identifier><eid>2-s2.0-84929688381</eid><dc:title>Myocardial blood flow quantification by Rb-82 cardiac PET/CT: A detailed reproducibility study between two semi-automatic analysis programs</dc:title><dc:creator>Dunet V.</dc:creator><prism:publicationName>Journal of Nuclear Cardiology</prism:publicationName><prism:issn>10713581</prism:issn><prism:eIssn>15326551</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12350-015-0151-2</prism:doi><dc:description>© 2015 The Author(s) Background: Several analysis software packages for myocardial blood flow (MBF) quantification from cardiac PET studies exist, but they have not been compared using concordance analysis, which can characterize precision and bias separately. Reproducible measurements are needed for quantification to fully develop its clinical potential. Methods: Fifty-one patients underwent dynamic Rb-82 PET at rest and during adenosine stress. Data were processed with PMOD and FlowQuant (Lortie model). MBF and myocardial flow reserve (MFR) polar maps were quantified and analyzed using a 17-segment model. Comparisons used Pearson’s correlation ρ (measuring precision), Bland and Altman limit-of-agreement and Lin’s concordance correlation ρ&lt;inf&gt;c&lt;/inf&gt; = ρ·C&lt;inf&gt;b&lt;/inf&gt; (C&lt;inf&gt;b&lt;/inf&gt; measuring systematic bias). Results: Lin’s concordance and Pearson’s correlation values were very similar, suggesting no systematic bias between software packages with an excellent precision ρ for MBF (ρ = 0.97, ρ&lt;inf&gt;c&lt;/inf&gt; = 0.96, C&lt;inf&gt;b&lt;/inf&gt; = 0.99) and good precision for MFR (ρ = 0.83, ρ&lt;inf&gt;c&lt;/inf&gt; = 0.76, C&lt;inf&gt;b&lt;/inf&gt; = 0.92). On a per-segment basis, no mean bias was observed on Bland-Altman plots, although PMOD provided slightly higher values than FlowQuant at higher MBF and MFR values (P &lt; .0001). Conclusions: Concordance between software packages was excellent for MBF and MFR, despite higher values by PMOD at higher MBF values. Both software packages can be used interchangeably for quantification in daily practice of Rb-82 cardiac PET.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023561</affiliation-url><afid>60023561</afid><affilname>Centre Hospitalier Universitaire Vaudois</affilname><name-variant>CHUV</name-variant><affiliation-city>Lausanne</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011635</affiliation-url><afid>60011635</afid><affilname>University of Ottawa Heart Institute</affilname><name-variant>University of Ottawa Heart Institute</name-variant><affiliation-city>Ottawa</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26427631400</author-url><authid>26427631400</authid><authname>Dunet V.</authname><surname>Dunet</surname><given-name>Vincent</given-name><initials>V.</initials><afid>60023561</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:16199747300</author-url><authid>16199747300</authid><authname>Klein R.</authname><surname>Klein</surname><given-name>Ran</given-name><initials>R.</initials><afid>60011635</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:19638634500</author-url><authid>19638634500</authid><authname>Allenbach G.</authname><surname>Allenbach</surname><given-name>Gilles</given-name><initials>G.</initials><afid>60023561</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35273141500</author-url><authid>35273141500</authid><authname>Renaud J.</authname><surname>Renaud</surname><given-name>Jennifer</given-name><initials>J.</initials><afid>60011635</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701554397</author-url><authid>6701554397</authid><authname>DeKemp R.</authname><surname>DeKemp</surname><given-name>Robert A.</given-name><initials>R.A.</initials><afid>60011635</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7103261783</author-url><authid>7103261783</authid><authname>Prior J.</authname><surname>Prior</surname><given-name>John O.</given-name><initials>J.O.</initials><afid>60023561</afid></author><authkeywords>accuracy | agreement | comparison | concordance | myocardial perfusion | PET | precision | quantification | rubidium-82 | Software</authkeywords><intid>35997266</intid><source-id>17229</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930089349"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930089349?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930089349&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930089349&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0092867415003761"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930089349</prism:url><dc:identifier>SCOPUS_ID:84930089349</dc:identifier><eid>2-s2.0-84930089349</eid><dc:title>Multivalent microtubule recognition by tubulin tyrosine ligase-like family glutamylases</dc:title><dc:creator>Garnham C.</dc:creator><prism:publicationName>Cell</prism:publicationName><prism:issn>00928674</prism:issn><prism:eIssn>10974172</prism:eIssn><prism:volume>161</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>1112-1123</prism:pageRange><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cell.2015.04.003</prism:doi><pii>S0092867415003761</pii><dc:description>© 2015 Elsevier Inc. Glutamylation, the most prevalent tubulin posttranslational modification, marks stable microtubules and regulates recruitment and activity of microtubule- interacting proteins. Nine enzymes of the tubulin tyrosine ligase-like (TTLL) family catalyze glutamylation. TTLL7, the most abundant neuronal glutamylase, adds glutamates preferentially to the β-tubulin tail. Coupled with ensemble and single-molecule biochemistry, our hybrid X-ray and cryo-electron microscopy structure of TTLL7 bound to the microtubule delineates a tripartite microtubule recognition strategy. The enzyme uses its core to engage the disordered anionic tails of α- and β-tubulin, and a flexible cationic domain to bind the microtubule and position itself for β-tail modification. Furthermore, we demonstrate that all single-chain TTLLs with known glutamylase activity utilize a cationic microtubule-binding domain analogous to that of TTLL7. Therefore, our work reveals the combined use of folded and intrinsically disordered substrate recognition elements as the molecular basis for specificity among the enzymes primarily responsible for chemically diversifying cellular microtubules.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013780</affiliation-url><afid>60013780</afid><affilname>National Institute of Neurological Disorders and Stroke</affilname><name-variant>NIH</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007103</affiliation-url><afid>60007103</afid><affilname>Scripps Research Institute</affilname><name-variant>Scripps Research Institute</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101480534</affiliation-url><afid>101480534</afid><affilname>National Heart</affilname><name-variant>National Heart</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14518878000</author-url><authid>14518878000</authid><authname>Garnham C.</authname><surname>Garnham</surname><given-name>Christopher P.</given-name><initials>C.P.</initials><afid>60013780</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55617885800</author-url><authid>55617885800</authid><authname>Vemu A.</authname><surname>Vemu</surname><given-name>Annapurna</given-name><initials>A.</initials><afid>60013780</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6603002624</author-url><authid>6603002624</authid><authname>Wilson-Kubalek E.</authname><surname>Wilson-Kubalek</surname><given-name>Elizabeth M.</given-name><initials>E.M.</initials><afid>60007103</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56622250400</author-url><authid>56622250400</authid><authname>Yu I.</authname><surname>Yu</surname><given-name>Ian</given-name><initials>I.</initials><afid>60013780</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701563670</author-url><authid>6701563670</authid><authname>Szyk A.</authname><surname>Szyk</surname><given-name>Agnieszka</given-name><initials>A.</initials><afid>60013780</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56622461300</author-url><authid>56622461300</authid><authname>Lander G.</authname><surname>Lander</surname><given-name>Gabriel C.</given-name><initials>G.C.</initials><afid>60007103</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005070569</author-url><authid>7005070569</authid><authname>Milligan R.</authname><surname>Milligan</surname><given-name>Ronald A.</given-name><initials>R.A.</initials><afid>60007103</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6506959001</author-url><authid>6506959001</authid><authname>Roll-Mecak A.</authname><surname>Roll-Mecak</surname><given-name>Antonina</given-name><initials>A.</initials><afid>60013780</afid><afid>101480534</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6506959001</author-url><authid>6506959001</authid><authname>Roll-Mecak A.</authname><surname>Roll-Mecak</surname><given-name>Antonina</given-name><initials>A.</initials><afid>60013780</afid><afid>101480534</afid></author><intid>1036058683</intid><source-id>18434</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929693053"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929693053?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929693053&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929693053&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929693053</prism:url><dc:identifier>SCOPUS_ID:84929693053</dc:identifier><eid>2-s2.0-84929693053</eid><dc:title>Clinical Feasibility of 3D Automated Coronary Atherosclerotic Plaque Quantification Algorithm on Coronary Computed Tomography Angiography: Comparison with Intravascular Ultrasound</dc:title><dc:creator>Park H.</dc:creator><prism:publicationName>European Radiology</prism:publicationName><prism:issn>09387994</prism:issn><prism:eIssn>14321084</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00330-015-3698-z</prism:doi><dc:description>© 2015 European Society of Radiology Objective: To evaluate the diagnostic performance of automated coronary atherosclerotic plaque quantification (QCT) by different users (expert/non-expert/automatic). Methods: One hundred fifty coronary artery segments from 142 patients who underwent coronary computed tomography angiography (CCTA) and intravascular ultrasound (IVUS) were analyzed. Minimal lumen area (MLA), maximal lumen area stenosis percentage (%AS), mean plaque burden percentage (%PB), and plaque volume were measured semi-automatically by expert, non-expert, and fully automatic QCT analyses, and then compared to IVUS. Results: Between IVUS and expert QCT analysis, the correlation coefficients (r) for the MLA, %AS, %PB, and plaque volume were excellent: 0.89 (p &lt; 0.001), 0.84 (p &lt; 0.001), 0.91 (p &lt; 0.001), and 0.94 (p &lt; 0.001), respectively. There were no significant differences in the mean parameters (all p values &gt;0.05) except %AS (p = 0.01). The automatic QCT analysis showed comparable performance to non-expert QCT analysis, showing correlation coefficients (r) of the MLA (0.80 vs. 0.82), %AS (0.82 vs. 0.80), %PB (0.84 vs. 0.73), and plaque volume (0.84 vs. 0.79) when they were compared to IVUS, respectively. Conclusion: Fully automatic QCT analysis showed clinical utility compared with IVUS, as well as a compelling performance when compared with semiautomatic analyses. Key Points: • Coronary CTA enables the assessment of coronary atherosclerotic plaque. • High-risk plaque characteristics and overall plaque burden can predict future cardiac events. • Coronary atherosclerotic plaque quantification is currently unfeasible in practice. • Quantitative computed tomography coronary plaque analysis software (QCT) enables feasible plaque quantification. • Fully automatic QCT analysis shows excellent performance.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60094974</affiliation-url><afid>60094974</afid><affilname>Yonsei University Health System</affilname><name-variant>Yonsei University Health System</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014200</affiliation-url><afid>60014200</afid><affilname>Myongji University</affilname><name-variant>Myong Ji University</name-variant><affiliation-city>Yongin</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60095571</affiliation-url><afid>60095571</afid><affilname>Severance Hospital</affilname><name-variant>Yonsei University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60094218</affiliation-url><afid>60094218</afid><affilname>National Health Insurance Cooperation Ilsan Hospital</affilname><name-variant>National Health Insurance Corporation</name-variant><affiliation-city>Iksan</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60094974</affiliation-url><afid>60094974</afid><affilname>Yonsei University Health System</affilname><name-variant>Yonsei University Health System</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016173</affiliation-url><afid>60016173</afid><affilname>Cedars-Sinai Medical Center</affilname><name-variant>Cedars-Sinai Medical Center</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015618</affiliation-url><afid>60015618</afid><affilname>Leiden University Medical Center - LUMC</affilname><name-variant>University Hospital</name-variant><affiliation-city>Leiden</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109412378</affiliation-url><afid>109412378</afid><affilname>Medis Medical Imaging Systems BV</affilname><name-variant>Medis Medical Imaging Systems bv</name-variant><affiliation-city>Leiden</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016912</affiliation-url><afid>60016912</afid><affilname>Yonsei University</affilname><name-variant>Yonsei University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018043</affiliation-url><afid>60018043</afid><affilname>New York Presbyterian Hospital</affilname><name-variant>New York Presbyterian Hospital</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">20</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56652775800</author-url><authid>56652775800</authid><authname>Park H.</authname><surname>Park</surname><given-name>Hyung Bok</given-name><initials>H.B.</initials><afid>60094974</afid><afid>60014200</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56652775800</author-url><authid>56652775800</authid><authname>Park H.</authname><surname>Park</surname><given-name>Hyung Bok</given-name><initials>H.B.</initials><afid>60094974</afid><afid>60014200</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56652785200</author-url><authid>56652785200</authid><authname>Lee B.</authname><surname>Lee</surname><given-name>Byoung Kwon</given-name><initials>B.K.</initials><afid>60095571</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56652872200</author-url><authid>56652872200</authid><authname>Shin S.</authname><surname>Shin</surname><given-name>Sanghoon</given-name><initials>S.</initials><afid>60094974</afid><afid>60094218</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56652872200</author-url><authid>56652872200</authid><authname>Shin S.</authname><surname>Shin</surname><given-name>Sanghoon</given-name><initials>S.</initials><afid>60094974</afid><afid>60094218</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602654091</author-url><authid>6602654091</authid><authname>Heo R.</authname><surname>Heo</surname><given-name>Ran</given-name><initials>R.</initials><afid>60094974</afid><afid>60094974</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602654091</author-url><authid>6602654091</authid><authname>Heo R.</authname><surname>Heo</surname><given-name>Ran</given-name><initials>R.</initials><afid>60094974</afid><afid>60094974</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36835294300</author-url><authid>36835294300</authid><authname>Arsanjani R.</authname><surname>Arsanjani</surname><given-name>Reza</given-name><initials>R.</initials><afid>60016173</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:24343922100</author-url><authid>24343922100</authid><authname>Kitslaar P.</authname><surname>Kitslaar</surname><given-name>Pieter H.</given-name><initials>P.H.</initials><afid>60015618</afid><afid>109412378</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:24343922100</author-url><authid>24343922100</authid><authname>Kitslaar P.</authname><surname>Kitslaar</surname><given-name>Pieter H.</given-name><initials>P.H.</initials><afid>60015618</afid><afid>109412378</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:15753317700</author-url><authid>15753317700</authid><authname>Broersen A.</authname><surname>Broersen</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60015618</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7101611206</author-url><authid>7101611206</authid><authname>Dijkstra J.</authname><surname>Dijkstra</surname><given-name>Jouke</given-name><initials>J.</initials><afid>60015618</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56652911500</author-url><authid>56652911500</authid><authname>Ahn S.</authname><surname>Ahn</surname><given-name>Sung Gyun</given-name><initials>S.G.</initials><afid>60016912</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56545044800</author-url><authid>56545044800</authid><authname>Min J.</authname><surname>Min</surname><given-name>James K.</given-name><initials>J.K.</initials><afid>60018043</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:8893464800</author-url><authid>8893464800</authid><authname>Chang H.</authname><surname>Chang</surname><given-name>Hyuk Jae</given-name><initials>H.J.</initials><afid>60094974</afid><afid>60094974</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:8893464800</author-url><authid>8893464800</authid><authname>Chang H.</authname><surname>Chang</surname><given-name>Hyuk Jae</given-name><initials>H.J.</initials><afid>60094974</afid><afid>60094974</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56652954000</author-url><authid>56652954000</authid><authname>Hong M.</authname><surname>Hong</surname><given-name>Myeong Ki</given-name><initials>M.K.</initials><afid>60094974</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56652970100</author-url><authid>56652970100</authid><authname>Jang Y.</authname><surname>Jang</surname><given-name>Yangsoo</given-name><initials>Y.</initials><afid>60094974</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:56425282100</author-url><authid>56425282100</authid><authname>Chung N.</authname><surname>Chung</surname><given-name>Namsik</given-name><initials>N.</initials><afid>60094974</afid><afid>60094974</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:56425282100</author-url><authid>56425282100</authid><authname>Chung N.</authname><surname>Chung</surname><given-name>Namsik</given-name><initials>N.</initials><afid>60094974</afid><afid>60094974</afid></author><authkeywords>Automatic quantification | Coronary atherosclerotic plaque | Coronary computed tomography angiography | Intravascular ultrasound | Plaque volume</authkeywords><intid>35997025</intid><source-id>16687</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929677873"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929677873?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929677873&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929677873&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929677873</prism:url><dc:identifier>SCOPUS_ID:84929677873</dc:identifier><eid>2-s2.0-84929677873</eid><dc:title>Gastric Band Surgery Leads to Improved Insulin Secretion in Overweight People with Type 2 Diabetes</dc:title><dc:creator>Wentworth J.</dc:creator><prism:publicationName>Obesity Surgery</prism:publicationName><prism:issn>09608923</prism:issn><prism:eIssn>17080428</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11695-015-1716-5</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Background: We aimed to determine the effects of laparoscopic adjustable gastric band (LAGB) on beta-cell function in overweight people with type 2 diabetes and to assess the relationship between baseline beta-cell function and glycemic outcomes. Methods: We studied 44 overweight but not obese people with type 2 diabetes who participated in a randomized trial whose primary outcome was the rate of diabetes remission after 2 years of multidisciplinary diabetes care (MDC group) or multidisciplinary care combined with LAGB. Dynamic beta-cell function was assessed by intravenous glucose challenge, and basal beta-cell function (HOMA-B) and insulin sensitivity (HOMA-S) were determined using the homeostatic model. Results: Twelve LAGB participants and two MDC participants were in diabetes remission at 2 years. HOMA-S and the C-peptide response to intravenous glucose increased significantly in LAGB but not in MDC participants. The insulin response to glucose did not change in LAGB participants, whereas their fasting C-peptide/insulin ratio increased. Baseline measures of beta-cell function correlated with diabetes remission but not with reduction in HbA1c following LAGB. Conclusions: In overweight people with diabetes, LAGB improves endogenous beta-cell function after 2 years. Baseline beta-cell function correlated with diabetes remission, but not with HbA1c change following LAGB.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019578</affiliation-url><afid>60019578</afid><affilname>Monash University</affilname><name-variant>Monash University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112578414</affiliation-url><afid>112578414</afid><affilname>Population Health and Immunity Division</affilname><name-variant>Immunity Divisions</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033409</affiliation-url><afid>60033409</afid><affilname>Baker IDI Heart and Diabetes Institute</affilname><name-variant>Baker Heart Research Institute</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55668448000</author-url><authid>55668448000</authid><authname>Wentworth J.</authname><surname>Wentworth</surname><given-name>John M.</given-name><initials>J.M.</initials><afid>60019578</afid><afid>112578414</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55668448000</author-url><authid>55668448000</authid><authname>Wentworth J.</authname><surname>Wentworth</surname><given-name>John M.</given-name><initials>J.M.</initials><afid>60019578</afid><afid>112578414</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:23470684000</author-url><authid>23470684000</authid><authname>Playfair J.</authname><surname>Playfair</surname><given-name>Julie</given-name><initials>J.</initials><afid>60019578</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7004335715</author-url><authid>7004335715</authid><authname>Laurie C.</authname><surname>Laurie</surname><given-name>Cheryl</given-name><initials>C.</initials><afid>60019578</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7404195776</author-url><authid>7404195776</authid><authname>Brown W.</authname><surname>Brown</surname><given-name>Wendy A.</given-name><initials>W.A.</initials><afid>60019578</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:26532264000</author-url><authid>26532264000</authid><authname>Burton P.</authname><surname>Burton</surname><given-name>Paul</given-name><initials>P.</initials><afid>60019578</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7403898480</author-url><authid>7403898480</authid><authname>Shaw J.</authname><surname>Shaw</surname><given-name>Jonathan E.</given-name><initials>J.E.</initials><afid>60033409</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56382411700</author-url><authid>56382411700</authid><authname>O’Brien P.</authname><surname>O’Brien</surname><given-name>Paul E.</given-name><initials>P.E.</initials><afid>60019578</afid></author><authkeywords>Bariatric surgery | Beta-cell function | Diabetes remission | First-phase insulin release | IVGTT | Type 2 diabetes | Weight loss</authkeywords><intid>1035993240</intid><source-id>22130</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929682998"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929682998?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929682998&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929682998&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929682998</prism:url><dc:identifier>SCOPUS_ID:84929682998</dc:identifier><eid>2-s2.0-84929682998</eid><dc:title>Targeted Overexpression of Astrocytic Endothelin-1 Attenuates Neuropathic Pain by Upregulating Spinal Excitatory Amino Acid Transporter-2</dc:title><dc:creator>Hung V.</dc:creator><prism:publicationName>Journal of Molecular Neuroscience</prism:publicationName><prism:issn>08958696</prism:issn><prism:eIssn>15591166</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12031-015-0581-y</prism:doi><dc:description>© 2015 Springer Science+Business Media New York We previously demonstrated that endogenous endothelin-1 (ET-1) inhibits pathological pain in a transgenic mouse model with astrocyte-specific ET-1 overexpression (GET-1 mice); however, the underlying mechanism is unclear. ET-1 regulates excitatory amino acid transporter-2 (EAAT-2), a predominant subtype of glutamate transporters that plays critical role in pain modulation in spinal astrocytes. We hypothesized that astrocytic ET-1 overexpression alleviates neuropathic pain through modulating EAAT-2. GET-1 or nontransgenic (NTg) mice either received sham operation or sciatic nerve ligation (SNL) with or without ceftriaxone (CEF, an EAAT-2 inducer, for 4 days before termination). In GET-1 mice, mRNA and protein expressions of EAAT-2, but not EAAT-1, were upregulated associated with reduced SNL-induced neuropathic pain. Despite that SNL induced a significant reduction of EAAT-2 mRNA expression in both genotypes of mice, post-SNL EAAT-2 mRNA expression was higher in GET-1 mice than that in NTg mice. EAAT-2 induction by CEF reduced SNL-induced neuropathic pain in both NTg and GET-1 mice. In cultured rat astrocytic cell line, overexpression of ET-1 mRNA expression also elevated EAAT-2 mRNA expression, which was reversed by ET receptor antagonists. In conclusion, overexpressed astrocytic ET-1 suppressed neuropathic pain by upregulating spinal EAAT-2 expression via ET receptors.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006541</affiliation-url><afid>60006541</afid><affilname>The University of Hong Kong</affilname><name-variant>University of Hong Kong</name-variant><affiliation-city>Pokfulam</affiliation-city><affiliation-country>Hong Kong</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006541</affiliation-url><afid>60006541</afid><affilname>The University of Hong Kong</affilname><name-variant>University of Hong Kong</name-variant><affiliation-city>Pokfulam</affiliation-city><affiliation-country>Hong Kong</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006541</affiliation-url><afid>60006541</afid><affilname>The University of Hong Kong</affilname><name-variant>University of Hong Kong</name-variant><affiliation-city>Pokfulam</affiliation-city><affiliation-country>Hong Kong</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006541</affiliation-url><afid>60006541</afid><affilname>The University of Hong Kong</affilname><name-variant>University of Hong Kong</name-variant><affiliation-city>Pokfulam</affiliation-city><affiliation-country>Hong Kong</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55112576200</author-url><authid>55112576200</authid><authname>Hung V.</authname><surname>Hung</surname><given-name>Victor K L</given-name><initials>V.K.L.</initials><afid>60006541</afid><afid>60006541</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55112576200</author-url><authid>55112576200</authid><authname>Hung V.</authname><surname>Hung</surname><given-name>Victor K L</given-name><initials>V.K.L.</initials><afid>60006541</afid><afid>60006541</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55324287000</author-url><authid>55324287000</authid><authname>Tai L.</authname><surname>Tai</surname><given-name>Lydia W.</given-name><initials>L.W.</initials><afid>60006541</afid><afid>60006541</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55324287000</author-url><authid>55324287000</authid><authname>Tai L.</authname><surname>Tai</surname><given-name>Lydia W.</given-name><initials>L.W.</initials><afid>60006541</afid><afid>60006541</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56067965900</author-url><authid>56067965900</authid><authname>Luo X.</authname><surname>Luo</surname><given-name>Xin</given-name><initials>X.</initials><afid>60006541</afid><afid>60006541</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56067965900</author-url><authid>56067965900</authid><authname>Luo X.</authname><surname>Luo</surname><given-name>Xin</given-name><initials>X.</initials><afid>60006541</afid><afid>60006541</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56652775100</author-url><authid>56652775100</authid><authname>Wang X.</authname><surname>Wang</surname><given-name>Xiao Min</given-name><initials>X.M.</initials><afid>60006541</afid><afid>60006541</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56652775100</author-url><authid>56652775100</authid><authname>Wang X.</authname><surname>Wang</surname><given-name>Xiao Min</given-name><initials>X.M.</initials><afid>60006541</afid><afid>60006541</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56549287500</author-url><authid>56549287500</authid><authname>Chung S.</authname><surname>Chung</surname><given-name>Sookja K.</given-name><initials>S.K.</initials><afid>60006541</afid><afid>60006541</afid><afid>60006541</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56549287500</author-url><authid>56549287500</authid><authname>Chung S.</authname><surname>Chung</surname><given-name>Sookja K.</given-name><initials>S.K.</initials><afid>60006541</afid><afid>60006541</afid><afid>60006541</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56549287500</author-url><authid>56549287500</authid><authname>Chung S.</authname><surname>Chung</surname><given-name>Sookja K.</given-name><initials>S.K.</initials><afid>60006541</afid><afid>60006541</afid><afid>60006541</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56070411400</author-url><authid>56070411400</authid><authname>Cheung C.</authname><surname>Cheung</surname><given-name>Chi Wai</given-name><initials>C.W.</initials><afid>60006541</afid><afid>60006541</afid><afid>60006541</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56070411400</author-url><authid>56070411400</authid><authname>Cheung C.</authname><surname>Cheung</surname><given-name>Chi Wai</given-name><initials>C.W.</initials><afid>60006541</afid><afid>60006541</afid><afid>60006541</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56070411400</author-url><authid>56070411400</authid><authname>Cheung C.</authname><surname>Cheung</surname><given-name>Chi Wai</given-name><initials>C.W.</initials><afid>60006541</afid><afid>60006541</afid><afid>60006541</afid></author><authkeywords>Astrocyte | Central nervous system | Endothelin-1 | Excitatory amino acid transporter-2 | GET-1 transgenic mouse | Neuropathic pain</authkeywords><intid>1035992740</intid><source-id>16732</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929430722"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929430722?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929430722&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929430722&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929430722</prism:url><dc:identifier>SCOPUS_ID:84929430722</dc:identifier><eid>2-s2.0-84929430722</eid><dc:title>Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes</dc:title><dc:creator>Von Scholten B.</dc:creator><prism:publicationName>Cardiovascular Diabetology</prism:publicationName><prism:eIssn>14752840</prism:eIssn><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>May 21, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12933-015-0225-0</prism:doi><dc:description>© 2015 von Scholten et al.; licensee BioMed Central. Background: In patients with type 2 diabetes, cardiovascular disease (CVD) is the major cause of morbidity and mortality. We evaluated the combination of NT-proBNP and coronary artery calcium score (CAC) for prediction of combined fatal and non-fatal CVD and mortality in patients with type 2 diabetes and microalbuminuria (&gt;30 mg/24-h), but without known coronary artery disease. Moreover, we assessed the predictive value of a predefined categorisation of patients into a high- and low-risk group at baseline. Methods: Prospective study including 200 patients. All received intensive multifactorial treatment. Patients with baseline NT-proBNP &gt;45.2 ng/L and/or CAC ≥400 were stratified as high-risk patients (n = 133). Occurrence of fatal- and nonfatal CVD (n = 40) and mortality (n = 26), was traced after 6.1 years (median). Results: High-risk patients had a higher risk of the composite CVD endpoint (adjusted hazard ratio [HR] 10.6 (95 % confidence interval [CI] 2.4-46.3); p = 0.002) and mortality (adjusted HR 5.3 (95 % CI 1.2-24.0); p = 0.032) compared to low-risk patients. In adjusted continuous analysis, both higher NT-proBNP and CAC were strong predictors of the composite CVD endpoint and mortality (p ≤ 0.0001). In fully adjusted models mutually including NT-proBNP and CAC, both risk factors remained associated with risk of CVD and mortality (p ≤ 0.022). There was no interaction between NT-proBNP and CAC for the examined endpoints (p ≥ 0.31). Conclusions: In patients with type 2 diabetes and microalbuminuria but without known coronary artery disease, NT-proBNP and CAC were strongly associated with fatal and nonfatal CVD, as well as with mortality. Their additive prognostic capability holds promise for identification of patients at high risk.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016428</affiliation-url><afid>60016428</afid><affilname>Steno Diabetes Center</affilname><name-variant>Steno Diabetes Center</name-variant><affiliation-city>Gentofte</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007006</affiliation-url><afid>60007006</afid><affilname>Frederiksberg Hospital</affilname><name-variant>Frederiksberg Hospital</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014959</affiliation-url><afid>60014959</afid><affilname>Amtssygehuset i Gentofte</affilname><name-variant>Gentofte Hospital</name-variant><affiliation-city>Hellerup</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006564</affiliation-url><afid>60006564</afid><affilname>Rigshospitalet</affilname><name-variant>Copenhagen University Hospital</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029616</affiliation-url><afid>60029616</afid><affilname>Aarhus Universitet</affilname><name-variant>University of Aarhus</name-variant><affiliation-city>Aarhus</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55776817100</author-url><authid>55776817100</authid><authname>Von Scholten B.</authname><surname>Von Scholten</surname><given-name>Bernt Johan</given-name><initials>B.J.</initials><afid>60016428</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35410412800</author-url><authid>35410412800</authid><authname>Reinhard H.</authname><surname>Reinhard</surname><given-name>Henrik</given-name><initials>H.</initials><afid>60016428</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35274875200</author-url><authid>35274875200</authid><authname>Hansen T.</authname><surname>Hansen</surname><given-name>Tine Willum</given-name><initials>T.W.</initials><afid>60016428</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55972505900</author-url><authid>55972505900</authid><authname>Lindhardt M.</authname><surname>Lindhardt</surname><given-name>Morten</given-name><initials>M.</initials><afid>60016428</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7202258266</author-url><authid>7202258266</authid><authname>Petersen C.</authname><surname>Petersen</surname><given-name>Claus Leth</given-name><initials>C.L.</initials><afid>60030840</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603906186</author-url><authid>6603906186</authid><authname>Wiinberg N.</authname><surname>Wiinberg</surname><given-name>Niels</given-name><initials>N.</initials><afid>60007006</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7403236446</author-url><authid>7403236446</authid><authname>Hansen P.</authname><surname>Hansen</surname><given-name>Peter Riis</given-name><initials>P.R.</initials><afid>60014959</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56240680800</author-url><authid>56240680800</authid><authname>Parving H.</authname><surname>Parving</surname><given-name>Hans Henrik</given-name><initials>H.H.</initials><afid>60006564</afid><afid>60030840</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56240680800</author-url><authid>56240680800</authid><authname>Parving H.</authname><surname>Parving</surname><given-name>Hans Henrik</given-name><initials>H.H.</initials><afid>60006564</afid><afid>60030840</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7101913318</author-url><authid>7101913318</authid><authname>Jacobsen P.</authname><surname>Jacobsen</surname><given-name>Peter Karl</given-name><initials>P.K.</initials><afid>60030840</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005170096</author-url><authid>7005170096</authid><authname>Rossing P.</authname><surname>Rossing</surname><given-name>Peter</given-name><initials>P.</initials><afid>60016428</afid><afid>60030840</afid><afid>60029616</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005170096</author-url><authid>7005170096</authid><authname>Rossing P.</authname><surname>Rossing</surname><given-name>Peter</given-name><initials>P.</initials><afid>60016428</afid><afid>60030840</afid><afid>60029616</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005170096</author-url><authid>7005170096</authid><authname>Rossing P.</authname><surname>Rossing</surname><given-name>Peter</given-name><initials>P.</initials><afid>60016428</afid><afid>60030840</afid><afid>60029616</afid></author><intid>1785956025</intid><source-id>25441</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929206634"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929206634?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929206634&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929206634&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929206634</prism:url><dc:identifier>SCOPUS_ID:84929206634</dc:identifier><eid>2-s2.0-84929206634</eid><dc:title>Tunable synthesis of self-assembled cyclic peptide nanotubes and nanoparticles</dc:title><dc:creator>Sun L.</dc:creator><prism:publicationName>Soft Matter</prism:publicationName><prism:issn>1744683X</prism:issn><prism:eIssn>17446848</prism:eIssn><prism:volume>11</prism:volume><prism:issueIdentifier>19</prism:issueIdentifier><prism:pageRange>3822-3832</prism:pageRange><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1039/c5sm00533g</prism:doi><dc:description>© The Royal Society of Chemistry 2015. While tremendous efforts have been made in investigating scalable approaches for fabricating nanoparticles, less progress has been made in scalable synthesis of cyclic peptide nanoparticles and nanotubes, despite their great potential for broader biomedical applications. In this paper, tunable synthesis of self-assembled cyclic peptide nanotubes and nanoparticles using three different methods, phase equilibrium, pH-driven, and pH-sensitive methods, were proposed and investigated. The goal is scalable nanomanufacturing of cyclic peptide nanoparticles and nanotubes with different sizes in large quality by controlling multiple process parameters. Cyclo-(l-Gln-d-Ala-l-Glu-d-Ala-)&lt;inf&gt;2&lt;/inf&gt; was applied to illustrate the proposed ideas. In the study, mass spectrometry and high performance liquid chromatography were employed to verify the chemical structures and purity of the cyclic peptides. Morphology and size of the synthesized nanomaterials were characterized using atomic force microscopy and dynamic light scattering. The dimensions of the self-assembled nanostructures were found to be strongly influenced by the cyclic peptide concentration, side chain modification, pH values, reaction time, stirring intensity, and sonication time. This paper proposed an overall strategy to integrate all the parameters to achieve optimal synthesis outputs. Mechanisms of the self-assembly of the cyclic peptide nanotubes and nanoparticles under variable conditions and tunable parameters were discussed. This study contributes to scalable nanomanufacturing of cyclic peptide based self-assembled nanoparticles and nanotubes for broader biomedical applications.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090016</affiliation-url><afid>60090016</afid><affilname>Dorothy M. Davis Heart and Lung Research Institute</affilname><name-variant>Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55621706500</author-url><authid>55621706500</authid><authname>Sun L.</authname><surname>Sun</surname><given-name>Leming</given-name><initials>L.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55621706500</author-url><authid>55621706500</authid><authname>Sun L.</authname><surname>Sun</surname><given-name>Leming</given-name><initials>L.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55621706500</author-url><authid>55621706500</authid><authname>Sun L.</authname><surname>Sun</surname><given-name>Leming</given-name><initials>L.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56640343900</author-url><authid>56640343900</authid><authname>Fan Z.</authname><surname>Fan</surname><given-name>Zhen</given-name><initials>Z.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56640343900</author-url><authid>56640343900</authid><authname>Fan Z.</authname><surname>Fan</surname><given-name>Zhen</given-name><initials>Z.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56640343900</author-url><authid>56640343900</authid><authname>Fan Z.</authname><surname>Fan</surname><given-name>Zhen</given-name><initials>Z.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56032565800</author-url><authid>56032565800</authid><authname>Wang Y.</authname><surname>Wang</surname><given-name>Yongzhong</given-name><initials>Y.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56032565800</author-url><authid>56032565800</authid><authname>Wang Y.</authname><surname>Wang</surname><given-name>Yongzhong</given-name><initials>Y.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56032565800</author-url><authid>56032565800</authid><authname>Wang Y.</authname><surname>Wang</surname><given-name>Yongzhong</given-name><initials>Y.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55573432700</author-url><authid>55573432700</authid><authname>Huang Y.</authname><surname>Huang</surname><given-name>Yujian</given-name><initials>Y.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55573432700</author-url><authid>55573432700</authid><authname>Huang Y.</authname><surname>Huang</surname><given-name>Yujian</given-name><initials>Y.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55573432700</author-url><authid>55573432700</authid><authname>Huang Y.</authname><surname>Huang</surname><given-name>Yujian</given-name><initials>Y.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56640296400</author-url><authid>56640296400</authid><authname>Schmidt M.</authname><surname>Schmidt</surname><given-name>Michael</given-name><initials>M.</initials><afid>60003500</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56648350500</author-url><authid>56648350500</authid><authname>Zhang M.</authname><surname>Zhang</surname><given-name>Mingjun</given-name><initials>M.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56648350500</author-url><authid>56648350500</authid><authname>Zhang M.</authname><surname>Zhang</surname><given-name>Mingjun</given-name><initials>M.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56648350500</author-url><authid>56648350500</authid><authname>Zhang M.</authname><surname>Zhang</surname><given-name>Mingjun</given-name><initials>M.</initials><afid>60003500</afid><afid>60090016</afid><afid>60003500</afid></author><intid>2035913394</intid><source-id>145691</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929612271"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929612271?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929612271&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929612271&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0090825815001390"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929612271</prism:url><dc:identifier>SCOPUS_ID:84929612271</dc:identifier><eid>2-s2.0-84929612271</eid><dc:title>Normal-weight obesity is associated with increased risk of subclinical atherosclerosis</dc:title><dc:creator>Kim S.</dc:creator><prism:publicationName>Cardiovascular Diabetology</prism:publicationName><prism:eIssn>14752840</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>May 21, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12933-015-0220-5</prism:doi><dc:description>© 2015 Kim et al. Background: Subjects with normal body mass index (BMI) but elevated amounts of body fat (normal-weight obesity; NWO) show cardiometabolic dysregulation compared to subjects with normal BMI and normal amounts of body fat (normal-weight lean; NWL). In this study, we aimed to evaluate whether NWO individuals have higher rates of subclinical atherosclerosis compared to NWL subjects. Methods: From a large-scale health checkup system, we identified 2078 normal weight (18.5 ≤ BMI &lt; 25 kg/m&lt;sup&gt;2&lt;/sup&gt;) subjects with no previous history of coronary artery disease who underwent analysis of atherosclerosis using coronary computed tomography angiography (CCTA) and pulse wave velocity (PWV). NWO was defined as normal BMI and highest tertile of body fat percentage by sex (men ≥25. 4 % and women ≥31.4 %). CCTA was performed using a 64-detector row CT. A plaque was defined as a structure &gt;1 mm&lt;sup&gt;2&lt;/sup&gt; within and/or adjacent to the vessel lumen and classified according to the presence/proportion of intraplaque calcification. Results: NWO subjects (n = 283) demonstrated metabolic dysregulation compared to NWL individuals (n = 1795). After adjusting for age, sex, and smoking, NWO individuals showed higher PWV values than NWL individuals (1474.0 ± 275.4 vs. 1380.7 ± 234.3 cm/s, p = 0.006 by ANCOVA). Compared with NWL subjects, NWO subjects had a higher prevalence of soft plaques even after age, sex, and smoking adjustment (21.6 % vs. 14.5 %, p = 0.039 by ANCOVA). The PWV value and the log{(number of segments with plaque) + 1} showed a positive correlation with numerous parameters such as age, systolic blood pressure, visceral fat, fasting glucose level, serum triglyceride level, and C-reactive protein (CRP) in contrast to the negative correlation with high-density lipoprotein-cholesterol level. The visceral fat was an independent determinant of log{(number of segments with plaque) + 1} (ß = 0.027, SE = 0.011, p = 0.016) even after adjustment for other significant factors. Most importantly, NWO was an independent risk factor for the presence of soft plaques (odds ratio 1.460, 95 % confidence interval 1.027-2.074, p = 0.035) even after further adjustment for multiple factors associated with atherosclerosis (blood pressure, blood glucose, lipid level, CRP, medication, smoking status, physical activity). Conclusions: NWO individuals carry a higher incidence of subclinical atherosclerosis compared with NWL individuals, regardless of other clinical risk factors for atherosclerosis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60095571</affiliation-url><afid>60095571</afid><affilname>Severance Hospital</affilname><name-variant>Yonsei University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016728</affiliation-url><afid>60016728</afid><affilname>Yonsei University College of Medicine</affilname><name-variant>Yonsei University College of Medicine</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021119</affiliation-url><afid>60021119</afid><affilname>Seoul National University Hospital</affilname><name-variant>Seoul National University Hospital</name-variant><affiliation-city>Jongno-gu</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60095571</affiliation-url><afid>60095571</afid><affilname>Severance Hospital</affilname><name-variant>Yonsei University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56090894800</author-url><authid>56090894800</authid><authname>Kim S.</authname><surname>Kim</surname><given-name>Sohee</given-name><initials>S.</initials><afid>60095571</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56016907000</author-url><authid>56016907000</authid><authname>Kyung C.</authname><surname>Kyung</surname><given-name>Chanhee</given-name><initials>C.</initials><afid>60095571</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56645179600</author-url><authid>56645179600</authid><authname>Park J.</authname><surname>Park</surname><given-name>Jong Suk</given-name><initials>J.S.</initials><afid>60095571</afid><afid>60016728</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56645179600</author-url><authid>56645179600</authid><authname>Park J.</authname><surname>Park</surname><given-name>Jong Suk</given-name><initials>J.S.</initials><afid>60095571</afid><afid>60016728</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55665415400</author-url><authid>55665415400</authid><authname>Lee S.</authname><surname>Lee</surname><given-name>Seung Pyo</given-name><initials>S.P.</initials><afid>60021119</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56091476200</author-url><authid>56091476200</authid><authname>Kim H.</authname><surname>Kim</surname><given-name>Hye Kyoung</given-name><initials>H.K.</initials><afid>60095571</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35268155500</author-url><authid>35268155500</authid><authname>Ahn C.</authname><surname>Ahn</surname><given-name>Chul Woo</given-name><initials>C.W.</initials><afid>60095571</afid><afid>60016728</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35268155500</author-url><authid>35268155500</authid><authname>Ahn C.</authname><surname>Ahn</surname><given-name>Chul Woo</given-name><initials>C.W.</initials><afid>60095571</afid><afid>60016728</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35169924600</author-url><authid>35169924600</authid><authname>Kim K.</authname><surname>Kim</surname><given-name>Kyung Rae</given-name><initials>K.R.</initials><afid>60095571</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55580532000</author-url><authid>55580532000</authid><authname>Kang S.</authname><surname>Kang</surname><given-name>Shinae</given-name><initials>S.</initials><afid>60095571</afid><afid>60016728</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55580532000</author-url><authid>55580532000</authid><authname>Kang S.</authname><surname>Kang</surname><given-name>Shinae</given-name><initials>S.</initials><afid>60095571</afid><afid>60016728</afid></author><authkeywords>Atherosclerosis | Coronary computed tomography angiography | Fat | Obesity | Plaque | Pulse wave velocity | Weight</authkeywords><intid>1785990023</intid><article-number>58</article-number><source-id>25441</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930198434"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930198434?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930198434&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930198434&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930198434</prism:url><dc:identifier>SCOPUS_ID:84930198434</dc:identifier><eid>2-s2.0-84930198434</eid><dc:title>The association between hyperandrogenemia and the metabolic syndrome in morbidly obese women</dc:title><dc:creator>Valderhaug T.</dc:creator><prism:publicationName>Diabetology and Metabolic Syndrome</prism:publicationName><prism:eIssn>17585996</prism:eIssn><prism:volume>7</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s13098-015-0040-5</prism:doi><dc:description>© 2015 Valderhaug et al.; licensee BioMed Central. Background: Female abdominal obesity is associated with hyperandrogenemia (HA), but few studies have addressed the possible association between HA and metabolic syndrome (MetS) among obese women. Some studies indicate that insulin resistance may cause HA through different mechanisms. On the other hand, a bidirectional relationship between HA and insulin resistance has been suggested. Thus, we aimed to investigate if morbidly obese women with HA had higher odds of MetS and its components than those without HA (controls), independent of polycystic ovarian syndrome (PCOS) status. Methods: This cross-sectional study comprised 1900 consecutive treatment seeking morbidly obese women &lt;50 years. Free testosterone index (FTI) &gt;0.6 defined HA. Women with previously diagnosed PCOS and those with oligo- / anovulation combined with clinical or biochemical hyperandrogenism were defined as having PCOS. Multiadjusted associations between HA and MetS were assessed by logistic regression analysis. Results: Out of 1900 morbidly obese women, 1089 (57 %), 846 (45 %) and 312 (16 %) had MetS, HA and PCOS, respectively. Compared with controls (without HA), women with HA were younger (34 [1] years vs. 39 [2], p&lt;0.001) had a higher prevalence of MetS (62 % vs. 53 %, p&lt;0.001), type 2 diabetes (18 % vs. 15 %, p=0.045), low HDL-cholesterol (65 % vs. 48 %, p&lt;0.001) and hypertriglyceridemia (48 % vs. 41 %, p=0.004), but a lower prevalence of raised blood pressure (53 % vs. 59 %, p=0.014). Multivariable analyses showed that HA was associated with increased odds of MetS (OR 1.61 [95 % CI 1.27, 2.02]), dysglycemia (1.65 [1.28, 2.11]), low HDL-cholesterol (1.58 [1.27, 1.97]), and hypertriglyceridemia (1.43 [1.15, 1.79]). After stratification for the presence of PCOS, the results remained largely unchanged in women without PCOS; MetS (1.52 [1.18, 1.96), dysglycemia (1.71 [1.30, 2.25]), low HDL-cholesterol (1.55 [1.22, 1.98]) and hypertriglyceridemia (1.36 [1.06, 1.74]). Conclusion: Morbidly obese women with HA had an approximately 1.5-fold increased odds of having MetS even in the absence of PCOS. Randomized controlled clinical trials, including therapeutic strategies to lower free testosterone levels, are however necessary to explore any cause-and-effect relationship.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080270</affiliation-url><afid>60080270</afid><affilname>Sykehuset I Vestfold</affilname><name-variant>Vestfold Hospital</name-variant><affiliation-city>Tonsberg</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068728</affiliation-url><afid>60068728</afid><affilname>Akershus University Hospital</affilname><name-variant>Akershus University Hospital</name-variant><affiliation-city>Lorenskog</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010348</affiliation-url><afid>60010348</afid><affilname>Universitetet i Oslo</affilname><name-variant>University of Oslo</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080270</affiliation-url><afid>60080270</afid><affilname>Sykehuset I Vestfold</affilname><name-variant>Vestfold Hospital</name-variant><affiliation-city>Tonsberg</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010348</affiliation-url><afid>60010348</afid><affilname>Universitetet i Oslo</affilname><name-variant>University of Oslo</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23006685600</author-url><authid>23006685600</authid><authname>Valderhaug T.</authname><surname>Valderhaug</surname><given-name>T. G.</given-name><initials>T.G.</initials><afid>60080270</afid><afid>60068728</afid><afid>60010348</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23006685600</author-url><authid>23006685600</authid><authname>Valderhaug T.</authname><surname>Valderhaug</surname><given-name>T. G.</given-name><initials>T.G.</initials><afid>60080270</afid><afid>60068728</afid><afid>60010348</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23006685600</author-url><authid>23006685600</authid><authname>Valderhaug T.</authname><surname>Valderhaug</surname><given-name>T. G.</given-name><initials>T.G.</initials><afid>60080270</afid><afid>60068728</afid><afid>60010348</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7007071291</author-url><authid>7007071291</authid><authname>Hertel J.</authname><surname>Hertel</surname><given-name>J. K.</given-name><initials>J.K.</initials><afid>60080270</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35793894100</author-url><authid>35793894100</authid><authname>Nordstrand N.</authname><surname>Nordstrand</surname><given-name>N.</given-name><initials>N.</initials><afid>60080270</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56654875400</author-url><authid>56654875400</authid><authname>Dale P.</authname><surname>Dale</surname><given-name>P. O.</given-name><initials>P.O.</initials><afid>60080270</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23489162700</author-url><authid>23489162700</authid><authname>Hofsø D.</authname><surname>Hofsø</surname><given-name>D.</given-name><initials>D.</initials><afid>60080270</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004508454</author-url><authid>7004508454</authid><authname>Hjelmesæth J.</authname><surname>Hjelmesæth</surname><given-name>J.</given-name><initials>J.</initials><afid>60080270</afid><afid>60010348</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004508454</author-url><authid>7004508454</authid><authname>Hjelmesæth J.</authname><surname>Hjelmesæth</surname><given-name>J.</given-name><initials>J.</initials><afid>60080270</afid><afid>60010348</afid></author><authkeywords>Hyperandrogenemia | Insulin resistance | Metabolic syndrome | Morbid obesity</authkeywords><intid>1036082183</intid><article-number>46</article-number><source-id>19700174930</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929393629"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929393629?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929393629&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929393629&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929393629</prism:url><dc:identifier>SCOPUS_ID:84929393629</dc:identifier><eid>2-s2.0-84929393629</eid><dc:title>Characterization of a novel chicken muscle disorder through differential gene expression and pathway analysis using RNA-sequencing</dc:title><dc:creator>Mutryn M.</dc:creator><prism:publicationName>BMC Genomics</prism:publicationName><prism:eIssn>14712164</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>May 21, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12864-015-1623-0</prism:doi><dc:description>© 2015 Mutryn et al.; licensee BioMed Central. Background: Improvements in poultry production within the past 50 years have led to increased muscle yield and growth rate, which may be contributing to an increased rate and development of new muscle disorders in chickens. Previously reported muscle disorders and conditions are generally associated with poor meat quality traits and have a significant negative economic impact on the poultry industry. Recently, a novel myopathy phenotype has emerged which is characterized by palpably "hard" or tough breast muscle. The objective of this study is to identify the underlying biological mechanisms that contribute to this emerging muscle disorder colloquially referred to as "Wooden Breast", through the use of RNA-sequencing technology. Methods: We constructed cDNA libraries from five affected and six unaffected breast muscle samples from a line of commercial broiler chickens. After paired-end sequencing of samples using the Illumina Hiseq platform, we used Tophat to align the resulting sequence reads to the chicken reference genome and then used Cufflinks to find significant changes in gene transcript expression between each group. By comparing our gene list to previously published histology findings on this disorder and using Ingenuity Pathways Analysis (IPA®), we aim to develop a characteristic gene expression profile for this novel disorder through analyzing genes, gene families, and predicted biological pathways. Results: Over 1500 genes were differentially expressed between affected and unaffected birds. There was an average of approximately 98 million reads per sample, across all samples. Results from the IPA analysis suggested "Diseases and Disorders" such as connective tissue disorders, "Molecular and Cellular Functions" such as cellular assembly and organization, cellular function and maintenance, and cellular movement, "Physiological System Development and Function" such as tissue development, and embryonic development, and "Top Canonical Pathways" such as, coagulation system, axonal guidance signaling, and acute phase response signaling, are associated with the Wooden Breast disease. Conclusions: There is convincing evidence by RNA-seq analysis to support localized hypoxia, oxidative stress, increased intracellular calcium, as well as the possible presence of muscle fiber-type switching, as key features of Wooden Breast Disease, which are supported by reported microscopic lesions of the disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023004</affiliation-url><afid>60023004</afid><affilname>University of Delaware</affilname><name-variant>University of Delaware</name-variant><affiliation-city>Newark</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114573170</affiliation-url><afid>114573170</afid><affilname>Maple Leaf Farms</affilname><name-variant>Maple Leaf Farms LLC</name-variant><affiliation-city>Leesburg</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56646521900</author-url><authid>56646521900</authid><authname>Mutryn M.</authname><surname>Mutryn</surname><given-name>Marie F.</given-name><initials>M.F.</initials><afid>60023004</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55440225100</author-url><authid>55440225100</authid><authname>Brannick E.</authname><surname>Brannick</surname><given-name>Erin M.</given-name><initials>E.M.</initials><afid>60023004</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56609660900</author-url><authid>56609660900</authid><authname>Fu W.</authname><surname>Fu</surname><given-name>Weixuan</given-name><initials>W.</initials><afid>60023004</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56606469100</author-url><authid>56606469100</authid><authname>Lee W.</authname><surname>Lee</surname><given-name>William R.</given-name><initials>W.R.</initials><afid>114573170</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:15753424300</author-url><authid>15753424300</authid><authname>Abasht B.</authname><surname>Abasht</surname><given-name>Behnam</given-name><initials>B.</initials><afid>60023004</afid></author><authkeywords>Broiler | Chicken | Myodegeneration | Myopathy | Pectoralis major | RNA-sequencing | Skeletal muscle | Wooden breast</authkeywords><intid>35955226</intid><article-number>399</article-number><source-id>21727</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929119727"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929119727?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929119727&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929119727&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929119727</prism:url><dc:identifier>SCOPUS_ID:84929119727</dc:identifier><eid>2-s2.0-84929119727</eid><dc:title>The positive influence of fullerene derivatives bonded to manganese(iii) porphyrins on water proton relaxation</dc:title><dc:creator>Zou T.</dc:creator><prism:publicationName>Dalton Transactions</prism:publicationName><prism:issn>14779226</prism:issn><prism:eIssn>14779234</prism:eIssn><prism:volume>44</prism:volume><prism:issueIdentifier>19</prism:issueIdentifier><prism:pageRange>9114-9119</prism:pageRange><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1039/c4dt03482a</prism:doi><dc:description>© The Royal Society of Chemistry 2015. Manganese-porphyrin compounds as MRI contrast agents have drawn particular attention due to high relaxivities and unique biodistribution. It has been reported that the charge density of the metal center and steric decompression of the substituents, rather than rotational correlation time, were the key factors to determine the relaxivities of manganese(iii) porphyrins. In this study, [6,6]-phenyl-C&lt;inf&gt;61&lt;/inf&gt;-butyric acid (PC&lt;inf&gt;61&lt;/inf&gt;BA) was introduced into 5-(4-aminophenyl)-10,15,20-tris (4-sulfonatophenyl) porphyrin (APTSPP) to investigate the influence on water proton relaxation. The obtained PC&lt;inf&gt;61&lt;/inf&gt;BA-APTSPP-Mn possesses a relaxivity of 19.2 mM&lt;sup&gt;-1&lt;/sup&gt; s&lt;sup&gt;-1&lt;/sup&gt;, which is greater than that of Mn-APTSPP (11.2 mM&lt;sup&gt;-1&lt;/sup&gt; s&lt;sup&gt;-1&lt;/sup&gt;) and clinically used Gd-DTPA (4.1 mM&lt;sup&gt;-1&lt;/sup&gt; s&lt;sup&gt;-1&lt;/sup&gt;) at 0.5 T, and even more effective compared with those binding manganese(iii) porphyrins to certain macromolecules. It was reasonably speculated that the high relaxivity of PC&lt;inf&gt;61&lt;/inf&gt;BA-APTSPP-Mn should ascribe to the charge density variation of Mn&lt;sup&gt;III&lt;/sup&gt; and steric decompression induced by PC&lt;inf&gt;61&lt;/inf&gt;BA. Both fluorescence emission spectra and cyclic voltammetry results verified the presence of electronic communication between PC&lt;inf&gt;61&lt;/inf&gt;BA and APTSPP-Mn. In addition, the hydrodynamic diameter of PC&lt;inf&gt;61&lt;/inf&gt;BA-APTSPP-Mn aggregates was much smaller than that of APTSPP-Mn aggregates, which may contribute to the higher relaxivity by inhibiting the formation of dimers of APTSPP-Mn. Therefore, the introduction of fullerene derivatives is suggested to be a good strategy for the improvement of the relaxivities of manganese(iii) porphyrins.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60102074</affiliation-url><afid>60102074</afid><affilname>Beijing National Laboratory for Molecular Sciences</affilname><name-variant>Chinese Academy of Sciences</name-variant><affiliation-city>Zhongguancun</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019499</affiliation-url><afid>60019499</afid><affilname>Chinese Academy of Sciences</affilname><name-variant>Chinese Academy of Sciences</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014966</affiliation-url><afid>60014966</afid><affilname>Peking University</affilname><name-variant>Peking University</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56637843700</author-url><authid>56637843700</authid><authname>Zou T.</authname><surname>Zou</surname><given-name>Toujun</given-name><initials>T.</initials><afid>60102074</afid><afid>60019499</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56637843700</author-url><authid>56637843700</authid><authname>Zou T.</authname><surname>Zou</surname><given-name>Toujun</given-name><initials>T.</initials><afid>60102074</afid><afid>60019499</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54790264700</author-url><authid>54790264700</authid><authname>Zhen M.</authname><surname>Zhen</surname><given-name>Mingming</given-name><initials>M.</initials><afid>60102074</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55566795800</author-url><authid>55566795800</authid><authname>Chen D.</authname><surname>Chen</surname><given-name>Daiqin</given-name><initials>D.</initials><afid>60102074</afid><afid>60019499</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55566795800</author-url><authid>55566795800</authid><authname>Chen D.</authname><surname>Chen</surname><given-name>Daiqin</given-name><initials>D.</initials><afid>60102074</afid><afid>60019499</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55566290700</author-url><authid>55566290700</authid><authname>Li R.</authname><surname>Li</surname><given-name>Ruimin</given-name><initials>R.</initials><afid>60102074</afid><afid>60019499</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55566290700</author-url><authid>55566290700</authid><authname>Li R.</authname><surname>Li</surname><given-name>Ruimin</given-name><initials>R.</initials><afid>60102074</afid><afid>60019499</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55308436300</author-url><authid>55308436300</authid><authname>Guan M.</authname><surname>Guan</surname><given-name>Mirong</given-name><initials>M.</initials><afid>60102074</afid><afid>60019499</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55308436300</author-url><authid>55308436300</authid><authname>Guan M.</authname><surname>Guan</surname><given-name>Mirong</given-name><initials>M.</initials><afid>60102074</afid><afid>60019499</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:9242250200</author-url><authid>9242250200</authid><authname>Shu C.</authname><surname>Shu</surname><given-name>Chunying</given-name><initials>C.</initials><afid>60102074</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56637474700</author-url><authid>56637474700</authid><authname>Han H.</authname><surname>Han</surname><given-name>Hongbin</given-name><initials>H.</initials><afid>60014966</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:9242250400</author-url><authid>9242250400</authid><authname>Wang C.</authname><surname>Wang</surname><given-name>Chunru</given-name><initials>C.</initials><afid>60102074</afid></author><intid>535901784</intid><source-id>9500153949</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929093688"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929093688?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929093688&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929093688&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929093688</prism:url><dc:identifier>SCOPUS_ID:84929093688</dc:identifier><eid>2-s2.0-84929093688</eid><dc:title>Mussel-inspired nanofibrous sheet for suture-less stomach incision surgery</dc:title><dc:creator>Jiang J.</dc:creator><prism:publicationName>Chemical Communications</prism:publicationName><prism:issn>13597345</prism:issn><prism:eIssn>1364548X</prism:eIssn><prism:volume>51</prism:volume><prism:issueIdentifier>41</prism:issueIdentifier><prism:pageRange>8695-8698</prism:pageRange><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1039/c5cc01898f</prism:doi><dc:description>© The Royal Society of Chemistry 2015. We report a dopamine-based crosslinker-conjugated gelatin/polycaprolactone nanofibrous sheet. The nanosheet was then employed to treat stomach incisions without sutures during surgery. The mussel-inspired nanosheets, combining the advantages adhesion and tissue repair, show promise for use in treatments of fragile tissues and to avoid suture-caused stress concentration.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009697</affiliation-url><afid>60009697</afid><affilname>University of Manitoba</affilname><name-variant>University of Manitoba</name-variant><affiliation-city>Winnipeg</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009697</affiliation-url><afid>60009697</afid><affilname>University of Manitoba</affilname><name-variant>University of Manitoba</name-variant><affiliation-city>Winnipeg</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018310</affiliation-url><afid>60018310</afid><affilname>Nanjing Medical University</affilname><name-variant>Nanjing Medical University</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009697</affiliation-url><afid>60009697</afid><affilname>University of Manitoba</affilname><name-variant>University of Manitoba</name-variant><affiliation-city>Winnipeg</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:110155371</affiliation-url><afid>110155371</afid><affilname>Manitoba Institute of Child Health</affilname><name-variant>Manitoba Institute of Child Health</name-variant><affiliation-city>Winnipeg</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56637337100</author-url><authid>56637337100</authid><authname>Jiang J.</authname><surname>Jiang</surname><given-name>J.</given-name><initials>J.</initials><afid>60009697</afid><afid>60009697</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56637337100</author-url><authid>56637337100</authid><authname>Jiang J.</authname><surname>Jiang</surname><given-name>J.</given-name><initials>J.</initials><afid>60009697</afid><afid>60009697</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56519130000</author-url><authid>56519130000</authid><authname>Wan W.</authname><surname>Wan</surname><given-name>W.</given-name><initials>W.</initials><afid>60009697</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56180204200</author-url><authid>56180204200</authid><authname>Ge L.</authname><surname>Ge</surname><given-name>L.</given-name><initials>L.</initials><afid>60009697</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56376770400</author-url><authid>56376770400</authid><authname>Bu S.</authname><surname>Bu</surname><given-name>S.</given-name><initials>S.</initials><afid>60018310</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7402328691</author-url><authid>7402328691</authid><authname>Zhong W.</authname><surname>Zhong</surname><given-name>W.</given-name><initials>W.</initials><afid>60009697</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:14013329500</author-url><authid>14013329500</authid><authname>Xing M.</authname><surname>Xing</surname><given-name>M.</given-name><initials>M.</initials><afid>60009697</afid><afid>60009697</afid><afid>110155371</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:14013329500</author-url><authid>14013329500</authid><authname>Xing M.</authname><surname>Xing</surname><given-name>M.</given-name><initials>M.</initials><afid>60009697</afid><afid>60009697</afid><afid>110155371</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:14013329500</author-url><authid>14013329500</authid><authname>Xing M.</authname><surname>Xing</surname><given-name>M.</given-name><initials>M.</initials><afid>60009697</afid><afid>60009697</afid><afid>110155371</afid></author><intid>1785902840</intid><source-id>22781</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930210718"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930210718?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930210718&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930210718&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930210718</prism:url><dc:identifier>SCOPUS_ID:84930210718</dc:identifier><eid>2-s2.0-84930210718</eid><dc:title>Abdominal wall hernia in cirrhotic patients: Emergency surgery results in higher morbidity and mortality Visceral and general surgery</dc:title><dc:creator>Andraus W.</dc:creator><prism:publicationName>BMC Surgery</prism:publicationName><prism:eIssn>14712482</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12893-015-0052-y</prism:doi><dc:description>© 2015 Andraus et al.; licensee BioMed Central. Background: Patients with cirrhosis have a high incidence of abdominal wall hernias and carry an elevated perioperative morbidity and mortality. The optimal surgical management strategy as well as timing of abdominal hernia repair remains controversial. Methods: A cohort study of 67 cirrhotic patients who underwent hernia repair during the period of January 1998-December 2009 at the University Hospital of Sao Paulo were included. After meeting study criteria, a total of 56 patients who underwent 61 surgeries were included in the final analysis. Patient characteristics, morbidity (Clavien score), mortality, Child-Turcotte-Pugh score, MELD score, use of prosthetic material, and elective or emergency surgery have been analysed with regards to morbidity and 30-day mortality. Results: The median MELD score of the patient population was 14 (range: 6 to 24). Emergency surgery was performed in 34 patients because of ruptured hernia (n=13), incarceration (n=10), strangulation (n=4), and skin necrosis or ulceration (n=7). Elective surgery was performed in 27 cases. After a multivariable analysis, emergency surgery (OR 7.31; p 0.017) and Child-Pugh C (OR 4.54; p 0.037) were risk factors for major complications. Moreover, emergency surgery was a unique independent risk factor for 30-day mortality (OR 10.83; p 0.028). Conclusions: Higher morbidity and mortality are associated with emergency surgery in advanced cirrhotic patients. Therefore, using cirrhosis as a contraindication for hernia repair in all patients may be reconsidered in the future, especially after controlling ascites and in those patients with hernias that are becoming symptomatic or show signs of possible skin necrosis and rupture. Future prospective randomized studies are needed to confirm this surgical strategy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Azienda Universitario-ospedaliera Pisana</affilname><name-variant>Department of Hepatic Surgery and Liver Transplantation</name-variant><affiliation-city>Pisa</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000874</affiliation-url><afid>60000874</afid><affilname>Universite Catholique de Louvain</affilname><name-variant>Université Catholique de Louvain</name-variant><affiliation-city>Louvain-la-Neuve</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6508153509</author-url><authid>6508153509</authid><authname>Andraus W.</authname><surname>Andraus</surname><given-name>Wellington</given-name><initials>W.</initials><afid>60008088</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15748435100</author-url><authid>15748435100</authid><authname>Pinheiro R.</authname><surname>Pinheiro</surname><given-name>Rafael Soares</given-name><initials>R.S.</initials><afid>60008088</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:25822653100</author-url><authid>25822653100</authid><authname>Lai Q.</authname><surname>Lai</surname><given-name>Quirino</given-name><initials>Q.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:26666003100</author-url><authid>26666003100</authid><authname>Haddad L.</authname><surname>Haddad</surname><given-name>Luciana B P</given-name><initials>L.B.P.</initials><afid>60008088</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:54399015300</author-url><authid>54399015300</authid><authname>Nacif L.</authname><surname>Nacif</surname><given-name>Lucas S.</given-name><initials>L.S.</initials><afid>60008088</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7003723493</author-url><authid>7003723493</authid><authname>D'Albuquerque L.</authname><surname>D'Albuquerque</surname><given-name>Luiz Augusto C</given-name><initials>L.A.C.</initials><afid>60008088</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:16491657300</author-url><authid>16491657300</authid><authname>Lerut J.</authname><surname>Lerut</surname><given-name>Jan</given-name><initials>J.</initials><afid>60000874</afid></author><authkeywords>Abdominal hernia | ascites | liver cirrhosis</authkeywords><intid>2036082601</intid><article-number>65</article-number><source-id>20524</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929466488"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929466488?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929466488&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929466488&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929466488</prism:url><dc:identifier>SCOPUS_ID:84929466488</dc:identifier><eid>2-s2.0-84929466488</eid><dc:title>Non-steroidal anti-inflammatory drugs and their benefits and harms: The challenge of interpreting meta-analyses and observational data sets when balanced data are not analyzed and reported</dc:title><dc:creator>Simon L.</dc:creator><prism:publicationName>Arthritis Research and Therapy</prism:publicationName><prism:issn>14786354</prism:issn><prism:eIssn>14786362</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>May 21, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13075-015-0650-1</prism:doi><dc:description>© 2015 Simon; licensee BioMed Central. A multitude of reports have delineated the risks of using non-steroidal anti-inflammatory drugs but have not been totally congruent. Meta-analyses of randomized controlled trials sometimes concur regarding gastrointestinal risk and cardiovascular risk but rarely report a balance of these risks for any one drug. Benefits measured in these studies are usually not reported. Observational data sets, supposedly reflective of 'real world' patients, do not always agree with the randomized controlled trial reports. Clinicians need assessments measuring the balance of harms and benefits so that better decisions based on their patients' unique risk factors can be reached.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106999150</affiliation-url><afid>106999150</afid><affilname>SDG LLC</affilname><name-variant>SDG LLC</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ed</subtype><subtypeDescription>Editorial</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36875438400</author-url><authid>36875438400</authid><authname>Simon L.</authname><surname>Simon</surname><given-name>Lee S.</given-name><initials>L.S.</initials><afid>106999150</afid></author><intid>35964310</intid><article-number>130</article-number><source-id>27592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929070400"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929070400?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929070400&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929070400&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929070400</prism:url><dc:identifier>SCOPUS_ID:84929070400</dc:identifier><eid>2-s2.0-84929070400</eid><dc:title>Functional optical coherence tomography: Principles and progress</dc:title><dc:creator>Kim J.</dc:creator><prism:publicationName>Physics in Medicine and Biology</prism:publicationName><prism:issn>00319155</prism:issn><prism:eIssn>13616560</prism:eIssn><prism:volume>60</prism:volume><prism:issueIdentifier>10</prism:issueIdentifier><prism:pageRange>R211-R237</prism:pageRange><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>21 May 2015</prism:coverDisplayDate><prism:doi>10.1088/0031-9155/60/10/R211</prism:doi><dc:description>© 2015 Institute of Physics and Engineering in Medicine. In the past decade, several functional extensions of optical coherence tomography (OCT) have emerged, and this review highlights key advances in instrumentation, theoretical analysis, signal processing and clinical application of these extensions. We review five principal extensions: Doppler OCT (DOCT), polarization-sensitive OCT (PS-OCT), optical coherence elastography (OCE), spectroscopic OCT (SOCT), and molecular imaging OCT. The former three have been further developed with studies in both ex vivo and in vivo human tissues. This review emphasizes the newer techniques of SOCT and molecular imaging OCT, which show excellent potential for clinical application but have yet to be well reviewed in the literature. SOCT elucidates tissue characteristics, such as oxygenation and carcinogenesis, by detecting wavelength-dependent absorption and scattering of light in tissues. While SOCT measures endogenous biochemical distributions, molecular imaging OCT detects exogenous molecular contrast agents. These newer advances in functional OCT broaden the potential clinical application of OCT by providing novel ways to understand tissue activity that cannot be accomplished by other current imaging methodologies.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008724</affiliation-url><afid>60008724</afid><affilname>Duke University</affilname><name-variant>Duke University</name-variant><affiliation-city>Durham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008724</affiliation-url><afid>60008724</afid><affilname>Duke University</affilname><name-variant>Duke University</name-variant><affiliation-city>Durham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56637293700</author-url><authid>56637293700</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Jina</given-name><initials>J.</initials><afid>60008724</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55472673800</author-url><authid>55472673800</authid><authname>Brown W.</authname><surname>Brown</surname><given-name>William</given-name><initials>W.</initials><afid>60008724</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56386801800</author-url><authid>56386801800</authid><authname>Maher J.</authname><surname>Maher</surname><given-name>Jason R.</given-name><initials>J.R.</initials><afid>60008724</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7102170864</author-url><authid>7102170864</authid><authname>Levinson H.</authname><surname>Levinson</surname><given-name>Howard</given-name><initials>H.</initials><afid>60008724</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003828657</author-url><authid>7003828657</authid><authname>Wax A.</authname><surname>Wax</surname><given-name>Adam</given-name><initials>A.</initials><afid>60008724</afid></author><intid>1535901911</intid><source-id>29203</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930212315"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930212315?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930212315&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930212315&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0022459614003144"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930212315</prism:url><dc:identifier>SCOPUS_ID:84930212315</dc:identifier><eid>2-s2.0-84930212315</eid><dc:title>Association of large intergenic noncoding RNA expression with disease activity and organ damage in systemic lupus erythematosus</dc:title><dc:creator>Wu Y.</dc:creator><prism:publicationName>Arthritis Research and Therapy</prism:publicationName><prism:issn>14786354</prism:issn><prism:eIssn>14786362</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-21</prism:coverDate><prism:coverDisplayDate>May 21, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13075-015-0632-3</prism:doi><dc:description>© 2015 Wu et al.; licensee BioMed Central. Introduction: Despite growing evidence that large intergenic noncoding RNAs (lincRNAs) can regulate gene expression and widely take part in normal physiological and disease conditions, our knowledge of systemic lupus erythematosus (SLE)-related lincRNAs remains limited. The aim of this study was to detect the levels of four lincRNAs (ENST00000500949: linc0949, ENST00000500597: linc0597, ENST00000501992: linc1992, and ENST00000523995: linc3995) involved in innate immunity in the peripheral blood mononuclear cells (PBMCs) of patients with SLE and correlate these lincRNA levels with disease activity, organ damage, clinical features and medical therapies. Methods: PBMCs were obtained from 102 patients with SLE, 54 patients with rheumatoid arthritis (RA) and 76 healthy donors. lincRNA expression levels were measured by real-time quantitative polymerase chain reaction. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores, and organ damage was evaluated with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Results: linc0949 and linc0597 were significantly decreased in patients with SLE compared with patients with RA and healthy control subjects. linc0949 was correlated with SLEDAI-2K score (r = -0.329, P = 0.0007), as well as with complement component C3 level (r = 0.348, P = 0.0003). The level of linc0949 was also reduced in patients with SLE who had the presence of cumulative organ damage. In addition, decreasing expression of linc0949 was associated with lupus nephritis. linc0949 expression significantly increased after treatment, whereas neither disease activity nor organ damage correlated with linc0597 expression. Conclusions: Our results provide novel empirical evidence that linc0949 could be a potential biomarker for diagnosis, disease activity and therapeutic response in SLE.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60087536</affiliation-url><afid>60087536</afid><affilname>Renji Hospital</affilname><name-variant>Shanghai Second Medical University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082819</affiliation-url><afid>60082819</afid><affilname>Shanghai Jiao Tong University School of Medicine</affilname><name-variant>Shanghai Jiao Tong University School of Medicine</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030440</affiliation-url><afid>60030440</afid><affilname>Cincinnati Children's Hospital Medical Center</affilname><name-variant>Children's Hospital Medical Center</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645312600</author-url><authid>56645312600</authid><authname>Wu Y.</authname><surname>Wu</surname><given-name>Yanfang</given-name><initials>Y.</initials><afid>60087536</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56645198100</author-url><authid>56645198100</authid><authname>Zhang F.</authname><surname>Zhang</surname><given-name>Feifei</given-name><initials>F.</initials><afid>60082819</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56645191300</author-url><authid>56645191300</authid><authname>Ma J.</authname><surname>Ma</surname><given-name>Jianyang</given-name><initials>J.</initials><afid>60082819</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56646666900</author-url><authid>56646666900</authid><authname>Zhang X.</authname><surname>Zhang</surname><given-name>Xiaoyan</given-name><initials>X.</initials><afid>60087536</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56645212900</author-url><authid>56645212900</authid><authname>Wu L.</authname><surname>Wu</surname><given-name>Lingling</given-name><initials>L.</initials><afid>60087536</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36659863700</author-url><authid>36659863700</authid><authname>Qu B.</authname><surname>Qu</surname><given-name>Bo</given-name><initials>B.</initials><afid>60087536</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56645643700</author-url><authid>56645643700</authid><authname>Xia S.</authname><surname>Xia</surname><given-name>Shiwei</given-name><initials>S.</initials><afid>60087536</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7410252382</author-url><authid>7410252382</authid><authname>Chen S.</authname><surname>Chen</surname><given-name>Shunle</given-name><initials>S.</initials><afid>60087536</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56645228600</author-url><authid>56645228600</authid><authname>Tang Y.</authname><surname>Tang</surname><given-name>Yuanjia</given-name><initials>Y.</initials><afid>60087536</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7102785475</author-url><authid>7102785475</authid><authname>Shen N.</authname><surname>Shen</surname><given-name>Nan</given-name><initials>N.</initials><afid>60087536</afid><afid>60082819</afid><afid>60030440</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7102785475</author-url><authid>7102785475</authid><authname>Shen N.</authname><surname>Shen</surname><given-name>Nan</given-name><initials>N.</initials><afid>60087536</afid><afid>60082819</afid><afid>60030440</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7102785475</author-url><authid>7102785475</authid><authname>Shen N.</authname><surname>Shen</surname><given-name>Nan</given-name><initials>N.</initials><afid>60087536</afid><afid>60082819</afid><afid>60030440</afid></author><intid>1036082338</intid><article-number>131</article-number><source-id>27592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929692955"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929692955?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929692955&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929692955&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929692955</prism:url><dc:identifier>SCOPUS_ID:84929692955</dc:identifier><eid>2-s2.0-84929692955</eid><dc:title>Utility of T-wave alternans during night time as a predictor for ventricular fibrillation in patients with Brugada syndrome</dc:title><dc:creator>Sakamoto S.</dc:creator><prism:publicationName>Heart and Vessels</prism:publicationName><prism:issn>09108327</prism:issn><prism:eIssn>16152573</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00380-015-0692-y</prism:doi><dc:description>© 2015 Springer Japan The prognostic value of T-wave alternans (TWA) during the night time in patients with Brugada syndrome (Br-S) remains unknown. We assessed TWA for risk stratification using 24-h multichannel Holter electrocardiogram (24-M-ECG) in Br-S. We enrolled 129 patients with Br-S [grouped according to histories of ventricular fibrillation (VF), n = 16; syncope, n = 10; or no symptoms (asymptomatic), n = 103] and 11 controls. Precordial electrodes were attached to the third (3L-V1, 3L-V2) and fourth (4L-V1, 4L-V2 and 4L-V5) intercostal spaces. We measured the values of maximum TWA (max-TWA) during the night time (12 a.m.–6 a.m.) and the day time (12 p.m.–6 p.m.) and calculated parameters of heart rate variability. Compared to the asymptomatic and control groups, the VF and syncope groups showed significantly greater 3L-V2 max-TWA during the night time. The cutoff value for the 3L-V2 max-TWA during the night time was determined as 20 µV (sensitivity 94 % and specificity 48 %; p = 0.01). Multivariate analysis revealed that 3L-V2 max-TWA during the night time ≥20 µV and previous VF episodes were independent predictors of future VF episodes. During a mean follow-up period of 68 ± 37 months, 16 patients experienced VF episodes. The incidence of VF episodes was the highest during the night time (p &lt; 0.001). The 3L-V2 max-TWA during the night time may be a useful predictor for VF episodes in patients with Br-S.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013722</affiliation-url><afid>60013722</afid><affilname>Osaka City University</affilname><name-variant>Osaka City University</name-variant><affiliation-city>Osaka</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56652992000</author-url><authid>56652992000</authid><authname>Sakamoto S.</authname><surname>Sakamoto</surname><given-name>Shogo</given-name><initials>S.</initials><afid>60013722</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35600996900</author-url><authid>35600996900</authid><authname>Takagi M.</authname><surname>Takagi</surname><given-name>Masahiko</given-name><initials>M.</initials><afid>60013722</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56653188500</author-url><authid>56653188500</authid><authname>Tatsumi H.</authname><surname>Tatsumi</surname><given-name>Hiroaki</given-name><initials>H.</initials><afid>60013722</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56653132400</author-url><authid>56653132400</authid><authname>Doi A.</authname><surname>Doi</surname><given-name>Atsushi</given-name><initials>A.</initials><afid>60013722</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56622452300</author-url><authid>56622452300</authid><authname>Sugioka K.</authname><surname>Sugioka</surname><given-name>Kenichi</given-name><initials>K.</initials><afid>60013722</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6701702353</author-url><authid>6701702353</authid><authname>Hanatani A.</authname><surname>Hanatani</surname><given-name>Akihisa</given-name><initials>A.</initials><afid>60013722</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56432348900</author-url><authid>56432348900</authid><authname>Yoshiyama M.</authname><surname>Yoshiyama</surname><given-name>Minoru</given-name><initials>M.</initials><afid>60013722</afid></author><authkeywords>Brugada syndrome | Heart rate variability | Holter electrocardiogram | T-wave alternans</authkeywords><intid>1035992286</intid><source-id>23221</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929688931"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929688931?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929688931&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929688931&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929688931</prism:url><dc:identifier>SCOPUS_ID:84929688931</dc:identifier><eid>2-s2.0-84929688931</eid><dc:title>Cardiac gene expression data and in silico analysis provide novel insights into human and mouse taste receptor gene regulation</dc:title><dc:creator>Foster S.</dc:creator><prism:publicationName>Naunyn-Schmiedeberg's Archives of Pharmacology</prism:publicationName><prism:issn>00281298</prism:issn><prism:eIssn>14321912</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00210-015-1118-1</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg G protein-coupled receptors are the principal mediators of the sweet, umami, bitter, and fat taste qualities in mammals. Intriguingly, the taste receptors are also expressed outside of the oral cavity, including in the gut, airways, brain, and heart, where they have additional functions and contribute to disease. However, there is little known about the mechanisms governing the transcriptional regulation of taste receptor genes. Following our recent delineation of taste receptors in the heart, we investigated the genomic loci encoding for taste receptors to gain insight into the regulatory mechanisms that drive their expression in the heart. Gene expression analyses of healthy and diseased human and mouse hearts showed coordinated expression for a subset of chromosomally clustered taste receptors. This chromosomal clustering mirrored the cardiac expression profile, suggesting that a common gene regulatory block may control the taste receptor locus. We identified unique domains with strong regulatory potential in the vicinity of taste receptor genes. We also performed de novo motif enrichment in the proximal promoter regions and found several overrepresented DNA motifs in cardiac taste receptor gene promoters corresponding to ubiquitous and cardiac-specific transcription factor binding sites. Thus, combining cardiac gene expression data with bioinformatic analyses, this study has provided insights into the noncoding regulatory landscape for taste GPCRs. These findings also have broader relevance for the study of taste GPCRs outside of the classical gustatory system, where understanding the mechanisms controlling the expression of these receptors may have implications for future therapeutic development.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031004</affiliation-url><afid>60031004</afid><affilname>University of Queensland</affilname><name-variant>The University of Queensland</name-variant><affiliation-city>Brisbane</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025709</affiliation-url><afid>60025709</afid><affilname>University of Sydney</affilname><name-variant>University of Sydney</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028333</affiliation-url><afid>60028333</afid><affilname>University of New South Wales (UNSW) Australia</affilname><name-variant>University of New South Wales</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011019</affiliation-url><afid>60011019</afid><affilname>Queensland University of Technology</affilname><name-variant>Queensland University of Technology</name-variant><affiliation-city>Brisbane</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031004</affiliation-url><afid>60031004</afid><affilname>University of Queensland</affilname><name-variant>The University of Queensland</name-variant><affiliation-city>Brisbane</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019578</affiliation-url><afid>60019578</afid><affilname>Monash University</affilname><name-variant>Monash University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55699824700</author-url><authid>55699824700</authid><authname>Foster S.</authname><surname>Foster</surname><given-name>Simon R.</given-name><initials>S.R.</initials><afid>60031004</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8280757800</author-url><authid>8280757800</authid><authname>Porrello E.</authname><surname>Porrello</surname><given-name>Enzo R.</given-name><initials>E.R.</initials><afid>60031004</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56275997900</author-url><authid>56275997900</authid><authname>Stefani M.</authname><surname>Stefani</surname><given-name>Maurizio</given-name><initials>M.</initials><afid>60025709</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15080819600</author-url><authid>15080819600</authid><authname>Smith N.</authname><surname>Smith</surname><given-name>Nicola J.</given-name><initials>N.J.</initials><afid>60028333</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24445789800</author-url><authid>24445789800</authid><authname>Molenaar P.</authname><surname>Molenaar</surname><given-name>Peter</given-name><initials>P.</initials><afid>60011019</afid><afid>60031004</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24445789800</author-url><authid>24445789800</authid><authname>Molenaar P.</authname><surname>Molenaar</surname><given-name>Peter</given-name><initials>P.</initials><afid>60011019</afid><afid>60031004</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56653222100</author-url><authid>56653222100</authid><authname>Dos Remedios C.</authname><surname>Dos Remedios</surname><given-name>Cristobal G.</given-name><initials>C.G.</initials><afid>60025709</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7402304806</author-url><authid>7402304806</authid><authname>Thomas W.</authname><surname>Thomas</surname><given-name>Walter G.</given-name><initials>W.G.</initials><afid>60031004</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8892483000</author-url><authid>8892483000</authid><authname>Ramialison M.</authname><surname>Ramialison</surname><given-name>Mirana</given-name><initials>M.</initials><afid>60019578</afid></author><authkeywords>Cis-regulatory modules | De novo motif discovery | Heart | Taste receptor | Transcription factor</authkeywords><intid>535998164</intid><source-id>20427</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929698422"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929698422?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929698422&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929698422&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929698422</prism:url><dc:identifier>SCOPUS_ID:84929698422</dc:identifier><eid>2-s2.0-84929698422</eid><dc:title>Purinergic signalling during development and ageing</dc:title><dc:creator>Burnstock G.</dc:creator><prism:publicationName>Purinergic Signalling</prism:publicationName><prism:issn>15739538</prism:issn><prism:eIssn>15739546</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11302-015-9452-9</prism:doi><dc:description>© 2015 Springer Science+Business Media Dordrecht Extracellular purines and pyrimidines play major roles during embryogenesis, organogenesis, postnatal development and ageing in vertebrates, including humans. Pluripotent stem cells can differentiate into three primary germ layers of the embryo but may also be involved in plasticity and repair of the adult brain. These cells express the molecular components necessary for purinergic signalling, and their developmental fates can be manipulated via this signalling pathway. Functional P1, P2Y and P2X receptor subtypes and ectonucleotidases are involved in the development of different organ systems, including heart, blood vessels, skeletal muscle, urinary bladder, central and peripheral neurons, retina, inner ear, gut, lung and vas deferens. The importance of purinergic signalling in the ageing process is suggested by changes in expression of A&lt;inf&gt;1&lt;/inf&gt; and A&lt;inf&gt;2&lt;/inf&gt; receptors in old rat brains and reduction of P2X receptor expression in ageing mouse brain. By contrast, in the periphery, increases in expression of P2X3 and P2X4 receptors are seen in bladder and pancreas.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029950</affiliation-url><afid>60029950</afid><affilname>UCL Medical School</affilname><name-variant>UCL Medical School</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026553</affiliation-url><afid>60026553</afid><affilname>University of Melbourne</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Parkville</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022020</affiliation-url><afid>60022020</afid><affilname>The University of Warwick</affilname><name-variant>University of Warwick</name-variant><affiliation-city>Coventry</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36037094600</author-url><authid>36037094600</authid><authname>Burnstock G.</authname><surname>Burnstock</surname><given-name>Geoffrey</given-name><initials>G.</initials><afid>60029950</afid><afid>60026553</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36037094600</author-url><authid>36037094600</authid><authname>Burnstock G.</authname><surname>Burnstock</surname><given-name>Geoffrey</given-name><initials>G.</initials><afid>60029950</afid><afid>60026553</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56256953200</author-url><authid>56256953200</authid><authname>Dale N.</authname><surname>Dale</surname><given-name>Nicholas</given-name><initials>N.</initials><afid>60022020</afid></author><authkeywords>Adenosine | ATP | Bladder | Cochlea | Heart | Lung | Retina | Skeletal muscle | Stem cells | Zebrafish</authkeywords><intid>2035992125</intid><source-id>130009</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929683341"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929683341?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929683341&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929683341&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929683341</prism:url><dc:identifier>SCOPUS_ID:84929683341</dc:identifier><eid>2-s2.0-84929683341</eid><dc:title>Clinical development of the automatic implantable defibrillator over 35 years: A success story | Klinische Entwicklung des implantierbaren Kardioverter-Defibrillators über 35 Jahre: Eine Erfolgsgeschichte</dc:title><dc:creator>Steinbeck G.</dc:creator><prism:publicationName>Herzschrittmachertherapie und Elektrophysiologie</prism:publicationName><prism:issn>09387412</prism:issn><prism:eIssn>14351544</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00399-015-0370-x</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg After 12 years of development and experimental evaluation, the first automatic implantable cardioverter–defibrillator (ICD) was implanted in man on February 4, 1980. This overview describes the technical and functional developments over 35 years from a simple shock-box, weighing 292 g, to the sophisticated 80 g device of today, delivering graded therapy to sustained ventricular arrhythmias and biventricular stimulation to treat heart failure. Finally, a special tribute is given to Michel Mirowski, one of the inventors of the ICD, as scientist and physician dedicated to patient care.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114707398</affiliation-url><afid>114707398</afid><affilname>Zentrum für Kardiologie am Klinikum Starnberg</affilname><name-variant>Zentrum für Kardiologie am Klinikum Starnberg</name-variant><affiliation-city>Starnberg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7103232590</author-url><authid>7103232590</authid><authname>Steinbeck G.</authname><surname>Steinbeck</surname><given-name>G.</given-name><initials>G.</initials><afid>114707398</afid></author><authkeywords>Heart insufficiency | Implantable cardioverter-defibrillator | Michel Mirowski | Pioneer | Sudden cardiac death</authkeywords><intid>1785998252</intid><source-id>23253</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929688124"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929688124?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929688124&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929688124&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929688124</prism:url><dc:identifier>SCOPUS_ID:84929688124</dc:identifier><eid>2-s2.0-84929688124</eid><dc:title>EFFICACY OF CARPENTIER-EDWARDS PERICARDIAL PROSTHESES: A SYSTEMATIC REVIEW AND META-ANALYSIS</dc:title><dc:creator>Magliano C.</dc:creator><prism:publicationName>International Journal of Technology Assessment in Health Care</prism:publicationName><prism:issn>02664623</prism:issn><prism:eIssn>14716348</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1017/S0266462315000148</prism:doi><pii>S0266462315000148</pii><dc:description>Copyright © Cambridge University Press 2015 Objectives: The Carpentier-Edwards pericardial (CEP) prostheses are the type of bioprostheses most used worldwide. Although they were designed to minimize the rate of valve deterioration and reoperation, their clinical superiority over other prostheses models still lacks confirmation. The objective of this study was to evaluate its effectiveness. Methods: We performed a systematic review and meta-analysis in the PubMed, Embase, Cochrane, and Lilacs databases. Operative mortality, overall mortality and reoperation rates after heart valve surgery were compared between the use of CEP and other cardiac prostheses. Two independent reviewers screened studies for inclusion and extracted the data. Disagreements were resolved by consensus. The GRADE criterion was used to assess the evidence quality. Results: A total of twenty-eight studies were selected, including 19,615 individuals. The studies presented a high heterogeneity and low quality of evidence what limited the reliability of the results. The pooled data from the selected studies did not demonstrate significant differences between CEP and porcine, pericardial or stentless prostheses regarding operative mortality, overall mortality and reoperation rates. However, the pooled data from 3 observational trials pointed out a higher risk for reoperation after valve replacement using CEP prostheses against mechanical prostheses (OR 4.92 [95 percent confidence interval 2.43–9.96]). Conclusions: The current data present in the literature still does not support a clinical advantage for the use of CEP prostheses over other bioprostheses. The quality of the studies in the literature is limited and further studies are needed to address if CEP prostheses will have a clinical advantage over other prostheses.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60065148</affiliation-url><afid>60065148</afid><affilname>Instituto Nacional de Cardiologia</affilname><name-variant>Instituto Nacional de Cardiologia</name-variant><affiliation-city>Laranjeiras</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026004</affiliation-url><afid>60026004</afid><affilname>Fundacao Oswaldo Cruz</affilname><name-variant>Fundacao Oswaldo Cruz</name-variant><affiliation-city>Rio de Janeiro</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60065148</affiliation-url><afid>60065148</afid><affilname>Instituto Nacional de Cardiologia</affilname><name-variant>Instituto Nacional de Cardiologia</name-variant><affiliation-city>Laranjeiras</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56653410900</author-url><authid>56653410900</authid><authname>Magliano C.</authname><surname>Magliano</surname><given-name>Carlos Alberto S</given-name><initials>C.A.S.</initials><afid>60065148</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56653259800</author-url><authid>56653259800</authid><authname>Saraiva R.</authname><surname>Saraiva</surname><given-name>Roberto M.</given-name><initials>R.M.</initials><afid>60026004</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8292519700</author-url><authid>8292519700</authid><authname>Azevedo V.</authname><surname>Azevedo</surname><given-name>Vitor Manuel P</given-name><initials>V.M.P.</initials><afid>60065148</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56653353200</author-url><authid>56653353200</authid><authname>Innocenzi A.</authname><surname>Innocenzi</surname><given-name>Adriana M.</given-name><initials>A.M.</initials><afid>60065148</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6603210685</author-url><authid>6603210685</authid><authname>Tura B.</authname><surname>Tura</surname><given-name>Bernardo R.</given-name><initials>B.R.</initials><afid>60065148</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56652926400</author-url><authid>56652926400</authid><authname>Santos M.</authname><surname>Santos</surname><given-name>Marisa</given-name><initials>M.</initials><afid>60065148</afid></author><authkeywords>Bioprostheses | Carpentier-Edwards prostheses | Meta-analysis | Systematic review</authkeywords><intid>1785998319</intid><source-id>27211</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929692334"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929692334?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929692334&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929692334&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929692334</prism:url><dc:identifier>SCOPUS_ID:84929692334</dc:identifier><eid>2-s2.0-84929692334</eid><dc:title>Lifestyle Factors and Indices of Kidney Function in the Framingham Heart Study</dc:title><dc:creator>Foster M.</dc:creator><prism:publicationName>American Journal of Nephrology</prism:publicationName><prism:issn>02508095</prism:issn><prism:eIssn>14219670</prism:eIssn><prism:pageRange>267-274</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1159/000430868</prism:doi><pii>000430868</pii><dc:description>Copyright © 2015, S. Karger AG. All rights reserved. Background and Objectives: Lifestyle characteristics are modifiable factors that could be targeted as part of chronic kidney disease (CKD) prevention. We sought to determine the association of lifestyle characteristics with incident estimated glomerular filtration rate (eGFR) &lt;60 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; and rapid eGFR decline in older adults in the United States. Methods: Prospective cohort study of Framingham Offspring participants with baseline eGFR &lt;60 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; (n = 1,802) who attended the seventh (1998-2001; baseline) and eighth (2005-2008; follow-up) examinations (mean age = 59 years, 54.8% women). Predictors included measures of diet quality, physical activity, alcohol intake, and current smoking status assessed during baseline. Outcomes were based on creatinine-based eGFR at baseline and follow-up and included incident eGFR &lt;60 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; (at follow-up) and rapid eGFR decline (annual eGFR decrease ≥3 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;). Results: Over an average follow-up of 6.6 years, 9.5% (n = 171) of participants developed incident eGFR &lt;60. A trend was observed across quartiles of diet quality, with higher levels of diet quality associated with a decreased odds ratio (OR) of incident eGFR &lt;60 (p trend = 0.045). Higher diet quality was associated with decreased odds of rapid eGFR decline (p trend = 0.03) and was attenuated with additional adjustment (p trend = 0.07). In sensitivity analysis for rapid eGFR decline using a secondary definition (annual eGFR decrease ≥3 and incident eGFR &lt;60), diet associations remained significant with additional adjustment (p trend = 0.04). No associations were observed with physical activity, smoking status, or alcohol intake with incident eGFR &lt;60 or rapid eGFR decline (all p &gt; 0.19). Conclusions: Higher diet quality may be associated with a decreased risk of incident eGFR &lt;60 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;, and rapid eGFR decline. Whether adherence to a healthy diet can prevent reduction in kidney function warrants further study. © 2015 S. Karger AG, Basel</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022386</affiliation-url><afid>60022386</afid><affilname>Framingham Heart Study</affilname><name-variant>Framingham Heart Study</name-variant><affiliation-city>Framingham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14321728500</author-url><authid>14321728500</authid><authname>Foster M.</authname><surname>Foster</surname><given-name>Meredith C.</given-name><initials>M.C.</initials><afid>60022386</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56652857600</author-url><authid>56652857600</authid><authname>Hwang S.</authname><surname>Hwang</surname><given-name>Shih Jen</given-name><initials>S.J.</initials></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56653216700</author-url><authid>56653216700</authid><authname>Massaro J.</authname><surname>Massaro</surname><given-name>Joseph M.</given-name><initials>J.M.</initials></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56653111000</author-url><authid>56653111000</authid><authname>Jacques P.</authname><surname>Jacques</surname><given-name>Paul F.</given-name><initials>P.F.</initials></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56271192200</author-url><authid>56271192200</authid><authname>Fox C.</authname><surname>Fox</surname><given-name>Caroline S.</given-name><initials>C.S.</initials></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56653084600</author-url><authid>56653084600</authid><authname>Chu A.</authname><surname>Chu</surname><given-name>Audrey Y.</given-name><initials>A.Y.</initials></author><intid>535998806</intid><source-id>19367</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929698351"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929698351?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929698351&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929698351&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929698351</prism:url><dc:identifier>SCOPUS_ID:84929698351</dc:identifier><eid>2-s2.0-84929698351</eid><dc:title>Early Detection of Bi-ventricular and Atrial Mechanical Dysfunction Using Two-Dimensional Speckle Tracking Echocardiography in Patients with Sarcoidosis</dc:title><dc:creator>Tigen K.</dc:creator><prism:publicationName>Lung</prism:publicationName><prism:issn>03412040</prism:issn><prism:eIssn>14321750</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00408-015-9748-0</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Purpose: Sarcoidosis is a systemic inflammatory disease with unknown etiology involving several organs. Myocardial involvement, pericarditis, severe rhythm abnormalities, and heart valve disease due to papillary muscle dysfunction are some of the cardiac manifestations. Conventional echocardiographic methods remain insufficient for the determination of subclinical myocardial dysfunction in patients with sarcoidosis. In our study, we investigated the impact of sarcoidosis on bi-ventricular and atrial functions using two-dimensional (2D) speckle tracking echocardiography (STE). Methods: Forty patients with sarcoidosis and 20 age and sex-matched controls were recruited into study. All subjects underwent a transthoracic echocardiography for the evaluation of ventricular and atrial functions with 2D STE. Results: Left ventricular (LV) dimensions, LV ejection fraction, and right ventricular (RV) systolic velocity were similar between the two groups. Left atrial (LA) diameter was significantly higher in sarcoidosis patients than controls. Eighteen (45 %) patients in the sarcoidosis group and 1 (5 %) patient in the control group had LV diastolic dysfunction. LV global longitudinal, radial, circumferential strain, twist, untwists, and RV global longitudinal strain values were significantly lower in sarcoidosis patients compared to controls. LA and RA reservoir functions were also significantly lower in sarcoidosis patients than controls. Conclusion: Although impaired LV diastolic function was detected using conventional parameters, only novel advanced echocardiographic modalities demonstrated impaired bi-ventricular and atrial mechanical functions in patients with sarcoidosis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004502</affiliation-url><afid>60004502</afid><affilname>Marmara Universitesi Tip Fakultesi</affilname><name-variant>Marmara University School of Medicine</name-variant><affiliation-city>Istanbul</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012324</affiliation-url><afid>60012324</afid><affilname>Istanbul Tip Fakultesi</affilname><name-variant>Istanbul University</name-variant><affiliation-city>Istanbul</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012324</affiliation-url><afid>60012324</afid><affilname>Istanbul Tip Fakultesi</affilname><name-variant>Istanbul University</name-variant><affiliation-city>Istanbul</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112625664</affiliation-url><afid>112625664</afid><affilname>Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital</affilname><name-variant>Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital</name-variant><affiliation-city>Istanbul</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104438</affiliation-url><afid>60104438</afid><affilname>Istanbul Medeniyet University</affilname><name-variant>Istanbul Medeniyet University</name-variant><affiliation-city>Istanbul</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027981</affiliation-url><afid>60027981</afid><affilname>Marmara Universitesi</affilname><name-variant>Marmara University</name-variant><affiliation-city>Istanbul</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:22836854300</author-url><authid>22836854300</authid><authname>Tigen K.</authname><surname>Tigen</surname><given-name>Kursat</given-name><initials>K.</initials><afid>60004502</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55193197200</author-url><authid>55193197200</authid><authname>Sunbul M.</authname><surname>Sunbul</surname><given-name>Murat</given-name><initials>M.</initials><afid>60004502</afid><afid>60027981</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55193197200</author-url><authid>55193197200</authid><authname>Sunbul M.</authname><surname>Sunbul</surname><given-name>Murat</given-name><initials>M.</initials><afid>60004502</afid><afid>60027981</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14424008000</author-url><authid>14424008000</authid><authname>Karaahmet T.</authname><surname>Karaahmet</surname><given-name>Tansu</given-name><initials>T.</initials><afid>60012324</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55203049200</author-url><authid>55203049200</authid><authname>Tasar O.</authname><surname>Tasar</surname><given-name>Onur</given-name><initials>O.</initials><afid>60012324</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:18633553200</author-url><authid>18633553200</authid><authname>Dundar C.</authname><surname>Dundar</surname><given-name>Cihan</given-name><initials>C.</initials><afid>60012324</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8839934100</author-url><authid>8839934100</authid><authname>Yalcinsoy M.</authname><surname>Yalcinsoy</surname><given-name>Murat</given-name><initials>M.</initials><afid>112625664</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:14520105500</author-url><authid>14520105500</authid><authname>Takir M.</authname><surname>Takir</surname><given-name>Mumtaz</given-name><initials>M.</initials><afid>60104438</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7003503549</author-url><authid>7003503549</authid><authname>Akkaya E.</authname><surname>Akkaya</surname><given-name>Esen</given-name><initials>E.</initials><afid>112625664</afid></author><authkeywords>Atrial function | Sarcoidosis | Speckle tracking echocardiography | Ventricular function</authkeywords><intid>535998533</intid><source-id>18533</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929692777"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929692777?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929692777&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929692777&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929692777</prism:url><dc:identifier>SCOPUS_ID:84929692777</dc:identifier><eid>2-s2.0-84929692777</eid><dc:title>Reduction of radiation exposure during ablation of atrial fibrillation | Verminderung der Strahlenbelastung bei Ablation wegen Vorhofflimmern</dc:title><dc:creator>Schneider R.</dc:creator><prism:publicationName>Herz</prism:publicationName><prism:issn>03409937</prism:issn><prism:eIssn>16156692</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00059-015-4307-2</prism:doi><dc:description>© 2015 Urban &amp; Vogel Aims: Pulmonary vein isolation (PVI) during ablation of atrial fibrillation (Afib) may be associated with long fluoroscopy duration. Although most current publications report on fluoroscopy time (FT), the dose–area product (DAP) may be a more valuable parameter for depicting radiation exposure. The aim of our study was to describe a method to reduce DAP by simple means during ablation of Afib. Methods: Patients undergoing Afib ablation using a three-dimensional (3D) mapping system were assigned to two fluoroscopy protocols: (1) standard settings with 7.5 pictures/s and collimation to the heart, fluoroscopy as needed for the convenience of the operator (standard group, SG); and (2) strict collimation to the left atrium, a frame rate of 4 pictures/s, shortened pulmonary vein angiography sequences, and maximal orientation by the 3D mapping system (redDAP group). The primary endpoint was DAP. Results: The study comprised 206 patients, who were assigned to the SG (n = 101, 49 %) or to the redDAP group (n = 105, 51 %). Mean FT was significantly reduced from 29.9 ± 11.3 min (SG) to 13.3 ± 8.3 min (redDAP group); mean DAP was reduced by approximately 90 % from 8,690 ± 5,727 to 837 ± 647 cGycm&lt;sup&gt;2&lt;/sup&gt;. The groups did not differ significantly in body mass index (28.8 ± 4.1 vs. 29.0 ± 5.0). PVI could be achieved in 98 of 101 patients (97 %) from the SG group and in all patients (100 %) from the redDAP group. Procedure time was significantly longer in the redDAP group (160.9 ± 35.7 vs. 138.1 ± 34.3 min). Conclusion: Radiation exposure during Afib ablation procedures can be reduced with simple means by strict collimation to the left atrium, a frame rate of 4 pictures/s, shortened pulmonary vein angiography sequences, and maximal 3D orientation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024766</affiliation-url><afid>60024766</afid><affilname>Universitat Rostock Uniklinikum und Medizinische Fakultat</affilname><name-variant>University Hospital Rostock</name-variant><affiliation-city>Rostock</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003615</affiliation-url><afid>60003615</afid><affilname>Universitat Rostock</affilname><name-variant>University of Rostock</name-variant><affiliation-city>Rostock</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55449214600</author-url><authid>55449214600</authid><authname>Schneider R.</authname><surname>Schneider</surname><given-name>Ralph</given-name><initials>R.</initials><afid>60024766</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506137196</author-url><authid>6506137196</authid><authname>Lauschke J.</authname><surname>Lauschke</surname><given-name>Jörg</given-name><initials>J.</initials><afid>60024766</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55782134400</author-url><authid>55782134400</authid><authname>Schneider C.</authname><surname>Schneider</surname><given-name>Cindy</given-name><initials>C.</initials><afid>60024766</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56022903400</author-url><authid>56022903400</authid><authname>Tischer T.</authname><surname>Tischer</surname><given-name>Tina</given-name><initials>T.</initials><afid>60024766</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56605893800</author-url><authid>56605893800</authid><authname>Glass A.</authname><surname>Glass</surname><given-name>Aenne</given-name><initials>A.</initials><afid>60003615</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6701857743</author-url><authid>6701857743</authid><authname>Bänsch D.</authname><surname>Bänsch</surname><given-name>Dietmar</given-name><initials>D.</initials><afid>60024766</afid></author><authkeywords>Atrial fibrillation | Dose–area product | Fluoroscopy time | Radiofrequency ablation | Three-dimensional electro-anatomical reconstruction</authkeywords><intid>1535998023</intid><source-id>23251</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929833213"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929833213?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929833213&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929833213&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929833213</prism:url><dc:identifier>SCOPUS_ID:84929833213</dc:identifier><eid>2-s2.0-84929833213</eid><dc:title>Mitral valve analysis adding a virtual semi-transparent annulus plane for detection of prolapsing segments</dc:title><dc:creator>Dumont K.</dc:creator><prism:publicationName>Cardiovascular Ultrasound</prism:publicationName><prism:eIssn>14767120</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>May 20, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12947-015-0019-2</prism:doi><dc:description>© 2015 Dumont et al.; licensee BioMed Central. Background: We hypothesized that a novel three-dimensional virtual semi-transparent annulus plane (3D VSAP) presented on a holographic screen can be used to visualize the prolapsing tissue in degenerative mitral valve disease and furthermore, provide us with geometrical data of the mitral valve apparatus. Phantom and patient studies were designed to demonstrate the feasibility of creating a semi-automatic, semi-transparent mitral annulus plane visualized on a holographic display. Methods: Ten pipe cleaners mimicking the mitral annulus with different shapes and three types of annuloplasty rings served as phantoms. We obtained 3D transoesophageal examination of the phantoms in a special designed box filled with water. Recordings were converted to the holographic display and a 3D VSAP was created. The ratio of the major and minor axes as well as the non-planar angles were calculated and compared with direct measures of the phantoms. Forty patients with degenerative mitral valve disease were then analyzed with 3D transthoracic echocardiography (TTE) and a 3D VSAP was created on the holographic display. A total of 240 segments were analyzed by two independent observers, one echo expert (observer I), and the other novice with limited echo experience (observer II). The two observers created the 3D VSAP in each patient before suggesting the valve pathology. Results: The major/minor axes ratio and non-planar angles by 3D VSAP correlated with direct measurements by r = 0.65, p &lt; 0.02 and r = 0.99, p &lt; 0.0001, respectively. The sensitivity and specificity of the 3D VSAP method in patients was 81 and 97 %, respectively (observer I) and for observer II 77 and 96 %, respectively. The accuracy and precisions were 93.9 and 89.4 %, respectively (observer I), 92.3 and 85.1 % (observer II). Mitral valve analysis adding a 3D VSAP was feasible with high accuracy and precision, providing a quick and less subjective method for diagnosing mitral valve prolapse. This novel method may improve preoperative diagnostics and may relieve a better understanding of the pathophysiology of mitral valve disease. Thus, based on the specific findings in each patient, a tailored surgical repair can be planned and hopefully enhance long-term repair patency in the future.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60105037</affiliation-url><afid>60105037</afid><affilname>Oslo University Hospital</affilname><name-variant>Oslo University Hospital</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112877588</affiliation-url><afid>112877588</afid><affilname>Kalkulo AS</affilname><name-variant>Kalkulo AS</name-variant><affiliation-city>Fornebu</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60105037</affiliation-url><afid>60105037</afid><affilname>Oslo University Hospital</affilname><name-variant>Oslo University Hospital</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60105037</affiliation-url><afid>60105037</afid><affilname>Oslo University Hospital</affilname><name-variant>Oslo University Hospital</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60105037</affiliation-url><afid>60105037</afid><affilname>Oslo University Hospital</affilname><name-variant>Oslo University Hospital</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55885467500</author-url><authid>55885467500</authid><authname>Dumont K.</authname><surname>Dumont</surname><given-name>Karl Andreas</given-name><initials>K.A.</initials><afid>60105037</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56417452900</author-url><authid>56417452900</authid><authname>Karlsen J.</authname><surname>Karlsen</surname><given-name>Jørn Skaarud</given-name><initials>J.S.</initials><afid>112877588</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:12244327100</author-url><authid>12244327100</authid><authname>Helle-Valle T.</authname><surname>Helle-Valle</surname><given-name>Thomas</given-name><initials>T.</initials><afid>60105037</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003322949</author-url><authid>7003322949</authid><authname>Fiane A.</authname><surname>Fiane</surname><given-name>Arnt Eltvedt</given-name><initials>A.E.</initials><afid>60105037</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:19735849200</author-url><authid>19735849200</authid><authname>Lundblad R.</authname><surname>Lundblad</surname><given-name>Runar</given-name><initials>R.</initials><afid>60105037</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603176183</author-url><authid>6603176183</authid><authname>Urheim S.</authname><surname>Urheim</surname><given-name>Stig</given-name><initials>S.</initials><afid>60105037</afid></author><authkeywords>3D echocardiography | Echocardiography | Mitral annulus | Valvular heart disease</authkeywords><intid>1036014238</intid><source-id>16598</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929682991"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929682991?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929682991&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929682991&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929682991</prism:url><dc:identifier>SCOPUS_ID:84929682991</dc:identifier><eid>2-s2.0-84929682991</eid><dc:title>Galectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients | Galectin-3 als neuer Biomarker diastolischer Funktionsstörung bei Hämodialysepatienten</dc:title><dc:creator>Gurel O.</dc:creator><prism:publicationName>Herz</prism:publicationName><prism:issn>03409937</prism:issn><prism:eIssn>16156692</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00059-015-4303-6</prism:doi><dc:description>© 2015 Urban &amp; Vogel Background: Galectin-3 (gal-3) is an emerging prognostic biomarker in heart failure (HF). Clinical and experimental studies suggest that gal-3 is an important mediator of HF. Here we aimed to examine the relationship between gal-3 and diastolic dysfunction in patients undergoing maintenance hemodialysis (HD). Methods: We examined the relationship between plasma gal-3 levels and left ventricular diastolic function. Plasma gal-3 was measured in 87 subjects with chronic HD and in 45 healthy controls using biochemical evaluations. Conventional echocardiography and pulsed tissue Doppler assessment were performed in all patients. Left ventricular diastolic dysfunction (LVDD) was defined as E’ &lt; 8 cm/s. The E/E’ ratio was used as the main determinant of LVDD grade. Results: The mean gal-3 concentrations were: 16.05 ng/ml (13.89–19.75) in healthy controls; 14.54 ng/ml (10.85–17.65) in HD patients with normal diastolic function; and 23.30 ng/ml (20.12–26.87) in HD patients with LVDD (p &lt; 0.01). Plasma gal-3 levels correlated with E/E’ (r = 0.933, p &lt; 0.01), left atrial volume index (r = 0.713, p &lt; 0.01), and E’ (r = -0.685, p &lt; 0.01). ROC analysis showed that the best gal-3 cut-off point for the diagnosis of LVDD was 20.12 ng/ml with a sensitivity of 67.6 % and specificity of 84.6 % (AUC = 0.803). Conclusion: We suggest that gal-3 may be a promising biomarker for the detection of LVDD in HD patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114352868</affiliation-url><afid>114352868</afid><affilname>Turgut Ozal University</affilname><name-variant>Turgut Özal University</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013116</affiliation-url><afid>60013116</afid><affilname>Ankara Oncology Education and Research Hospital</affilname><name-variant>Ankara Oncology Education and Research Hospital</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114352868</affiliation-url><afid>114352868</afid><affilname>Turgut Ozal University</affilname><name-variant>Turgut Özal University</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114352868</affiliation-url><afid>114352868</afid><affilname>Turgut Ozal University</affilname><name-variant>Turgut Özal University</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:12760073800</author-url><authid>12760073800</authid><authname>Gurel O.</authname><surname>Gurel</surname><given-name>Ozgul Malcok</given-name><initials>O.M.</initials><afid>114352868</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54880058200</author-url><authid>54880058200</authid><authname>Yilmaz H.</authname><surname>Yilmaz</surname><given-name>Hakki</given-name><initials>H.</initials><afid>60013116</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56653139700</author-url><authid>56653139700</authid><authname>Celik T.</authname><surname>Celik</surname><given-name>T. H.</given-name><initials>T.H.</initials><afid>114352868</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56215909300</author-url><authid>56215909300</authid><authname>Cakmak M.</authname><surname>Cakmak</surname><given-name>Muzaffer</given-name><initials>M.</initials><afid>114352868</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24342010600</author-url><authid>24342010600</authid><authname>Namuslu M.</authname><surname>Namuslu</surname><given-name>Mehmet</given-name><initials>M.</initials><afid>114352868</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56653227400</author-url><authid>56653227400</authid><authname>Bilgiç A.</authname><surname>Bilgiç</surname><given-name>A. M.</given-name><initials>A.M.</initials><afid>60013116</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602949247</author-url><authid>6602949247</authid><authname>Bavbek N.</authname><surname>Bavbek</surname><given-name>Nuket</given-name><initials>N.</initials><afid>60013116</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55808519200</author-url><authid>55808519200</authid><authname>Akcay A.</authname><surname>Akcay</surname><given-name>Ali</given-name><initials>A.</initials><afid>60013116</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55964246400</author-url><authid>55964246400</authid><authname>Eryonucu B.</authname><surname>Eryonucu</surname><given-name>Beyhan</given-name><initials>B.</initials><afid>114352868</afid></author><authkeywords>Biomarker | Diastolic dysfunction | Doppler echocardiography | Galectin-3 | Hemodialysis</authkeywords><intid>1535997451</intid><source-id>23251</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929671023"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929671023?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929671023&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929671023&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929671023</prism:url><dc:identifier>SCOPUS_ID:84929671023</dc:identifier><eid>2-s2.0-84929671023</eid><dc:title>Retrospective Analysis of Vancomycin Nephrotoxicity in Elderly Chinese Patients</dc:title><dc:creator>Liu Y.</dc:creator><prism:publicationName>Pharmacology</prism:publicationName><prism:issn>00317012</prism:issn><prism:eIssn>14230313</prism:eIssn><prism:pageRange>279-284</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1159/000381783</prism:doi><pii>000381783</pii><dc:description>Copyright © 2015, S. Karger AG. All rights reserved. This study explored nephrotoxicity in elderly Chinese patients after exposure to vancomycin and other nephrotoxic risk factors. This was a single-center retrospective study. The patient population included those who were ≥60 years of age, had normal baseline serum creatinine values, and received vancomycin for ≥48 h between January 1, 2013 and August 30, 2014. Nephrotoxicity occurred in 29% of 124 patients. A baseline creatinine clearance ≥63.5 ml/min was more common in the nephrotoxic group. Patients with high (≥15 mg/l) rather than low (&lt;15 mg/l) average vancomycin troughs had elevated nephrotoxicity (47.2 vs. 27.3%, p = 0.0001). Of the comorbid conditions evaluated, there were more patients with shock (p = 0.001), hypertension (p = 0.020) and congestive heart failure (p = 0.04) in the nephrotoxic group. Drugs frequently given at the same time with vancomycin, such as angiotensin receptor blockers and furosemide, were also associated with increased nephrotoxic risk. In conclusion, nephrotoxicity was frequently observed in patients with concurrent vancomycin trough concentrations ≥15 μg/ml and hypertension, shock, congestive heart failure. In addition, drugs concurrently used with vancomycin may also increase its nephrotoxicity. Therefore, renal function and vancomycin serum troughs should be closely monitored, especially in patients with other renal injury risk factors. © 2015 S. Karger AG, Basel</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025084</affiliation-url><afid>60025084</afid><affilname>Shanghai Jiaotong University</affilname><name-variant>Shanghai Jiaotong University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56278833900</author-url><authid>56278833900</authid><authname>Liu Y.</authname><surname>Liu</surname><given-name>Yan</given-name><initials>Y.</initials><afid>60025084</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56652885300</author-url><authid>56652885300</authid><authname>Yin Y.</authname><surname>Yin</surname><given-name>You</given-name><initials>Y.</initials></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56653095000</author-url><authid>56653095000</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xin Zhu</given-name><initials>X.Z.</initials></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56652931500</author-url><authid>56652931500</authid><authname>Yao H.</authname><surname>Yao</surname><given-name>Hui Juan</given-name><initials>H.J.</initials></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56653174500</author-url><authid>56653174500</authid><authname>Li L.</authname><surname>Li</surname><given-name>Li Xia</given-name><initials>L.X.</initials></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56653551500</author-url><authid>56653551500</authid><authname>Chen J.</authname><surname>Chen</surname><given-name>Ji Hui</given-name><initials>J.H.</initials></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56652780500</author-url><authid>56652780500</authid><authname>Chen T.</authname><surname>Chen</surname><given-name>Ting</given-name><initials>T.</initials></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56652801000</author-url><authid>56652801000</authid><authname>Lu X.</authname><surname>Lu</surname><given-name>Xiao Tong</given-name><initials>X.T.</initials></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56653150700</author-url><authid>56653150700</authid><authname>Bu S.</authname><surname>Bu</surname><given-name>Shu Hong</given-name><initials>S.H.</initials></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56653550700</author-url><authid>56653550700</authid><authname>Zhang J.</authname><surname>Zhang</surname><given-name>Jian</given-name><initials>J.</initials></author><intid>1035993574</intid><source-id>21194</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929650503"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929650503?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929650503&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929650503&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929650503</prism:url><dc:identifier>SCOPUS_ID:84929650503</dc:identifier><eid>2-s2.0-84929650503</eid><dc:title>Quantitative metabolic profiling of NMR spectral signatures of branched chain amino acids in blood serum</dc:title><dc:creator>Ghosh S.</dc:creator><prism:publicationName>Amino Acids</prism:publicationName><prism:issn>09394451</prism:issn><prism:eIssn>14382199</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00726-015-1994-1</prism:doi><dc:description>© 2015 Springer-Verlag Wien Branched Chain Amino Acids (BCAAs) are related to different aspects of diseases like pathogenesis, diagnosis and even prognosis. While in some diseases, levels of all the BCAAs are perturbed; in some cases, perturbation occurs in one or two while the rest remain unaltered. In case of ischemic heart disease, there is an enhanced level of plasma leucine and isoleucine but valine level remains unaltered. In ‘Hypervalinemia’, valine is elevated in serum and urine, but not leucine and isoleucine. Therefore, identification of these metabolites and profiling of individual BCAA in a quantitative manner in body-fluid like blood plasma/serum have long been in demand. &lt;sup&gt;1&lt;/sup&gt;H NMR resonances of the BCAAs overlap with each other which complicates quantification of individual BCAAs. Further, the situation is limited by the overlap of broad resonances of lipoprotein with the resonances of BCAAs. The widely used commercially available kits cannot differentially estimate the BCAAs. Here, we have achieved proper identification and characterization of these BCAAs in serum in a quantitative manner employing a Nuclear Magnetic Resonance-based technique namely T&lt;inf&gt;2&lt;/inf&gt;-edited Correlation Spectroscopy (COSY). This approach can easily be extended to other body fluids like bile, follicular fluids, saliva, etc.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031855</affiliation-url><afid>60031855</afid><affilname>Tata Institute of Fundamental Research</affilname><name-variant>Tata Institute of Fundamental Research</name-variant><affiliation-city>Mumbai</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017252</affiliation-url><afid>60017252</afid><affilname>National Institute on Aging</affilname><name-variant>National Institute on Aging</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115261413</affiliation-url><afid>115261413</afid><affilname>University of Pennlsylvania</affilname><name-variant>University of Pennlsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014097</affiliation-url><afid>60014097</afid><affilname>Indian Institute of Science</affilname><name-variant>Indian Institute of Science</name-variant><affiliation-city>Bangalore</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021931</affiliation-url><afid>60021931</afid><affilname>Johannes Kepler Universitat Linz</affilname><name-variant>Johannes Kepler University</name-variant><affiliation-city>Linz</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55248370200</author-url><authid>55248370200</authid><authname>Ghosh S.</authname><surname>Ghosh</surname><given-name>Soumita</given-name><initials>S.</initials><afid>60031855</afid><afid>60017252</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55248370200</author-url><authid>55248370200</authid><authname>Ghosh S.</authname><surname>Ghosh</surname><given-name>Soumita</given-name><initials>S.</initials><afid>60031855</afid><afid>60017252</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37862205100</author-url><authid>37862205100</authid><authname>Sengupta A.</authname><surname>Sengupta</surname><given-name>Arjun</given-name><initials>A.</initials><afid>60031855</afid><afid>115261413</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37862205100</author-url><authid>37862205100</authid><authname>Sengupta A.</authname><surname>Sengupta</surname><given-name>Arjun</given-name><initials>A.</initials><afid>60031855</afid><afid>115261413</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56651864200</author-url><authid>56651864200</authid><authname>Chandra K.</authname><surname>Chandra</surname><given-name>Kousik</given-name><initials>K.</initials><afid>60031855</afid><afid>60014097</afid><afid>60021931</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56651864200</author-url><authid>56651864200</authid><authname>Chandra K.</authname><surname>Chandra</surname><given-name>Kousik</given-name><initials>K.</initials><afid>60031855</afid><afid>60014097</afid><afid>60021931</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56651864200</author-url><authid>56651864200</authid><authname>Chandra K.</authname><surname>Chandra</surname><given-name>Kousik</given-name><initials>K.</initials><afid>60031855</afid><afid>60014097</afid><afid>60021931</afid></author><authkeywords>BCAA | COSY | CPMG | Metabolites | NMR</authkeywords><intid>535990906</intid><source-id>16783</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929692724"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929692724?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929692724&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929692724&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929692724</prism:url><dc:identifier>SCOPUS_ID:84929692724</dc:identifier><eid>2-s2.0-84929692724</eid><dc:title>The Effects of Oxygen Therapy on Myocardial Salvage in ST Elevation Myocardial Infarction Treated with Acute Percutaneous Coronary Intervention: The Supplemental Oxygen in Catheterized Coronary Emergency Reperfusion (SOCCER) Study</dc:title><dc:creator>Khoshnood A.</dc:creator><prism:publicationName>Cardiology (Switzerland)</prism:publicationName><prism:issn>00086312</prism:issn><prism:eIssn>14219751</prism:eIssn><prism:pageRange>16-21</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1159/000398786</prism:doi><pii>000398786</pii><dc:description>Copyright © 2015, S. Karger AG. All rights reserved. Objectives: Despite a lack of scientific evidence, oxygen has long been a part of standard treatment for patients with acute myocardial infarction (AMI). However, several studies suggest that oxygen therapy may have negative cardiovascular effects. We here describe a randomized controlled trial, i.e. Supplemental Oxygen in Catheterized Coronary Emergency Reperfusion (SOCCER), aiming to evaluate the effect of oxygen therapy on myocardial salvage and infarct size in patients with ST elevation myocardial infarction (STEMI) treated with a primary percutaneous coronary intervention (PCI). Methods: One hundred normoxic STEMI patients accepted for a primary PCI are randomized in the ambulance to either standard oxygen therapy or no supplemental oxygen. All patients undergo cardiovascular magnetic resonance imaging (CMR) 2-6 days after the primary PCI, and a subgroup of 50 patients undergo an extended echocardiography during admission and at 6 months. All patients are followed for 6 months for hospital admission for heart failure and subjective perception of health. The primary endpoint is the myocardial salvage index on CMR. Discussion: Even though oxygen therapy is a part of standard care, oxygen may not be beneficial for patients with AMI and is possibly even harmful. The results of the present and concurrent oxygen trials may change international treatment guidelines for patients with AMI or ischemia. © 2015 S. Karger AG, Basel</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029170</affiliation-url><afid>60029170</afid><affilname>Lunds Universitet</affilname><name-variant>University of Lund</name-variant><affiliation-city>Lund</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14045258300</author-url><authid>14045258300</authid><authname>Khoshnood A.</authname><surname>Khoshnood</surname><given-name>Ardavan</given-name><initials>A.</initials><afid>60029170</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35423407600</author-url><authid>35423407600</authid><authname>Carlsson M.</authname><surname>Carlsson</surname><given-name>Marcus</given-name><initials>M.</initials></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55326837300</author-url><authid>55326837300</authid><authname>Akbarzadeh M.</authname><surname>Akbarzadeh</surname><given-name>Mahin</given-name><initials>M.</initials></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6507242581</author-url><authid>6507242581</authid><authname>Bhiladvala P.</authname><surname>Bhiladvala</surname><given-name>Pallonji</given-name><initials>P.</initials></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602197694</author-url><authid>6602197694</authid><authname>Roijer A.</authname><surname>Roijer</surname><given-name>Anders</given-name><initials>A.</initials></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:37046762300</author-url><authid>37046762300</authid><authname>Bodetoft S.</authname><surname>Bodetoft</surname><given-name>Stefan</given-name><initials>S.</initials></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56653197400</author-url><authid>56653197400</authid><authname>Höglund P.</authname><surname>Höglund</surname><given-name>Peter</given-name><initials>P.</initials></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55835811500</author-url><authid>55835811500</authid><authname>Zughaft D.</authname><surname>Zughaft</surname><given-name>David</given-name><initials>D.</initials></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56653311100</author-url><authid>56653311100</authid><authname>Todorova L.</authname><surname>Todorova</surname><given-name>Lizbet</given-name><initials>L.</initials></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005319185</author-url><authid>7005319185</authid><authname>Erlinge D.</authname><surname>Erlinge</surname><given-name>David</given-name><initials>D.</initials></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7004141339</author-url><authid>7004141339</authid><authname>Ekelund U.</authname><surname>Ekelund</surname><given-name>Ulf</given-name><initials>U.</initials></author><intid>1785998382</intid><source-id>22522</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929692537"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929692537?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929692537&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929692537&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929692537</prism:url><dc:identifier>SCOPUS_ID:84929692537</dc:identifier><eid>2-s2.0-84929692537</eid><dc:title>The association between socio-economic position and diet quality in Australian adults</dc:title><dc:creator>Backholer K.</dc:creator><prism:publicationName>Public Health Nutrition</prism:publicationName><prism:issn>13689800</prism:issn><prism:eIssn>14752727</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1017/S1368980015001470</prism:doi><pii>S1368980015001470</pii><dc:description>Copyright © The Authors 2015 Objective: We aimed to investigate the association between multiple measures of socio-economic position (SEP) and diet quality, using a diet quality index representing current national dietary guidelines, in the Australian adult population. Design: Cross-sectional study. Linear regression analyses were used to estimate the association between indicators of SEP (educational attainment, level of income and area-level disadvantage) and diet quality (measured using the Dietary Guideline Index (DGI)) in the total sample and stratified by sex and age (≤55 years and &gt;55 years). Setting: A large randomly selected sample of the Australian adult population. Subjects: Australian adults (n 9296; aged ≥25 years) from the Australian Diabetes, Obesity and Lifestyle Study. Results: A higher level of educational attainment and income and a lower level of area-level disadvantage were significantly associated with a higher DGI score, across the gradient of SEP. The association between indicators of SEP and DGI score was consistently stronger among those aged ≤55 years compared with their older counterparts. The most disadvantaged group had a DGI score between 2 and 5 units lower (depending on the marker of SEP) compared with the group with the least disadvantage. Conclusions: A higher level of SEP was consistently associated with a higher level of diet quality for all indicators of SEP examined. In order to reduce socio-economic inequalities in diet quality, healthy eating initiatives need to act across the gradient of socio-economic disadvantage with a proportionate focus on those with greater socio-economic disadvantage.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033409</affiliation-url><afid>60033409</afid><affilname>Baker IDI Heart and Diabetes Institute</affilname><name-variant>Baker Heart Research Institute</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033409</affiliation-url><afid>60033409</afid><affilname>Baker IDI Heart and Diabetes Institute</affilname><name-variant>Baker Heart Research Institute</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018805</affiliation-url><afid>60018805</afid><affilname>Deakin University</affilname><name-variant>Deakin University</name-variant><affiliation-city>Geelong</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033409</affiliation-url><afid>60033409</afid><affilname>Baker IDI Heart and Diabetes Institute</affilname><name-variant>Baker Heart Research Institute</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6507444541</author-url><authid>6507444541</authid><authname>Backholer K.</authname><surname>Backholer</surname><given-name>Kathryn</given-name><initials>K.</initials><afid>60033409</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56653110900</author-url><authid>56653110900</authid><authname>Spencer E.</authname><surname>Spencer</surname><given-name>Elizabeth</given-name><initials>E.</initials><afid>60033409</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55651517900</author-url><authid>55651517900</authid><authname>Gearon E.</authname><surname>Gearon</surname><given-name>Emma</given-name><initials>E.</initials><afid>60033409</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602280096</author-url><authid>6602280096</authid><authname>Magliano D.</authname><surname>Magliano</surname><given-name>Dianna J.</given-name><initials>D.J.</initials><afid>60033409</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005425137</author-url><authid>7005425137</authid><authname>McNaughton S.</authname><surname>McNaughton</surname><given-name>Sarah A.</given-name><initials>S.A.</initials><afid>60018805</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56443232400</author-url><authid>56443232400</authid><authname>Shaw J.</authname><surname>Shaw</surname><given-name>Jonathan E.</given-name><initials>J.E.</initials><afid>60033409</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102329188</author-url><authid>7102329188</authid><authname>Peeters A.</authname><surname>Peeters</surname><given-name>Anna</given-name><initials>A.</initials><afid>60033409</afid></author><authkeywords>Diet quality | Education | Obesity | Socio-economic position</authkeywords><intid>2035992413</intid><source-id>27997</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226758"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226758?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226758&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226758&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226758</prism:url><dc:identifier>SCOPUS_ID:84930226758</dc:identifier><eid>2-s2.0-84930226758</eid><dc:title>Photo-cross-linkable methacrylated gelatin and hydroxyapatite hybrid hydrogel for modularly engineering biomimetic osteon</dc:title><dc:creator>Zuo Y.</dc:creator><prism:publicationName>ACS Applied Materials and Interfaces</prism:publicationName><prism:issn>19448244</prism:issn><prism:eIssn>19448252</prism:eIssn><prism:volume>7</prism:volume><prism:issueIdentifier>19</prism:issueIdentifier><prism:pageRange>10386-10394</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1021/acsami.5b01433</prism:doi><dc:description>© 2015 American Chemical Society. Modular tissue engineering holds great potential in regenerating natural complex tissues by engineering three-dimensional modular scaffolds with predefined geometry and biological characters. In modular tissue-like construction, a scaffold with an appropriate mechanical rigidity for assembling fabrication and high biocompatibility for cell survival is the key to the successful bioconstruction. In this work, a series of composite hydrogels (GH0, GH1, GH2, and GH3) based on a combination of methacrylated gelatin (GelMA) and hydroxyapatite (HA) was exploited to enhance hydrogel mechanical rigidity and promote cell functional expression for osteon biofabrication. These composite hydrogels presented a lower swelling ratio, higher mechanical moduli, and better biocompatibility when compared to the pure GelMA hydrogel. Furthermore, on the basis of the composite hydrogel and photolithograph technology, we successfully constructed an osteon-like concentric double-ring structure in which the inner ring encapsulating human umbilical vascular endothelial cells (HUVECs) was designed to imitate blood vessel tubule while the outer ring encapsulating human osteoblast-like cells (MG63s) acts as part of bone. During the coculture period, MG63s and HUVECs exhibited not only satisfying growth status but also the enhanced genic expression of osteogenesis-related and angiogenesis-related differentiations. These results demonstrate this GelMA-HA composite hydrogel system is promising for modular tissue engineering.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016521</affiliation-url><afid>60016521</afid><affilname>Sichuan University</affilname><name-variant>Sichuan University</name-variant><affiliation-city>Chengdu</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55277193600</author-url><authid>55277193600</authid><authname>Zuo Y.</authname><surname>Zuo</surname><given-name>Yicong</given-name><initials>Y.</initials><afid>60016521</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662587600</author-url><authid>56662587600</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xiaolu</given-name><initials>X.</initials><afid>60016521</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55701216700</author-url><authid>55701216700</authid><authname>Wei D.</authname><surname>Wei</surname><given-name>Dan</given-name><initials>D.</initials><afid>60016521</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55547135700</author-url><authid>55547135700</authid><authname>Sun J.</authname><surname>Sun</surname><given-name>Jing</given-name><initials>J.</initials><afid>60016521</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35328537000</author-url><authid>35328537000</authid><authname>Xiao W.</authname><surname>Xiao</surname><given-name>Wenqian</given-name><initials>W.</initials><afid>60016521</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55991698400</author-url><authid>55991698400</authid><authname>Zhao H.</authname><surname>Zhao</surname><given-name>Huan</given-name><initials>H.</initials><afid>60016521</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7403156325</author-url><authid>7403156325</authid><authname>Guo L.</authname><surname>Guo</surname><given-name>Likun</given-name><initials>L.</initials><afid>60016521</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8707062400</author-url><authid>8707062400</authid><authname>Wei Q.</authname><surname>Wei</surname><given-name>Qingrong</given-name><initials>Q.</initials><afid>60016521</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35232827400</author-url><authid>35232827400</authid><authname>Fan H.</authname><surname>Fan</surname><given-name>Hongsong</given-name><initials>H.</initials><afid>60016521</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:35104173000</author-url><authid>35104173000</authid><authname>Zhang X.</authname><surname>Zhang</surname><given-name>Xingdong</given-name><initials>X.</initials><afid>60016521</afid></author><authkeywords>hydroxyapatite | methacrylated gelatin | modular tissue engineering | osteon</authkeywords><intid>36086177</intid><source-id>19700171101</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929643514"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929643514?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929643514&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929643514&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929643514</prism:url><dc:identifier>SCOPUS_ID:84929643514</dc:identifier><eid>2-s2.0-84929643514</eid><dc:title>“Spleen Contraction and Hemoconcentration” Regarding the Review “Hemoconcentration and Hemostasis During Acute Stress: Interacting and Independent Effects” by Austin et al. 2011</dc:title><dc:creator>Engan H.</dc:creator><prism:publicationName>Annals of Behavioral Medicine</prism:publicationName><prism:issn>08836612</prism:issn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12160-015-9707-2</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60105080</affiliation-url><afid>60105080</afid><affilname>Mid Sweden University, Ostersund</affilname><name-variant>Mid Sweden University</name-variant><affiliation-city>Ostersund</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60105080</affiliation-url><afid>60105080</afid><affilname>Mid Sweden University, Ostersund</affilname><name-variant>Mid Sweden University</name-variant><affiliation-city>Ostersund</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112735187</affiliation-url><afid>112735187</afid><affilname>Norwegian Heart and Lung Patient Organization</affilname><name-variant>Norwegian Heart and Lung Patient Organization</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55128177500</author-url><authid>55128177500</authid><authname>Engan H.</authname><surname>Engan</surname><given-name>Harald</given-name><initials>H.</initials><afid>60105080</afid><afid>60105080</afid><afid>112735187</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55128177500</author-url><authid>55128177500</authid><authname>Engan H.</authname><surname>Engan</surname><given-name>Harald</given-name><initials>H.</initials><afid>60105080</afid><afid>60105080</afid><afid>112735187</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55128177500</author-url><authid>55128177500</authid><authname>Engan H.</authname><surname>Engan</surname><given-name>Harald</given-name><initials>H.</initials><afid>60105080</afid><afid>60105080</afid><afid>112735187</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603554135</author-url><authid>6603554135</authid><authname>Schagatay E.</authname><surname>Schagatay</surname><given-name>Erika</given-name><initials>E.</initials><afid>60105080</afid><afid>60105080</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603554135</author-url><authid>6603554135</authid><authname>Schagatay E.</authname><surname>Schagatay</surname><given-name>Erika</given-name><initials>E.</initials><afid>60105080</afid><afid>60105080</afid></author><intid>2035983619</intid><source-id>27473</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929691958"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929691958?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929691958&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929691958&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929691958</prism:url><dc:identifier>SCOPUS_ID:84929691958</dc:identifier><eid>2-s2.0-84929691958</eid><dc:title>PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N-of-1 Trials</dc:title><dc:creator>Swiger K.</dc:creator><prism:publicationName>Drug Safety</prism:publicationName><prism:issn>01145916</prism:issn><prism:eIssn>11791942</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s40264-015-0296-6</prism:doi><dc:description>© 2015 Springer International Publishing Switzerland Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel class of medications that greatly lower low-density lipoprotein cholesterol (LDL-C) by upregulating LDL receptor availability. In early 2014, the US Food and Drug Administration (FDA) directed developers of PCSK9 inhibitors to monitor neurocognitive adverse effects and consider neurocognitive testing in at least a subset of participants in ongoing late-stage trials. Available trial evidence indicates that neurocognitive adverse events may occur more commonly in individuals receiving an antibody to PCSK9, but these events are uncommon and have not been associated with on-treatment LDL-C levels. Moreover, it is unclear to what extent closer monitoring of trial participants allocated to PCSK9 inhibitors has led to an ascertainment bias. Regardless, further trial data are needed, and long-term outcomes trials are ongoing, with at least one including a neurocognitive substudy. Considering lessons learned from the statin experience, high-quality prospective cohort studies and randomized trials may not be enough to allay concerns or settle debate since the focus of effect in these studies is the group average. Therefore, we suggest that n-of-1 trials could be considered to bring the focus to the individual while retaining the benefits of blinding and randomization in evidence generation. Ultimately, any neurocognitive adverse effects that might exist with PCSK9 inhibition and lipid lowering must be weighed against potential benefits of therapy, including avoidance of myocardial infarction and stroke, and a reduced risk of dementia due to neurovascular benefits from long-term lipid lowering.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106675197</affiliation-url><afid>106675197</afid><affilname>Johns Hopkins Ciccarone Center for the Prevention of Heart Disease</affilname><name-variant>Johns Hopkins Ciccarone Center for the Prevention of Heart Disease</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55649884100</author-url><authid>55649884100</authid><authname>Swiger K.</authname><surname>Swiger</surname><given-name>Kristopher J.</given-name><initials>K.J.</initials><afid>106675197</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55450099100</author-url><authid>55450099100</authid><authname>Martin S.</authname><surname>Martin</surname><given-name>Seth S.</given-name><initials>S.S.</initials><afid>106675197</afid></author><intid>35996067</intid><source-id>21237</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929429850"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929429850?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929429850&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929429850&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929429850</prism:url><dc:identifier>SCOPUS_ID:84929429850</dc:identifier><eid>2-s2.0-84929429850</eid><dc:title>Aquaporin-4 autoantibodies increase vasogenic edema formation and infarct size in a rat stroke model</dc:title><dc:creator>Juenemann M.</dc:creator><prism:publicationName>BMC Immunology</prism:publicationName><prism:eIssn>14712172</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>May 20, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12865-015-0087-y</prism:doi><dc:description>© 2015 Juenemann et al.; licensee BioMed Central. Background: Neuromyelitis optica (NMO) is an autoimmune disorder of the central nervous system, which is characterized by autoantibodies directed against the water channel aquaporin-4 (AQP4). As one of the main water regulators in the central nervous system, APQ4 is supposed to be involved in the dynamics of brain edema. Cerebral edema seriously affects clinical outcome after ischemic stroke; we therefore aimed to investigate whether NMO-antibodies may exert the same functional effects as an AQP4-inhibitor in-vivo in acute ischemic stroke. Methods: Sixteen male Wistar rats were randomized into two groups twice receiving either purified NMO-IgG or immune globulin from healthy controls, 24 hours and 30 minutes before middle cerebral artery occlusion (MCAO) was performed. T2-weighted MRI was carried out 24 hours after MCAO. Results: MRI-examination showed a significant increase of infarct size in relation to the cerebral hemisphere volume with NMO-IgG treated animals (27.1% ± 11.1% vs. 14.3% ± 7.2%; p &lt; 0.05) when corrected for the space-occupying effect of vasogenic edema formation and similar results without edema correction (34.4% ± 16.4% vs. 17.5% ± 9.3%; p &lt; 0.05). Furthermore, T2-RT revealed a significant increase in cortical brain water content of the treatment group (19.5 ms ± 9.7 ms vs. 9.2 ms ± 5.2 ms; p &lt; 0.05). Conclusions: These results support the functional impact of NMO-antibodies and also offer an in-vivo-applicable animal model to investigate the properties of AQP4 in ischemic stroke.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017134</affiliation-url><afid>60017134</afid><affilname>Justus Liebig University Giessen</affilname><affiliation-city>Giessen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017134</affiliation-url><afid>60017134</afid><affilname>Justus Liebig University Giessen</affilname><affiliation-city>Giessen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072281</affiliation-url><afid>60072281</afid><affilname>Kerckhoff-Klinik</affilname><name-variant>Kerckhoff Heart Center</name-variant><affiliation-city>Bad Nauheim</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016415</affiliation-url><afid>60016415</afid><affilname>Max-Planck-Institut fur Herz- und Lungenforschung</affilname><affiliation-city>Bad Nauheim</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022735</affiliation-url><afid>60022735</afid><affilname>Kreiskrankenhaus Gummersbach</affilname><name-variant>Kreiskrankenhaus Gummersbach</name-variant><affiliation-city>Gummersbach</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115246254</affiliation-url><afid>115246254</afid><affilname>Buergerhospital Friedberg</affilname><name-variant>Buergerhospital Friedberg</name-variant><affiliation-city>Friedberg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55786596500</author-url><authid>55786596500</authid><authname>Juenemann M.</authname><surname>Juenemann</surname><given-name>Martin</given-name><initials>M.</initials><afid>60017134</afid><afid>60017134</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55786596500</author-url><authid>55786596500</authid><authname>Juenemann M.</authname><surname>Juenemann</surname><given-name>Martin</given-name><initials>M.</initials><afid>60017134</afid><afid>60017134</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56645812700</author-url><authid>56645812700</authid><authname>Braun T.</authname><surname>Braun</surname><given-name>Tobias</given-name><initials>T.</initials><afid>60017134</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36604227800</author-url><authid>36604227800</authid><authname>Doenges S.</authname><surname>Doenges</surname><given-name>Simone</given-name><initials>S.</initials><afid>60017134</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603353497</author-url><authid>6603353497</authid><authname>Nedelmann M.</authname><surname>Nedelmann</surname><given-name>Max</given-name><initials>M.</initials><afid>60017134</afid><afid>60017134</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603353497</author-url><authid>6603353497</authid><authname>Nedelmann M.</authname><surname>Nedelmann</surname><given-name>Max</given-name><initials>M.</initials><afid>60017134</afid><afid>60017134</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35567138500</author-url><authid>35567138500</authid><authname>Mueller C.</authname><surname>Mueller</surname><given-name>Clemens</given-name><initials>C.</initials><afid>60072281</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35571318200</author-url><authid>35571318200</authid><authname>Bachmann G.</authname><surname>Bachmann</surname><given-name>Georg</given-name><initials>G.</initials><afid>60072281</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56645382200</author-url><authid>56645382200</authid><authname>Singh P.</authname><surname>Singh</surname><given-name>Pratibha</given-name><initials>P.</initials><afid>60016415</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603843833</author-url><authid>6603843833</authid><authname>Blaes F.</authname><surname>Blaes</surname><given-name>Franz</given-name><initials>F.</initials><afid>60017134</afid><afid>60022735</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603843833</author-url><authid>6603843833</authid><authname>Blaes F.</authname><surname>Blaes</surname><given-name>Franz</given-name><initials>F.</initials><afid>60017134</afid><afid>60022735</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004598344</author-url><authid>7004598344</authid><authname>Gerriets T.</authname><surname>Gerriets</surname><given-name>Tibo</given-name><initials>T.</initials><afid>60017134</afid><afid>60017134</afid><afid>115246254</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004598344</author-url><authid>7004598344</authid><authname>Gerriets T.</authname><surname>Gerriets</surname><given-name>Tibo</given-name><initials>T.</initials><afid>60017134</afid><afid>60017134</afid><afid>115246254</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004598344</author-url><authid>7004598344</authid><authname>Gerriets T.</authname><surname>Gerriets</surname><given-name>Tibo</given-name><initials>T.</initials><afid>60017134</afid><afid>60017134</afid><afid>115246254</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:21935519400</author-url><authid>21935519400</authid><authname>Tschernatsch M.</authname><surname>Tschernatsch</surname><given-name>Marlene</given-name><initials>M.</initials><afid>60017134</afid></author><authkeywords>Aquaporin-4 | Cerebral edema | Infarct size | Neuromyelitis optica | Stroke animal model</authkeywords><intid>1035950591</intid><source-id>20691</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929815722"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929815722?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929815722&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929815722&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929815722</prism:url><dc:identifier>SCOPUS_ID:84929815722</dc:identifier><eid>2-s2.0-84929815722</eid><dc:title>Axillary vein thrombosis induced by an increasingly popular oscillating dumbbell exercise device: A case report</dc:title><dc:creator>Shennib H.</dc:creator><prism:publicationName>Journal of Cardiothoracic Surgery</prism:publicationName><prism:eIssn>17498090</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>May 20, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13019-015-0264-3</prism:doi><dc:description>© 2015 Shennib et al.; licensee BioMed Central. A 53 year-old male presented with a one-day history of a swollen arm and dull, aching pain in the right upper extremity. The patient reported commencing exercising daily over the prior week with a modified, oscillating dumbbell; commonly referred to as a Shake Weight. Imaging revealed an occlusive thrombus in the right axillary, proximal brachial and basilic veins. The patient was treated with a 24-hour tPA infusion followed by mechanical thrombectomy, balloon angioplasty, and stent placement for a residual thrombus and stenosis. The patient was discharged the following day on warfarin and aspirin. This is the first report of effort-induced thrombosis of the upper extremity following the use of a modified, oscillating dumbbell. Due to the growing popularity of modified dumbbells and the possible risk for axillary vein thrombosis, consideration should be made to caution consumers of this potential complication.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012758</affiliation-url><afid>60012758</afid><affilname>Arizona Heart Hospital</affilname><name-variant>Arizona Heart Hospital</name-variant><affiliation-city>Phoenix</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010065</affiliation-url><afid>60010065</afid><affilname>University of Arizona</affilname><name-variant>University of Arizona</name-variant><affiliation-city>Tucson</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006658989</author-url><authid>7006658989</authid><authname>Shennib H.</authname><surname>Shennib</surname><given-name>Hani</given-name><initials>H.</initials><afid>60012758</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56610388000</author-url><authid>56610388000</authid><authname>Hickle K.</authname><surname>Hickle</surname><given-name>Kelli</given-name><initials>K.</initials><afid>60010065</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56610017200</author-url><authid>56610017200</authid><authname>Bowles B.</authname><surname>Bowles</surname><given-name>Bradley</given-name><initials>B.</initials><afid>60010065</afid></author><authkeywords>Axillary vein thrombosis | Dumbbell | Paget-Schroetter syndrome | Shake Weight | Thoracic outlet syndrome | Thrombolytic therapy mechanical thrombectomy | Upper extremity | Venous thrombosis</authkeywords><intid>536020617</intid><source-id>5800179605</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929145622"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929145622?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929145622&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929145622&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929145622</prism:url><dc:identifier>SCOPUS_ID:84929145622</dc:identifier><eid>2-s2.0-84929145622</eid><dc:title>Decisional impairments in cocaine addiction, reward bias, and cortical oscillation “unbalance”</dc:title><dc:creator>Balconi M.</dc:creator><prism:publicationName>Neuropsychiatric Disease and Treatment</prism:publicationName><prism:issn>11766328</prism:issn><prism:eIssn>11782021</prism:eIssn><prism:volume>11</prism:volume><prism:pageRange>777-786</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.2147/NDT.S79696</prism:doi><dc:description>© 2015 Balconi and Finocchiaro. A vast amount of research has suggested that subjects with substance use disorder (SUD) might have difficulty making advantageous decisions that opt in favor of a longer-term, larger reward than an immediate, smaller reward. The current research explored the impact of reward bias and cortical frontal asymmetry (left lateralization effect) in SUD in response to a decisional task (Iowa Gambling Task). Fifty SUD participants and 40 controls (CG) were tested using the Iowa Gambling Task. Electrophysiology (electroencephalography) recording was performed during task execution. We measured left and right dorsolateral prefrontal cortex power activity. Behavioral responses (gain/loss options); frequency band modulation (asymmetry index) for delta, theta, alpha, and beta band; and cortical source localization (standardized low-resolution brain electromagnetic tomography) were considered. The SUD group opted in favor of the immediate reward option (loss) more frequently than the long-term option (gain) when compared to the CG. Secondly, SUD showed increased left-hemisphere activation in response to losing (with immediate reward) choices in comparison with the CG. The left hemispheric unbalance effect and the “reward bias” were adduced to explain the decisional impairment in SUD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024053</affiliation-url><afid>60024053</afid><affilname>Universita Cattolica del Sacro Cuore</affilname><name-variant>Università Cattolica del Sacro Cuore</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8272040400</author-url><authid>8272040400</authid><authname>Balconi M.</authname><surname>Balconi</surname><given-name>Michela</given-name><initials>M.</initials><afid>60024053</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56060885700</author-url><authid>56060885700</authid><authname>Finocchiaro R.</authname><surname>Finocchiaro</surname><given-name>Roberta</given-name><initials>R.</initials><afid>60024053</afid></author><authkeywords>Cortical brain oscillations | Drug addiction | Iowa Gambling Task | Left lateralization effect | Reward mechanism</authkeywords><intid>1035913658</intid><source-id>4100151703</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929774413"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929774413?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929774413&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929774413&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929774413</prism:url><dc:identifier>SCOPUS_ID:84929774413</dc:identifier><eid>2-s2.0-84929774413</eid><dc:title>Association of Toll-like receptor 4 polymorphism with age-dependent systolic blood pressure increase in patients with coronary artery disease</dc:title><dc:creator>Schneider S.</dc:creator><prism:publicationName>Immunity and Ageing</prism:publicationName><prism:eIssn>17424933</prism:eIssn><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>May 20, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12979-015-0031-2</prism:doi><dc:description>© 2015 Schneider et al.; licensee BioMed Central. Background: Systolic blood pressure (SBP) increases steadily with age and bears an independent continuous relationship with the incidence of cardiovascular events. Low-grade inflammation is a suspected pathomechanism causing vascular aging and promote coronary artery disease (CAD). Recent animal studies give evidence that Toll-like receptor 4 (TLR4) modulate inflammation and contribute to age-dependent SBP increase. However, there are no data about TLR4 and age-dependent blood pressure increase in human. Methods and results: We therefor investigate a human cohort of 2679 patients with CAD aged between 50-80 years. Genotypes were determined for the TLR4 single nucleotide polymorphism rs4986790 (TLR4 896A/G). Patients were stratified according to tertiles of age and the upper tertile was compared to lower tertiles. Conclusion: We demonstrate an association between the TLR4 SNP rs4986790 genotype and age-dependant blood pressure increase in patients with coronary artery disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015035</affiliation-url><afid>60015035</afid><affilname>Klinikum rechts der Isar</affilname><name-variant>Technische Universität München</name-variant><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015035</affiliation-url><afid>60015035</afid><affilname>Klinikum rechts der Isar</affilname><name-variant>Technische Universität München</name-variant><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019722</affiliation-url><afid>60019722</afid><affilname>Technische Universitat Munchen</affilname><name-variant>Technische Universität München</name-variant><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115268162</affiliation-url><afid>115268162</afid><affilname>German Centre for Cardiovascular Research (DZHK)</affilname><name-variant>German Centre for Cardiovascular Research (DZHK)</name-variant><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54785064200</author-url><authid>54785064200</authid><authname>Schneider S.</authname><surname>Schneider</surname><given-name>Simon</given-name><initials>S.</initials><afid>60015035</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55561872900</author-url><authid>55561872900</authid><authname>Koch W.</authname><surname>Koch</surname><given-name>Werner</given-name><initials>W.</initials><afid>60019722</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:13406380200</author-url><authid>13406380200</authid><authname>Hoppmann P.</authname><surname>Hoppmann</surname><given-name>Petra</given-name><initials>P.</initials><afid>60015035</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56556925600</author-url><authid>56556925600</authid><authname>Ubrich R.</authname><surname>Ubrich</surname><given-name>Romy</given-name><initials>R.</initials><afid>60015035</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:54974268000</author-url><authid>54974268000</authid><authname>Kemmner S.</authname><surname>Kemmner</surname><given-name>Stephan</given-name><initials>S.</initials><afid>60015035</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56074278200</author-url><authid>56074278200</authid><authname>Steinlechner E.</authname><surname>Steinlechner</surname><given-name>Eva</given-name><initials>E.</initials><afid>60015035</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:26643385000</author-url><authid>26643385000</authid><authname>Heemann U.</authname><surname>Heemann</surname><given-name>Uwe</given-name><initials>U.</initials><afid>60015035</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603873440</author-url><authid>6603873440</authid><authname>Laugwitz K.</authname><surname>Laugwitz</surname><given-name>Karl Ludwig</given-name><initials>K.L.</initials><afid>60015035</afid><afid>115268162</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603873440</author-url><authid>6603873440</authid><authname>Laugwitz K.</authname><surname>Laugwitz</surname><given-name>Karl Ludwig</given-name><initials>K.L.</initials><afid>60015035</afid><afid>115268162</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7006721247</author-url><authid>7006721247</authid><authname>Kastrati A.</authname><surname>Kastrati</surname><given-name>Adnan</given-name><initials>A.</initials><afid>60019722</afid><afid>115268162</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7006721247</author-url><authid>7006721247</authid><authname>Kastrati A.</authname><surname>Kastrati</surname><given-name>Adnan</given-name><initials>A.</initials><afid>60019722</afid><afid>115268162</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:22955245200</author-url><authid>22955245200</authid><authname>Baumann M.</authname><surname>Baumann</surname><given-name>Marcus</given-name><initials>M.</initials><afid>60015035</afid></author><authkeywords>Ageing | Hypertension | TLR4 | Toll-like receptor 4</authkeywords><intid>1036014306</intid><source-id>4400151516</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929574790"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929574790?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929574790&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929574790&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929574790</prism:url><dc:identifier>SCOPUS_ID:84929574790</dc:identifier><eid>2-s2.0-84929574790</eid><dc:title>Sex influenced association of directly measured insulin sensitivity and serum transaminase levels: Why alanine aminotransferase only predicts cardiovascular risk in men?</dc:title><dc:creator>Buday B.</dc:creator><prism:publicationName>Cardiovascular Diabetology</prism:publicationName><prism:eIssn>14752840</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>May 20, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12933-015-0222-3</prism:doi><dc:description>© 2015 Buday et al.; licensee BioMed Central. Background: Non alcoholic fatty liver disease (NAFLD) is an independent cardiovascular (CV) risk factor which is closely associated with insulin resistance measured by both direct or indirect methods. Gender specific findings in the relationship between alanine aminotransferase (ALT) and CV disease, the prevalence of NAFLD and type 2 diabetes (T2DM) have been published recently. Patients and methods: 158 female (47 normal and 111 impaired glucose intolerant) and 148 male (74 normal and 74 impaired glucose tolerant) subjects were included (mean age: 46.5 ± 8.31 vs. 41.6 ± 11.3, average Hba1c &lt; 6.1 %, i.e. prediabetic population, drug naive at the time of the study). Subjects underwent a hyperinsulinemic normoglycemic clamp to determine muscle glucose uptake (M&lt;inf&gt;3&lt;/inf&gt;), besides liver function tests and other fasting metabolic and anthropometric parameters were determined. Results: Significant bivariate correlations were found between clamp measured M&lt;inf&gt;3&lt;/inf&gt; and all three liver enzymes (ALT, aspartate aminotransferase and gamma-glutamyl transferase) in both sexes. When data were adjusted for possible metabolic confounding factors correlations ceased in the male population but stayed significant in the female group. Feature selection analysis showed that ALT is an important attribute for M&lt;inf&gt;3&lt;/inf&gt; in the female but not in male group (mean Z: 3.85 vs. 0.107). Multiple regression analysis confirmed that BMI (p &lt; 0.0001) and ALT (p = 0.00991) significantly and independently predicted clamp measured muscle glucose uptake in women (R&lt;sup&gt;2&lt;/sup&gt; = 0.5259), while in men serum fasting insulin (p = 0.0210) and leptin levels (p = 0.0294) but none of the liver enzymes were confirmed as significant independent predictors of M&lt;inf&gt;3&lt;/inf&gt; (R&lt;sup&gt;2&lt;/sup&gt; = 0.4989). Conclusion: There is a gender specific association between insulin sensitivity, metabolic risk factors and liver transaminase levels. This might explain the sex difference in the predictive role of ALT elevation for CV disease. Moreover, ALT may be used as a simple diagnostic tool to identify insulin resistant subjects only in the female population according to our results.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101824390</affiliation-url><afid>101824390</afid><affilname>Drug Research Center</affilname><name-variant>Drug Research Center</name-variant><affiliation-city/><affiliation-country>Hungary</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115259237</affiliation-url><afid>115259237</afid><affilname>Tritoo Informatics Ltd.</affilname><name-variant>Tritoo Informatics Ltd.</name-variant><affiliation-city/><affiliation-country>Hungary</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068464</affiliation-url><afid>60068464</afid><affilname>University of Szeged Faculty of Medicine</affilname><name-variant>Albert Szent-Györgyi Medical University</name-variant><affiliation-city>Szeged</affiliation-city><affiliation-country>Hungary</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:18433294400</author-url><authid>18433294400</authid><authname>Buday B.</authname><surname>Buday</surname><given-name>Barbara</given-name><initials>B.</initials><afid>101824390</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507510129</author-url><authid>6507510129</authid><authname>Pach P.</authname><surname>Pach</surname><given-name>Peter Ferenc</given-name><initials>P.F.</initials><afid>115259237</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:22035397200</author-url><authid>22035397200</authid><authname>Literati-Nagy B.</authname><surname>Literati-Nagy</surname><given-name>Botond</given-name><initials>B.</initials><afid>101824390</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6507688841</author-url><authid>6507688841</authid><authname>Vitai M.</authname><surname>Vitai</surname><given-name>Marta</given-name><initials>M.</initials><afid>101824390</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55917053100</author-url><authid>55917053100</authid><authname>Kovacs G.</authname><surname>Kovacs</surname><given-name>Gyorgyi</given-name><initials>G.</initials><afid>101824390</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55765888100</author-url><authid>55765888100</authid><authname>Vecsei Z.</authname><surname>Vecsei</surname><given-name>Zsuzsa</given-name><initials>Z.</initials><afid>101824390</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006733615</author-url><authid>7006733615</authid><authname>Koranyi L.</authname><surname>Koranyi</surname><given-name>Laszlo</given-name><initials>L.</initials><afid>101824390</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56650197300</author-url><authid>56650197300</authid><authname>Lengyel C.</authname><surname>Lengyel</surname><given-name>Csaba</given-name><initials>C.</initials><afid>60068464</afid></author><authkeywords>Alanin aminotransferase | Gender difference | Insulin sensitivity</authkeywords><intid>1035977444</intid><article-number>55</article-number><source-id>25441</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930212435"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930212435?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930212435&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930212435&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930212435</prism:url><dc:identifier>SCOPUS_ID:84930212435</dc:identifier><eid>2-s2.0-84930212435</eid><dc:title>Associations between active travel and weight, blood pressure and diabetes in six middle income countries: A cross-sectional study in older adults</dc:title><dc:creator>Laverty A.</dc:creator><prism:publicationName>International Journal of Behavioral Nutrition and Physical Activity</prism:publicationName><prism:eIssn>14795868</prism:eIssn><prism:volume>12</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>May 20, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12966-015-0223-3</prism:doi><dc:description>© 2015 Laverty et al.; licensee BioMed Central. Background: There is little published data on the potential health benefits of active travel in low and middle-income countries. This is despite increasing levels of adiposity being linked to increases in physical inactivity and non-communicable diseases. This study will examine: (1) socio-demographic correlates of using active travel (walking or cycling for transport) among older adults in six populous middle-income countries (2) whether use of active travel is associated with adiposity, systolic blood pressure and self-reported diabetes in these countries. Methods: Data are from the WHO Study on Global Ageing and Adult Health (SAGE) of China, India, Mexico, Ghana, Russia and South Africa with a total sample size of 40,477. Correlates of active travel (≥150 min/week) were examined using logistic regression. Logistic and linear regression analyses were used to examine health related outcomes according to three groups of active travel use per week. Results: 46.4 % of the sample undertook ≥150 min of active travel per week (range South Africa: 21.9 % Ghana: 57.8 %). In pooled analyses those in wealthier households were less likely to meet this level of active travel (Adjusted Risk Ratio (ARR) 0.77, 95 % Confidence Intervals 0.67; 0.88 wealthiest fifth vs. poorest). Older people and women were also less likely to use active travel for ≥150 min per week (ARR 0.71, 0.62; 0.80 those aged 70+ years vs. 18-29 years old, ARR 0.82, 0.74; 0.91 women vs. men). Conclusions: In middle-income countries use of active travel for ≥150 min per week is more common in lower socio-economic groups and appears to confer similar health benefits to those identified in high-income settings. Efforts to increase active travel levels should be integral to strategies to maintain healthy weight and reduce disease burden in these settings.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015150</affiliation-url><afid>60015150</afid><affilname>Imperial College London</affilname><name-variant>Imperial College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017293</affiliation-url><afid>60017293</afid><affilname>Universita degli Studi di Napoli Federico II</affilname><name-variant>University of Naples Federico II</name-variant><affiliation-city>Naples</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname/><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:38862033100</author-url><authid>38862033100</authid><authname>Laverty A.</authname><surname>Laverty</surname><given-name>Anthony A.</given-name><initials>A.A.</initials><afid>60015150</afid><afid/></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:38862033100</author-url><authid>38862033100</authid><authname>Laverty A.</authname><surname>Laverty</surname><given-name>Anthony A.</given-name><initials>A.A.</initials><afid>60015150</afid><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56063818100</author-url><authid>56063818100</authid><authname>Palladino R.</authname><surname>Palladino</surname><given-name>Raffaele</given-name><initials>R.</initials><afid>60015150</afid><afid>60017293</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56063818100</author-url><authid>56063818100</authid><authname>Palladino R.</authname><surname>Palladino</surname><given-name>Raffaele</given-name><initials>R.</initials><afid>60015150</afid><afid>60017293</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37102143600</author-url><authid>37102143600</authid><authname>Lee J.</authname><surname>Lee</surname><given-name>John Tayu</given-name><initials>J.T.</initials><afid>60015150</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8610765600</author-url><authid>8610765600</authid><authname>Millett C.</authname><surname>Millett</surname><given-name>Christopher</given-name><initials>C.</initials><afid>60015150</afid></author><intid>1786087782</intid><article-number>65</article-number><source-id>14875</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225649"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225649?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225649&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225649&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225649</prism:url><dc:identifier>SCOPUS_ID:84930225649</dc:identifier><eid>2-s2.0-84930225649</eid><dc:title>Design and synthesis of amphiphilic and luminescent tris-cyclometalated iridium(III) complexes containing cationic peptides as inducers and detectors of cell death via a calcium-dependent pathway</dc:title><dc:creator>Hisamatsu Y.</dc:creator><prism:publicationName>Bioconjugate Chemistry</prism:publicationName><prism:issn>10431802</prism:issn><prism:eIssn>15204812</prism:eIssn><prism:volume>26</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>857-879</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1021/acs.bioconjchem.5b00095</prism:doi><dc:description>© 2015 American Chemical Society. Cationic amphiphilic peptides have the potential to function as agents for the treatment of microbial infections and cancer therapy. The cationic and hydrophobic parts of these molecules allow them to associate strongly with negatively charged bacterial or cancer cell membranes, thus exerting antimicrobial and anticancer activities through membrane disruption. Meanwhile, cyclometalated iridium(III) complexes such as fac-Ir(ppy)&lt;inf&gt;3&lt;/inf&gt; (ppy = 2-phenylpyridine) and fac-Ir(tpy)&lt;inf&gt;3&lt;/inf&gt; (tpy = 2-(4′-tolyl)pyridine) possess C&lt;inf&gt;3&lt;/inf&gt;-symmetric structures and excellent photophysical properties as phosphorescence materials, which make them important candidates for use in biological applications such as chemosensors, biolabeling, living cell staining, in vivo tumor imaging, and anticancer agents. We recently reported on some regioselective substitution reactions of Ir(tpy)&lt;inf&gt;3&lt;/inf&gt; and Ir(ppy)&lt;inf&gt;3&lt;/inf&gt; at the 5′-position (p-position with respect to the C-Ir bond) on the 2-phenylpyridine ligands and their subsequent conversions to a variety of functional groups. We report here on the design and synthesis of amphiphilic and luminescent tris-cyclometalated Ir complexes in which cationic peptides are attached through alkyl chain linkers that work as inducers and detectors of cell death. Ir complexes containing cationic peptides such as a KKGG sequence and alkyl chain linkers of adequate length (C6 and C8) exhibit considerable cytotoxicity against cancer cells such as Jurkat, Molt-4, HeLa-S3, and A549 cells, and that dead cells are well stained with these Ir complexes. Furthermore, an Ir complex in which the KKGG peptide is attached through a C6 linker displayed lower cytotoxicity against normal mouse lymphocytes. Mechanistic studies suggest that Ir complexes containing the KKGG peptide interact with anionic molecules on the cell surface and/or membrane receptors to trigger the Ca&lt;sup&gt;2+&lt;/sup&gt; dependent pathway and intracellular Ca&lt;sup&gt;2+&lt;/sup&gt; response, resulting in necrosis accompanied by membrane disruption.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025141</affiliation-url><afid>60025141</afid><affilname>Tokyo University of Science</affilname><name-variant>Science University of Tokyo</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025141</affiliation-url><afid>60025141</afid><affilname>Tokyo University of Science</affilname><name-variant>Science University of Tokyo</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025141</affiliation-url><afid>60025141</afid><affilname>Tokyo University of Science</affilname><name-variant>Science University of Tokyo</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56363470600</author-url><authid>56363470600</authid><authname>Hisamatsu Y.</authname><surname>Hisamatsu</surname><given-name>Yosuke</given-name><initials>Y.</initials><afid>60025141</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662809400</author-url><authid>56662809400</authid><authname>Shibuya A.</authname><surname>Shibuya</surname><given-name>Ai</given-name><initials>A.</initials><afid>60025141</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662646700</author-url><authid>56662646700</authid><authname>Suzuki N.</authname><surname>Suzuki</surname><given-name>Nozomi</given-name><initials>N.</initials><afid>60025141</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56367613300</author-url><authid>56367613300</authid><authname>Suzuki T.</authname><surname>Suzuki</surname><given-name>Toshihiro</given-name><initials>T.</initials><afid>60025141</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56367298500</author-url><authid>56367298500</authid><authname>Abe R.</authname><surname>Abe</surname><given-name>Ryo</given-name><initials>R.</initials><afid>60025141</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35336179200</author-url><authid>35336179200</authid><authname>Aoki S.</authname><surname>Aoki</surname><given-name>Shin</given-name><initials>S.</initials><afid>60025141</afid><afid>60025141</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35336179200</author-url><authid>35336179200</authid><authname>Aoki S.</authname><surname>Aoki</surname><given-name>Shin</given-name><initials>S.</initials><afid>60025141</afid><afid>60025141</afid></author><intid>536087963</intid><source-id>16876</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929590762"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929590762?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929590762&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929590762&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929590762</prism:url><dc:identifier>SCOPUS_ID:84929590762</dc:identifier><eid>2-s2.0-84929590762</eid><dc:title>ASK1 modulates the expression of microRNA Let7A in microglia under high glucose in vitro condition</dc:title><dc:creator>Song J.</dc:creator><prism:publicationName>Frontiers in Cellular Neuroscience</prism:publicationName><prism:issn>16625102</prism:issn><prism:volume>9</prism:volume><prism:issueIdentifier>MAY</prism:issueIdentifier><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.3389/fncel.2015.00198</prism:doi><dc:description>© 2015 Song and Lee. Hyperglycemia results in oxidative stress and leads to neuronal apoptosis in the brain. Diabetes studies show that microglia participate in the progression of neuropathogenesis through their involvement in inflammation in vivo and in vitro. In high-glucose-induced inflammation, apoptosis signal regulating kinase 1 (ASK1) triggers the release of apoptosis cytokines and apoptotic gene expression. MicroRNA-Let7A (miR-Let7A) is reported to be a regulator of inflammation. In the present study, we investigated whether miR-Let7A regulates the function of microglia by controlling ASK1 in response to high-glucose-induced oxidative stress. We performed reverse transcription (RT) polymerase chain reaction, Taqman assay, real-time polymerase chain reaction, and immunocytochemistry to confirm the alteration of microglia function. Our results show that miR-Let7A is associated with the activation of ASK1 and the expression of anti-inflammatory cytokine (interleukin (IL)-10) and Mycs (c-Myc and N-Myc). Thus, the relationship between Let-7A and ASK1 could be a novel target for enhancing the beneficial function of microglia in central nervous system (CNS) disorders.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016728</affiliation-url><afid>60016728</afid><affilname>Yonsei University College of Medicine</affilname><name-variant>Yonsei University College of Medicine</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016728</affiliation-url><afid>60016728</afid><affilname>Yonsei University College of Medicine</affilname><name-variant>Yonsei University College of Medicine</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55998484600</author-url><authid>55998484600</authid><authname>Song J.</authname><surname>Song</surname><given-name>Juhyun</given-name><initials>J.</initials><afid>60016728</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8403862900</author-url><authid>8403862900</authid><authname>Lee J.</authname><surname>Lee</surname><given-name>Jong Eun</given-name><initials>J.E.</initials><afid>60016728</afid><afid>60016728</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8403862900</author-url><authid>8403862900</authid><authname>Lee J.</authname><surname>Lee</surname><given-name>Jong Eun</given-name><initials>J.E.</initials><afid>60016728</afid><afid>60016728</afid></author><authkeywords>Apoptosis signal regulating kinase 1 (ASK1) | C-Myc | Cytokine | Microglia BV2 | MicroRNA-Let7A (miR-Let7A) | N-Myc</authkeywords><intid>35980222</intid><source-id>19700175163</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930221889"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930221889?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930221889&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930221889&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930221889</prism:url><dc:identifier>SCOPUS_ID:84930221889</dc:identifier><eid>2-s2.0-84930221889</eid><dc:title>Carnosic Acid as a Major Bioactive Component in Rosemary Extract Ameliorates High-Fat-Diet-Induced Obesity and Metabolic Syndrome in Mice</dc:title><dc:creator>Zhao Y.</dc:creator><prism:publicationName>Journal of Agricultural and Food Chemistry</prism:publicationName><prism:issn>00218561</prism:issn><prism:eIssn>15205118</prism:eIssn><prism:volume>63</prism:volume><prism:issueIdentifier>19</prism:issueIdentifier><prism:pageRange>4843-4852</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1021/acs.jafc.5b01246</prism:doi><dc:description>© 2015 American Chemical Society. In this study, we investigated the preventive effects of carnosic acid (CA) as a major bioactive component in rosemary extract (RE) on high-fat-diet-induced obesity and metabolic syndrome in mice. The mice were given a low-fat diet, a high-fat diet or a high-fat diet supplemented with either 0.14% or 0.28% (w/w) CA-enriched RE (containing 80% CA, RE#1L and RE#1H), or 0.5% (w/w) RE (containing 45% CA, RE#2), for a period of 16 weeks. There was the same CA content in the RE#1H and RE#2 diets and half of this amount in the RE#1L diet. The dietary RE supplementation significantly reduced body weight gain, percent of fat, plasma ALT, AST, glucose, insulin levels, liver weight, liver triglyceride, and free fatty acid levels in comparison with the mice fed with a HF diet without RE treatment. RE administration also decreased the levels of plasma and liver malondialdehyde, advanced glycation end products (AGEs), and the liver expression of receptor for AGE (RAGE) in comparison with those for mice of the HF group. Histological analyses of liver samples showed decreased lipid accumulation in hepatocytes in mice administrated with RE in comparison with that of HF-diet-fed mice. Meanwhile, RE administration enhanced fecal lipid excretion to inhibit lipid absorption and increased the liver GSH/GSSG ratio to perform antioxidant activity compared with HF group. Our results demonstrate that rosemary is a promising dietary agent to reduce the risk of obesity and metabolic syndrome.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015564</affiliation-url><afid>60015564</afid><affilname>North Carolina Agricultural and Technical State University</affilname><name-variant>North Carolina A&amp;T State Univ</name-variant><affiliation-city>Greensboro</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56508580100</author-url><authid>56508580100</authid><authname>Zhao Y.</authname><surname>Zhao</surname><given-name>Yantao</given-name><initials>Y.</initials><afid>60015564</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:13005279900</author-url><authid>13005279900</authid><authname>Sedighi R.</authname><surname>Sedighi</surname><given-name>Rashin</given-name><initials>R.</initials><afid>60015564</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56500867900</author-url><authid>56500867900</authid><authname>Wang P.</authname><surname>Wang</surname><given-name>Pei</given-name><initials>P.</initials><afid>60015564</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:37361077300</author-url><authid>37361077300</authid><authname>Chen H.</authname><surname>Chen</surname><given-name>Huadong</given-name><initials>H.</initials><afid>60015564</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:22939278700</author-url><authid>22939278700</authid><authname>Zhu Y.</authname><surname>Zhu</surname><given-name>Yingdong</given-name><initials>Y.</initials><afid>60015564</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006277967</author-url><authid>7006277967</authid><authname>Sang S.</authname><surname>Sang</surname><given-name>Shengmin</given-name><initials>S.</initials><afid>60015564</afid></author><authkeywords>carnosic acid | high-fat diet | metabolic syndrome | obesity | oxidative stress | rosemary</authkeywords><intid>536087511</intid><source-id>33722</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929603232"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929603232?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929603232&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929603232&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929603232</prism:url><dc:identifier>SCOPUS_ID:84929603232</dc:identifier><eid>2-s2.0-84929603232</eid><dc:title>Antibacterial activity of fresh pomegranate juice against clinical strains of Staphylococcus epidermidis</dc:title><dc:creator>Betanzos-Cabrera G.</dc:creator><prism:publicationName>Food and Nutrition Research</prism:publicationName><prism:issn>16546628</prism:issn><prism:volume>59</prism:volume><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.3402/fnr.v59.27620</prism:doi><dc:description>© 2015 Gabriel Betanzos-Cabrera et al. Background: Polyphenols have received a great deal of attention due to their biological functions. Pomegranate (Punica granatum L.) is a polyphenol-rich fruit. In the past decade, studies testing the antimicrobial activity of pomegranates almost exclusively used solvent extracts instead of fresh pomegranate juice (FPJ). The use of FPJ instead of solvent extracts would reduce toxicity issues while increasing patient acceptance. We established a model to test FPJ as a natural antimicrobial agent. Objective: To evaluate the antimicrobial activity of FPJ on clinical isolates of multidrug-resistant Staphylococcus epidermidis strains. Design: Sixty strains of S. epidermidis isolated from ocular infections were grown in the presence of FPJ, and minimum inhibitory concentration (MIC) was determined by broth and agar dilution methods. Results: FPJ at 20% had a MIC equal to 100% (MIC&lt;inf&gt;100%&lt;/inf&gt;) on all 60 strains tested. This inhibition of FPJ was confirmed by the growth kinetics of a multidrug-resistant strain exposed to different concentrations of FPJ. Additionally, the antimicrobial activity of FPJ was compared against commercial beverages containing pomegranate: Ocean Spray® had a MIC&lt;inf&gt;100%&lt;/inf&gt; at 20%, followed by Del Valle® with a MIC&lt;inf&gt;15%&lt;/inf&gt; at 20% concentration only. The beverages Jumex® and Sonrisa® did not have any antimicrobial activity. FPJ had the highest polyphenol content and antioxidant capacity. Conclusions: Overall, FPJ had antimicrobial activity, which might be attributed to its high polyphenol content and antioxidant capacity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027135</affiliation-url><afid>60027135</afid><affilname>Universidad Autonoma del Estado de Hidalgo</affilname><name-variant>Universidad Autónoma del Estado de Hidalgo</name-variant><affiliation-city>Pachuca</affiliation-city><affiliation-country>Mexico</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106441648</affiliation-url><afid>106441648</afid><affilname>Dale Bumpers National Rice Research Center</affilname><name-variant>Dale Bumpers Natl. Rice Res. Center</name-variant><affiliation-city>Stuttgart</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019176</affiliation-url><afid>60019176</afid><affilname>Instituto Politecnico Nacional</affilname><name-variant>IPN</name-variant><affiliation-city>Mexico City</affiliation-city><affiliation-country>Mexico</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23488158900</author-url><authid>23488158900</authid><authname>Betanzos-Cabrera G.</authname><surname>Betanzos-Cabrera</surname><given-name>Gabriel</given-name><initials>G.</initials><afid>60027135</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56650898400</author-url><authid>56650898400</authid><authname>Montes-Rubio P.</authname><surname>Montes-Rubio</surname><given-name>Perla Y.</given-name><initials>P.Y.</initials><afid>60027135</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56650943200</author-url><authid>56650943200</authid><authname>Fabela-Illescas H.</authname><surname>Fabela-Illescas</surname><given-name>Héctor E.</given-name><initials>H.E.</initials><afid>60027135</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55922679100</author-url><authid>55922679100</authid><authname>Belefant-Miller H.</authname><surname>Belefant-Miller</surname><given-name>Helen</given-name><initials>H.</initials><afid>106441648</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56477424400</author-url><authid>56477424400</authid><authname>Cancino-Diaz J.</authname><surname>Cancino-Diaz</surname><given-name>Juan C.</given-name><initials>J.C.</initials><afid>60019176</afid></author><authkeywords>Antimicrobial activity | Antioxidant capacity | Ocular infections | Pomegranate juice | Staphylococcus epidermidis</authkeywords><intid>35981300</intid><article-number>27620</article-number><source-id>19700173130</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225983"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225983?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225983&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225983&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225983</prism:url><dc:identifier>SCOPUS_ID:84930225983</dc:identifier><eid>2-s2.0-84930225983</eid><dc:title>Lipid-Encapsulated Echium Oil (Echium plantagineum) Increases the Content of Stearidonic Acid in Plasma Lipid Fractions and Milk Fat of Dairy Cows</dc:title><dc:creator>Bainbridge M.</dc:creator><prism:publicationName>Journal of Agricultural and Food Chemistry</prism:publicationName><prism:issn>00218561</prism:issn><prism:eIssn>15205118</prism:eIssn><prism:volume>63</prism:volume><prism:issueIdentifier>19</prism:issueIdentifier><prism:pageRange>4827-4835</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1021/acs.jafc.5b00857</prism:doi><dc:description>© 2015 American Chemical Society. The objective of this study was to evaluate the impact of feeding lipid-encapsulated echium oil (EEO) on animal performance and milk fatty acid profile. Twelve Holstein dairy cows were used in a 3 × 3 Latin Square design with 14 day periods. Treatments were a control diet (no supplemental fat), 1.5% dry matter (DM) as EEO and 3.0% DM as EEO. Treatments had no negative effect on animal performance (dry matter intake, milk yield, and fat yield). The milk fat content of total n-3 fatty acids and stearidonic acid (SDA) increased with EEO supplementation (P &lt; 0.001). The proportion of SDA increased in all plasma lipid fractions with EEO supplementation (P &lt; 0.001). Transfer of SDA from EEO into milk fat was 3.4 and 3.2% for the 1.5 and 3% EEO treatments, respectively. In conclusion, EEO increases the content of n-3 fatty acids in milk fat; however, the apparent transfer efficiency was low.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009500</affiliation-url><afid>60009500</afid><affilname>University of Vermont</affilname><name-variant>University of Vermont</name-variant><affiliation-city>Burlington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031707</affiliation-url><afid>60031707</afid><affilname>Michigan State University</affilname><name-variant>Michigan State University</name-variant><affiliation-city>East Lansing</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662881000</author-url><authid>56662881000</authid><authname>Bainbridge M.</authname><surname>Bainbridge</surname><given-name>Melissa L.</given-name><initials>M.L.</initials><afid>60009500</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005056256</author-url><authid>7005056256</authid><authname>Lock A.</authname><surname>Lock</surname><given-name>Adam L.</given-name><initials>A.L.</initials><afid>60031707</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102467963</author-url><authid>7102467963</authid><authname>Kraft J.</authname><surname>Kraft</surname><given-name>Jana</given-name><initials>J.</initials><afid>60009500</afid></author><authkeywords>bioactive fatty acids | blood metabolites | plasma lipid fractions | transfer efficiency | γ-linolenic acid</authkeywords><intid>2036082648</intid><source-id>33722</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930221882"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930221882?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930221882&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930221882&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930221882</prism:url><dc:identifier>SCOPUS_ID:84930221882</dc:identifier><eid>2-s2.0-84930221882</eid><dc:title>The up-scaling of ecosystem functions in a heterogeneous world</dc:title><dc:creator>Lohrer A.</dc:creator><prism:publicationName>Scientific Reports</prism:publicationName><prism:eIssn>20452322</prism:eIssn><prism:volume>5</prism:volume><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1038/srep10349</prism:doi><pii>srep10349</pii><dc:description>Earth is in the midst of a biodiversity crisis that is impacting the functioning of ecosystems and the delivery of valued goods and services. However, the implications of large scale species losses are often inferred from small scale ecosystem functioning experiments with little knowledge of how the dominant drivers of functioning shift across scales. Here, by integrating observational and manipulative experimental field data, we reveal scale-dependent influences on primary productivity in shallow marine habitats, thus demonstrating the scalability of complex ecological relationships contributing to coastal marine ecosystem functioning. Positive effects of key consumers (burrowing urchins, Echinocardium cordatum) on seafloor net primary productivity (NPP) elucidated by short-term, single-site experiments persisted across multiple sites and years. Additional experimentation illustrated how these effects amplified over time, resulting in greater primary producer biomass sediment chlorophyll a content (Chla) in the longer term, depending on climatic context and habitat factors affecting the strengths of mutually reinforcing feedbacks. The remarkable coherence of results from small and large scales is evidence of real-world ecosystem function scalability and ecological self-organisation. This discovery provides greater insights into the range of responses to broad-scale anthropogenic stressors in naturally heterogeneous environmental settings.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024594</affiliation-url><afid>60024594</afid><affilname>National Institute of Water and Atmospheric Research, New Zealand</affilname><name-variant>National Institute of Water and Atmospheric Research</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005686</affiliation-url><afid>60005686</afid><affilname>University of Auckland</affilname><name-variant>University of Auckland</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025641</affiliation-url><afid>60025641</afid><affilname>Universitat Freiburg im Breisgau</affilname><name-variant>Universität Freiburg</name-variant><affiliation-city>Freiburg im Breisgau</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603376200</author-url><authid>6603376200</authid><authname>Lohrer A.</authname><surname>Lohrer</surname><given-name>Andrew M.</given-name><initials>A.M.</initials><afid>60024594</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005855740</author-url><authid>7005855740</authid><authname>Thrush S.</authname><surname>Thrush</surname><given-name>Simon F.</given-name><initials>S.F.</initials><afid>60005686</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55844629200</author-url><authid>55844629200</authid><authname>Hewitt J.</authname><surname>Hewitt</surname><given-name>Judi E.</given-name><initials>J.E.</initials><afid>60024594</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15519294400</author-url><authid>15519294400</authid><authname>Kraan C.</authname><surname>Kraan</surname><given-name>Casper</given-name><initials>C.</initials><afid>60024594</afid><afid>60025641</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15519294400</author-url><authid>15519294400</authid><authname>Kraan C.</authname><surname>Kraan</surname><given-name>Casper</given-name><initials>C.</initials><afid>60024594</afid><afid>60025641</afid></author><intid>1786088325</intid><article-number>10349</article-number><source-id>21100200805</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930216339"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930216339?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930216339&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930216339&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930216339</prism:url><dc:identifier>SCOPUS_ID:84930216339</dc:identifier><eid>2-s2.0-84930216339</eid><dc:title>SIRT1 protects rat lung tissue against severe burn-induced remote ALI by attenuating the apoptosis of PMVECs via p38 MAPK signaling</dc:title><dc:creator>Bai X.</dc:creator><prism:publicationName>Scientific Reports</prism:publicationName><prism:eIssn>20452322</prism:eIssn><prism:volume>5</prism:volume><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1038/srep10277</prism:doi><pii>srep10277</pii><dc:description>Silent information regulator type-1 (SIRT1) has been reported to be involved in the cardiopulmonary protection. However, its role in the pathogenesis of burn-induced remote acute lung injury (ALI) is currently unknown. The present study aims to investigate the role of SIRT1 in burn-induced remote ALI and the involved signaling pathway. We observed that SIRT1 expression in rat lung tissue after burn injury appeared an increasing trend after a short period of suppression. The upregulation of SIRT1 stimulated by resveratrol exhibited remission of histopathologic changes, reduction of cell apoptosis, and downregulation of pro-inflammatory cytokines in rat pulmonary tissues suffering from severe burn. We next used primary pulmonary microvascular endothelial cells (PMVECs) challenged by burn serum (BS) to simulate in vivo rat lung tissue after burn injury, and found that BS significantly suppressed SIRT1 expression, increased cell apoptosis, and activated p38 MAPK signaling. The use of resveratrol reversed these effects, while knockdown of SIRT1 by shRNA further augmented BS-induced increase of cell apoptosis and activation of p38 MAPK. Taken together, these results indicate that SIRT1 might protect lung tissue against burn-induced remote ALI by attenuating PMVEC apoptosis via p38 MAPK signaling, suggesting its potential therapeutic effects on the treatment of ALI.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069708</affiliation-url><afid>60069708</afid><affilname>Xijing Hospital</affilname><name-variant>Fourth Military Medical University</name-variant><affiliation-city>Xi'an</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113570397</affiliation-url><afid>113570397</afid><affilname>People's Liberation Army 205 Hospital</affilname><name-variant>No.205 Hospital of Chinese People's Liberation Army</name-variant><affiliation-city>Jinzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56397462000</author-url><authid>56397462000</authid><authname>Bai X.</authname><surname>Bai</surname><given-name>Xiaozhi</given-name><initials>X.</initials><afid>60069708</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56397436300</author-url><authid>56397436300</authid><authname>Fan L.</authname><surname>Fan</surname><given-name>Lei</given-name><initials>L.</initials><afid>60069708</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56497458500</author-url><authid>56497458500</authid><authname>He T.</authname><surname>He</surname><given-name>Ting</given-name><initials>T.</initials><afid>60069708</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56237602600</author-url><authid>56237602600</authid><authname>Jia W.</authname><surname>Jia</surname><given-name>Wenbin</given-name><initials>W.</initials><afid>60069708</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56237889300</author-url><authid>56237889300</authid><authname>Yang L.</authname><surname>Yang</surname><given-name>Longlong</given-name><initials>L.</initials><afid>60069708</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56493362400</author-url><authid>56493362400</authid><authname>Zhang J.</authname><surname>Zhang</surname><given-name>Jun</given-name><initials>J.</initials><afid>113570397</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56034182000</author-url><authid>56034182000</authid><authname>Liu Y.</authname><surname>Liu</surname><given-name>Yang</given-name><initials>Y.</initials><afid>60069708</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56397341300</author-url><authid>56397341300</authid><authname>Shi J.</authname><surname>Shi</surname><given-name>Jihong</given-name><initials>J.</initials><afid>60069708</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56175274700</author-url><authid>56175274700</authid><authname>Su L.</authname><surname>Su</surname><given-name>Linlin</given-name><initials>L.</initials><afid>60069708</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7402585366</author-url><authid>7402585366</authid><authname>Hu D.</authname><surname>Hu</surname><given-name>Dahai</given-name><initials>D.</initials><afid>60069708</afid></author><intid>2036081349</intid><article-number>10277</article-number><source-id>21100200805</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929161101"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929161101?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929161101&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929161101&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929161101</prism:url><dc:identifier>SCOPUS_ID:84929161101</dc:identifier><eid>2-s2.0-84929161101</eid><dc:title>Predictors of premature discontinuation of outpatient treatment after discharge of patients with posttraumatic stress disorder</dc:title><dc:creator>Wang H.</dc:creator><prism:publicationName>Neuropsychiatric Disease and Treatment</prism:publicationName><prism:issn>11766328</prism:issn><prism:eIssn>11782021</prism:eIssn><prism:volume>11</prism:volume><prism:pageRange>787-792</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.2147/NDT.S78212</prism:doi><dc:description>© 2015 Wang et al. Objective: This study aimed to examine the sociodemographic and disease-related variables associated with the premature discontinuation of psychiatric outpatient treatment after discharge among patients with noncombat-related posttraumatic stress disorder. Methods: We retrospectively reviewed the medical records of patients who were discharged with a diagnosis of posttraumatic stress disorder. Results: Fifty-five percent of subjects (57/104) prematurely discontinued outpatient treatment within 6 months of discharge. Comparing sociodemographic variables between the 6-month non-follow-up group and 6-month follow-up group, there were no variables that differed between the two groups. However, comparing disease-related variables, the 6-month follow-up group showed a longer hospitalization duration and higher Global Assessment of Function score at discharge. The logistic regression analysis showed that a shorter duration of hospitalization predicted premature discontinuation of outpatient treatment within 6 months of discharge. Conclusion: The duration of psychiatric hospitalization for posttraumatic stress disorder appeared to influence the premature discontinuation of outpatient treatment after discharge.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003087</affiliation-url><afid>60003087</afid><affilname>The Catholic University of Korea</affilname><name-variant>The Catholic University of Korea</name-variant><affiliation-city>Youngdeungpo</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55917959800</author-url><authid>55917959800</authid><authname>Wang H.</authname><surname>Wang</surname><given-name>Hee Ryung</given-name><initials>H.R.</initials><afid>60003087</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102661538</author-url><authid>7102661538</authid><authname>Woo Y.</authname><surname>Woo</surname><given-name>Young Sup</given-name><initials>Y.S.</initials><afid>60003087</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005323658</author-url><authid>7005323658</authid><authname>Jun T.</authname><surname>Jun</surname><given-name>Tae Youn</given-name><initials>T.Y.</initials><afid>60003087</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701501415</author-url><authid>6701501415</authid><authname>Bahk W.</authname><surname>Bahk</surname><given-name>Won Myong</given-name><initials>W.M.</initials><afid>60003087</afid></author><authkeywords>Compliance | Discontinuation | Posttraumatic stress disorder | Predictor</authkeywords><intid>535919606</intid><source-id>4100151703</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923185265"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923185265?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923185265&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923185265&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0144861715000223"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923185265</prism:url><dc:identifier>SCOPUS_ID:84923185265</dc:identifier><eid>2-s2.0-84923185265</eid><dc:title>Self-healable hydrogel on tumor cell as drug delivery system for localized and effective therapy</dc:title><dc:creator>Chang G.</dc:creator><prism:publicationName>Carbohydrate Polymers</prism:publicationName><prism:issn>01448617</prism:issn><prism:volume>122</prism:volume><prism:pageRange>336-342</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.carbpol.2014.12.077</prism:doi><pii>S0144861715000223</pii><dc:description>© 2015 Elsevier Ltd. All rights reserved. A self-healable chitosan(CS)/polyvinyl alcohol (PVA) hydrogel as an injectable drug carrier was first prepared in situ on tumor cells for effective and localized therapy. PVA molecules have a synergistic effect on the formation and maintenance of 3D network conformation of hydrogel. The hydrogel shows good biocompatibility and could be easily and rapidly formed. When loaded with fluorouracil (5-FU), the hydrogel possessed good drug retention ability at pH 7.4, which can prevent the loss of drug to normal cells and reduce the side effect. As well, the hydrogel shows continuous and controllable drug release, with the final cumulative releasing amount of 84.8% at pH 5.0. Therefore, the hydrogel not only could maintain a higher 5-FU concentration around tumor cells to enhance the antitumor effect, but also can achieve pH sensitive controllable drug release at the lesion site. Meantime, the attractive self-healing ability of the CS/PVA hydrogel is first revealed in this study, which contributes to the regeneration of its integral network from the broken fragments. The CS/PVA hydrogel may hold promise for better applications in anti-tumor therapy.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001455</affiliation-url><afid>60001455</afid><affilname>Anhui University</affilname><name-variant>Anhui University</name-variant><affiliation-city>Hefei</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100371467</affiliation-url><afid>100371467</afid><affilname>Huangshan University</affilname><name-variant>Huangshan University</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001455</affiliation-url><afid>60001455</afid><affilname>Anhui University</affilname><name-variant>Anhui University</name-variant><affiliation-city>Hefei</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56522254300</author-url><authid>56522254300</authid><authname>Chang G.</authname><surname>Chang</surname><given-name>Guanru</given-name><initials>G.</initials><afid>60001455</afid><afid>100371467</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56522254300</author-url><authid>56522254300</authid><authname>Chang G.</authname><surname>Chang</surname><given-name>Guanru</given-name><initials>G.</initials><afid>60001455</afid><afid>100371467</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56521963900</author-url><authid>56521963900</authid><authname>Chen Y.</authname><surname>Chen</surname><given-name>Yan</given-name><initials>Y.</initials><afid>60001455</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56522319400</author-url><authid>56522319400</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yanjie</given-name><initials>Y.</initials><afid>60001455</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56317169500</author-url><authid>56317169500</authid><authname>Li S.</authname><surname>Li</surname><given-name>Shikuo</given-name><initials>S.</initials><afid>60001455</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56522116500</author-url><authid>56522116500</authid><authname>Huang F.</authname><surname>Huang</surname><given-name>Fangzhi</given-name><initials>F.</initials><afid>60001455</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7404766824</author-url><authid>7404766824</authid><authname>Shen Y.</authname><surname>Shen</surname><given-name>Yuhua</given-name><initials>Y.</initials><afid>60001455</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:17347061500</author-url><authid>17347061500</authid><authname>Xie A.</authname><surname>Xie</surname><given-name>Anjian</given-name><initials>A.</initials><afid>60001455</afid></author><authkeywords>5-FU | Controllable release | Hydrogel shell | Localized injection therapy | Self-healable hydrogel</authkeywords><intid>2034928164</intid><source-id>25801</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930206510"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930206510?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930206510&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930206510&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930206510</prism:url><dc:identifier>SCOPUS_ID:84930206510</dc:identifier><eid>2-s2.0-84930206510</eid><dc:title>A new method to image heme-Fe, total Fe, and aggregated protein levels after intracerebral hemorrhage</dc:title><dc:creator>Hackett M.</dc:creator><prism:publicationName>ACS Chemical Neuroscience</prism:publicationName><prism:eIssn>19487193</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>761-770</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1021/acschemneuro.5b00037</prism:doi><dc:description>© 2015 American Chemical Society. An intracerebral hemorrhage (ICH) is a devastating stroke that results in high mortality and significant disability in survivors. Unfortunately, the underlying mechanisms of this injury are not yet fully understood. After the primary (mechanical) trauma, secondary degenerative events contribute to ongoing cell death in the peri-hematoma region. Oxidative stress is thought to be a key reason for this delayed injury, which is likely due to free-Fe-catalyzed free radical reactions. Unfortunately, this is difficult to prove with conventional biochemical assays that fail to differentiate between alterations that occur within the hematoma and peri-hematoma zone. This is a critical limitation, as the hematoma contains tissue severely damaged by the initial hemorrhage and is unsalvageable, whereas the peri-hematoma region is less damaged but at risk from secondary degenerative events. Such events include oxidative stress mediated by free Fe presumed to originate from hemoglobin breakdown. Therefore, minimizing the damage caused by oxidative stress following hemoglobin breakdown and Fe release is a major therapeutic target. However, the extent to which free Fe contributes to the pathogenesis of ICH remains unknown. This investigation used a novel imaging approach that employed resonance Raman spectroscopic mapping of hemoglobin, X-ray fluorescence microscopic mapping of total Fe, and Fourier transform infrared spectroscopic imaging of aggregated protein following ICH in rats. This multimodal spectroscopic approach was used to accurately define the hematoma/peri-hematoma boundary and quantify the Fe concentration and the relative aggregated protein content, as a marker of oxidative stress, within each region. The results revealed total Fe is substantially increased in the hematoma (0.90 μg cm&lt;sup&gt;-2&lt;/sup&gt;), and a subtle but significant increase in Fe that is not in the chemical form of hemoglobin is present within the peri-hematoma zone (0.32 μg cm&lt;sup&gt;-2&lt;/sup&gt;) within 1 day of ICH, relative to sham animals (0.22 μg cm&lt;sup&gt;-2&lt;/sup&gt;). Levels of aggregated protein were significantly increased within both the hematoma (integrated band area 0.10 AU) and peri-hematoma zone (integrated band area 0.10 AU) relative to sham animals (integrated band area 0.056 AU), but no significant difference in aggregated protein content was observed between the hematoma and peri-hematoma zone. This result suggests that the chemical form of Fe and its ability to generate free radicals is likely to be a more critical predictor of tissue damage than the total Fe content of the tissue. Furthermore, this article describes a novel approach to colocalize nonheme Fe and aggregated protein in the peri-hematoma zone following ICH, a significant methodological advancement for the field.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015186</affiliation-url><afid>60015186</afid><affilname>University of Saskatchewan</affilname><name-variant>University of Saskatchewan</name-variant><affiliation-city>Saskatoon</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030835</affiliation-url><afid>60030835</afid><affilname>University of Alberta</affilname><name-variant>University of Alberta</name-variant><affiliation-city>Edmonton</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082715</affiliation-url><afid>60082715</afid><affilname>Universidade Federal do Pampa</affilname><name-variant>Universidade Federal do Pampa</name-variant><affiliation-city>Bage</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015186</affiliation-url><afid>60015186</afid><affilname>University of Saskatchewan</affilname><name-variant>University of Saskatchewan</name-variant><affiliation-city>Saskatoon</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Canadian Light Source</affilname><affiliation-city>Saskatoon</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015186</affiliation-url><afid>60015186</afid><affilname>University of Saskatchewan</affilname><name-variant>University of Saskatchewan</name-variant><affiliation-city>Saskatoon</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35240056500</author-url><authid>35240056500</authid><authname>Hackett M.</authname><surname>Hackett</surname><given-name>Mark J.</given-name><initials>M.J.</initials><afid>60015186</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662918300</author-url><authid>56662918300</authid><authname>Desouza M.</authname><surname>Desouza</surname><given-name>Mauren</given-name><initials>M.</initials><afid>60030835</afid><afid>60082715</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662918300</author-url><authid>56662918300</authid><authname>Desouza M.</authname><surname>Desouza</surname><given-name>Mauren</given-name><initials>M.</initials><afid>60030835</afid><afid>60082715</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56480299700</author-url><authid>56480299700</authid><authname>Caine S.</authname><surname>Caine</surname><given-name>Sally</given-name><initials>S.</initials><afid>60015186</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:22833641100</author-url><authid>22833641100</authid><authname>Bewer B.</authname><surname>Bewer</surname><given-name>Brian</given-name><initials>B.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701715069</author-url><authid>6701715069</authid><authname>Nichol H.</authname><surname>Nichol</surname><given-name>Helen</given-name><initials>H.</initials><afid>60015186</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7102201286</author-url><authid>7102201286</authid><authname>Paterson P.</authname><surname>Paterson</surname><given-name>Phyllis G.</given-name><initials>P.G.</initials><afid>60015186</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003954709</author-url><authid>7003954709</authid><authname>Colbourne F.</authname><surname>Colbourne</surname><given-name>Frederick</given-name><initials>F.</initials><afid>60030835</afid></author><authkeywords>hemoglobin | intracerebral hemorrhage | iron | oxidative stress | Spectroscopic imaging | stroke</authkeywords><intid>2036082800</intid><source-id>19700172804</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929156788"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929156788?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929156788&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929156788&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929156788</prism:url><dc:identifier>SCOPUS_ID:84929156788</dc:identifier><eid>2-s2.0-84929156788</eid><dc:title>The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension</dc:title><dc:creator>Duong H.</dc:creator><prism:publicationName>Small</prism:publicationName><prism:issn>16136810</prism:issn><prism:eIssn>16136829</prism:eIssn><prism:volume>11</prism:volume><prism:issueIdentifier>19</prism:issueIdentifier><prism:pageRange>2291-2304</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1002/smll.201402870</prism:doi><dc:description>© 2015 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim. Polymeric nanoparticles are designed to transport and deliver nitric oxide (NO) into hepatic stellate cells (HSCs) for the potential treatment of both liver fibrosis and portal hypertension. The nanoparticles, incorporating NO donor molecules (S-nitrosoglutathione compound), are designed for liver delivery, minimizing systemic delivery of NO. The nanoparticles are decorated with vitamin A to specifically target HSCs. We demonstrate, using in vitro and in vivo experiments, that the targeted nanoparticles are taken up specifically by rat primary HSCs and the human HSC cell line accumulating in the liver. When nanoparticles, coated with vitamin A, release NO in liver cells, we find inhibition of collagen I and α-smooth muscle actin (α-SMA), fibrogenic genes associated with activated HSCs expression in primary rat liver and human activated HSCs without any obvious cytotoxic effects. Finally, NO-releasing nanoparticles targeted with vitamin A not only attenuate endothelin-1 (ET-1) which elicites HSC contraction but also acutely alleviates haemodynamic disorders in bile duct-ligated-induced portal hypertension evidenced by decreasing portal pressure (≈20%) and unchanging mean arterial pressure. This study clearly shows, for the first time, the potential for HSC targeted nanoparticle delivery of NO as a treatment for liver diseases with proven efficacy for alleviating both liver fibrosis and portal hypertension. Nanoparticles with a typical size of 35 nm are presented for the delivery of nitric oxide to hepatic stellate cells for the potential treatment of liver fibrosis and portal hypertension. The introduction of vitamin A on the nanoparticles surface allows to specifically target hepatic stellate cells. In vivo experiments, using rat models, demonstrate the accumulation of nanoparticles in liver.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028333</affiliation-url><afid>60028333</afid><affilname>University of New South Wales (UNSW) Australia</affilname><name-variant>University of New South Wales</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025709</affiliation-url><afid>60025709</afid><affilname>University of Sydney</affilname><name-variant>University of Sydney</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025084</affiliation-url><afid>60025084</afid><affilname>Shanghai Jiaotong University</affilname><name-variant>Shanghai Jiaotong University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019578</affiliation-url><afid>60019578</afid><affilname>Monash University</affilname><name-variant>Monash University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022020</affiliation-url><afid>60022020</afid><affilname>The University of Warwick</affilname><name-variant>University of Warwick</name-variant><affiliation-city>Coventry</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36455657500</author-url><authid>36455657500</authid><authname>Duong H.</authname><surname>Duong</surname><given-name>Hien T T</given-name><initials>H.T.T.</initials><afid>60028333</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:50561412400</author-url><authid>50561412400</authid><authname>Dong Z.</authname><surname>Dong</surname><given-name>Zhixia</given-name><initials>Z.</initials><afid>60025709</afid><afid>60025084</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:50561412400</author-url><authid>50561412400</authid><authname>Dong Z.</authname><surname>Dong</surname><given-name>Zhixia</given-name><initials>Z.</initials><afid>60025709</afid><afid>60025084</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35216488900</author-url><authid>35216488900</authid><authname>Su L.</authname><surname>Su</surname><given-name>Lin</given-name><initials>L.</initials><afid>60025709</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:10339815000</author-url><authid>10339815000</authid><authname>Boyer C.</authname><surname>Boyer</surname><given-name>Cyrille</given-name><initials>C.</initials><afid>60028333</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55702520976</author-url><authid>55702520976</authid><authname>George J.</authname><surname>George</surname><given-name>Jacob</given-name><initials>J.</initials><afid>60025709</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36051395100</author-url><authid>36051395100</authid><authname>Davis T.</authname><surname>Davis</surname><given-name>Thomas P.</given-name><initials>T.P.</initials><afid>60019578</afid><afid>60022020</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36051395100</author-url><authid>36051395100</authid><authname>Davis T.</authname><surname>Davis</surname><given-name>Thomas P.</given-name><initials>T.P.</initials><afid>60019578</afid><afid>60022020</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56204564200</author-url><authid>56204564200</authid><authname>Wang J.</authname><surname>Wang</surname><given-name>Jianhua</given-name><initials>J.</initials><afid>60025709</afid></author><authkeywords>drug delivery | medicine | nanoparticles | polymers</authkeywords><intid>2035911827</intid><source-id>3200147828</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929575446"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929575446?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929575446&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929575446&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929575446</prism:url><dc:identifier>SCOPUS_ID:84929575446</dc:identifier><eid>2-s2.0-84929575446</eid><dc:title>Protective role of p120-catenin in maintaining the integrity of adherens and tight junctions in ventilator-induced lung injury</dc:title><dc:creator>Gu C.</dc:creator><prism:publicationName>Respiratory Research</prism:publicationName><prism:issn>14659921</prism:issn><prism:eIssn>1465993X</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>May 20, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12931-015-0217-3</prism:doi><dc:description>© 2015 Gu et al. Background: Ventilator-induced lung injury (VILI) is one of the most common complications for patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Although p120 is an important protein in the regulation of cell junctions, further mechanisms should be explored for prevention and treatment of VILI. Methods: Mouse lung epithelial cells (MLE-12), which were transfected with p120 small interfering (si)RNA, p120 cDNA, wild-type E-cadherin juxtamembrane domain or a K83R mutant juxtamembrane domain (K83R-JMD), were subjected to 20 % cyclic stretches for 2 or 4 h. Furthermore, MLE-12 cells and mice, which were pretreated with the c-Src inhibitor PP&lt;inf&gt;2&lt;/inf&gt; or RhoA inhibitor Y27632, underwent 20 % cyclic stretches or mechanical stretching, respectively. Moreover, wild-type C57BL/6 mice were transfected with p120 siRNA-liposome complexes before mechanical ventilation. Cell lysates and lung tissues were then analyzed to detect lung injury. Results: cyclic stretches of 20 % actived c-Src, which induced degradation of E-cadherin, p120 and occludin. However, loss of p120 increased the degradation and endocytosis of E-cadherin. Immunoprecipitation and Immunofluorescence results showed a decrease in the association between p120 and E-cadherin, while gap formation increased in p120 siRNA and K83R-JMD groups after 20 % cyclic stretches. Loss of p120 also reduced the occludin level and decreased the association of occludin and ZO-1 by enhancing RhoA activity. However, the altered levels of occludin and E-cadherin were reversed by PP&lt;inf&gt;2&lt;/inf&gt; or Y27632 treatments compared with the cyclic stretch group. Consistently, the expression, redistribution and disassociation of junction proteins were all restored in the p120 overexpression group after 20 % cyclic stretches. Moreover, the role of p120 in VILI was confirmed by increased wet/dry weigh ratio and enhanced production of cytokines (tumor necrosis factor- α and interleukin-six) in p120-depleted mice under mechanical ventilation. Conclusions: p120 protected against VILI by regulating both adherens and tight junctions. p120 inhibited E-cadherin endocytosis by increasing the association between p120 and juxtamembrane domain of E-cadherin. Furthermore, p120 reduced the degradation of occludin by inhibiting RhoA activity. These findings illustrated further mechanisms of p120 in the prevention of VILI, especially for patients with ALI or ARDS.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031031</affiliation-url><afid>60031031</afid><affilname>Shandong University</affilname><name-variant>Shandong University</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56178975400</author-url><authid>56178975400</authid><authname>Gu C.</authname><surname>Gu</surname><given-name>Changping</given-name><initials>C.</initials><afid>60031031</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56179414700</author-url><authid>56179414700</authid><authname>Liu M.</authname><surname>Liu</surname><given-name>Mengjie</given-name><initials>M.</initials><afid>60031031</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56609622400</author-url><authid>56609622400</authid><authname>Zhao T.</authname><surname>Zhao</surname><given-name>Tao</given-name><initials>T.</initials><afid>60031031</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56645109700</author-url><authid>56645109700</authid><authname>Wang D.</authname><surname>Wang</surname><given-name>Dong</given-name><initials>D.</initials><afid>60031031</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:53265048500</author-url><authid>53265048500</authid><authname>Wang Y.</authname><surname>Wang</surname><given-name>Yuelan</given-name><initials>Y.</initials><afid>60031031</afid></author><authkeywords>Adherens junction | p120 | Tight junction | VILI</authkeywords><intid>35981435</intid><article-number>58</article-number><source-id>18640</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225614"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225614?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225614&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225614&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225614</prism:url><dc:identifier>SCOPUS_ID:84930225614</dc:identifier><eid>2-s2.0-84930225614</eid><dc:title>AzoCholine enables optical control of alpha 7 nicotinic acetylcholine receptors in neural networks</dc:title><dc:creator>Damijonaitis A.</dc:creator><prism:publicationName>ACS Chemical Neuroscience</prism:publicationName><prism:eIssn>19487193</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>701-707</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1021/acschemneuro.5b00030</prism:doi><dc:description>© 2015 American Chemical Society. Nicotinic acetylcholine receptors (nAChRs) are essential for cellular communication in higher organisms. Even though a vast pharmacological toolset to study cholinergic systems has been developed, control of endogenous neuronal nAChRs with high spatiotemporal precision has been lacking. To address this issue, we have generated photoswitchable nAChR agonists and re-evaluated the known photochromic ligand, BisQ. Using electrophysiology, we found that one of our new compounds, AzoCholine, is an excellent photoswitchable agonist for neuronal α7 nAChRs, whereas BisQ was confirmed to be an agonist for the muscle-type nAChR. AzoCholine could be used to modulate cholinergic activity in a brain slice and in dorsal root ganglion neurons. In addition, we demonstrate light-dependent perturbation of behavior in the nematode, Caenorhabditis elegans.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028717</affiliation-url><afid>60028717</afid><affilname>Ludwig-Maximilians-Universitat Munchen</affilname><name-variant>University of Munich</name-variant><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007762</affiliation-url><afid>60007762</afid><affilname>Johann Wolfgang Goethe Universitat Frankfurt am Main</affilname><affiliation-city>Frankfurt am Main</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017134</affiliation-url><afid>60017134</afid><affilname>Justus Liebig University Giessen</affilname><affiliation-city>Giessen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56275676800</author-url><authid>56275676800</authid><authname>Damijonaitis A.</authname><surname>Damijonaitis</surname><given-name>Arunas</given-name><initials>A.</initials><afid>60028717</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35758235200</author-url><authid>35758235200</authid><authname>Broichhagen J.</authname><surname>Broichhagen</surname><given-name>Johannes</given-name><initials>J.</initials><afid>60028717</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6508307679</author-url><authid>6508307679</authid><authname>Urushima T.</authname><surname>Urushima</surname><given-name>Tatsuya</given-name><initials>T.</initials><afid>60028717</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55349798500</author-url><authid>55349798500</authid><authname>Hüll K.</authname><surname>Hüll</surname><given-name>Katharina</given-name><initials>K.</initials><afid>60028717</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56526604600</author-url><authid>56526604600</authid><authname>Nagpal J.</authname><surname>Nagpal</surname><given-name>Jatin</given-name><initials>J.</initials><afid>60007762</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36028217000</author-url><authid>36028217000</authid><authname>Laprell L.</authname><surname>Laprell</surname><given-name>Laura</given-name><initials>L.</initials><afid>60028717</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:25226311300</author-url><authid>25226311300</authid><authname>Schönberger M.</authname><surname>Schönberger</surname><given-name>Matthias</given-name><initials>M.</initials><afid>60028717</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56662982000</author-url><authid>56662982000</authid><authname>Woodmansee D.</authname><surname>Woodmansee</surname><given-name>David H.</given-name><initials>D.H.</initials><afid>60028717</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:41361748400</author-url><authid>41361748400</authid><authname>Rafiq A.</authname><surname>Rafiq</surname><given-name>Amir</given-name><initials>A.</initials><afid>60017134</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56486024900</author-url><authid>56486024900</authid><authname>Sumser M.</authname><surname>Sumser</surname><given-name>Martin P.</given-name><initials>M.P.</initials><afid>60028717</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:17035091600</author-url><authid>17035091600</authid><authname>Kummer W.</authname><surname>Kummer</surname><given-name>Wolfgang</given-name><initials>W.</initials><afid>60017134</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:35598072100</author-url><authid>35598072100</authid><authname>Gottschalk A.</authname><surname>Gottschalk</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60007762</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7006165081</author-url><authid>7006165081</authid><authname>Trauner D.</authname><surname>Trauner</surname><given-name>Dirk</given-name><initials>D.</initials><afid>60028717</afid></author><authkeywords>AzoCholine | BisQ | cholinergic system | nicotinic acetylcholine receptor | photochromic ligand | Photopharmacology</authkeywords><intid>1536087349</intid><source-id>19700172804</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930208800"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930208800?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930208800&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930208800&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930208800</prism:url><dc:identifier>SCOPUS_ID:84930208800</dc:identifier><eid>2-s2.0-84930208800</eid><dc:title>The role of cyclooxygenase-2, interleukin-1β and fibroblast growth factor-2 in the activation of matrix metalloproteinase-1 in sheared-chondrocytes and articular cartilage</dc:title><dc:creator>Guan P.</dc:creator><prism:publicationName>Scientific Reports</prism:publicationName><prism:eIssn>20452322</prism:eIssn><prism:volume>5</prism:volume><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1038/srep10412</prism:doi><pii>srep10412</pii><dc:description>MMP-1 expression is detected in fluid shear stress (20 dyn/cm&lt;sup&gt;2&lt;/sup&gt;)-activated and osteoarthritic human chondrocytes, however, the precise mechanisms underlying shear-induced MMP-1 synthesis remain unknown. Using primary chondrocytes and T/C-28a2 chondrocytic cells as model systems, we report that prolonged application of high fluid shear to human chondrocytes induced the synthesis of cyclooxygenase-2 (COX-2), interleukin-1β (IL-1β) and fibroblast growth factor-2 (FGF-2), which led to a marked increase in MMP-1 expression. IL-1β, COX-2-dependent PGE&lt;inf&gt;2&lt;/inf&gt; activated the PI3-K/AKT and p38 signaling pathways, which were in turn responsible for MMP-1 synthesis via NF-κB- and c-Jun-transactivating pathways. Prolonged shear stress exposure (&gt;12 h) induced 15-Deoxy-Δ&lt;sup&gt;12,14&lt;/sup&gt;-prostaglandin J&lt;inf&gt;2&lt;/inf&gt; (15d-PGJ&lt;inf&gt;2&lt;/inf&gt;) synthesis. Although 15d-PGJ&lt;inf&gt;2&lt;/inf&gt; suppressed PI3-K/AKT and p38 signaling pathways, it stimulated MMP-1 expression via activating heme oxygenase 1 (HO-1). The critical role of COX-2 in regulating MMP-1 expression in articular cartilage in vivo was demonstrated using COX-2&lt;sup&gt;+/-&lt;/sup&gt; transgenic mice in the absence or presence of rofecoxib oral administration. These findings provide novel insights for developing therapeutic strategies to combat OA.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031863</affiliation-url><afid>60031863</afid><affilname>Northeastern University China</affilname><name-variant>Northeastern University</name-variant><affiliation-city>Shenyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005248</affiliation-url><afid>60005248</afid><affilname>Johns Hopkins University</affilname><name-variant>Johns Hopkins University</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005248</affiliation-url><afid>60005248</afid><affilname>Johns Hopkins University</affilname><name-variant>Johns Hopkins University</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005248</affiliation-url><afid>60005248</afid><affilname>Johns Hopkins University</affilname><name-variant>Johns Hopkins University</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005248</affiliation-url><afid>60005248</afid><affilname>Johns Hopkins University</affilname><name-variant>Johns Hopkins University</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35519633800</author-url><authid>35519633800</authid><authname>Guan P.</authname><surname>Guan</surname><given-name>Pei Pei</given-name><initials>P.P.</initials><afid>60031863</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662594300</author-url><authid>56662594300</authid><authname>Guo J.</authname><surname>Guo</surname><given-name>Jing Wen</given-name><initials>J.W.</initials><afid>60031863</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35104208800</author-url><authid>35104208800</authid><authname>Yu X.</authname><surname>Yu</surname><given-name>Xin</given-name><initials>X.</initials><afid>60031863</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55667305100</author-url><authid>55667305100</authid><authname>Wang Y.</authname><surname>Wang</surname><given-name>Yue</given-name><initials>Y.</initials><afid>60031863</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56228206300</author-url><authid>56228206300</authid><authname>Wang T.</authname><surname>Wang</surname><given-name>Tao</given-name><initials>T.</initials><afid>60031863</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56664679700</author-url><authid>56664679700</authid><authname>Konstantopoulos K.</authname><surname>Konstantopoulos</surname><given-name>Konstantinos</given-name><initials>K.</initials><afid>60005248</afid><afid>60005248</afid><afid>60005248</afid><afid>60005248</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56664679700</author-url><authid>56664679700</authid><authname>Konstantopoulos K.</authname><surname>Konstantopoulos</surname><given-name>Konstantinos</given-name><initials>K.</initials><afid>60005248</afid><afid>60005248</afid><afid>60005248</afid><afid>60005248</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56664679700</author-url><authid>56664679700</authid><authname>Konstantopoulos K.</authname><surname>Konstantopoulos</surname><given-name>Konstantinos</given-name><initials>K.</initials><afid>60005248</afid><afid>60005248</afid><afid>60005248</afid><afid>60005248</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56664679700</author-url><authid>56664679700</authid><authname>Konstantopoulos K.</authname><surname>Konstantopoulos</surname><given-name>Konstantinos</given-name><initials>K.</initials><afid>60005248</afid><afid>60005248</afid><afid>60005248</afid><afid>60005248</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7410051758</author-url><authid>7410051758</authid><authname>Wang Z.</authname><surname>Wang</surname><given-name>Zhan You</given-name><initials>Z.Y.</initials><afid>60031863</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:22735289500</author-url><authid>22735289500</authid><authname>Wang P.</authname><surname>Wang</surname><given-name>Pu</given-name><initials>P.</initials><afid>60031863</afid></author><intid>1536087196</intid><article-number>10412</article-number><source-id>21100200805</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930196772"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930196772?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930196772&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930196772&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930196772</prism:url><dc:identifier>SCOPUS_ID:84930196772</dc:identifier><eid>2-s2.0-84930196772</eid><dc:title>Impact of malnutrition on postoperative delirium development after on pump coronary artery bypass grafting</dc:title><dc:creator>Ringaitiene D.</dc:creator><prism:publicationName>Journal of Cardiothoracic Surgery</prism:publicationName><prism:eIssn>17498090</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>May 20, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13019-015-0278-x</prism:doi><dc:description>© 2015 Ringaitiene et al.; licensee BioMed Central. Background &amp; aims: Even though malnutrition is frequently observed in cardiac population outcome data after cardiac surgery in malnourished patients is very rare. No thorough research was done concerning the impact of malnutrition on neuropsychological outcomes after cardiac surgery. The aim of our study was to analyze the incidence of postoperative delirium development in malnourished patients undergoing on pump bypass grafting. Methods: We performed a cohort study of adults admitted to Vilnius University Hospital Santariskiu Clinics for elective coronary artery bypass grafting. The nutritional status of the patients was assessed by Nutritional Risk Screening 2002 (NRS-2002) questionnaire the day before surgery. Patients were considered as having no risk of malnutrition when NRS-2002 score was less than 3 and at risk of malnutrition when NRS-2002 score was ≥3. During ICU stay patients were screened for postoperative delirium development using the CAM-ICU method. and divided into two groups: delirium and non delirium. The statistical analysis was preformed to evaluate the differences between the two independent groups. The logistic regression model was used to evaluate the potential preoperative and intraoperative risk factors of postoperative delirium. Results: Ninety-nine patients were enrolled in the study. Preoperative risk of malnutrition was detected in 24 % (n = 24) of the patients. The incidence of early postoperative delirium in overall study population was 8.0 % (n = 8). The incidence of the patients at risk of malnutrition was significantly higher in the delirium group (5 (62.5 %) vs 19 (20.9 %), p &lt;0.0191). In multivariate logistic regression analysis risk of malnutrition defined by NRS 2002 was an independent preoperative and intraoperative risk factor of postoperative delirium after coronary artery bypass grafting (OR: 6.316, 95 % CI: 1.384-28.819 p = 0.0173). Conclusions: Preoperative malnutrition is common in patients undergoing elective coronary artery bypass grafting.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60041628</affiliation-url><afid>60041628</afid><affilname>Vilnius University Faculty of Medicine</affilname><name-variant>Vilnius University</name-variant><affiliation-city>Vilnius</affiliation-city><affiliation-country>Lithuania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60041628</affiliation-url><afid>60041628</afid><affilname>Vilnius University Faculty of Medicine</affilname><name-variant>Vilnius University</name-variant><affiliation-city>Vilnius</affiliation-city><affiliation-country>Lithuania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60036277</affiliation-url><afid>60036277</afid><affilname>Vilnius University Hospital</affilname><name-variant>Vilnius University Hospital Santariskiu Clinics</name-variant><affiliation-city>Vilnius</affiliation-city><affiliation-country>Lithuania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60041628</affiliation-url><afid>60041628</afid><affilname>Vilnius University Faculty of Medicine</affilname><name-variant>Vilnius University</name-variant><affiliation-city>Vilnius</affiliation-city><affiliation-country>Lithuania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60036277</affiliation-url><afid>60036277</afid><affilname>Vilnius University Hospital</affilname><name-variant>Vilnius University Hospital Santariskiu Clinics</name-variant><affiliation-city>Vilnius</affiliation-city><affiliation-country>Lithuania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60041628</affiliation-url><afid>60041628</afid><affilname>Vilnius University Faculty of Medicine</affilname><name-variant>Vilnius University</name-variant><affiliation-city>Vilnius</affiliation-city><affiliation-country>Lithuania</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15846535000</author-url><authid>15846535000</authid><authname>Ringaitiene D.</authname><surname>Ringaitiene</surname><given-name>Donata</given-name><initials>D.</initials><afid>60041628</afid><afid>60036277</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15846535000</author-url><authid>15846535000</authid><authname>Ringaitiene D.</authname><surname>Ringaitiene</surname><given-name>Donata</given-name><initials>D.</initials><afid>60041628</afid><afid>60036277</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56660617300</author-url><authid>56660617300</authid><authname>Gineityte D.</authname><surname>Gineityte</surname><given-name>Dalia</given-name><initials>D.</initials><afid>60041628</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56660652400</author-url><authid>56660652400</authid><authname>Vicka V.</authname><surname>Vicka</surname><given-name>Vaidas</given-name><initials>V.</initials><afid>60041628</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:38362790800</author-url><authid>38362790800</authid><authname>Žvirblis T.</authname><surname>Žvirblis</surname><given-name>Tadas</given-name><initials>T.</initials><afid>60036277</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6506934489</author-url><authid>6506934489</authid><authname>Šipylaite J.</authname><surname>Šipylaite</surname><given-name>Jurate</given-name><initials>J.</initials><afid>60041628</afid><afid>60036277</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6506934489</author-url><authid>6506934489</authid><authname>Šipylaite J.</authname><surname>Šipylaite</surname><given-name>Jurate</given-name><initials>J.</initials><afid>60041628</afid><afid>60036277</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6507361529</author-url><authid>6507361529</authid><authname>Irnius A.</authname><surname>Irnius</surname><given-name>Algimantas</given-name><initials>A.</initials><afid>60041628</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602862950</author-url><authid>6602862950</authid><authname>Ivaškevicius J.</authname><surname>Ivaškevicius</surname><given-name>Juozas</given-name><initials>J.</initials><afid>60041628</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:15769532400</author-url><authid>15769532400</authid><authname>Kacergius T.</authname><surname>Kacergius</surname><given-name>Tomas</given-name><initials>T.</initials><afid>60041628</afid></author><authkeywords>Cardiac surgery | Delirium | Malnutrition | Postoperative outcomes</authkeywords><intid>1536086964</intid><article-number>74</article-number><source-id>5800179605</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930002780"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930002780?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930002780&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930002780&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930002780</prism:url><dc:identifier>SCOPUS_ID:84930002780</dc:identifier><eid>2-s2.0-84930002780</eid><dc:title>Autophagy attenuates noise-induced hearing loss by reducing oxidative stress</dc:title><dc:creator>Yuan H.</dc:creator><prism:publicationName>Antioxidants and Redox Signaling</prism:publicationName><prism:issn>15230864</prism:issn><prism:eIssn>15577716</prism:eIssn><prism:volume>22</prism:volume><prism:issueIdentifier>15</prism:issueIdentifier><prism:pageRange>1308-1324</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1089/ars.2014.6004</prism:doi><dc:description>© 2015, Mary Ann Liebert, Inc. Aims: Reactive oxygen species play a dual role in mediating both cell stress and defense pathways. Here, we used pharmacological manipulations and siRNA silencing to investigate the relationship between autophagy and oxidative stress under conditions of noise-induced temporary, permanent, and severe permanent auditory threshold shifts (temporary threshold shift [TTS], permanent threshold shift [PTS], and severe PTS [sPTS], respectively) in adult CBA/J mice. Results: Levels of oxidative stress markers (4-hydroxynonenal [4-HNE] and 3-nitrotyrosine [3-NT]) increased in outer hair cells (OHCs) in a noise-dose-dependent manner, whereas levels of the autophagy marker microtubule-associated protein light chain 3 B (LC3B) were sharply elevated after TTS but rose only slightly in response to PTS and were unaltered by sPTS noise. Furthermore, green fluorescent protein (GFP) intensity increased in GFP-LC3 mice after TTS-noise exposure. Treatment with rapamycin, an autophagy activator, significantly increased LC3B expression, while diminishing 4-HNE and 3-NT levels, reducing noise-induced hair cell loss, and, subsequently, noise-induced hearing loss (NIHL). In contrast, treatment with either the autophagy inhibitor 3-methyladenine (3MA) or LC3B siRNA reduced LC3B expression, increased 3-NT and 4-HNE levels, and exacerbated TTS to PTS. Innovation: This study demonstrates a relationship between oxidative stress and autophagy in OHCs and reveals that autophagy is an intrinsic cellular process that protects against NIHL by attenuating oxidative stress. Conclusions: The results suggest that the lower levels of oxidative stress incurred by TTS-noise exposure induce autophagy, which promotes OHC survival. However, excessive oxidative stress under sPTS-noise conditions overwhelms the beneficial potential of autophagy in OHCs and leads to OHC death and NIHL.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023222</affiliation-url><afid>60023222</afid><affilname>Medical University of South Carolina</affilname><name-variant>Medical University of South Carolina</name-variant><affiliation-city>Charleston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023222</affiliation-url><afid>60023222</afid><affilname>Medical University of South Carolina</affilname><name-variant>Medical University of South Carolina</name-variant><affiliation-city>Charleston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069744</affiliation-url><afid>60069744</afid><affilname>General Hospital of People's Liberation Army</affilname><name-variant>General Hospital of Chinese PLA</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56562241600</author-url><authid>56562241600</authid><authname>Yuan H.</authname><surname>Yuan</surname><given-name>Hu</given-name><initials>H.</initials><afid>60023222</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56530277200</author-url><authid>56530277200</authid><authname>Wang X.</authname><surname>Wang</surname><given-name>Xianren</given-name><initials>X.</initials><afid>60023222</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:54949280600</author-url><authid>54949280600</authid><authname>Hill K.</authname><surname>Hill</surname><given-name>Kayla</given-name><initials>K.</initials><afid>60023222</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55838466100</author-url><authid>55838466100</authid><authname>Chen J.</authname><surname>Chen</surname><given-name>Jun</given-name><initials>J.</initials><afid>60023222</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:17035432100</author-url><authid>17035432100</authid><authname>Lemasters J.</authname><surname>Lemasters</surname><given-name>John</given-name><initials>J.</initials><afid>60023222</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56226224700</author-url><authid>56226224700</authid><authname>Yang S.</authname><surname>Yang</surname><given-name>Shi Ming</given-name><initials>S.M.</initials><afid>60069744</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003378776</author-url><authid>7003378776</authid><authname>Sha S.</authname><surname>Sha</surname><given-name>Su Hua</given-name><initials>S.H.</initials><afid>60023222</afid></author><intid>2036044358</intid><source-id>27514</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930205599"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930205599?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930205599&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930205599&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930205599</prism:url><dc:identifier>SCOPUS_ID:84930205599</dc:identifier><eid>2-s2.0-84930205599</eid><dc:title>Human transport protein carrier for controlled photoactivation of antitumor prodrug and real-time intracellular tumor imaging</dc:title><dc:creator>Li X.</dc:creator><prism:publicationName>Bioconjugate Chemistry</prism:publicationName><prism:issn>10431802</prism:issn><prism:eIssn>15204812</prism:eIssn><prism:volume>26</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>955-961</prism:pageRange><prism:coverDate>2015-05-20</prism:coverDate><prism:coverDisplayDate>20 May 2015</prism:coverDisplayDate><prism:doi>10.1021/acs.bioconjchem.5b00170</prism:doi><dc:description>© 2015 American Chemical Society. Current anticancer chemotherapy often suffers from poor tumor selectivity and serious drug resistance. Proper vectors for targeted delivery and controlled drug release play crucial roles in improving the therapeutic selectivity to tumor areas and also overcoming the resistance of cancer cells. In this work, we developed a novel human serum albumin (HSA) protein-based nanocarrier system, which combines the photoactivatable Pt(IV) antitumor prodrug for realizing the controlled release and fluorescent light-up probe for evaluations of drug action and efficacy. The constructed Pt(IV)-probe@HSA platform can be locally activated by light irradiation to release the active Pt species, which results in enhanced cell death at both drug-sensitive A2780 and cisplatin-resistant A2780cis cell lines when compared to the free prodrug molecules. Simultaneously, the cytotoxicity caused by light controlled drug release would further lead to the cellular apoptosis and trigger the activation of caspases 3, one crucial protease enzyme in apoptotic process, which could cleave the recognition peptide moiety (DEVD) with a flanking fluorescent resonance energy transfer (FRET) pair containing near-infrared (NIR) fluorophore Cy5 and quencher Qsy21 on the HSA nanocarrier surface. The turn-on fluorescence in response to caspase-3 could be assessed by fluorescence microscopy and flow cytometry analysis. Our results supported the hypothesis that such a unique design may present a successful platform for multiple roles: (i) a biocompatible protein-based nanocarrier for drug delivery, (ii) the controlled drug release with strengthened therapeutic effects, (iii) real-time monitoring of antitumor drug efficacy at the earlier stage.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005510</affiliation-url><afid>60005510</afid><affilname>Nanyang Technological University</affilname><name-variant>Nanyang Technological University</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662781700</author-url><authid>56662781700</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xi</given-name><initials>X.</initials><afid>60005510</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56167865600</author-url><authid>56167865600</authid><authname>Mu J.</authname><surname>Mu</surname><given-name>Jing</given-name><initials>J.</initials><afid>60005510</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56169013100</author-url><authid>56169013100</authid><authname>Liu F.</authname><surname>Liu</surname><given-name>Fang</given-name><initials>F.</initials><afid>60005510</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662711000</author-url><authid>56662711000</authid><authname>Tan E.</authname><surname>Tan</surname><given-name>Eddy Wei Ping</given-name><initials>E.W.P.</initials><afid>60005510</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24168863500</author-url><authid>24168863500</authid><authname>Khezri B.</authname><surname>Khezri</surname><given-name>Bahareh</given-name><initials>B.</initials><afid>60005510</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56510324300</author-url><authid>56510324300</authid><authname>Webster R.</authname><surname>Webster</surname><given-name>Richard D.</given-name><initials>R.D.</initials><afid>60005510</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602298951</author-url><authid>6602298951</authid><authname>Yeow E.</authname><surname>Yeow</surname><given-name>Edwin Kok Lee</given-name><initials>E.K.L.</initials><afid>60005510</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7005212019</author-url><authid>7005212019</authid><authname>Xing B.</authname><surname>Xing</surname><given-name>Bengang</given-name><initials>B.</initials><afid>60005510</afid></author><intid>1036081823</intid><source-id>16876</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929593560"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929593560?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929593560&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929593560&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929593560</prism:url><dc:identifier>SCOPUS_ID:84929593560</dc:identifier><eid>2-s2.0-84929593560</eid><dc:title>Loop-based multiple heart-cutting two-dimensional liquid chromatography for target analysis in complex matrices</dc:title><dc:creator>Pursch M.</dc:creator><prism:publicationName>Analytical Chemistry</prism:publicationName><prism:issn>00032700</prism:issn><prism:eIssn>15206882</prism:eIssn><prism:volume>87</prism:volume><prism:issueIdentifier>10</prism:issueIdentifier><prism:pageRange>5310-5317</prism:pageRange><prism:coverDate>2015-05-19</prism:coverDate><prism:coverDisplayDate>19 May 2015</prism:coverDisplayDate><prism:doi>10.1021/acs.analchem.5b00492</prism:doi><dc:description>© 2015 American Chemical Society. Loop-based multiple heart-cutting (MHC) two-dimensional liquid chromatography (2D-LC) is presented as a solution to quantify target components in complex matrices, such as additives in polymers, at very high chromatographic resolution. The determination of hexabromocyclododecane (HBCD) in polystyrene (PS) is described. One dimensional (&lt;sup&gt;1&lt;/sup&gt;D) LC analysis with UV detection did not allow quantitation of the main isomers of HBCD due to peak overlap with polymer components. MHC 2D-LC analysis provided the separation power, accuracy, and repeatability needed for quantitative analysis of the additives of interest. Heart-cuts from peaks of the &lt;sup&gt;1&lt;/sup&gt;D-chromatogram or entire regions of interest are sampled into loops, where they remain parked until their sequential reinjection onto the second dimension (&lt;sup&gt;2&lt;/sup&gt;D) column. A column set consisting of phenyl (&lt;sup&gt;1&lt;/sup&gt;D) and C&lt;inf&gt;18&lt;/inf&gt; (&lt;sup&gt;2&lt;/sup&gt;D) stationary phases gave baseline separation in &lt;sup&gt;2&lt;/sup&gt;D between HBCD and PS background. Linearity for spiked polymer samples was achieved over a range of 0.02-1.00 wt % HBCD relative to the amount of polymer. The limit of quantitation was estimated at 0.01 wt % HBCD in PS. A peak area RSD of 0.7% obtained for ten replicates of a real sample demonstrated excellent repeatability of the analysis. MHC 2D-LC is an elegant solution for quantitative analyses of difficult-to-separate samples when conventional &lt;sup&gt;1&lt;/sup&gt;D separation fails.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60088538</affiliation-url><afid>60088538</afid><affilname>Dow Deutschland GmbH</affilname><name-variant>Dow Deutschland Inc</name-variant><affiliation-city>Rheinmunster</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020536</affiliation-url><afid>60020536</afid><affilname>Hewlett-Packard</affilname><name-variant>Hewlett-Packard Co</name-variant><affiliation-city>Palo Alto</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003573057</author-url><authid>7003573057</authid><authname>Pursch M.</authname><surname>Pursch</surname><given-name>Matthias</given-name><initials>M.</initials><afid>60088538</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506609981</author-url><authid>6506609981</authid><authname>Buckenmaier S.</authname><surname>Buckenmaier</surname><given-name>Stephan</given-name><initials>S.</initials><afid>60020536</afid></author><intid>1035976457</intid><source-id>23915</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929692518"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929692518?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929692518&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929692518&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929692518</prism:url><dc:identifier>SCOPUS_ID:84929692518</dc:identifier><eid>2-s2.0-84929692518</eid><dc:title>Heart failure: Mesenchymal stromal cell therapy improves myocardial function after severe ischaemic heart failure</dc:title><dc:creator>Duarte J.</dc:creator><prism:publicationName>Nature Reviews Cardiology</prism:publicationName><prism:issn>17595002</prism:issn><prism:eIssn>17595010</prism:eIssn><prism:coverDate>2015-05-19</prism:coverDate><prism:coverDisplayDate>19 May 2015</prism:coverDisplayDate><prism:doi>10.1038/nrcardio.2015.77</prism:doi><pii>nrcardio.2015.77</pii><citedby-count>0</citedby-count><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56201640700</author-url><authid>56201640700</authid><authname>Duarte J.</authname><surname>Duarte</surname><given-name>João H.</given-name><initials>J.H.</initials></author><intid>535998207</intid><source-id>17700156509</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929378321"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929378321?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929378321&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929378321&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0006291X15000297"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929378321</prism:url><dc:identifier>SCOPUS_ID:84929378321</dc:identifier><eid>2-s2.0-84929378321</eid><dc:title>Vitamin D cell signalling in health and disease</dc:title><dc:creator>Berridge M.</dc:creator><prism:publicationName>Biochemical and Biophysical Research Communications</prism:publicationName><prism:issn>0006291X</prism:issn><prism:eIssn>10902104</prism:eIssn><prism:volume>460</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>53-71</prism:pageRange><prism:coverDate>2015-05-19</prism:coverDate><prism:coverDisplayDate>19 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbrc.2015.01.008</prism:doi><pii>S0006291X15000297</pii><dc:description>© 2015 Elsevier Inc. Vitamin D deficiency has been linked to many human diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), hypertension and cardiovascular disease. A Vitamin D phenotypic stability hypothesis, which is developed in this review, attempts to describe how this vital hormone acts to maintain healthy cellular functions. This role of Vitamin D as a guardian of phenotypic stability seems to depend on its ability to maintain the redox and Ca&lt;sup&gt;2+&lt;/sup&gt; signalling systems. It is argued that its primary action is to maintain the expression of those signalling components responsible for stabilizing the low resting state of these two signalling pathways. This phenotypic stability role is facilitated through the ability of vitamin D to increase the expression of both Nrf2 and the anti-ageing protein Klotho, which are also major regulators of Ca&lt;sup&gt;2+&lt;/sup&gt; and redox signalling. A decline in Vitamin D levels will lead to a decline in the stability of this regulatory signalling network and may account for why so many of the major diseases in man, which have been linked to vitamin D deficiency, are associated with a dysregulation in both ROS and Ca&lt;sup&gt;2+&lt;/sup&gt; signalling.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000661</affiliation-url><afid>60000661</afid><affilname>The Babraham Institute</affilname><name-variant>Babraham Institute</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55231943900</author-url><authid>55231943900</authid><authname>Berridge M.</authname><surname>Berridge</surname><given-name>Michael J.</given-name><initials>M.J.</initials><afid>60000661</afid></author><authkeywords>Alzheimer's disease | Calcium | Parkinson's disease | Reactive oxygen species | Schizophrenia | Vitamin D</authkeywords><intid>1535944293</intid><source-id>16845</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929429574"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929429574?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929429574&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929429574&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929429574</prism:url><dc:identifier>SCOPUS_ID:84929429574</dc:identifier><eid>2-s2.0-84929429574</eid><dc:title>Second degree AV block and severely impaired contractility in cardiac myxedema: A case report</dc:title><dc:creator>Chatzitomaris A.</dc:creator><prism:publicationName>Thyroid Research</prism:publicationName><prism:eIssn>17566614</prism:eIssn><prism:coverDate>2015-05-19</prism:coverDate><prism:coverDisplayDate>May 19, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13044-015-0018-2</prism:doi><dc:description>© 2015 Chatzitomaris et al.; licensee BioMed Central. The heart is a major target organ for thyroid hormone action. Severe overt hypothyroidism can result in diastolic hypertension, lowered cardiac output, impaired left ventricular contractility and diastolic relaxation, pericardial effusion and bradycardia. However, the function of the atrial pacemaker is usually normal and the degree by which the heart rate slows down is often modest. Here we report the case of a 20 year old male Caucasian with severe overt hypothyroidism. He presented with syncopation due to second degree atrioventricular block type Mobitz 2 and heart failure with reduced ejection fraction (38 %). Laboratory testing revealed a severe overt hypothyroidism with markedly elevated TSH (&gt;100 mIU/L) and reduced fT3 and fT4 levels. The condition was caused by hypothyroid Graves' disease (Graves' disease with Hashimoto component). Although magnetic resonance imaging of the heart demonstrated decreased cardiac contractility and pericardial effusion, suggesting peri-myocarditis, plasma levels for BNP and troponin I were low. A possible infectious cause was unlikely, since testing for cardiotropic viruses was negative. The patient was treated with intravenous levothyroxine and after peripheral euthyroidism had been achieved, left ventricular ejection fraction returned to normal and pericardial effusion dissolved. Additionally, bradycardiac episodes abated, although intermittent second degree AV block was still occasionally present during the night. In conclusion, overt hypothyroidism may be associated by cardiac myxedema affecting both electrophysiology and contractility, observations that underscore the necessity of thyroid testing in different phenotypes of heart failure.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005322</affiliation-url><afid>60005322</afid><affilname>Universitat Bochum</affilname><name-variant>Ruhr-Universität Bochum</name-variant><affiliation-city>Bochum</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011532</affiliation-url><afid>60011532</afid><affilname>Helios Klinikum Berlin-Buch</affilname><name-variant>HELIOS Klinikum Berlin-Buch</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005322</affiliation-url><afid>60005322</afid><affilname>Universitat Bochum</affilname><name-variant>Ruhr-Universität Bochum</name-variant><affiliation-city>Bochum</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005322</affiliation-url><afid>60005322</afid><affilname>Universitat Bochum</affilname><name-variant>Ruhr-Universität Bochum</name-variant><affiliation-city>Bochum</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115246612</affiliation-url><afid>115246612</afid><affilname>MVZ Radiologie - Institut für Kinderradiologie</affilname><name-variant>MVZ Radiologie - Institut für Kinderradiologie</name-variant><affiliation-city>Bochum</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56646606000</author-url><authid>56646606000</authid><authname>Chatzitomaris A.</authname><surname>Chatzitomaris</surname><given-name>Apostolos</given-name><initials>A.</initials><afid>60005322</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506879723</author-url><authid>6506879723</authid><authname>Scheeler M.</authname><surname>Scheeler</surname><given-name>Michael</given-name><initials>M.</initials><afid>60011532</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8318090500</author-url><authid>8318090500</authid><authname>Gotzmann M.</authname><surname>Gotzmann</surname><given-name>Michael</given-name><initials>M.</initials><afid>60005322</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8296475200</author-url><authid>8296475200</authid><authname>Köditz R.</authname><surname>Köditz</surname><given-name>Roland</given-name><initials>R.</initials><afid>60005322</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:50961604100</author-url><authid>50961604100</authid><authname>Schildroth J.</authname><surname>Schildroth</surname><given-name>Janice</given-name><initials>J.</initials><afid>60005322</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:14045471200</author-url><authid>14045471200</authid><authname>Knyhala K.</authname><surname>Knyhala</surname><given-name>Kathy Miriam</given-name><initials>K.M.</initials><afid>60005322</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006205278</author-url><authid>7006205278</authid><authname>Nicolas V.</authname><surname>Nicolas</surname><given-name>Volkmar</given-name><initials>V.</initials><afid>60005322</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56646155100</author-url><authid>56646155100</authid><authname>Heyer C.</authname><surname>Heyer</surname><given-name>Christoph</given-name><initials>C.</initials><afid>115246612</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55198089300</author-url><authid>55198089300</authid><authname>Mügge A.</authname><surname>Mügge</surname><given-name>Andreas</given-name><initials>A.</initials><afid>60005322</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7403471811</author-url><authid>7403471811</authid><authname>Klein H.</authname><surname>Klein</surname><given-name>Harald H.</given-name><initials>H.H.</initials><afid>60005322</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:12804649900</author-url><authid>12804649900</authid><authname>Dietrich J.</authname><surname>Dietrich</surname><given-name>Johannes W.</given-name><initials>J.W.</initials><afid>60005322</afid></author><authkeywords>Cardiac myxedema | Hypothyroid Graves' disease | Peri-myocarditis | Thyrocardiac axis</authkeywords><intid>2035950138</intid><source-id>19700183044</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929589634"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929589634?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929589634&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929589634&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929589634</prism:url><dc:identifier>SCOPUS_ID:84929589634</dc:identifier><eid>2-s2.0-84929589634</eid><dc:title>Adlayer-mediated antibody immobilization to stainless steel for potential application to endothelial progenitor cell capture</dc:title><dc:creator>Benvenuto P.</dc:creator><prism:publicationName>Langmuir</prism:publicationName><prism:issn>07437463</prism:issn><prism:eIssn>15205827</prism:eIssn><prism:volume>31</prism:volume><prism:issueIdentifier>19</prism:issueIdentifier><prism:pageRange>5423-5431</prism:pageRange><prism:coverDate>2015-05-19</prism:coverDate><prism:coverDisplayDate>19 May 2015</prism:coverDisplayDate><prism:doi>10.1021/acs.langmuir.5b00812</prism:doi><dc:description>© 2015 American Chemical Society. This work describes the straightforward surface modification of 316L stainless steel with BTS, S-(11-trichlorosilylundecanyl)-benzenethiosulfonate, a thiol-reactive trichlorosilane cross-linker molecule designed to form intermediary coatings with subsequent biofunctionalization capability. The strategy is more specifically exemplified with the immobilization of intact antibodies and their Fab′ fragments. Both surface derivatization steps are thoroughly characterized by means of X-ray photoelectron spectroscopy. The antigen binding capability of both types of biofunctionalized surfaces is subsequently assessed by fluorescence microscopy. It was determined that BTS adlayers achieve robust immobilization of both intact and fragmented antibodies, while preserving antigen binding activity. Another key finding was the observation that the Fab′ fragment immobilization strategy would constitute a preferential option over that involving intact antibodies in the context of in vivo capture of endothelial progenitor cells in stent applications.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114044193</affiliation-url><afid>114044193</afid><affilname>Econous Systems Inc.</affilname><name-variant>Econous Systems Inc.</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017018</affiliation-url><afid>60017018</afid><affilname>Saint Michael's Hospital University of Toronto</affilname><name-variant>St. Michael's Hospital</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24330570500</author-url><authid>24330570500</authid><authname>Benvenuto P.</authname><surname>Benvenuto</surname><given-name>Pasquale</given-name><initials>P.</initials><afid>60016849</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36572121200</author-url><authid>36572121200</authid><authname>Neves M.</authname><surname>Neves</surname><given-name>Miguel A D</given-name><initials>M.A.D.</initials><afid>60016849</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7801357384</author-url><authid>7801357384</authid><authname>Blaszykowski C.</authname><surname>Blaszykowski</surname><given-name>Christophe</given-name><initials>C.</initials><afid>114044193</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003868805</author-url><authid>7003868805</authid><authname>Romaschin A.</authname><surname>Romaschin</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60017018</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56650505500</author-url><authid>56650505500</authid><authname>Chung T.</authname><surname>Chung</surname><given-name>Timothy</given-name><initials>T.</initials><afid>60016849</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56650734400</author-url><authid>56650734400</authid><authname>Kim S.</authname><surname>Kim</surname><given-name>Sa Rang</given-name><initials>S.R.</initials><afid>60016849</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35556592900</author-url><authid>35556592900</authid><authname>Thompson M.</authname><surname>Thompson</surname><given-name>Michael</given-name><initials>M.</initials><afid>60016849</afid><afid>114044193</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35556592900</author-url><authid>35556592900</authid><authname>Thompson M.</authname><surname>Thompson</surname><given-name>Michael</given-name><initials>M.</initials><afid>60016849</afid><afid>114044193</afid></author><intid>1785982966</intid><source-id>26987</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929589794"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929589794?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929589794&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929589794&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929589794</prism:url><dc:identifier>SCOPUS_ID:84929589794</dc:identifier><eid>2-s2.0-84929589794</eid><dc:title>The Regressive Recovery: Distribution, Inequality and State Power in Britain's Post-Crisis Political Economy</dc:title><dc:creator>Green J.</dc:creator><prism:publicationName>New Political Economy</prism:publicationName><prism:issn>13563467</prism:issn><prism:eIssn>14699923</prism:eIssn><prism:coverDate>2015-05-19</prism:coverDate><prism:coverDisplayDate>19 May 2015</prism:coverDisplayDate><prism:doi>10.1080/13563467.2015.1041478</prism:doi><dc:description>© 2015 Taylor &amp; Francis This article interrogates the underlying mechanisms at the heart of Britain's post-crisis political economy. We argue that the contemporary economic recovery has been characterised by a dynamic of ‘regressive redistribution’: a socially regressive dynamic of state-led economic restructuring that has worked through two axes at the centre of the recovery. The first axis, a monetary policy framework centred upon Quantitative Easing, has driven asset-price inflation to the benefit of the wealthiest asset holders. The second axis centres upon the politics of regressive labour market restructuring which has provoked widespread wage deflation. In combination, these two axes have been central to defining the contours of the Britain's post-crisis political economy paradigm: characterised by rising asset wealth for the few, and falling living standards alongside increasing economic insecurity for wage earners. The opportunity to change path from the trends of deepening inequality that defined the pre-crisis era has not been taken. Instead, the prevailing policy paradigm of the post-crisis period – discursively unified and sustained by David Cameron's government – has intensified the regressively redistributive dynamics at the core of the neo-liberal project. Ultimately, this is likely to further entrench structural weaknesses in Britain's economy in the years ahead.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020650</affiliation-url><afid>60020650</afid><affilname>University of Bristol</affilname><name-variant>University of Bristol</name-variant><affiliation-city>Bristol</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001881</affiliation-url><afid>60001881</afid><affilname>University of Sheffield</affilname><name-variant>University of Sheffield</name-variant><affiliation-city>Sheffield</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56403765900</author-url><authid>56403765900</authid><authname>Green J.</authname><surname>Green</surname><given-name>Jeremy</given-name><initials>J.</initials><afid>60020650</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56650785600</author-url><authid>56650785600</authid><authname>Lavery S.</authname><surname>Lavery</surname><given-name>Scott</given-name><initials>S.</initials><afid>60001881</afid></author><authkeywords>Britain | crisis | inequality | labour market | Quantitative Easing | recovery</authkeywords><intid>1535981045</intid><source-id>29032</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929589654"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929589654?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929589654&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929589654&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929589654</prism:url><dc:identifier>SCOPUS_ID:84929589654</dc:identifier><eid>2-s2.0-84929589654</eid><dc:title>Fe(II)-polypyridines as chromophores in dye-sensitized solar cells: A computational perspective</dc:title><dc:creator>Jakubikova E.</dc:creator><prism:publicationName>Accounts of Chemical Research</prism:publicationName><prism:issn>00014842</prism:issn><prism:eIssn>15204898</prism:eIssn><prism:volume>48</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>1441-1449</prism:pageRange><prism:coverDate>2015-05-19</prism:coverDate><prism:coverDisplayDate>19 May 2015</prism:coverDisplayDate><prism:doi>10.1021/ar500428t</prism:doi><dc:description>© 2015 American Chemical Society. ConspectusOver the past two decades, dye-sensitized solar cells (DSSCs) have become a viable and relatively cheap alternative to conventional crystalline silicon-based systems. At the heart of a DSSC is a wide band gap semiconductor, typically a TiO&lt;inf&gt;2&lt;/inf&gt; nanoparticle network, sensitized with a visible light absorbing chromophore. Ru(II)-polypyridines are often utilized as chromophores thanks to their chemical stability, long-lived metal-to-ligand charge transfer (MLCT) excited states, tunable redox potentials, and near perfect quantum efficiency of interfacial electron transfer (IET) into TiO&lt;inf&gt;2&lt;/inf&gt;. More recently, coordination compounds based on first row transition metals, such as Fe(II)-polypyridines, gained some attention as potential sensitizers in DSSCs due to their low cost and abundance. While such complexes can in principle sensitize TiO&lt;inf&gt;2&lt;/inf&gt;, they do so very inefficiently since their photoactive MLCT states undergo intersystem crossing (ISC) into low-lying metal-centered states on a subpicosecond time scale. Competition between the ultrafast ISC events and IET upon initial excitation of Fe(II)-polypyridines is the main obstacle to their utilization in DSSCs. Suitability of Fe(II)-polypyridines to serve as sensitizers could therefore be improved by adjusting relative rates of the ISC and IET processes, with the goal of making the IET more competitive with ISC.Our research program in computational inorganic chemistry utilizes a variety of tools based on density functional theory (DFT), time-dependent density functional theory (TD-DFT) and quantum dynamics to investigate structure-property relationships in Fe(II)-polypyridines, specifically focusing on their function as chromophores. One of the difficult problems is the accurate determination of energy differences between electronic states with various spin multiplicities (i.e., &lt;sup&gt;1&lt;/sup&gt;A, &lt;sup&gt;1,3&lt;/sup&gt;MLCT, &lt;sup&gt;3&lt;/sup&gt;T, &lt;sup&gt;5&lt;/sup&gt;T) in the ISC cascade. We have shown that DFT is capable of predicting the trends in the energy ordering of these electronic states in a set of structurally related complexes with the help of appropriate benchmarks, based either on experimental data or higher-level ab initio calculations.Models based on TD-DFT and quantum dynamics approaches have proven very useful in understanding IET processes in Fe(II)-polypyridine-TiO&lt;inf&gt;2&lt;/inf&gt; assemblies. For example, they helped us to elucidate the origin of "band selective" sensitization in the [Fe(bpy-dca)&lt;inf&gt;2&lt;/inf&gt;(CN)&lt;inf&gt;2&lt;/inf&gt;]-TiO&lt;inf&gt;2&lt;/inf&gt; assembly (bpy-dca = 2,2′-bipyridine-4,4′-dicarboxylic acid), first observed by Ferrere and Gregg [ Ferrere, S.; Gregg, B. A. J. Am. Chem. Soc. 1998, 120, 843. ]. They also shed light on the relationship between the linker group that anchors Fe(II)-polypyridines onto the TiO&lt;inf&gt;2&lt;/inf&gt; surface and the speed of IET in Fe(II)-polypyridine-TiO&lt;inf&gt;2&lt;/inf&gt; assemblies.More interestingly, our results show that the IET efficiency is strongly correlated with the amount of electron density on the linker group and that one can obtain insights into the IET in dye-semiconductor assemblies based on ground state electronic structure calculations alone. This may be useful for quick screening of a large number of complexes for use as potential sensitizers in DSSCs, especially if followed up by TD-DFT and quantum dynamics simulations for selected target compounds to confirm efficient sensitization. While our focus over the past few years has been exclusively on Fe(II)-polypyridines, the computational strategies outlined in this Account are applicable to a wide variety of sensitizers.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004923</affiliation-url><afid>60004923</afid><affilname>North Carolina State University</affilname><name-variant>North Carolina State University</name-variant><affiliation-city>Raleigh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23396939800</author-url><authid>23396939800</authid><authname>Jakubikova E.</authname><surname>Jakubikova</surname><given-name>Elena</given-name><initials>E.</initials><afid>60004923</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55243724700</author-url><authid>55243724700</authid><authname>Bowman D.</authname><surname>Bowman</surname><given-name>David N.</given-name><initials>D.N.</initials><afid>60004923</afid></author><intid>2035976252</intid><source-id>22657</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929521469"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929521469?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929521469&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929521469&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378775315008137"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929521469</prism:url><dc:identifier>SCOPUS_ID:84929521469</dc:identifier><eid>2-s2.0-84929521469</eid><dc:title>Electrical conductivity of PEMFC under loading</dc:title><dc:creator>Hamour M.</dc:creator><prism:publicationName>Journal of Power Sources</prism:publicationName><prism:issn>03787753</prism:issn><prism:volume>289</prism:volume><prism:pageRange>160-167</prism:pageRange><prism:coverDate>2015-05-19</prism:coverDate><prism:coverDisplayDate>19 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jpowsour.2015.04.145</prism:doi><pii>S0378775315008137</pii><dc:description>© 2015 Published by Elsevier B.V. Conducting an experimental investigation, we show that the electrical conductivity σ (Sm&lt;sup&gt;-1&lt;/sup&gt;) of the gas diffusion layer (GDL) and bipolar plates in stainless steel foam (SSF), as the heart of a Proton Exchange Membrane Fuel Cell (PEMFC), depends in fact strongly on mechanical compression arising in an operating system. Thus, this mechanical compression significantly affects the current density and σ; while it is not so far introduced in modelling and performance analysis. By mean of a developed metrology for this purpose and using Van der Pauw method, we studied, upon applied mechanical loads by varying the compression p, the electrical properties of different layers of a carbon cloth for GDL, of SSF, and, as in operating fuel cell, of the combination GDL + SSF in a sandwich form. A strong dependency is observed for each of these materials and their combination up to saturation for high enough p which is seen then to reduce the electrical resistance; while the number of layers has no influence. The obtained results are analysed in term of rate of increase of σ with an interesting conclusion for their application.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068750</affiliation-url><afid>60068750</afid><affilname>Universite Mouloud Mammeri de Tizi Ouzou</affilname><name-variant>Université Mouloud Mammeri</name-variant><affiliation-city>Tizi Ouzou</affiliation-city><affiliation-country>Algeria</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032653</affiliation-url><afid>60032653</afid><affilname>Universite de Poitiers</affilname><name-variant>Université de Poitiers</name-variant><affiliation-city>Poitiers</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009701</affiliation-url><afid>60009701</afid><affilname>ENSMA Ecole Nationale Superieure de Mecanique et dAerotechnique</affilname><name-variant>ENSMA</name-variant><affiliation-city>Chasseneuil du Poitou</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115228350</affiliation-url><afid>115228350</afid><affilname>Département Fluides</affilname><name-variant>Département Fluides</name-variant><affiliation-city>Poitiers</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:46261171900</author-url><authid>46261171900</authid><authname>Hamour M.</authname><surname>Hamour</surname><given-name>M.</given-name><initials>M.</initials><afid>60068750</afid><afid>60032653</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:46261171900</author-url><authid>46261171900</authid><authname>Hamour M.</authname><surname>Hamour</surname><given-name>M.</given-name><initials>M.</initials><afid>60068750</afid><afid>60032653</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603300569</author-url><authid>6603300569</authid><authname>Grandidier J.</authname><surname>Grandidier</surname><given-name>J. C.</given-name><initials>J.C.</initials><afid>60032653</afid><afid>60009701</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603300569</author-url><authid>6603300569</authid><authname>Grandidier J.</authname><surname>Grandidier</surname><given-name>J. C.</given-name><initials>J.C.</initials><afid>60032653</afid><afid>60009701</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602853418</author-url><authid>6602853418</authid><authname>Ouibrahim A.</authname><surname>Ouibrahim</surname><given-name>A.</given-name><initials>A.</initials><afid>60068750</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55635683700</author-url><authid>55635683700</authid><authname>Martemianov S.</authname><surname>Martemianov</surname><given-name>S.</given-name><initials>S.</initials><afid>60032653</afid><afid>115228350</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55635683700</author-url><authid>55635683700</authid><authname>Martemianov S.</authname><surname>Martemianov</surname><given-name>S.</given-name><initials>S.</initials><afid>60032653</afid><afid>115228350</afid></author><authkeywords>Carbon cloth | Electrical conductivity | Fuel cell | Gas diffusion layer | Stainless steel foam | Van der Pauw method</authkeywords><intid>1535968399</intid><source-id>18063</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929692037"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929692037?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929692037&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929692037&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929692037</prism:url><dc:identifier>SCOPUS_ID:84929692037</dc:identifier><eid>2-s2.0-84929692037</eid><dc:title>A Review of Element-Based Galerkin Methods for Numerical Weather Prediction: Finite Elements, Spectral Elements, and Discontinuous Galerkin</dc:title><dc:creator>Marras S.</dc:creator><prism:publicationName>Archives of Computational Methods in Engineering</prism:publicationName><prism:issn>11343060</prism:issn><prism:coverDate>2015-05-19</prism:coverDate><prism:coverDisplayDate>19 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11831-015-9152-1</prism:doi><dc:description>© 2015 US Government Numerical weather prediction (NWP) is in a period of transition. As resolutions increase, global models are moving towards fully nonhydrostatic dynamical cores, with the local and global models using the same governing equations; therefore we have reached a point where it will be necessary to use a single model for both applications. The new dynamical cores at the heart of these unified models are designed to scale efficiently on clusters with hundreds of thousands or even millions of CPU cores and GPUs. Operational and research NWP codes currently use a wide range of numerical methods: finite differences, spectral transform, finite volumes and, increasingly, finite/spectral elements and discontinuous Galerkin, which constitute element-based Galerkin (EBG) methods.Due to their important role in this transition, will EBGs be the dominant power behind NWP in the next 10 years, or will they just be one of many methods to choose from? One decade after the review of numerical methods for atmospheric modeling by Steppeler et al. (Meteorol Atmos Phys 82:287–301, 2003), this review discusses EBG methods as a viable numerical approach for the next-generation NWP models. One well-known weakness of EBG methods is the generation of unphysical oscillations in advection-dominated flows; special attention is hence devoted to dissipation-based stabilization methods. Since EBGs are geometrically flexible and allow both conforming and non-conforming meshes, as well as grid adaptivity, this review is concluded with a short overview of how mesh generation and dynamic mesh refinement are becoming as important for atmospheric modeling as they have been for engineering applications for many years.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033012</affiliation-url><afid>60033012</afid><affilname>Naval Postgraduate School</affilname><name-variant>Naval Postgraduate School</name-variant><affiliation-city>Monterey</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60098014</affiliation-url><afid>60098014</afid><affilname>Exa Corporation</affilname><name-variant>EXA Corporation</name-variant><affiliation-city>Burlington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60097745</affiliation-url><afid>60097745</afid><affilname>Centro Nacional de Supercomputacion</affilname><name-variant>Barcelona Supercomputing Center (BSC)</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname/><affiliation-city>Bellaterra</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60097745</affiliation-url><afid>60097745</afid><affilname>Centro Nacional de Supercomputacion</affilname><name-variant>Barcelona Supercomputing Center (BSC)</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36662316500</author-url><authid>36662316500</authid><authname>Marras S.</authname><surname>Marras</surname><given-name>Simone</given-name><initials>S.</initials><afid>60033012</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56652900000</author-url><authid>56652900000</authid><authname>Kelly J.</authname><surname>Kelly</surname><given-name>James F.</given-name><initials>J.F.</initials><afid>60098014</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55546244700</author-url><authid>55546244700</authid><authname>Moragues M.</authname><surname>Moragues</surname><given-name>Margarida</given-name><initials>M.</initials><afid>60097745</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56404944500</author-url><authid>56404944500</authid><authname>Müller A.</authname><surname>Müller</surname><given-name>Andreas</given-name><initials>A.</initials><afid>60033012</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56285707500</author-url><authid>56285707500</authid><authname>Kopera M.</authname><surname>Kopera</surname><given-name>Michal A.</given-name><initials>M.A.</initials><afid>60033012</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7401539932</author-url><authid>7401539932</authid><authname>Vázquez M.</authname><surname>Vázquez</surname><given-name>Mariano</given-name><initials>M.</initials><afid>60097745</afid><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7401539932</author-url><authid>7401539932</authid><authname>Vázquez M.</authname><surname>Vázquez</surname><given-name>Mariano</given-name><initials>M.</initials><afid>60097745</afid><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004429544</author-url><authid>7004429544</authid><authname>Giraldo F.</authname><surname>Giraldo</surname><given-name>Francis X.</given-name><initials>F.X.</initials><afid>60033012</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55901894500</author-url><authid>55901894500</authid><authname>Houzeaux G.</authname><surname>Houzeaux</surname><given-name>Guillaume</given-name><initials>G.</initials><afid>60097745</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:8080847900</author-url><authid>8080847900</authid><authname>Jorba O.</authname><surname>Jorba</surname><given-name>Oriol</given-name><initials>O.</initials><afid>60097745</afid></author><intid>535998735</intid><source-id>18093</source-id></entry></search-results>
